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In recent years research on ischemic stroke has developed powerful therapeutic tools. 
The novel frontiers of stem cells therapy and of hypothermia have been explored, 
and novel brain repair mechanisms have been discovered. Limits to intravenous 
thrombolysis have been advanced and powerful endovascular tools have been put at 
the clinicians’ disposal. Surgical decompression in malignant stroke has significantly 
improved the prognosis of this often fatal condition. This book includes contributions 
from scientists active in this innovative research. Stroke physicians, students, nurses 
and technicians will hopefully use it as a tool of continuing medical education to 
update their knowledge in this rapidly changing field.
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The last decade or so has witnessed unprecedented advances in the therapy of 
ischemic stroke. Intensive preclinical and clinical research in what used to be an 
almost incurable disease is finally putting at the clinicians’ disposal powerful 
therapeutic tools. While intravenous thrombolysis with recombinant tissue 
plasminogen activator has been the first and is still the most used tool, other ways of 
interventions have entered the clinical arena, dramatically improving the therapy of 
ischemic stroke. As it always happens at times of rapid changes, clinical practice lags 
behind research findings. While at times it must be so, since clinical practice must wait 
for evidence confirmation, very often the clinician finds it difficult to receive and 
process the relevant information in what may appear an overflow of data. 
While an all-inclusive review of all available innovations in stroke therapy would 
probably be impossible in a single book, this one does provide reviews and updated 
information in several hot issues. 
Hypothermia is the first such issue. This powerful therapy is finally coming of age, so 
far the sole survivor of a host of “neuroprotective” therapies that animal research had 
developed. While all other neuroprotective therapies have failed in the clinics, 
hypothermia has grown to become now, basically, recommended practice in the rescue 
therapy after cardiac arrest, a condition very similar albeit not identical to ischemic 
stroke. Its application in stroke is currently not routine practice, because of technical 
difficulties, of still significant side effects (let’s not forget that cardiac arrest often 
occurs in young people, ischemic stroke in elder persons) and because of limited 
clinical trials. However, there is probably sufficient evidence for considering it on a 
case-by-case basis in hospitals that have experience in its application. In this book, the 
contribution by Campbell et al. provide a fine review of both preclinical and clinical 
issues of hypothermia. Both Nares-López et al. and Shintani and Terao convincingly 
review the very extensive mechanisms of protection by hypothermia, while Doshi and 
Hirashima report results from animal research concerning duration and timing of 
hypothermia, results that are relevant to clinical applications of this technique. 
Second, brain regeneration is considered. The last decade of the 20th century has 
finally rejected the old myth that neurons remain unchanged in number from birth to 
death and, if damaged, cannot be replaced. On the contrary, we now know that a 
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lively neuronal regeneration is routinely under way in the brain (for example, new 
neurons are continuously generated in the hippocampal dentate gyrus, a fact that is 
probably important for memory). Endogenous regeneration is certainly a repair 
mechanism that occurs after stroke, although still a poorly understood one. In this 
book, two chapters (by Gu and Wester and by Wappler et al.) provide novel 
interesting knowledge on the relevance and on the mechanisms of endogenous 
regeneration after experimental animal ischemic stroke. Moreover, stem cells 
administration has been extensively investigated, in the hope to replace the neurons 
that had died after stroke. Unfortunately, human clinical trials in this field have been 
surprisingly scarce, a fact that still leaves largely unanswered basic questions like: is 
stem cells administration really useful for stroke, does it really work by replacing dead 
neurons, or does it rather favor endogenous regeneration and healing, what types of 
stem cells are better, what stroke types benefit the most from this therapy. Answer to 
these questions is of paramount importance also because several private hospitals are 
now offering expensive stem cells transplantation, a legitimate business that however 
underlines an urgent need to answer the above questions. In this book the two 
chapters by Afzal and Mocco and by Mitkari et al. help the interested professional 
navigate this difficult field. 
Clot-removal therapies for ischemic stroke (both intravenous thrombolysis and 
endovascular techniques) entered the neurological armamentarium  at the very end of 
the last century, changing forever the way stroke is treated. As we all recall, they were 
met with a mix of enthusiasm for their effectiveness and fear for their side effects, 
chiefly haemorrage. Fear of haemorrhage caused a long list of exclusion criteria that, at 
least in Europe, prevented intravenous thrombolysis from being administered to 
many, probably most, patients. In the following years several such criteria were 
challenged or revised, for example the maximum acceptable time from onset is 
currently no longer considered 3 hours (as it is still stated in the official approval 
documents of the therapy) but rather 4.5 hours, following the successful ECASS-III 
study, and most centers are now administering intravenous thrombolysis off-label 
between 3 and 4.5 hours from symptoms onset. At the time of this writing (January 
2012) we are waiting for the results of the IST-3 trial, that will hopefully clarify other 
issues in the administration of intravenous thrombolysis (for example, time up to 6 
hours from onset, simptoms very mild or too severe, onset with epileptic seizures, and 
so on). A major issue is patients’ age, in fact in Europe  r-TPA for intravenous 
thrombolysis is still officially approved for treatment only in patients younger than 80 
y.o. However, this boundary is being strongly challenged, and in this book we 
(Balestrino et al.) are reporting our so far successful experience with intravenous 
thrombolysis in patients even older than 90 years. 
Endovascular therapy has recently raised great interest both in the therapy of acute 
stroke and in the therapy of  symptomatic or asymptomatic carotid artery stenosis. As 
for acute stroke, the only randomized, controlled, multicenter, open-label clinical trial 
with blinded follow-up that has been so far completed is the PROACT-II, that 
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demonstrated superiority of intra-arterial thrombolysis with urokinase plus heparin 
compared to heparin alone within 6 hours from onset. Such efficacy occurred at the 
expense of an increased rate of cerebral hemorrhages that was of borderline statistical 
significance (p=0.06). After that study, several series of patients have been published, 
that generally support the effectiveness of this procedure. It is noteworthy, and it 
should not be forgot, that intra-arterial thrombolysis is a complex procedure, whose 
preliminary activities (angiography, catheterization, etc.) allow it to be started, as an 
average, one hour later than intravenous thrombolysis. During this hour brain cells 
continue to die, and nobody has ever demonstrated how intra-arterial and intra-
venous thrombolysis compare for safety and effectiveness. At the time of this writing 
(January 2012) a pivotal study (“Synthesis-Expansion”, randomizing patients to 
intravenous vs. intra-arterial thrombolysis within 4.5 hours from onset) is reaching its 
end and will soon provide much needed answers on whether the two treatments have 
different efficacy or safety. Waiting for the results of this study, both therapies are 
largely practiced. In this book, Lacman and Charvát review a popular technique of 
endoscopic (intra-arterial) treatment, i.e. mechanical thrombectomy (not requiring 
drugs, only physical disruption of the clot). As we know, this technique is very 
interesting, not least because it is supposed (lacking the thrombolytic drug) to 
minimize the bleeding risk. For this reason it is often used also as a “rescue” treatment 
after failed intravenous thrombolysis. 
Another popular application of endovascular techniques is carotid artery stenosis, 
both asymptomatic (in a person that never had stroke or TIA) and symptomatic. 
Randomized, controlled clinical trials have underlined how carotid “stenting” is more 
often loaded with a burden of complications heavier than open-neck conventional 
surgery, nevertheless this technique still has specific indications (for example, critical 
patients who could not tolerate open-neck surgery), and it is widely practiced. In this 
book Tavares and Caldas address relevant technical issues of carotid “stenting”. 
Interestingly, they specifically discuss two consequences of this technique that are 
often poorly understood. One is the “reperfusion syndrome”, a possible harmful 
consequence of carotid artery recanalization, the other is the effects of carotid artery 
recanalization on cerebral blood flow and on cognitive defects. Concerning the latter, 
we should remember that procedures to reopen a clogged carotid artery are usually 
undertaken to prevent a stroke, but restoration of normal cognitive function could in 
theory be one more reason to restore carotid artery patency. 
Last but not least, research is tackling a fearful complication of ischemic stroke, severe 
intracranial hypertension in what is called “malignant” infarction of the middle 
cerebral artery, a condition that in most cases ends with death or severe disability. 
Hypothermia has been successfully used for this condition, however decompressive 
surgery is probably the most largely practiced intervention, perhaps due to its larger 
availability. In this book, Scozzafava et al. review the therapy of cerebral edema, while 
Valença et al. describe a novel very interesting way (opening the skull “like a 
window”) that they invented to improve this surgery. 
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In the end, I am grateful to the Authors of the above chapters for providing 
stimulating and updated reports on many innovative issues in treating ischemic 
stroke. I am also indebted to the InTech publisher for having stimulated me to edit this 
book and having provided me, in this process, with powerful online tools and with 
professional human assistance. In particular, I would like to thank Ms. Ana Pantar for 
her skill and determination in starting this project and making it possible, and Ms. 
Maja Bozicevic for her kind, extensive and continuous assistance in streamlining the 
publishing procedure. 
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Cerebral Ischemia and Post-Ischemic  
Treatment with Hypothermia 
Kym Campbell, Neville W. Knuckey and Bruno P. Meloni 
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, 
Australian Neuromuscular Research Institute, Department of Neurosurgery,  
Sir Charles Gairdner Hospital, Nedlands, WA, 
Australia 
1. Introduction 
With its strict dependence on a continuous supply of oxygen and glucose to meet its energy 
needs and its high metabolic rate, the brain is particularly sensitive to any compromise of 
blood supply. Brain ischemia, as occurs in a number of disease states but most importantly 
in ischemic stroke and during cardiac arrest, rapidly results in exhaustion of ATP, triggering 
an energy crisis. Within minutes, the failure of ion pumps sees the depolarisation of 
neuronal cell membranes and the consequent release of stored presynaptic glutamate, 
leading, by way of overstimulation of glutamate receptors (=excitotoxicity), to many-fold 
increases in intracellular calcium and zinc concentrations. Severely affected cells die within 
only a few minutes. In those cells that are less severely injured, ongoing cellular and tissue 
damage occurs due to activation of proteolytic enzymes, oxidative and nitrosative stress 
(Forder & Tymianski, 2009), altered calcium homeostasis, initiation of active cell death 
pathways (apoptosis, necrosis, autophagy and necroptosis), inflammation (microglia and 
astrocyte activation, neutrophil infiltration within 4 - 6 hours), cortical spreading 
depressions, disruption of the blood brain barrier (BBB; starting at 2 hours, followed by a 
second phase from 24 - 72 hours; Brouns & De Deyn, 2009), microvascular injury (which 
promotes BBB disruption, inflammation and impairs vascular control of blood flow), 
hemostatic activation (platelet activation and the intrinsic pathway) and edema. 
Additionally, though reperfusion is the cornerstone of treatment, when/if it is established, 
many of these damaging events can be exacerbated.  
These processes are interconnected, rather than sequential, and presenting them as a list 
might be misleading if it were to be taken that counteracting one event would therefore 
prevent those occurring later in the list, even if they do in fact occur later in time. The list 
only acts as a summary of the damaging events, against which can be checked the likelihood 
of a potential therapy to do some good. The importance of each process waxes and wanes at 
different times during and after the ischemic episode, so an important principle of effective 
therapy is that it will need to be applied at the time of the injurious events to counteract its 
effect. In many respects hypothermia is, in theory, the ideal therapy, with multiple 
mechanisms of action in opposition to the consequences of ischemia.  
 1 
Cerebral Ischemia and Post-Ischemic  
Treatment with Hypothermia 
Kym Campbell, Neville W. Knuckey and Bruno P. Meloni 
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, 
Australian Neuromuscular Research Institute, Department of Neurosurgery,  
Sir Charles Gairdner Hospital, Nedlands, WA, 
Australia 
1. Introduction 
With its strict dependence on a continuous supply of oxygen and glucose to meet its energy 
needs and its high metabolic rate, the brain is particularly sensitive to any compromise of 
blood supply. Brain ischemia, as occurs in a number of disease states but most importantly 
in ischemic stroke and during cardiac arrest, rapidly results in exhaustion of ATP, triggering 
an energy crisis. Within minutes, the failure of ion pumps sees the depolarisation of 
neuronal cell membranes and the consequent release of stored presynaptic glutamate, 
leading, by way of overstimulation of glutamate receptors (=excitotoxicity), to many-fold 
increases in intracellular calcium and zinc concentrations. Severely affected cells die within 
only a few minutes. In those cells that are less severely injured, ongoing cellular and tissue 
damage occurs due to activation of proteolytic enzymes, oxidative and nitrosative stress 
(Forder & Tymianski, 2009), altered calcium homeostasis, initiation of active cell death 
pathways (apoptosis, necrosis, autophagy and necroptosis), inflammation (microglia and 
astrocyte activation, neutrophil infiltration within 4 - 6 hours), cortical spreading 
depressions, disruption of the blood brain barrier (BBB; starting at 2 hours, followed by a 
second phase from 24 - 72 hours; Brouns & De Deyn, 2009), microvascular injury (which 
promotes BBB disruption, inflammation and impairs vascular control of blood flow), 
hemostatic activation (platelet activation and the intrinsic pathway) and edema. 
Additionally, though reperfusion is the cornerstone of treatment, when/if it is established, 
many of these damaging events can be exacerbated.  
These processes are interconnected, rather than sequential, and presenting them as a list 
might be misleading if it were to be taken that counteracting one event would therefore 
prevent those occurring later in the list, even if they do in fact occur later in time. The list 
only acts as a summary of the damaging events, against which can be checked the likelihood 
of a potential therapy to do some good. The importance of each process waxes and wanes at 
different times during and after the ischemic episode, so an important principle of effective 
therapy is that it will need to be applied at the time of the injurious events to counteract its 
effect. In many respects hypothermia is, in theory, the ideal therapy, with multiple 
mechanisms of action in opposition to the consequences of ischemia.  
 
Advances in the Treatment of Ischemic Stroke 
 
4 
2. Background of therapeutic hypothermia  
Cooling of the body for therapeutic purposes is not a new concept in medicine. For example, 
in 1941 the British Medical Journal noted that generalised therapeutic hypothermia was 
under investigation for the treatment of various cancers, such as bladder carcinoma 
(Anonymous, 1941). It was also suggested that whole body cooling might find use in 
patients with intractable pain, morphine addiction, leukaemia, and schizophrenia, though 
no mention was made at this time of stroke or cardiac arrest. In the early 1950s, however, 
studies were being performed in which animals were cooled to very low temperatures (16 - 
19ºC in macacus rhesus monkeys, 2.5 - 5ºC in groundhogs) to permit cardiac surgery 
(Bigelow & McBirnie, 1953). Cardiac output was completely stopped in these experiments 
for long periods (15 - 24 minutes in the monkeys, 1 - 2 hours in the groundhogs) with few 
deaths, and no apparent neurological deficits when the animals were recovered.  
Thus, it has been known for several decades at least that a state of hypothermia decreases 
central neurological injury in the face of ischemia. This has led to many animal studies, of 
various designs, which have tended to confirm the potential for hypothermia to reduce 
ischemic brain damage (for review see Meloni et al., 2008). In recent years, clinical trials 
have proven that moderate hypothermia, using a target body temperature of 33ºC, improves 
outcomes for cardiac arrest survivors (Bernard et al., 2002; Hypothermia after cardiac arrest 
study group, 2002; Meloni et al., 2008), and its use is, at the time of writing, under 
investigation in several ongoing or planned trials following ischemic and hemorrhagic 
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3. Neuroprotective mechanisms of hypothermia 
There is evidence that therapeutic hypothermia has beneficial effects by numerous 
mechanisms including reduction of metabolic rate, promotion of energy recovery after 
ischemia, inhibition of glutamate release, inhibition of cell death pathways, inhibition of free 
radical formation, inhibition of inflammation, preservation of the BBB, stimulation of 
neurotrophin expression, and numerous effects on molecular responses to ischemia (e.g., 
inhibition of AMPK and MAPK activation, inhibition of SMAC/Diablo, p53).  
Intuitively, a reduced metabolic rate might be expected to be one of the more important 
means by which hypothermia could protect against ischemia, and it does make a 
contribution, though the effect is easily overestimated. It has been calculated that, on the 
measure of reduced metabolic oxygen consumption, 5 minutes of ischemia at 37ºC would 
cause approximately equivalent damage to 15 minutes of ischemia at 27ºC (Schaller & Graf, 
2003). Thus, the benefit is only moderate even at substantially lower temperatures than are 
usually considered suitable for most therapeutic purposes. There is evidence, however, that 
hypothermia also expedites the recovery of ATP stores after a period of ischemia, as well as 
improving the return of energy metabolism to pre-ischemic levels (Erecinska et al., 2003; 
Zhao et al., 2007). The combination of reduced demand and improved recovery both during 
and after what is a state of failed energy supply is perhaps enough to explain the 
outstanding neuroprotection afforded by intraischemic hypothermia. That is, without taking 
into account any of its other actions, hypothermia reduces the severity of any one incidence 
of cerebral ischemia. Its influence does not end there, however, though clearly hypothermia 
will necessarily be less effective when delayed. 
While excitotoxicity, principally attributable to overstimulation of the NMDA subtype of 
glutamate receptor, is a critical component of the ischemic cascade, its very early occurrence 
means it is likely to remain a frustrating target for therapeutic intervention. That said, there 
is fair evidence that hypothermia reduces, or at least delays, the release of glutamate from 
ischemic neurons, probably by delaying the onset of anoxic depolarisation (Zhao et al., 
2007). Using a cardiac arrest model, it was shown that hypothermia (31ºC/20min) either 
during ischemia or initiated at the time of reperfusion reduced extracellular glutamate 
concentrations (measured at the hippocampus), but not when the initiation of hypothermia 
was delayed by as little as 5 minutes after reperfusion (Takata et al., 2005). Hachimi-Idrissi 
et al. (2004) found a long lasting (more than 2 hours) inhibition of both glutamate and 
dopamine release in hypothermia (34°C/1h) treated animals when commenced after 
resuscitation in an asphyxiation/cardiac arrest model.  
Importantly, the activity of hypothermia in reducing oxidative damage after ischemia or 
ischemia-like insults is well-supported. Shin et al. (2010) found that, in rats, the death of 
neurons induced by hypoglycemia could be reduced by maintaining brain temperature at  
33 - 34ºC for 1 hour, and that this was associated with reductions in zinc ion 
release/translocation, generation of ROS, and activation of microglia. Maier et al. (2002) 
reported that intra-ischemic hypothermia (33°C/2h) reduced production of the superoxide 
anion after transient focal cerebral ischemia, and Van Hemelrijck et al. (2005) showed that 
hypothermia (34°C/2h during ischemia) reduced hydroxyl radical formation, by inhibition 
of neuronal NOS, during the resuscitative phase after focal cerebral ischemia.  
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There is general agreement from several studies that hypothermia improves membrane 
stability, reducing disruption of the BBB as well as protecting neuronal cell membranes. 
Kiyatkin and Sharma, 2009, found that hypothermia at 34 - 35ºC in normal brains slightly 
increased BBB permeability to albumin (compared to normothermia), but this did not result 
in edema. The mechanism appears to be related to temperature dependent variations in the 
sodium and chloride content of brain tissue, such that hypothermia reduces these ions by an 
undescribed mechanism, preventing osmotic draw into this tissue and producing a relative 
dehydration. In any case, the effect was mild, certainly compared to hyperthermia, which 
markedly increased both BBB permeability and edema. Baumann et al. (2009) found, on the 
other hand, that after global ischemia hypothermia (32ºC/6h commencing after reperfusion) 
stabilised blood vessels and decreased BBB permeability, probably by preservation of the 
basement membrane. Nagel et al. (2008) measured extravasation of MRI contrast agent after 
transient focal ischemia (tMCAO), and found that hypothermia (33ºC/4h starting 60min into 
90min MCAO) greatly reduced BBB disruption. Huang et al. (1999) showed that 
hypothermia (29°C/6h commencing after reperfusion) particularly reduces the second 
phase of BBB disruption that occurs around 24 hours after transient focal ischemia.  
Besides these non-specific harmful processes, there are in the penumbra a variety of pro-
apoptotic responses to ischemia that are mediated by particular molecular pathways. 
Identifying these pathways and investigating interventions to counteract them is a field of 
substantial current activity. There is too much to summarise here, and any such attempt 
would be likely to be out of date very soon. Nevertheless, a couple of examples are useful to 
give the flavour of the work being done, but for more additional information see recent 
reviews by Zhao et al. (2007) and González-Ibarra et al. (2011). 
AMP-activated protein kinase (AMPK) is responsive to energy stress, and, when 
phosphorylated, suppresses anabolic and promotes catabolic activity, evidently in order to 
maintain ATP supplies. Perhaps paradoxically, AMPK inhibition reduces ischemic brain 
damage, and there is evidence that hypothermia (32ºC/6h commencing after reperfusion) 
inhibits AMPK activation after transient focal cerebral ischemia in mice (Li et al., 2011). Li & 
Wang (2011) demonstrated that hypothermia (33ºC during transient focal ischemia) reduced 
expression of the protein complex second mitochondrion-derived activator of caspases 
(SMAC), an important molecule in the activation of apoptosis, which is upregulated in 
response to a variety of insults. The reduction in SMAC expression was also associated with 
reduced neurological impairment in rats after focal ischemia.  
4. Hypothermia and glial cells  
The best neurological outcomes will be achieved by measures taken to address the 
consequences of ischemia not just in neurons and the BBB, but in glial cells as well. Studies 
of the effects of hypothermia on glia are relatively few, but those there are suggest that 
hypothermia promotes survival and inhibits pathological responses in microglia and 
astrocytes. Hypothermia does reduce activation and proliferation of microglia, thus 
reducing oxidative and nitrosative stress (Si et al., 1997). Reduced activation of microglia 
associated with hypothermia has been demonstrated by several studies using different 
animal models, for example, during and after global cerebral ischemia (Kumar and Evans, 
1997; Webster et al., 2009), after transient focal cerebral ischemia (Inamasu et al., 2000), and 
after hypoxia/ischemia (Fukui et al., 2006). Hachimi-Idrissi et al. (2004) found that astrocyte 
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proliferation is also inhibited by hypothermia after asphyxiation/cardiac arrest and 
resuscitation. Haun et al. (1993) found that astrocyte cultures were made relatively resistant 
to an in vitro glucose-oxygen deprivation injury by hypothermia.  
5. Depth of hypothermia 
The efficacy of hypothermia increases as the depth of hypothermia increases, though the 
response is not linear. In a large meta-analysis of animal studies, van der Worp et al. (2007) 
found that the greatest therapeutic response (reducing mean infarct volumes by 
approximately 55%) was achieved by cooling to below 30ºC, though cooling to even 35ºC, 
the highest level of hypothermia included, still resulted in a considerable positive response 
(infarct volume reduction of 30%). What’s more, the adverse effects of the treatment 
(specifically cardiac arrhythmias, coagulopathies and immunosuppression) also increase 
with increasing depth, as do the technical difficulties involved in bringing patients to deeper 
body temperatures in the first place. Therefore, the optimum target will be the best balance 
between therapeutic effect versus detrimental effect versus practicality. While the optimum 
target temperature is still to be determined, based on preclinical and clinical studies it will 
probably be in the range 33 to 35ºC, that is, what is usually referred to as moderate or mild 
hypothermia. As mentioned earlier hypothermia at 33°C is being used following cardiac 
arrest in comatose survivors admitted to intensive care wards. However, from a clinical 
standpoint, hypothermia of 35°C offers the advantage of being achievable in awake subjects 
outside of intensive care units, which would comprise the majority of stroke patients. 
Furthermore several of the ongoing and planned stroke trials listed in Table 1 will provide 
data that aims to specifically address the question of the relative efficacy of hypothermia at 
33°C versus 35°C.  
It is worth considering here the use of hypothermia during (when it is most effective) 
cardiothoracic and neurosurgical procedures, in which body temperatures are lowered from 
anywhere from 26 - 35°C, specifically to protect tissues, including the brain, during an 
anticipated period of compromised blood supply. For example during cardiac surgery, there 
are two distinct levels of hypothermia that are commonly used; a target body temperature of 
34 - 35ºC is now becoming accepted as the standard for Cardiopulmonary Bypass (CPB), 
while in especially critical cases surgeons may opt to use Deep Hypothermic Circulatory 
Arrest (DHCA) in which patients are cooled to a rather extreme 15 - 26ºC (Choi et al., 2009; 
Cook, 2009; Mackensen et al., 2009).  
6. Timing and duration of hypothermia 
As noted earlier, the pathophysiology of cerebral ischemia is dynamic and multifaceted, 
with numerous damaging mechanisms occurring, becoming important at different times, 
and lasting for different durations, many of which interact to exacerbate the effect of 
another. It is an oversimplification to say that hypothermia reduces the impact of all of these 
damaging processes, but it’s fair to say that that is the trend. Consequently, the earlier 
hypothermia is commenced and the longer it is maintained while the ischemic damaging 
processes are occurring will permit the greatest neuroprotective effect. This contention is, 
however, not particularly well borne out by the evidence from animal trials (van der Worp 
et al., 2007), though there are some possible reasons for this finding (van der Worp et al., 
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2010). In the bulk of animal trials, hypothermic treatment is used during or very soon after 
ischemia, when it is most effective. Prolonging hypothermia in this situation allows little 
opportunity to improve on the highly effective neuroprotection afforded by early treatment, 
while permitting the adverse effects of hypothermia treatment (eg. coagulopathies, 
immunosuppression, pneumonia) to become significant. Furthermore, there will be a time 
after ischemia where delayed hypothermia will not be effective at inhibiting 
neuroregenerative processes. There is evidence, however, that the longer treatment is 
delayed, short periods of hypothermia have little or no effect, while prolonged hypothermia 
(>24h) can be very effective (Clark et al., 2008; Colbourne et al., 1999ab; Zhu et al., 2005).  
Again, however longer treatment consumes more resources and also increases the health 
risks, particularly in patients who require sedation or anaesthesia to maintain the 
hypothermic state. The optimum duration of hypothermia will most likely be in the range 12 
- 48 hours, and is likely also to be dependent on factors such as the specific cause of ischemia 
(stroke, cardiac arrest), severity of ischemia, age of patient and the time delay to 
commencing hypothermia after ischemia. In terms of therapeutic window, this will vary 
depending on the type of ischemia (focal vs global) and severity, but could be up to 6 hours 
following stroke (focal ischemia; Ohta et al., 2007) and up to 12 hours following global 
ischemia (Colbourne et al., 1999b; Coimbra & Walsh, 1994). With respect to rewarming it is 
becoming increasingly accepted that slow rewarming at the rate of 0.2 - 0.3°C/hour is most 
desirable (Bardutzky & Schwab, 2007; Bernard & Buist, 2003).  
7. Cooling methods  
One of the most significant barriers to therapeutic hypothermia is the technical difficulty 
involved in inducing the target temperature in the target tissue in a timely and safe manner. 
Large mammals such as humans are very efficient at maintaining a normal body 
temperature in the face of attempts to cool the body. Available techniques are surface 
cooling by refrigerative blankets, cooling helmets, cold air blowers, intravascular heat 
exchangers, intravascular cold fluids and, which is currently under investigation, intranasal 
evaporative cooling (Castrén et al., 2010; Jordan & Carhuapoma, 2007). An alternative 
approach is the use of pharmaceutical agents, such as the neurotensin analogue NT77 to 
alter the body’s temperature set-point as monitored and controlled by the hypothalamus, 
thus allowing an effectively physiological induction of hypothermia (Katz et al., 2004). Each 
of these has advantages and disadvantages in cost, accuracy, degree of control, rate of 
cooling and ease of application. Mild hypothermia can be induced in awake patients, as long 
as steps are taken to manage the associated discomfort (see below), but moderate to deep 
hypothermia requires sedation or anaesthesia with intubation, ventilation and intensive care 
measures.  
At present the intravenous infusion of cold salt solutions (4°C) at a rate of 20 - 30ml/kg over 
20 - 30 minutes is gaining acceptance as the method of choice to induce hypothermia 
(Bernard et al., 2003; Polderman et al., 2005; Moore et al., 2008). The cold saline infusion 
procedure has several attractions as it is: i) inexpensive ii) safe; iii) relatively straight 
forward; iv) fast at inducing mild to moderate hypothermia (33 - 35°C); v) applicable in the 
field allowing early hypothermia induction; vi) suited for use in both comatose and awake 
subjects; and vii) often indicated anyway as a means of improving physiological parameters 
(blood pressure, renal function, acid-base homeostasis; Bernard et al., 2003). Following 
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field allowing early hypothermia induction; vi) suited for use in both comatose and awake 
subjects; and vii) often indicated anyway as a means of improving physiological parameters 
(blood pressure, renal function, acid-base homeostasis; Bernard et al., 2003). Following 
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hypothermia induction by cold saline infusion one or more of the cooling procedures 
outlined above would then be implemented to provide a more precise control of body 
temperature. 
To further aid the induction and maintenance of hypothermia the use of pethidine 
(meperidine) alone or with other agents, such as, the anxiolytic buspirone or magnesium are 
being used (Kliegel et al., 2007; Mokhtarani et al., 2001; Martin-Schild et al., 2009; Zweifler et 
al., 2004; Table 1). The use of these agents, along with simple measures such as warm gloves 
and socks is especially useful when inducing hypothermia in awake patients to minimize 
discomfort and shivering (Mahmood & Zweifler, 2007). 
8. Combination with other treatments  
A substantial advantage of hypothermia is that it presents little or no obstacle to the 
application of other treatments, and in fact has been shown to enhance or act synergistically 
with some other neuroprotective approaches (Campbell et al., 2008; Zhu et al., 2005). In 
reviewing the literature, we have found that hypothermia in combination treatments 
generally has additive or synergistic effects, and in several instances medications which 
were thought to be neuroprotective were later found to induce hypothermia and in fact 
were not neuroprotective at all when normal body temperatures were maintained 
(Campbell et al., 2007; Nurse & Corbett, 1996). It is especially important that any potential 
stroke treatment should be compatible with tPA thrombolysis, and in this respect it appears 
based on in vitro data that at least for mild hypothermia (i.e. 35°C), it will not significantly 
reduce the effectiveness of tPA (Schwarzenberg et al., 1998; Shaw et al., 2007; Yenari et al., 
1995). 
9. Concluding remarks  
There is compelling experimental and clinical evidence that mild to moderate hypothermia 
is effective following global and focal (ischemic stroke) cerebral ischemia. However, it is 
likely that the depth and duration of hypothermia that provides the best benefit to patients 
will vary depending on the type (global vs focal) and severity of brain ischemia, the time 
that hypothermia is commenced, and patient age and presence of co-morbidities (diabetes, 
hypertension). Therefore further experimental and clinical trials will be required to 
determine hypothermia protocols that best suit individual patients. Moreover, based upon 
the available human studies, it appears that the use of hypothermia, in particular mild 
hypothermia (35°C) is feasible and safe to implement in clinical situations. In addition, 
based on current information therapeutic hypothermia should be commenced as soon as 
possible after the ischemic event, and maintained for durations of 12 - 48 hours to achieve a 
sustained benefit in terms of neuronal recovery and survival and functional benefits. To this 
end, future experimental studies in global and focal ischemia models and the results of the 
clinical stroke trials, will no doubt, help address further refinement of therapeutic 
hypothermia protocols to better suit individual cases. In addition, evaluation of the 
effectiveness of hypothermia in combination with other potential neuroprotective agents 
such as magnesium, caffeinol, glutamate antagonists and anti-oxidants could further 
improve efficacy.  
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1. Introduction 
Cerebral ischemia results from the decrease in oxygen and glucose supply by the transient 
or permanent reduction of cerebral blood flow, triggering excitotoxic, oxidative, 
inflammatory and apoptotic events which end up in brain tissue death. Cerebral ischemia is 
one of the leading causes of death in industrialized countries, a medical emergency with few 
specific treatments available to minimize the acute injury and provide neuroprotection and 
brain repair. In fact, current therapies are limited to clot removal, aspirin, and 
decompressive hemicraniectomy for ischemic stroke. To date, alteplase, recombinant tissue-
type plasminogen activator (rt-PA) is the only approved therapy for acute ischemic stroke. 
A relevant concern in stroke research is that despite the increase in pharmacological studies, 
these treatments have shown to be ineffective or to cause adverse effects. Among more than 
700 drugs which have been studied and found to be effective in animal stroke models, yet 
none has been proved efficacious in clinical studies.  
The reduction of cerebral blood flow as a consequence of a thrombus or embolus occlusion 
results in brain injury with metabolic and functional deficits. The extent of damage depends 
on the severity and duration of cerebral blood flow decrease; and according to the 
remaining blood supply, an ischemic core and a penumbra area can be identified. 
The core is defined by almost complete energetic failure that ends up in necrotic cell death. 
Cells in the hypoperfused penumbra are non-functional, however, structural integrity and 
viability are retained. Experimental and medical evidence indicates that if the blood flow is 
not restored throughout reperfusion within hours, the penumbral region becomes part of 
the core. Hence, penumbra is the target to rescue since brain tissue at this region remains 
potentially viable for 16 to 48 hours, enabling clinicians to intervene and reduce post-stroke 
disability. 
In addition to medication, the development of novel and rational strategies directed to 
reduce impairments after stroke have been improved. Ischemic preconditioning, 
electroacupuncture, hypothermia and stem cell therapy are the most relevant non-
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pharmacological strategies for the management of the patient who suffers an ischemic 
stroke, which is at present, one of the most frequent diseases at adult age and the principal 
cause of disability in many countries.  
Hypothermia is considered as one of the most effective options to treat stroke patients in the 
management of the adverse events taking place in the brain. Hypothermia alters different 
events in cerebral injury including reduction in metabolic and enzymatic activity, release 
and re-uptake of glutamate, inflammation, production of reactive oxygen species, blood-
brain barrier breakdown and shift of cell death and survival pathways. Although stroke 
models vary in methodology, several laboratories have consistently shown that 
hypothermia reduces the extent of neurologic damage and improves neurologic function.  
The aim of this chapter is to provide a recent review of basic research in hypothermia 
treatment. Beside the clinical studies that incorporate hypothermia, numerous efforts have 
been performed in recent years to understand the mechanisms underlying protection by 
hypothermia. The clinical and basic research concurrence will allow a better understanding 
of hypothermia mechanisms in the near future, making its incorporation more efficient as a 
co-adyuvant in stroke treatment.  
2. Protective hypothermia  
The reduction of body temperature or hypothermia during an adverse event such as cardiac 
arrest, cardiopulmonary resuscitation (Hassani, 2010), neonatal hypoxia, hepatic 
encephalopathy (Barba et al., 2008) and ischemic stroke has been applied in humans as well 
as in animal models. In all cases, hypothermia has shown to preserve cerebral function. 
Clinical trials have proved that hypothermia is an effective protector of brain injury (Jacobs 
et al., 2007), and laboratory animal studies provided a considerable amount of evidence 
supporting hypothermia protection after focal, global, transient and permanent cerebral 
ischemia models as well as in vitro approaches with ischemia or hypoxia treatments (van der 
Worp et al., 2010; Yenari & Hemmen, 2010).  
The amelioration of ischemia/reperfusion-induced oxidative stress, inflammatory and 
apoptotic responses are the most promising mechanisms to understand the biological action 
of hypothermia protection. There is relevant evidence that suggests that hypothermic 
protection occurs mainly by reducing cerebral metabolism, supporting the protective effects 
of hypothermia in the different steps of the ischemic cascade as we explain below.  
2.1 Hypothermia Induction  
Mild (>32ºC) to moderate (28-32ºC) systemic hypothermia has been studied widely. It has 
been reported that mild hypothermia improves neurological function suppressing apoptosis 
pathogenesis, and moderate hypothermia limits some of the metabolic responses by altering 
neurotransmitter release, attenuating energy depletion, decreasing radical oxygen species 
production and reducing neuronal death and apoptosis.  
In clinical stroke, hypothermia is an effective neuroprotective strategy when applied for a 
long period after the ischemic event, since it has been observed that the optimum conditions 
for hypothermic neuroprotection are mostly affected by the duration and timing of cooling. 
Several works have been performed to determine the timing, duration and deepness of 
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experimental hypothermia. In gerbils subjected to a global ischemia model, the immediate 
induction or the intensification of hypothermia improved survival rate, suppressed post-
ischemic hypoperfusion and prevented vasoconstriction. However, the therapeutic 
hypothermia time window was narrow, suggesting that it should be induced immediately 
after the onset of ischemia in order to improve survival (Noguchi et al., 2011).  
There are different methods for hypothermia induction in stroke patients and in basic 
research with in vivo models of ischemia. In clinical practice, the main methods to perform 
hypothermia are surface cooling and endovascular cooling. Both methods have advantages 
and disadvantages. Surface cooling can be induced with inexpensive methods such as air 
blankets, alcohol bathing and even fans to decrease temperature. Ice packs, neck bands and 
head caps are more sophisticated and practical techniques. In addition, surface cooling can 
be performed in awake patients with ischemic stroke. It is non-expensive, non invasive and 
allows the use of hypothermia in combination with thrombolytics. In fact, the combination 
of hypothermia with intravenous tissue plasminogen activator in patients treated within 6 h 
after ischemic stroke has shown hopeful results (Hemmen et al., 2010). However, complete 
control of body temperature is not possible with surface cooling, shivering and discomfort 
of the patient may occur (reviewed in Yenari et al., 2008).  
Endovascular cooling seems to be a more efficient way to generate and control hypothermia. 
Its invasive nature leads to time loss and also requires trained personal in endovascular 
techniques (Polderman & Herold, 2009). A pilot study with patients with acute ischemic 
stroke included within 3 h after symptom onset suggests that ice cold saline infusion 
combined with pethidine and buspirone (to prevent shivering), lowered body temperature 
to 35.40.7 ºC in a fast manner and without major side effects. The results of this small 
uncontrolled case series work, suggest that the induction of hypothermia with an infusion 
represents a fast approach for induction of hypothermia that could ameliorate the damage 
caused by the delayed induction observed in the majority of clinical cases (Kollmar et al., 
2009). The authors suggest that this rapid induction of hypothermia by ice cold saline 
infusion is an effective and rapid way to induce mild to moderate hypothermia for stroke 
treatment in an ambulance car. 
The procedure to induce hypothermia also has an important effect in its neuroprotective 
effect in animal models. Recently, Wang et al (2010) reported the use of systemic, head or 
local vascular ischemia in rats with middle cerebral artery occlusion. Their results showed 
that the use of vascular cooling is the most effective procedure to reduce infarct volume as 
well as in the functional outcome rather than the other two methods (Wang et al., 2010). 
However in animal models many methods to induce hypothermia are used, including the 
removal of heating blanket with a spontaneously decrease in temperature (Doshi et al., 
2009). 
2.2 Alternative agents to induce hypothermia 
2.2.1 Helium 
Inert gases such as xenon and helium have also been used to produce hypothermia. Helium 
is considered a “cost-efficient” inert gas with no anesthetic properties, in contrast to the 
availability and cost of xenon. David et al (2009) have shown that rats subjected to transient 
middle cerebral artery occlusion and hypothermia generated by helium administered after 
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reperfusion showed an improvement in neuroprotection. Helium produces cortical 
protection evaluated by infarct size and reduction of behavioral motor deficits at 25 ºC 
hypothermia but not at 33 ºC. The post-ischemic helium hypothermia administration is 
important as a possible clinical application.  
3. Hypothermia amelioration of ischemic damage 
3.1 The ischemic cascade  
The decrease in oxygen and glucose supply by the transient or permanent reduction of 
cerebral blood flow in cerebral ischemia triggers a series of excitotoxic, oxidative, 
inflammatory and apoptotic events known as the “ischemic cascade” which ends up in brain 
tissue death. 
Brain cells are dependent almost exclusively on oxygen and glucose supply for energy 
production through oxidative phosphorylation. The oxygen and glucose reduction causes 
accumulation of lactate increasing acidosis. ATP depletion triggers a series of pathologic 
events including the loss of membrane potential, peri-infarct depolarizations, glutamate and 
aspartate excitotoxicity, the increase in Ca2+ concentration, oxidative stress and free radical 
generation, protein synthesis inhibition, inflammation and apoptosis. The disruption of ion 
homeostasis originated by the disturbance of Na+/K+-ATPase and Ca2+/H-ATPase pumps, 
and the reversed Na+-Ca2+ transporter, triggers an increase in intracellular Na+, Cl- and Ca2+ 
concentrations, as well as extracellular K+. Besides this biochemical response, within 
minutes after the onset of ischemia, there is an increase in gene expression. Cells respond to 
stress by adjusting the gene expression program in order to deal with the stress condition, to 
trigger a recovery process or to lead to signaling for additional tissue injury (Dirnalg, 1999; 
Durukan & Tatlisumak, 2007).  
3.1.1 Brain edema and blood brain barrier breakdown 
The effects of hypothermia on the disruption of the blood brain barrier have been implicated 
in many studies. The role of temperature in blood brain barrier function has been studied in 
cortex, thalamus, hippocampus and hypothalamus of rats subjected to hyperthermia. 
Astrocytic activation, a larger content of brain water, Na+, K+ and Cl- as well as structural 
abnormalities that suggest brain edema were observed, demonstrating that brain 
temperature is an important factor in regulating blood brain barrier integrity, permeability 
and brain edema (Kiyatkin & Sharma, 2009). The effect of temperature in blood brain barrier 
integrity has also been studied using hypoxia and high ambient temperature to follow the 
permeability to Na+ and the expression of the endothelial barrier antigen, a protein 
associated with blood brain barrier. A clear effect in the increase of Na+ and a reduction in 
the endothelial barrier antigen were observed, as well as an exacerbation with hyperthermia 
(Natah et al., 2009).  
The dependence of blood brain barrier integrity and brain edema with temperature has 
important implications, since even the thrombolytic therapy using rTPA is able to cause 
hemorrhagic damage. In a work by Hamann et al (2004), it has been proposed that 
hypothermia could be used as a protection to basal lamina, a component along with the 
interendothelial tight junctions and perivascular astrocytes of the blood brain barrier. Basal 
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lamina has the main function of preventing extravasation of cellular blood elements, and the 
loss of its integrity results in hemorrhage. In order to determine whether hypothermia could 
maintain microvascular integrity in ischemic stroke, the loss of collagen type IV component 
of the basal lamina, the non-cellular proteolytic system that degrades basal lamina matrix 
metalloproteinase (MMP)-2 and MMP-9, plasminogen-plasmin system urokinase-type 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) were determined. 
Rats were subjected to 3 h ischemia and 24 h reperfusion with the suture model and 
hypothermia between 32-34ºC was applied 30 min before reperfusion. Results were 
compared with a normothermic group. This work shows that infarct size was considerably 
reduced in hypothermia treated rats; collagen type IV loss from basal lamina of cerebral 
microvessels was considerable reduced, as well as MMP-2, MMP-9, tPA and uPA activities, 
showing that hypothermia preserves microvascular integrity and reduces hemorrhage and 
the activities of MMP-2, MMP-9, uPA, and tPA (Hamman et al., 2004). 
Even that hypothermia has been successful in the protection against neuronal death in 
several models of ischemia, a recent work using C57BL/6J mice subjected to occlusion of 
bilateral common carotid arteries , demonstrated that hypothermia induced by the removal 
of heating blanket with a spontaneously decrease in temperature was an effective protection 
against neuronal death detected by histological damage and terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL). However, brain edema 
was not prevented by hypothermia treatment (Doshi et al., 2009). 
3.1.2 Metabolic downregulation 
As mentioned before, in cerebral ischemia two main regions of damage can be defined 
according to the severity and duration of the cerebral blood flow reduction: 1) The core, 
where complete abolishment of blood supply occurs (less than 12 ml/100g/min) and 2) the 
penumbra, in which collateral blood supply from surrounding arteries assures a flow of 
approximately 30 ml/100g/min. In normal non pathological conditions cerebral blood flow 
is decreased under hypothermic conditions, however, the effect of hypothermia in cerebral 
blood flow during ischemia events is not completely clear since some works support that 
hypothermia reduces or has no effect in cerebral blood flow and other reports show that it is 
increased during ischemia. Metabolic suppression has been proposed as one of the most 
relevant mechanisms underlying the hypothermic treatment. Hypothermia (in the range of 
22 to 37 ºC) reduces the rate of oxygen consumption fall in body temperature by 
approximately 5% per degree Celsius. It also decreases glucose consumption and lactate 
levels (Yenari et al., 2008).  
The deepness and extent of hypothermia stimulus has been considered of importance to the 
outcome and success of therapeutic hypothermia, and the developing methods to monitor 
and control hypothermia treatments is significant. Single voxel proton magnetic resonance 
spectroscopy (H´-MRS) is an important tool to detect metabolites and mechanisms that 
could be changing during hypothermia. Recently, using H´-MRS 7 Tesla MRI scanner, Chan 
et al (2010) determined the levels of metabolites in response to normothermia and 
hypothermia. Cortex and thalamus changes of metabolites involved in osmolality, brain 
temperature and energy metabolism were detected with important implications in the 
understanding of hypothermia protective mechanisms. For example, it was observed that 
lactate, the substrate of energy responsible for anaerobic metabolism and anaerobic 
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and the reversed Na+-Ca2+ transporter, triggers an increase in intracellular Na+, Cl- and Ca2+ 
concentrations, as well as extracellular K+. Besides this biochemical response, within 
minutes after the onset of ischemia, there is an increase in gene expression. Cells respond to 
stress by adjusting the gene expression program in order to deal with the stress condition, to 
trigger a recovery process or to lead to signaling for additional tissue injury (Dirnalg, 1999; 
Durukan & Tatlisumak, 2007).  
3.1.1 Brain edema and blood brain barrier breakdown 
The effects of hypothermia on the disruption of the blood brain barrier have been implicated 
in many studies. The role of temperature in blood brain barrier function has been studied in 
cortex, thalamus, hippocampus and hypothalamus of rats subjected to hyperthermia. 
Astrocytic activation, a larger content of brain water, Na+, K+ and Cl- as well as structural 
abnormalities that suggest brain edema were observed, demonstrating that brain 
temperature is an important factor in regulating blood brain barrier integrity, permeability 
and brain edema (Kiyatkin & Sharma, 2009). The effect of temperature in blood brain barrier 
integrity has also been studied using hypoxia and high ambient temperature to follow the 
permeability to Na+ and the expression of the endothelial barrier antigen, a protein 
associated with blood brain barrier. A clear effect in the increase of Na+ and a reduction in 
the endothelial barrier antigen were observed, as well as an exacerbation with hyperthermia 
(Natah et al., 2009).  
The dependence of blood brain barrier integrity and brain edema with temperature has 
important implications, since even the thrombolytic therapy using rTPA is able to cause 
hemorrhagic damage. In a work by Hamann et al (2004), it has been proposed that 
hypothermia could be used as a protection to basal lamina, a component along with the 
interendothelial tight junctions and perivascular astrocytes of the blood brain barrier. Basal 
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lamina has the main function of preventing extravasation of cellular blood elements, and the 
loss of its integrity results in hemorrhage. In order to determine whether hypothermia could 
maintain microvascular integrity in ischemic stroke, the loss of collagen type IV component 
of the basal lamina, the non-cellular proteolytic system that degrades basal lamina matrix 
metalloproteinase (MMP)-2 and MMP-9, plasminogen-plasmin system urokinase-type 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) were determined. 
Rats were subjected to 3 h ischemia and 24 h reperfusion with the suture model and 
hypothermia between 32-34ºC was applied 30 min before reperfusion. Results were 
compared with a normothermic group. This work shows that infarct size was considerably 
reduced in hypothermia treated rats; collagen type IV loss from basal lamina of cerebral 
microvessels was considerable reduced, as well as MMP-2, MMP-9, tPA and uPA activities, 
showing that hypothermia preserves microvascular integrity and reduces hemorrhage and 
the activities of MMP-2, MMP-9, uPA, and tPA (Hamman et al., 2004). 
Even that hypothermia has been successful in the protection against neuronal death in 
several models of ischemia, a recent work using C57BL/6J mice subjected to occlusion of 
bilateral common carotid arteries , demonstrated that hypothermia induced by the removal 
of heating blanket with a spontaneously decrease in temperature was an effective protection 
against neuronal death detected by histological damage and terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL). However, brain edema 
was not prevented by hypothermia treatment (Doshi et al., 2009). 
3.1.2 Metabolic downregulation 
As mentioned before, in cerebral ischemia two main regions of damage can be defined 
according to the severity and duration of the cerebral blood flow reduction: 1) The core, 
where complete abolishment of blood supply occurs (less than 12 ml/100g/min) and 2) the 
penumbra, in which collateral blood supply from surrounding arteries assures a flow of 
approximately 30 ml/100g/min. In normal non pathological conditions cerebral blood flow 
is decreased under hypothermic conditions, however, the effect of hypothermia in cerebral 
blood flow during ischemia events is not completely clear since some works support that 
hypothermia reduces or has no effect in cerebral blood flow and other reports show that it is 
increased during ischemia. Metabolic suppression has been proposed as one of the most 
relevant mechanisms underlying the hypothermic treatment. Hypothermia (in the range of 
22 to 37 ºC) reduces the rate of oxygen consumption fall in body temperature by 
approximately 5% per degree Celsius. It also decreases glucose consumption and lactate 
levels (Yenari et al., 2008).  
The deepness and extent of hypothermia stimulus has been considered of importance to the 
outcome and success of therapeutic hypothermia, and the developing methods to monitor 
and control hypothermia treatments is significant. Single voxel proton magnetic resonance 
spectroscopy (H´-MRS) is an important tool to detect metabolites and mechanisms that 
could be changing during hypothermia. Recently, using H´-MRS 7 Tesla MRI scanner, Chan 
et al (2010) determined the levels of metabolites in response to normothermia and 
hypothermia. Cortex and thalamus changes of metabolites involved in osmolality, brain 
temperature and energy metabolism were detected with important implications in the 
understanding of hypothermia protective mechanisms. For example, it was observed that 
lactate, the substrate of energy responsible for anaerobic metabolism and anaerobic 
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glycolysis increased 43% in the cortex during hypothermia. This observation has been 
considered as a change in energy metabolism associated with neuroprotection which results 
from an increase in glycolysis and depression of tricarboxilic acid cycle. 
Myo-inositol, a metabolite involved in diverse cellular processes such as signal transduction, 
membrane structure, vesicular trafficking and as an osmolite modulating cell volume, was 
increased 21 % in cortex during normothermia. They showed that this technique is able to 
detect metabolic changes in specific regions of the brain in alive animals in a noninvasively 
manner. In thalamus, taurine was 16% increased during hypothermia suggesting its role as a 
regulator of temperature and protecting neurons via its agonistic gamma-aminobutyric acid 
effect. In the same region choline decreased 29%, and authors suggest that this decrease 
could imply thermoregulation via muscarinic receptors which act against hypothermia. The 
main contribution of this work is the demonstration that this noninvasive method can detect 
changes in vivo, of significant metabolites involved in neuroprotective hypothermia (Chan et 
al., 2010).  
Using acid-base related parameters as well as the antioxidant-oxidant effects of deep (21-
22ºC) hypothermia before acute hypoxic insults in rats, it was observed that during 
hypothermia mild metabolic acidosis appeared in arterial blood. It suggests that 
hypothermia induced acidosis contributes to a reduction of potential in liver (Alva et al., 
2010). The determination of lactate levels showed that blood lactate increased in 
normothermia, and hypothermia prevents this increase contributing to the prevention of 
tissue damage.  
3.1.3 Glutamate release and peri-infarct depolarizations 
One of the critical steps in cerebral ischemia damage is excitotoxicity by glutamate and 
aspartate release as a result of membrane depolarization. The activation of glutamate 
receptors and increase in Ca2+, Na+ and Cl- levels initiate molecular events that end in cell 
death by excitotoxicity. The release of glutamate into the extracellular compartment is one of 
the early and most intense events of the ischemic cascade. The reduction of glutamate 
release in hypothermia supports the idea of protection through metabolism downregulation. 
It has been observed that the increase in glutamate levels is delayed in the ischemic core as a 
consequence of hypothermia treatment in permanent focal cerebral ischemia (Baker et al., 
1995) and the extracellular glutamate concentration is reduced in the penumbra when 
analyzed by microdialysis after permanent middle cerebral artery occlusion. This last study 
suggests that the protection observed by hypothermia probably involves a reduction in the 
pool of diffusible glutamate in the core but has little effect on glutamate release in the 
penumbra (Winfree et al., 1996). The increase in glutamate is related to the initiation of peri-
infarct depolarizations. Results using the N-methyl-D-aspartate receptor antagonist MK 801 
and moderate hypothermia (32-34 ºC) have shown neuroprotective effects alone and in 
combination supporting these observations (Alkan et al., 2001). Several studies have shown 
that hypothermia decreased glutamate efflux by attenuating the initial rise of extracelluar K+ 
and preventing Ca2+ accumulation (reviewed in Yenari et al., 2008).  
As a result of glutamate excitotoxicity, peri-infarct depolarizations contribute to the increase 
in infarct volume. The use of temporal NADH fluorescence images to obtain temporal and 
spatial resolutions to follow the propagation of peri-infarct depolarizations was performed 
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with spontaneously hypertensive rats subjected to permanent focal ischemia by occlusion of 
the middle cerebral and left common carotid arteries. Hypothermia (30ºC) maintained 2 h 
and applied before ischemia, showed that hypothermia delays the appearance, however 
does not modify the dynamics of propagation of peri-infarct depolarizations. The authors 
suggest that peri-infarct depolarizations could have a greater effect on the infarct area in 
hypothermic rats (Sasaki et al., 2009) and that the inefficacy to suppress peri-infarct 
depolarizations is the cause of the absence of hypothermia protection in several models of 
cerebral ischemia.  
3.1.4 Oxidative stress 
The generation of reactive oxygen species (ROS), reactive nitrogen species and free radicals 
is increased as a consequence of ischemic damage and particularly by the restoration of 
blood supply. Xantine oxidase, cyclooxygenase, NADPH oxidase, the mitochondrial 
respiratory chain and the inflammatory response are the major sources of free radicals in 
cerebral ischemia (Margaill et al., 2005). Reactive species play an important role in both 
necrotic and apoptotic cell death in cerebral ischemia and reperfusion. ROS generate 
oxidative stress and triggers tissue inflammation, cause damage to the cellular membrane by 
lipid peroxidation, DNA damage and disruption of cellular processes. Particularly, 
superoxide radical has an important responsibility of ischemia damage, since a number of 
ROS are derived from superoxide.  
Using an in vivo real-time quantitative superoxide analysis system with an electrochemical 
sensor previously developed, it has been demonstrated the increase in superoxide in the 
jugular veins of rats during ischemia/reperfusion in a forebrain ischemia model (Aki et al., 
2009). The effect of pre-ischemic hypothermia (32ºC) in the generation of superoxide or as a 
post ischemia treatment (immediately after reperfusion) was determined in the same model. 
Both pre and post ischemic hypothermia successfully decreased the superoxide generated 
by ischemic rats. Hypothermia also decreased oxidative stress, early inflammation and 
endothelial injury markers in both treatments (Koda et al., 2010).  
It has been observed that hypothermia maintains the glutation potential of the liver in an in 
vivo acute hypoxia model, it also avoids the increase in malondialdehide and prevents tissue 
damage induced by hypoxia (Alva et al., 2010).  
The inhibition of superoxide generation using hypothermia was also evaluated in an 
insulin-induced hypoglycemia model. They showed that intracellular accumulation of zinc 
promotes the production of ROS through NADPH oxidase activation after hypoglycemia 
(Shin et al., 2010). This work also provides evidence that hypothermia could affect other 
mechanisms such as vesicular Zn2+ release and translocation, which affects part of the 
excitotoxic neuronal death. Hypothermia prevents massive Zn2+ release which ends in cell 
death, and hyperthermia aggravates it, showing that Zn2+ release is dependent on 
temperature (Suh et al., 2004, Shin et al., 2010). However, despite all the evidences of ROS 
reduction and hypothermia protection, the determination of ROS during the first 60 minutes 
of ischemia in normothermic and hypothermic conditions using a global cerebral ischemia-
reperfusion model, showed that the widely hypothermia protection effect observed does not 
correlate with the oxidative stress induced by ROS, as observed with electron spin 
resonance system (Kunimatsu et al., 2001). The use of different ischemia models, time and 
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glycolysis increased 43% in the cortex during hypothermia. This observation has been 
considered as a change in energy metabolism associated with neuroprotection which results 
from an increase in glycolysis and depression of tricarboxilic acid cycle. 
Myo-inositol, a metabolite involved in diverse cellular processes such as signal transduction, 
membrane structure, vesicular trafficking and as an osmolite modulating cell volume, was 
increased 21 % in cortex during normothermia. They showed that this technique is able to 
detect metabolic changes in specific regions of the brain in alive animals in a noninvasively 
manner. In thalamus, taurine was 16% increased during hypothermia suggesting its role as a 
regulator of temperature and protecting neurons via its agonistic gamma-aminobutyric acid 
effect. In the same region choline decreased 29%, and authors suggest that this decrease 
could imply thermoregulation via muscarinic receptors which act against hypothermia. The 
main contribution of this work is the demonstration that this noninvasive method can detect 
changes in vivo, of significant metabolites involved in neuroprotective hypothermia (Chan et 
al., 2010).  
Using acid-base related parameters as well as the antioxidant-oxidant effects of deep (21-
22ºC) hypothermia before acute hypoxic insults in rats, it was observed that during 
hypothermia mild metabolic acidosis appeared in arterial blood. It suggests that 
hypothermia induced acidosis contributes to a reduction of potential in liver (Alva et al., 
2010). The determination of lactate levels showed that blood lactate increased in 
normothermia, and hypothermia prevents this increase contributing to the prevention of 
tissue damage.  
3.1.3 Glutamate release and peri-infarct depolarizations 
One of the critical steps in cerebral ischemia damage is excitotoxicity by glutamate and 
aspartate release as a result of membrane depolarization. The activation of glutamate 
receptors and increase in Ca2+, Na+ and Cl- levels initiate molecular events that end in cell 
death by excitotoxicity. The release of glutamate into the extracellular compartment is one of 
the early and most intense events of the ischemic cascade. The reduction of glutamate 
release in hypothermia supports the idea of protection through metabolism downregulation. 
It has been observed that the increase in glutamate levels is delayed in the ischemic core as a 
consequence of hypothermia treatment in permanent focal cerebral ischemia (Baker et al., 
1995) and the extracellular glutamate concentration is reduced in the penumbra when 
analyzed by microdialysis after permanent middle cerebral artery occlusion. This last study 
suggests that the protection observed by hypothermia probably involves a reduction in the 
pool of diffusible glutamate in the core but has little effect on glutamate release in the 
penumbra (Winfree et al., 1996). The increase in glutamate is related to the initiation of peri-
infarct depolarizations. Results using the N-methyl-D-aspartate receptor antagonist MK 801 
and moderate hypothermia (32-34 ºC) have shown neuroprotective effects alone and in 
combination supporting these observations (Alkan et al., 2001). Several studies have shown 
that hypothermia decreased glutamate efflux by attenuating the initial rise of extracelluar K+ 
and preventing Ca2+ accumulation (reviewed in Yenari et al., 2008).  
As a result of glutamate excitotoxicity, peri-infarct depolarizations contribute to the increase 
in infarct volume. The use of temporal NADH fluorescence images to obtain temporal and 
spatial resolutions to follow the propagation of peri-infarct depolarizations was performed 
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with spontaneously hypertensive rats subjected to permanent focal ischemia by occlusion of 
the middle cerebral and left common carotid arteries. Hypothermia (30ºC) maintained 2 h 
and applied before ischemia, showed that hypothermia delays the appearance, however 
does not modify the dynamics of propagation of peri-infarct depolarizations. The authors 
suggest that peri-infarct depolarizations could have a greater effect on the infarct area in 
hypothermic rats (Sasaki et al., 2009) and that the inefficacy to suppress peri-infarct 
depolarizations is the cause of the absence of hypothermia protection in several models of 
cerebral ischemia.  
3.1.4 Oxidative stress 
The generation of reactive oxygen species (ROS), reactive nitrogen species and free radicals 
is increased as a consequence of ischemic damage and particularly by the restoration of 
blood supply. Xantine oxidase, cyclooxygenase, NADPH oxidase, the mitochondrial 
respiratory chain and the inflammatory response are the major sources of free radicals in 
cerebral ischemia (Margaill et al., 2005). Reactive species play an important role in both 
necrotic and apoptotic cell death in cerebral ischemia and reperfusion. ROS generate 
oxidative stress and triggers tissue inflammation, cause damage to the cellular membrane by 
lipid peroxidation, DNA damage and disruption of cellular processes. Particularly, 
superoxide radical has an important responsibility of ischemia damage, since a number of 
ROS are derived from superoxide.  
Using an in vivo real-time quantitative superoxide analysis system with an electrochemical 
sensor previously developed, it has been demonstrated the increase in superoxide in the 
jugular veins of rats during ischemia/reperfusion in a forebrain ischemia model (Aki et al., 
2009). The effect of pre-ischemic hypothermia (32ºC) in the generation of superoxide or as a 
post ischemia treatment (immediately after reperfusion) was determined in the same model. 
Both pre and post ischemic hypothermia successfully decreased the superoxide generated 
by ischemic rats. Hypothermia also decreased oxidative stress, early inflammation and 
endothelial injury markers in both treatments (Koda et al., 2010).  
It has been observed that hypothermia maintains the glutation potential of the liver in an in 
vivo acute hypoxia model, it also avoids the increase in malondialdehide and prevents tissue 
damage induced by hypoxia (Alva et al., 2010).  
The inhibition of superoxide generation using hypothermia was also evaluated in an 
insulin-induced hypoglycemia model. They showed that intracellular accumulation of zinc 
promotes the production of ROS through NADPH oxidase activation after hypoglycemia 
(Shin et al., 2010). This work also provides evidence that hypothermia could affect other 
mechanisms such as vesicular Zn2+ release and translocation, which affects part of the 
excitotoxic neuronal death. Hypothermia prevents massive Zn2+ release which ends in cell 
death, and hyperthermia aggravates it, showing that Zn2+ release is dependent on 
temperature (Suh et al., 2004, Shin et al., 2010). However, despite all the evidences of ROS 
reduction and hypothermia protection, the determination of ROS during the first 60 minutes 
of ischemia in normothermic and hypothermic conditions using a global cerebral ischemia-
reperfusion model, showed that the widely hypothermia protection effect observed does not 
correlate with the oxidative stress induced by ROS, as observed with electron spin 
resonance system (Kunimatsu et al., 2001). The use of different ischemia models, time and 
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temperature are probably the explanation to contradictory results with respect to ROS 
generation.  
3.1.5 Inflammation 
Hypothermia attenuates inflammation by suppressing activating kinases of nuclear factor-
kappa B (NFkappaB). In a global cerebral ischemia model by bilateral carotid artery 
occlusion, microglial activation was observed and hypothermia decreased this activation as 
well as nuclear NFkappaB translocation and activation (Webster et al., 2009). NFkappaB is 
activated in cerebral ischemia, controlling the expression of inflammatory genes. In a study 
using middle cerebral artery occlusion by 2 h and hypothermia at 33 ºC, it was observed that 
the decrease in temperature decreased NFkappaB translocation and binding activity. 
Regulatory proteins such as IkappaB kinase were also affected decreasing its activity, 
suggesting that hypothermia exerts its protective effect by NFkappaB inhibition (Han et al., 
2003). 
3.2 Hypothermia and apoptosis signaling pathways 
3.2.1 Protein kinases activated by hypoxia 
In order to understand the protective mechanisms of hypothermia several efforts have been 
performed along years. It has been proposed that the mitochondria and the 
phosphatidylinositol 3-kinase (PI3-K)/Akt (protein kinase B) signaling pathway are 
determinant for neuronal survival controlling proapoptosis and antiapoptosis in ischemic 
neurons during stroke. Akt activity has been implicated in the endogenous neuroprotection 
observed by preconditioning (Miyawaki et al., 2008) and as part of the neuroprotective 
response to cerebral ischemia (Kamada et al., 2007). Several pharmacological efforts have 
been performed to target PI3-K/Akt pathway, since it is known that PI3-K/Akt downstream 
phosphorylated Bad and proline-rich Akt substrate survival signaling cascades are 
upregulated in surviving neurons in the ischemic brain (Chan et al., 2004).  
One of the most relevant efforts is the demonstration that PI3/Akt pathways are involved in 
neuroprotection by hypothermia. After the distal middle cerebral artery occlusion of rats 
using intra-ischemic hypothermia (30ºC), Zhao et al (2005) observed a reduction in infarct 
size and the improvement of neurological outcome up to two months. Relevant information 
was obtained from this work besides observed tissue protection and functional response: 1) 
decrease of Akt activity observed in normothermic animals after stroke was attenuated by 
hypothermia; 2) hypothermia improved phosphorylation and attenuates dephosphorylation 
of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and 
phosphoinositide-dependent protein kinase 1 (PDK1); 3) consequent to the observed tissue 
protection and the involvement of the Akt pathway, the inhibition of PI3K (an upstream 
activator of Akt) increases infarct size of hypothermic ischemic rats; 4) phosphorylation of 
forkhead transcription factor (FKHR) was improved by hypothermia attenuating its 
apoptotic effects, since dephosphorylated FKHR acts as a transcription factor increasing Bcl-
2 interacting mediator of cell death (Bim) and Fas ligand; 5) the nuclear translocation of the 
transcription factor P--catenin, observed in stroke normothermic rats was blocked by 
hypothermia in the penumbra, but not in the ischemic core, suggesting an important role of 
-catenin in stroke excitotoxicity (Zhao et al., 2005).  
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The same group evaluated the effect of hypothermia in the activation of a kinase implicated in 
neuroprotection in vitro, the epsilon protein kinase C (PKC), demonstrating that PKC 
preservation is an important component in the protective effect of hypothermia. Using the 
permanent distal middle cerebral artery occlusion plus 1 h of transient bilateral common 
carotid artery occlusion in normothermic (37ºC) and hypothermic (30ºC) rats, the neuronal full 
length PKC expression and localization was evaluated with inmmunofluorescence by 
confocal microscopy and western blot. Normothermic ischemic rats showed a decrease of 
PKC in the ischemic core at 4 h after common carotid artery release, hypothermia blocked this 
decrease. Hypothermia also affects cellular distribution. In non ischemic rats, PKC is in the 
cytoplasm of neurons. When cellular PKC distribution was determined, normothermic 
ischemic rats showed an PKC decrease in cytosol as well as in membranal fractions of the 
ischemic core, blocked by hypothermia. In the penumbra, the membranal PKC was decreased 
after the ischemic damage in normothermic rats and hypothermia blocked this decrease. Even 
hypothermia blocks PKC cleavage, inhibition of caspase-3 assays showed that this caspase is 
not involved in this process, suggesting the action of other proteases (Shimohata et al., 2007a). 
In contrast to PKC protective effect, delta protein kinase C (PKC) is involved in the tissue 
damage by ischemia. PKC activation depends on catalytic cleavage, phosphorylation and 
translocation to membranes. The inhibition of PKC activity using the specific inhibitor V1-1, 
decreased infarct size after transient cerebral ischemia (Brigth et al., 2004). The translocation to 
the nucleus and mitochondria, the caspase-3 dependent proteolytic cleavage to generate the 
PKC catalytic fragment (which increased in the membrane fraction, mitochondria, and 
nuclei); and the release of cytochrome c as earlier as 10 min after reperfusion, are processes 
triggered by common carotid artery occlusion. Hypothermia blocked all these processes; in 
fact, the subcellular translocation of the activated PKC was attenuated in the penumbra but 
not in the ischemic core (Shimohata et al., 2007b). All these protective effects were 
corroborated with the use of a specific PKC activator, RACK, in the hypothermic rats.  
Primary targets of ischemia-reperfusion injury are vascular endothelial cells through the 
stimulation of calcium overload, ROS generation and the triggering of inflammatory 
process, which in turn begin apoptotic programs. In order to determine mechanisms 
involved in hypothermia protection to ischemia and reperfusion damage, human umbilical 
endothelial cells were used. Using hypothermia (33ºC), a clear reduction in cell apoptosis 
induced by ischemia/reperfusion was observed. Characterization of this process showed 
that hypothermia reduces ischemia/reperfusion-induced apoptosis as observed by TUNEL, 
expression of activated caspase-3 and poly-ADP ribose polymerase (PARP). Hypothermia 
also reversed Fas/caspase 8 activation pathway and attenuated the Bax/Bcl-2 ratio 
compared with normothermic cells. Since JNK1/2 and p38 MAPK signaling pathways play 
an important role in oxidative stress-induced apoptosis, the effect of hypothermia in this 
pathway was studied, showing that hypothermia inhibits both extrinsic- and intrinsic-
dependent apoptotic pathways and activation of JNK1/2 activation via MKP-1 induction 
(Yang et al., 2009). 
3.2.2 Apoptotic proteins  
The decrease in apoptosis contributes in a significant manner to hypothermia protection. 
Ischemia and reperfusion have shown to increase the number of active caspase-3 
 
Advances in the Treatment of Ischemic Stroke 
 
22
temperature are probably the explanation to contradictory results with respect to ROS 
generation.  
3.1.5 Inflammation 
Hypothermia attenuates inflammation by suppressing activating kinases of nuclear factor-
kappa B (NFkappaB). In a global cerebral ischemia model by bilateral carotid artery 
occlusion, microglial activation was observed and hypothermia decreased this activation as 
well as nuclear NFkappaB translocation and activation (Webster et al., 2009). NFkappaB is 
activated in cerebral ischemia, controlling the expression of inflammatory genes. In a study 
using middle cerebral artery occlusion by 2 h and hypothermia at 33 ºC, it was observed that 
the decrease in temperature decreased NFkappaB translocation and binding activity. 
Regulatory proteins such as IkappaB kinase were also affected decreasing its activity, 
suggesting that hypothermia exerts its protective effect by NFkappaB inhibition (Han et al., 
2003). 
3.2 Hypothermia and apoptosis signaling pathways 
3.2.1 Protein kinases activated by hypoxia 
In order to understand the protective mechanisms of hypothermia several efforts have been 
performed along years. It has been proposed that the mitochondria and the 
phosphatidylinositol 3-kinase (PI3-K)/Akt (protein kinase B) signaling pathway are 
determinant for neuronal survival controlling proapoptosis and antiapoptosis in ischemic 
neurons during stroke. Akt activity has been implicated in the endogenous neuroprotection 
observed by preconditioning (Miyawaki et al., 2008) and as part of the neuroprotective 
response to cerebral ischemia (Kamada et al., 2007). Several pharmacological efforts have 
been performed to target PI3-K/Akt pathway, since it is known that PI3-K/Akt downstream 
phosphorylated Bad and proline-rich Akt substrate survival signaling cascades are 
upregulated in surviving neurons in the ischemic brain (Chan et al., 2004).  
One of the most relevant efforts is the demonstration that PI3/Akt pathways are involved in 
neuroprotection by hypothermia. After the distal middle cerebral artery occlusion of rats 
using intra-ischemic hypothermia (30ºC), Zhao et al (2005) observed a reduction in infarct 
size and the improvement of neurological outcome up to two months. Relevant information 
was obtained from this work besides observed tissue protection and functional response: 1) 
decrease of Akt activity observed in normothermic animals after stroke was attenuated by 
hypothermia; 2) hypothermia improved phosphorylation and attenuates dephosphorylation 
of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and 
phosphoinositide-dependent protein kinase 1 (PDK1); 3) consequent to the observed tissue 
protection and the involvement of the Akt pathway, the inhibition of PI3K (an upstream 
activator of Akt) increases infarct size of hypothermic ischemic rats; 4) phosphorylation of 
forkhead transcription factor (FKHR) was improved by hypothermia attenuating its 
apoptotic effects, since dephosphorylated FKHR acts as a transcription factor increasing Bcl-
2 interacting mediator of cell death (Bim) and Fas ligand; 5) the nuclear translocation of the 
transcription factor P--catenin, observed in stroke normothermic rats was blocked by 
hypothermia in the penumbra, but not in the ischemic core, suggesting an important role of 
-catenin in stroke excitotoxicity (Zhao et al., 2005).  
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The same group evaluated the effect of hypothermia in the activation of a kinase implicated in 
neuroprotection in vitro, the epsilon protein kinase C (PKC), demonstrating that PKC 
preservation is an important component in the protective effect of hypothermia. Using the 
permanent distal middle cerebral artery occlusion plus 1 h of transient bilateral common 
carotid artery occlusion in normothermic (37ºC) and hypothermic (30ºC) rats, the neuronal full 
length PKC expression and localization was evaluated with inmmunofluorescence by 
confocal microscopy and western blot. Normothermic ischemic rats showed a decrease of 
PKC in the ischemic core at 4 h after common carotid artery release, hypothermia blocked this 
decrease. Hypothermia also affects cellular distribution. In non ischemic rats, PKC is in the 
cytoplasm of neurons. When cellular PKC distribution was determined, normothermic 
ischemic rats showed an PKC decrease in cytosol as well as in membranal fractions of the 
ischemic core, blocked by hypothermia. In the penumbra, the membranal PKC was decreased 
after the ischemic damage in normothermic rats and hypothermia blocked this decrease. Even 
hypothermia blocks PKC cleavage, inhibition of caspase-3 assays showed that this caspase is 
not involved in this process, suggesting the action of other proteases (Shimohata et al., 2007a). 
In contrast to PKC protective effect, delta protein kinase C (PKC) is involved in the tissue 
damage by ischemia. PKC activation depends on catalytic cleavage, phosphorylation and 
translocation to membranes. The inhibition of PKC activity using the specific inhibitor V1-1, 
decreased infarct size after transient cerebral ischemia (Brigth et al., 2004). The translocation to 
the nucleus and mitochondria, the caspase-3 dependent proteolytic cleavage to generate the 
PKC catalytic fragment (which increased in the membrane fraction, mitochondria, and 
nuclei); and the release of cytochrome c as earlier as 10 min after reperfusion, are processes 
triggered by common carotid artery occlusion. Hypothermia blocked all these processes; in 
fact, the subcellular translocation of the activated PKC was attenuated in the penumbra but 
not in the ischemic core (Shimohata et al., 2007b). All these protective effects were 
corroborated with the use of a specific PKC activator, RACK, in the hypothermic rats.  
Primary targets of ischemia-reperfusion injury are vascular endothelial cells through the 
stimulation of calcium overload, ROS generation and the triggering of inflammatory 
process, which in turn begin apoptotic programs. In order to determine mechanisms 
involved in hypothermia protection to ischemia and reperfusion damage, human umbilical 
endothelial cells were used. Using hypothermia (33ºC), a clear reduction in cell apoptosis 
induced by ischemia/reperfusion was observed. Characterization of this process showed 
that hypothermia reduces ischemia/reperfusion-induced apoptosis as observed by TUNEL, 
expression of activated caspase-3 and poly-ADP ribose polymerase (PARP). Hypothermia 
also reversed Fas/caspase 8 activation pathway and attenuated the Bax/Bcl-2 ratio 
compared with normothermic cells. Since JNK1/2 and p38 MAPK signaling pathways play 
an important role in oxidative stress-induced apoptosis, the effect of hypothermia in this 
pathway was studied, showing that hypothermia inhibits both extrinsic- and intrinsic-
dependent apoptotic pathways and activation of JNK1/2 activation via MKP-1 induction 
(Yang et al., 2009). 
3.2.2 Apoptotic proteins  
The decrease in apoptosis contributes in a significant manner to hypothermia protection. 
Ischemia and reperfusion have shown to increase the number of active caspase-3 
 
Advances in the Treatment of Ischemic Stroke 
 
24
immunoreactive nuclei, and hypothermia clearly reduced this induction (Kunimatsu et al., 
2001).  
Recently, Li & Wang (2011) used mild hypothermia (33 ºC) in rats subjected to middle 
cerebral artery occlusion and determined neurological impairment and the expression of 
Second Mitochondrion-derived Activator of Caspases (SMAC) as an index of cellular 
apoptosis. Mild hypothermia significantly improved the neurological deficit scores while 
results from protein and transcript expression of SMAC showed a significantly decrease, 
suggesting that mild hypothermia could be protecting the functions of cells by attenuating 
apoptotic death (Li & Wang, 2011). 
It has been previously shown that the pro-apoptotic protein SMAC/DIABLO expression is 
increased in cortex and hippocampus in transient cerebral ischemia as well as in ischemia-
reperfusion injury (Saito et al., 2003; Scarabelli & Stephanou, 2004; Siegelin et al., 2005). 
SMAC increases 3 h after cerebral ischemia with a peak at 24 h. Apparently, hypothermia 
could be down-regulating SMAC production attenuating caspases activation. Cell apoptosis 
via SMAC involve mitochondrial and death receptor pathways, inducing changes in 
mitochondrial membrane permeability and subsequently release membrane proteins, such 
as SMAC, into the cytoplasm. SMAC leads cells toward apoptosis through apoptosis-related 
protein. The prevention of loss of mitochondrial transmembrane potential, release of 
apoptotic proteins (citochrome c and apoptosis inducing factor [AIF]) and the activation of 
apoptotic proteins such as caspase 3, as well as the attenuation in the elevation of oxidative 
stress markers have been observed also in in vitro cells with hypothermia in a model of iron 
and ascorbic acid neurotoxicity (Hasegawa et al., 2009).  
Rats subjected to global cerebral ischemia with the four-vessel occlusion model with 
hypothermia (31-32 ºC) and hyperthermia (41-42ºC) confirmed the protective effects of 
hypothermia in the decrease of mortality rate (at 72 and 168 h post reperfusion), and in the 
increase of surviving neurons in hippocampus under hypothermic conditions. Hypothermia 
clearly reduced p53 and increased bcl-2 proteins reducing neuronal death. In addition 
hyperthermia had the opposite effect in the expression of both proteins (Zhang et al., 2010). 
3.3 Regulation of gene and protein expression 
Hypothermia induces changes in inflammatory, apoptotic and metabolic genes as the result 
of gene expression regulation.  
In general, it is considered that hypothermia downregulates gene expression. However, 
there are reports that show the upregulation of certain genes, particularly those involved in 
cell survival. The understanding of gene and protein expression as result of hypothermia in 
cerebral ischemia could lead to the possible therapeutic target genes or pathways regulated 
as a result of decreasing body temperature.  
Recently, an analysis of gene and protein expression using DNA microarrays and 
proteomics approach in a 2 h middle cerebral artery occlusion model and mild hypothermia 
(35ºC) has shown that it is possible to determine target molecules. The authors proposed 
that suppression of neuroinflammatory cascades MIP-3-CCR could contribute to the 
neuroprotective effects of hypothermia and also identified Hsp 70 as a neuroprotective 
factor stimulated by hypothermia (Shintani et al., 2010; Terao et al., 2009,).  
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3.3.1 Effect of hypothermia in proteins involved in gene expression 
The decrease in temperature and/or the decrease in oxygen concentration involve a series of 
events that modulate transcription and translation. Novel proteins have been discovered in 
the last decades. Here we show the role of cold inducible proteins and hypoxia inducible 
factor-1 as proteins that regulate the efficient transcription and translation of proteins in 
ischemia and ischemia/hypothermia events.  
3.3.1.1 Cold-inducible RNA-binding proteins 
Cold inducible proteins have the function to ensure the efficient translation of specific 
mRNAs at temperatures below the physiological standard. Hypothermia induces the 
synthesis of amino terminal consensus sequence RNA-binding domain proteins (CS-RBD). 
The “cold-inducible RNA-binding protein” (CIRP) is one of these proteins, and has been 
involved in protection as the result of hypothermia treatment in in vitro studies. CIRP 
regulates gene expression at translational level. It binds to the 5´-untranslated region (5´-
UTR) or 3´-UTR of specific transcripts, affecting translation and transcript stability (Lleonart, 
2010).  
CIRP has been proposed as a therapeutic target in cerebral ischemia by Liu et al (2010). They 
determined mRNA expression in hippocampus and cortex of rat brains subjected to 
hypothermia (30º), cerebral ischemia (by four vessel occlusion model of forebrain ischemia) 
and hypothermia plus cerebral ischemia by real time quantitative PCR analysis. mRNA 
CIRP expression was followed at 2, 6 and 24 h showing an increase in cortex after cerebral 
ischemia with a previous hypothermia treatment. In order to clarify the relationship 
between CIRP and energy metabolism, they determined lactate and piruvate concentrations, 
showing that CIRP has a neuroprotective effect in hypothermia; however, it is not related to 
energy metabolism.  
The contribution of CIRP to the neuroprotection observed by hypothermia has also been 
studied using MEMB5 cells, a neural stem cell line from mouse forebrain (Saito et al., 2010). 
These cells proliferate in the presence of epidermal growth factor (EGF). EGF deprivation at 
37 ºC results in apoptosis induction, as well as a decrease of the nestin neural stem cell 
marker and an increase of the astrocyte marker glial fibrillary acidic protein (GFAP). In 
contrast, MEMB5 cells at moderate hypothermia prevented apoptosis and decreased the 
observed GFAP expression of normothermic cells. This observation is important because it 
suggests that hypothermia prevents neural stem cells differentiation, and it has been 
hypothesized that the preservation of neural stem cells is one of the neuroprotective 
mechanisms of therapeutic hypothermia, since it could maintain the capability of cells to 
differentiate and proliferate after an ischemic event. CIRP mRNA and protein was increased 
in the MEB5 in hypothermic cells, a response according to previous observations showing 
that ischemia/reperfusion decreases CIRP mRNA (Xue et al., 1999) whereas hypothermia 
increases it in an in vivo cerebral ischemia model (Liu et al., 2010).  
The relevance of CIRP expression was confirmed using CIRP iRNA, increasing apoptosis in 
hypothermic cells without EGF. This result suggests that the induced CIRP plays the role of a 
survival factor in neural stem cells. The prevention of apoptosis observed with induced CIRP 
at hypothermia has been suggested to be the result of the activation of extracellular signal-
regulated kinase ERK (Artero-Castro et al., 2009; Sakurai et al., 2006; Schmitt et al., 2007).  
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3.3.1.2 Hypoxia inducible factor  
Hypoxia inducible factor is a transcription factor which binds to hypoxic response elements-
driven promoters of genes that mediate adaptive reactions to reduction in oxygen 
availability. Hypoxia inducible factor is regulated by oxygen accessibility and has been 
considered as a therapeutic target in cerebral ischemia (Aguilera et al., 2009). Recently it has 
been reported that persisting low temperature affects its stabilization and protein 
accumulation. Since the normal regulatory degradation processes of HIF are not affected by 
hypothermia, it has been hypothesized that probably hypothermia elevates intracellular 
oxygen tension by decreasing oxygen consumption, suppressing in turn HIF-1 alpha 
subunit induction. These results were obtained with different cell lines (T98G cells from 
human glioblastoma multiform, HeLa cells (derived from human cervical carcinoma) and 
Hep3B cells (derived from human hepatoma) as well as mice subjected to hypoxia and 
hypothermia (18ºC in a mouse incubator). The translation of HIF-1 alpha protein showed to 
be dependent on time exposure to hypothermia. The down-regulation of HIF protein 
expression observed with hypothermia has relevant implications in ischemia and 
hypothermia studies, since this transcription factor is a master regulator of the hypoxic 
response to oxygen decrease (Tanaka et al., 2010). 
3.3.2 Gene and protein expression in CA1 neurons as result of hypothermia 
Hippocampal CA1 layer is a region that presents a typical apoptosis cell death after ischemic 
damage. As a matter of fact , accumulating evidence has indicated that the postischemic 
DNA fragmentation in the hippocampal CA1 area in experimental ischemic models is a key 
phenomenon for the delayed neuronal death and is considered as apoptosis. Hypothermia 
has shown to protect CA1 neurons attenuating the down-regulation of GluR2 mRNA in a 
model of forebrain ischemia using two days of mild hypothermia induced after 1 h cerebral 
ischemia, suggesting that the observed attenuation and CA1 neurons protection responds to 
cooling (Colbourne et al., 2003). Another interesting protein is the -galactosidase-binding 
lectin Galectin-3, which has been observed expressed in experimental models of stroke 
(Walther et al., 2000; Yan et al., 2009) and increased in microgial cells in the hippocampal 
CA1 layer after a transient ischemic insult. Galectin-3 is a protein involved in apoptotic 
regulation, inflammation and cell differentiation and used as a marker of activated 
microglia. After 5 min of bilateral common carotid arteries of gerbils, galectin-3 expression 
was observed in microglial cells in CA1 region. Hypothermia (31ºC) prevents galectin-3 
expression suggesting that hypothermia protection occurs through the inhibition of 
microglial activation and probably by preventing neuronal death (Satoh et al., 2011). Even 
when galectin-3 has been considered apoptotic, its role as an inflammatory mediator in 
neonatal hypoxia ischemia injury through the modulation of the inflammatory response has 
been reported (Doverhag et al., 2010).  
4. Combined therapies 
The preservation of tissue and reduction of brain damage observed during hypothermia and 
the easiness to achieve and maintain low temperatures, constitute an attractive alternative 
against stroke. However, because of the complexity of the pathophysiological mechanisms 
involved in the ischemic cascade, it is common to observe the use of one or two drugs 
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besides hypothermia in the search of a neuroprotective compound capable of blocking the 
metabolic insult. Combination therapy is based in the extension of the therapeutic window 
of hypothermia using pharmacotherapy and establishes an interesting approach in 
hypothermia research. 
4.1 Hypothermia, tirilazad and magnesium 
The combined administration of the antioxidant tirilazad, magnesium and hypothermia has 
shown that the hypothermia protection increases with the use of pharmacotherapy, 
extending the therapeutic window of hypothermia treatment. Zausinger et al (2003) used 
hypothermia (2 h, 33ºC) at 0, 1, 3 and 5 h after transient focal ischemia induction combined 
with two administrations of tirilazad (3 mg/kg) and magnesium (1 mmol.L-1.kg-1) in 1 h 
intervals. Infarct volume was reduced by 74%, 49% and 45% when hypothermia was applied 
at 0, 1 and 3 h. No improvements were observed at 5 h. The same combination therapy was 
performed in a permanent ischemia with middle cerebral artery occlusion. Two h at 33 ºC 
hypothermia and two times of drug administration (30 min before and 1 h after middle 
cerebral artery occlusion) showed a 52 % infarct size reduction after 6 h occlusion. 
Interestingly, a separate group with 7 days of permanent middle cerebral artery occlusion 
was followed daily with neurological tests and body weight. Even high mortality ocurred in 
this group, neurological recovery was observed in survivor rats, as well as a decrease in 
infarct size (Schöller et al., 2004).  
Moderate hypothermia (30ºC) has shown higher protection than mild hypothermia (33ºC), 
however moderate hypothermia is associated with severe side effects. Nonetheless, the 
combined effect observed with mild hypothermia, magnesium and tirilazad showed a 
comparable protection with that observed using moderate hypothermia, suggesting that 
combination therapy could be a promising approach in clinical applications.  
4.2 Hypothermia and magnesium 
Combination therapy with magnesium has generated controversy, because magnesium 
treatment alone has shown to be ineffective in normothermic rats subjected to ischemia (Zhu 
et al., 2004, a and b). The quantification of infarct volumes at magnesium 360 or 720 
umol/kg in rats subjected to middle cerebral artery occlusion showed that the 360 umol/kg 
dose reduces the striatal infarct volume by 32 %. The authors observed that mild 
spontaneous hypothermia was responsible of the observed neuroprotective effect of 
magnesium (Campbell et al 2008a).  
The therapeutic time window of combined magnesium and mild hypothermia treatment 
was determined after permanent middle cerebral artery occlusion. The administration of a 
magnesium sulfate infusion (360 μmol/kg, then 120 μmol/kg/h) and mild hypothermia 
(35ºC) after 2, 4 or 6 h ischemia showed that combination therapy considerably reduced 
infarct volumes at 2 and 4 h but not at 6 h, supporting the use of combined therapy even at 
delayed hours after ischemia onset (Campbell et al 2008b). 
Although the controversy in the use of magnesium and hypothermia in cerebral ischemia 
exists, a lot of experimental evidence demonstrates its efficacy in laboratory studies and it is 
necessary to perform more clinical trials to translate this combinatorial therapy to clinical 
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use. Actually, combined mild hypothermia (35ºC) and magnesium is recognized as a 
neuroprotective treatment able to minimize ischemic damage, even in delayed treatments 
(Meloni et al., 2009). 
4.3 Hypothermia and citicoline 
Hypothermia has been combined with other compounds. One of them is citicoline, an 
endogenous compound that has shown to stabilize membrane function and reduce free 
radical generation during ischemia (Rao et al., 2000).  
Mild hypothermia combined with citicoline resulted in an additive effect in attenuating 
apoptosis in focal cerebral ischemia/reperfusion injury. Hypothermia (341ºC) during 
middle cerebral artery occlusion (2 h) followed by 24 h reperfusion was used in combination 
with 4000 mg/kg i.p. citicoline. Combined therapy with citicoline and hypothermia resulted 
in reduced apoptotic cell death before the development of the apoptosome, thus preventing 
apoptosis and neuronal damage. Bcl-2, caspases 3 and 9 as well as Bax proteins were 
immunohistochemistry tested, showing that the use of citicoline with hypothermia is more 
effective than citicoline or hypothermia used alone. A decrease in cerebral injury was 
observed and apparently, the tissue protection is due to the suppression of apoptotic 
processes (Sahin et al., 2010).  
4.4 Hypothermia and ginkgolides 
Despite the neuroprotective role of hypothermia, the combined use of hypothermia with 
protective compounds not always has a synergistic effect. This is the case of hypothermia 
and ginkgolides in astrocytes subjected to ischemia and reperfusion in which hypothermia 
attenuates, rather than enhances, the protective effect of ginkgolides on astrocytes from 
ischemia and reperfusion-induced injury. Co-treatment with different doses of ginkgolides 
at 32 and 28 ºC hypothermia during 24, 48 and 72 h before 24 h ischemia followed by 24 h 
reperfusion showed that the use of ginkgolides without hypothermia treatment had an 
improvement in cell viabilities and in anti-apoptotic properties, and this protective effects 
were not observed in the co-treatment (Fang et al., 2009).  
4.5 Hypothermia and xenon 
Xenon has been considered a great promise used as a neuroprotectant in in vivo and in vitro 
studies. Combined therapy with hypothermia in a neonatal rat hypoxia-ischemia model has 
shown that the combination of 50% xenon and hypothermia of 32°C has a protective effect 
in the restoration of long-term functional outcomes and global histopathology, showing that 
the combined xenon/hypothermia has a greater protection (Hobbs et al., 2008).  
5. Conclusion 
Despite all the efforts to develop pharmacological treatments to contend with cerebral 
ischemic damage, nowadays, there are no efficient treatments to deal with this pathology. 
Non-pharmacological treatments emerge as reasonable approaches to compete against 
ischemic damage.  
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Hypothermia has shown positive results in cardiac arrest and neonatal hypoxic ischemia 
and in patients with acute brain injury. However, there are no large clinical stroke studies 
that could assist in the comprehension of the hypothermia role in stroke. In laboratory 
studies, hypothermia is a consistent protective agent. The present chapter shows the 
contribution of hypothermia research in the last years to understand its participation during 
the different stages of the ischemic damage cascade. Blood brain barrier integrity, metabolic 
rate decrease, redox state changes, inflammatory, apoptotic, signalling and gene regulation 
are targets where hypothermia protection participates. Hypothermia is affected by diverse 
factors such as timing, duration and deepness. All these factors contribute to disparity in 
obtained results. However, it is clear that this research is necessary in order to determine the 
exact targets, the time when hypothermia begins and duration of hypothermia. 
Additionally, since brain ischemia is a multifactorial problem and hypothermia has 
demonstrated to decrease damage in several stages of the process, combination therapy is an 
alternative to improve treatments by the extension of the therapeutic time window of 
hypothermia protection.  
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use. Actually, combined mild hypothermia (35ºC) and magnesium is recognized as a 
neuroprotective treatment able to minimize ischemic damage, even in delayed treatments 
(Meloni et al., 2009). 
4.3 Hypothermia and citicoline 
Hypothermia has been combined with other compounds. One of them is citicoline, an 
endogenous compound that has shown to stabilize membrane function and reduce free 
radical generation during ischemia (Rao et al., 2000).  
Mild hypothermia combined with citicoline resulted in an additive effect in attenuating 
apoptosis in focal cerebral ischemia/reperfusion injury. Hypothermia (341ºC) during 
middle cerebral artery occlusion (2 h) followed by 24 h reperfusion was used in combination 
with 4000 mg/kg i.p. citicoline. Combined therapy with citicoline and hypothermia resulted 
in reduced apoptotic cell death before the development of the apoptosome, thus preventing 
apoptosis and neuronal damage. Bcl-2, caspases 3 and 9 as well as Bax proteins were 
immunohistochemistry tested, showing that the use of citicoline with hypothermia is more 
effective than citicoline or hypothermia used alone. A decrease in cerebral injury was 
observed and apparently, the tissue protection is due to the suppression of apoptotic 
processes (Sahin et al., 2010).  
4.4 Hypothermia and ginkgolides 
Despite the neuroprotective role of hypothermia, the combined use of hypothermia with 
protective compounds not always has a synergistic effect. This is the case of hypothermia 
and ginkgolides in astrocytes subjected to ischemia and reperfusion in which hypothermia 
attenuates, rather than enhances, the protective effect of ginkgolides on astrocytes from 
ischemia and reperfusion-induced injury. Co-treatment with different doses of ginkgolides 
at 32 and 28 ºC hypothermia during 24, 48 and 72 h before 24 h ischemia followed by 24 h 
reperfusion showed that the use of ginkgolides without hypothermia treatment had an 
improvement in cell viabilities and in anti-apoptotic properties, and this protective effects 
were not observed in the co-treatment (Fang et al., 2009).  
4.5 Hypothermia and xenon 
Xenon has been considered a great promise used as a neuroprotectant in in vivo and in vitro 
studies. Combined therapy with hypothermia in a neonatal rat hypoxia-ischemia model has 
shown that the combination of 50% xenon and hypothermia of 32°C has a protective effect 
in the restoration of long-term functional outcomes and global histopathology, showing that 
the combined xenon/hypothermia has a greater protection (Hobbs et al., 2008).  
5. Conclusion 
Despite all the efforts to develop pharmacological treatments to contend with cerebral 
ischemic damage, nowadays, there are no efficient treatments to deal with this pathology. 
Non-pharmacological treatments emerge as reasonable approaches to compete against 
ischemic damage.  
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Hypothermia has shown positive results in cardiac arrest and neonatal hypoxic ischemia 
and in patients with acute brain injury. However, there are no large clinical stroke studies 
that could assist in the comprehension of the hypothermia role in stroke. In laboratory 
studies, hypothermia is a consistent protective agent. The present chapter shows the 
contribution of hypothermia research in the last years to understand its participation during 
the different stages of the ischemic damage cascade. Blood brain barrier integrity, metabolic 
rate decrease, redox state changes, inflammatory, apoptotic, signalling and gene regulation 
are targets where hypothermia protection participates. Hypothermia is affected by diverse 
factors such as timing, duration and deepness. All these factors contribute to disparity in 
obtained results. However, it is clear that this research is necessary in order to determine the 
exact targets, the time when hypothermia begins and duration of hypothermia. 
Additionally, since brain ischemia is a multifactorial problem and hypothermia has 
demonstrated to decrease damage in several stages of the process, combination therapy is an 
alternative to improve treatments by the extension of the therapeutic time window of 
hypothermia protection.  
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1. Introduction 
Hypothermia (HT) is one of the most effective neuroprotective therapies for brain injury 
caused by cardiac arrest in humans (Benard et al., 2002), although there is as yet no evidence 
of such an effect of HT on cerebrovascular diseases from a large-scale clinical trial. We 
recently reported the experimental studies on the importance of timing of HT using global 
cerebral ischemia in mice (Doshi et al., 2009, 2011). we summarized our findings in this 
chapter because our results may be relevant to clinical studies. 
2. Experimental methods 
2.1 Global cerebral ischemia using C57BL/6J mice 
Transient forebrain ischemia (global cerebral ischemia), which is induced by occlusion of the 
bilateral common carotid arteries (BCCA) in mice, causes delayed neuronal death in the 
hippocampus and is known as a model of brain injury following transient cardiac arrest 
(Kawase et al., 1999). C57BL/6J mice are widely used as a background strain for genetic 
alterations and have been valuable for investigating the molecular mechanism of delayed 
neuronal death following transient forebrain ischemia (Yang et al., 1997; Tajiri et al., 2004). We 
recently demonstrated that acute brain edema, one of the most important disorders following 
cerebral ischemia, occurred in the forebrain in this C57BL/6J mouse model (Doshi et al., 2009).  
Forebrain ischemia was induced by BCCA occlusion with clips for 15 min under 1 % 
halothane anesthesia in air using a face mask. Rectal temperature was monitored using a 
digital thermometer and maintained at 37±0.5℃ with a heating blanket (normothermia, NT). 
The control mice underwent a sham operation without BCCA occlusion under halothane 
anesthesia for 15 min. 
2.2 Evaluation of delayed neuronal death and acute brain edema 
Delayed neuronal death in the hippocampus 7 days after reperfusion was determined by 
both hematoxylin-eosin (HE) staining and TdT-mediated dUTP-biotin nick end labeling 
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of such an effect of HT on cerebrovascular diseases from a large-scale clinical trial. We 
recently reported the experimental studies on the importance of timing of HT using global 
cerebral ischemia in mice (Doshi et al., 2009, 2011). we summarized our findings in this 
chapter because our results may be relevant to clinical studies. 
2. Experimental methods 
2.1 Global cerebral ischemia using C57BL/6J mice 
Transient forebrain ischemia (global cerebral ischemia), which is induced by occlusion of the 
bilateral common carotid arteries (BCCA) in mice, causes delayed neuronal death in the 
hippocampus and is known as a model of brain injury following transient cardiac arrest 
(Kawase et al., 1999). C57BL/6J mice are widely used as a background strain for genetic 
alterations and have been valuable for investigating the molecular mechanism of delayed 
neuronal death following transient forebrain ischemia (Yang et al., 1997; Tajiri et al., 2004). We 
recently demonstrated that acute brain edema, one of the most important disorders following 
cerebral ischemia, occurred in the forebrain in this C57BL/6J mouse model (Doshi et al., 2009).  
Forebrain ischemia was induced by BCCA occlusion with clips for 15 min under 1 % 
halothane anesthesia in air using a face mask. Rectal temperature was monitored using a 
digital thermometer and maintained at 37±0.5℃ with a heating blanket (normothermia, NT). 
The control mice underwent a sham operation without BCCA occlusion under halothane 
anesthesia for 15 min. 
2.2 Evaluation of delayed neuronal death and acute brain edema 
Delayed neuronal death in the hippocampus 7 days after reperfusion was determined by 
both hematoxylin-eosin (HE) staining and TdT-mediated dUTP-biotin nick end labeling 
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(TUNEL) assay. To evaluate the acute brain edema, the water content in the forebrain 1 hour 
after reperfusion was determined by the weight differences between wet and dry samples. 
The percentage of water in the forebrain was calculated as follows: ((wet weight-dry weight) 
/ wet weight)×100. 
2.3 Induction of hypothermia 
HT during ischemia was spontaneously induced by removing the heating blanket, and the 
mice were allowed to recover from anesthesia at room temperature (23-25℃) until 1 hr after 
reperfusion. In contrast, artificial HT after reperfusion (rHT) was induced by placing the 
mice on a refrigerant, which was maintained at 18-19℃ until 1 hr after reperfusion in a 
styrofoam box. In NT mice, rectal temperature was maintained at 37±0.5℃ during ischemia. 
In HT mice, rectal temperature significantly decreased by 28-30℃ during ischemia. On the 
other hand, the patterns of the change in rectal temperature after reperfusion in rHT mice 
were significantly lower than that in HT mice (Fig. 1). 
 
Fig. 1. Changes in rectal temperature after reperfusion in both HT and rHT mice. 
Forebrain ischemia was induced by BCCA occlusion for 15 min under 1 % halothane 
anesthesia in both HT and rHT mice, as described in the Materials and Methods. The control 
mice (Control) underwent a sham operation without BCCA occlusion under halothane 
anesthesia for 15 min. The rectal temperature was monitored 0, 30, and 60 min after 
reperfusion. Data are expressed as mean ± SE (control : n=3, I-R : n=7). Statistical analysis 
was performed by analysis of variance (ANOVA) of repeated measures for the comparison 
of the changes in rectal temperature between the HT and rHT groups. 
3. Effect of hypothermia during ischemia on occurrence of delayed neuronal 
death 
HT during ischemia has been shown to protect against delayed neuronal death in several 
animal models of cerebral ischemia including the global cerebral ischemia in C57BL/6J mice 
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delayed neuronal death in the hippocampus under our experimental conditions. As shown 
in Table 1, there were no histological changes in the hippocampus 7 d after reperfusion in all 
HT mice, whereas delayed neuronal death occurred in three of the four NT mice. In this 
model, controlled NT during cerebral ischemia is important for the induction of neuronal 
death following cerebral ischemia (Ohtaki et al., 2006), supported by data revealing that HT 
during ischemia protects against neuronal death in the BCCA occlusion C57BL/6J mouse 
model (Yang et al., 1997). Our data in this study were consistent with previous data. 
However, the neuroprotective effect of HT after ischemia-reperfusion still remains to be 
solved in NT mice. 
  
Mice The number of delayed neuronal death-positive mice / total mice 
NT (ischemia 15 min) 3 / 4 
HT (ischemia 15 min) 0 / 5* 
HT (ischemia 45 min) 0 / 5* 
*p<0.05 vs NT (Fisher’s exact test) 
Table 1. Effect of HT during ischemia on occurrence of delayed neuronal death in 
hippocampus of C57BL/6J mice. 
4. Effect of timing of hypothermia on occurrence of acute brain edema 
Brain edema, defined as an increase in brain water content, is one of the major reperfusion 
pathologies following cerebral ischemia along with delayed neuronal death and infarction. 
The increase in brain water content results in serious pathologic situations such as elevation 
of intracranial pressure and reduction of cerebral blood flow, and subsequently causes 
cerebral herniation and death (Kempski, 2001). Even now, the treatment options for brain 
edema are limited to the use of hyperosmotic agents, such as glycerol or mannitol, and 
surgical decompression. That is, despite the clinical significance of brain edema, the 
mechanisms of brain water transport and edema formation in ischemic injuries remain 
unclear.  
Several studies have shown that HT, which was monitored by measuring rectal 
temperature, protects against delayed neuronal death and infarction (Maier et al., 1998; 
Tsuchiya et al., 2002), but few studies have investigated the effects of HT on brain edema in 
mouse models of cerebral ischemia. Therefore, we investigated the effect of HT on the 
occurrence of acute brain edema following the global cerebral ischemia in C57BL/6J mice. 
4.1 Effect of hypothermia during ischemia on occurrence of acute brain edema 
We first investigated the effect of HT during global cerebral ischemia on the occurrence of 
acute brain edema in the C57BL/6J mouse model. In both NT and HT mice, the water 
content 1 h after reperfusion was significantly higher than that of the control mice, but no 
significant differences were detected between the NT and HT mice (Fig. 2). This data 
indicated the ineffectiveness of HT during ischemia against acute brain edema, unlike its 
effect on neuronal death, suggesting that HT during ischemia may not necessarily be an 
effective therapy for all reperfusion pathologies following cerebral ischemia. However, we 
found that the rectal temperature of the HT mice recovers from HT during ischemia to NT 
mice levels within 1 hr after reperfusion. Therefore, we speculated that the ineffectiveness of 
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HT during ischemia against acute brain edema is due to the immediate recovery of rectal 
temperature after reperfusion at room temperature in the C57BL/6J mouse model. 
 
Fig. 2. Effect of HT during ischemia on occurrence of brain edema in C57BL/6J mice. 
Forebrain ischemia was induced by BCCA occlusion for 15 min under 1 % halothane 
anesthesia in both normothermia (NT) and hypothermia (HT). The control mice (Control) 
underwent a sham operation without BCCA occlusion under halothane anesthesia for 15 
min. The water content in the forebrain treated with BCCA occlusion for 15 min and 1 h 
after reperfusion (I-R) was measured. Data are expressed as the mean ± SE (control : n=3, I-
R : n=5). Statistical analysis was performed by two-way ANOVA and an unpaired Student’s 
t-test for comparison between control and I-R mice groups (*p<0.01 vs control). 
4.2 Effect of hypothermia after reperfusion on occurrence of acute brain edema 
 We next investigated the effect of rHT on acute brain edema in the C57BL/6J mouse model. 
The water content 1 hr after reperfusion was significantly higher in both the HT and rHT 
mice than in the control mice (p<0.05). However, the water content 1 hr after reperfusion 
was significantly lower in the rHT mice than in the HT mice (Fig. 3). Already, we have 
shown an increase in brain water content during BCCA occlusion in a previous study (Doshi 
et al., 2009). Therefore, these results indicated that rHT suppresses the additional increase in 
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Fig. 3. Effect of HT after reperfusion on occurrence of brain edema in the BCCA occlusion 
C57BL/6J mouse model.  
Forebrain ischemia was induced by BCCA occlusion for 15 min under 1 % halothane 
anesthesia in both HT and rHT mice. The control mice (Control) underwent a sham 
operation without BCCA occlusion under halothane anesthesia for 15 min. The water 
content in the forebrain treated with BCCA occlusion for 15 min and 1 hr after reperfusion 
(I-R) was measured. Data are expressed as mean ± SE (control : n=3, I-R : n=7).  
Statistical analysis was performed by two-way ANOVA and the unpaired Student’s t-test  
(*p<0.05 vs HT). 
5. Conclusion 
HT during ischemia protects against delayed neuronal death in the hippocampus. In 
addition, rHT suppresses aggravation of acute brain edema following global cerebral 
ischemia in mice. Therefore, these findings indicate that the timing of therapeutic HT differs 
depending on the pathology following global cerebral ischemia. Further experimental 
studies should be performed to establish a standard method for the clinical application of 
therapeutic HT because there are still several controversial issues in the development of 
cooling techniques and in the determination of optimal duration and temperature. 
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1. Introduction 
Cerebral ischemia is a serious dynamic event in the brain involving heterogeneous cell 
types. Neuroprotective agents represent a potential approach for the treatment of acute 
stroke. Presently, recombinant tissue plasminogen activator (rtPA) is the only drug that is 
approved for the management of acute ischaemic stroke, except for the antioxidant 
Edaravone in Japan (Yoshida et al., 2006). Although stroke patients can receive rtPA therapy 
within the initial 3 h therapeutic window, there is an increased risk of intracranial 
haemorrhage, disruption of the blood brain barrier, seizures, or the progression of neuronal 
damage (Laloux, 2001). Thus, there is a continued need to explore novel neuroprotective 
strategies for the management of ischemic stroke. A large number of therapeutic agents 
have been tested, including N-methyl-D-aspartate receptor antagonists, calcium channel 
blockers, and antioxidants, for the management of stroke, but none has provided significant 
neuroprotection in clinical trials (Green et al., 2003; Kidwell et al., 2001). 
Therapeutic hypothermia lowers a patient‘s body temperature in order to reduce the risk of 
the ischemic injury to the brain following a period of insufficient blood flow (Lampe and 
Becker, 2011; Yenari and Hemmen, 2010). The normal human adult body temperature is 
between 34.4–37.8°C and is maintained at a constant level through homeostasis or 
thermoregulation. Therapeutic hypothermia is defined as the artificial maintenance of the 
body temperature at <35°C and is subdivided into 4 different categories: mild (32–35°C), 
moderate (28–32°C), severe (20–28°C), and profound (<20°C). Nowadays, mild-to-moderate 
hypothermia (31–33°C) is usually applied for neuroprotection. The practical usage of 
hypothermia for clinical purposes was begun by the ancient Egyptians, Greeks, and Romans 
(Polderman, 2004). Ancient people observed the clinical usefulness of hypothermia for 
accidents and applied it to various diseases/symptoms. Modern clinical interest in 
hypothermia began in the 1930s with the description of the successful rescue of a drowned 
person with hypothermia after a prolonged period of asphyxia. After the first scientific 
report in 1945, which described the clinical application of hypothermia to patients with a 
severe head injury, hypothermia was subsequently applied to intracerebral aneurysm 
surgery and cerebral protection during complete circulatory arrest.  
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In the past few decades, the neuroprotective effects of hypothermia have been well 
established in experimental animals (Kawai et al., 2000; Miyazawa et al., 2003; Yanamoto et 
al., 2001) and in patients with cardiac arrest (THCASG, 2002 and Bernard et al., 2002). The 
initiation of moderate hypothermia within a few hours of severe ischemia can reduce the 
subsequent neuronal death and profoundly improve behavioural recovery. Although 
hypothermia is the only clinical intervention that appears to be neuroprotective after the 
initial injury, its key mechanisms have not been clarified. In other words, the 
neuroprotective effects of hypothermia provide many insights into the pathology of stroke, 
and thus may reveal clues for novel drug targets. 
2. Neuroprotection against cerebral ischemia by hypothermia 
Ischemia and cerebral hemorrhage are the two main causes of strokes. Ischemia accounts for 
~85% of all reported incidents of stroke, and occurs when a thrombus or embolus blocks 
cerebral blood flow, resulting in cerebral ischemia and consequently neuronal damage and 
cell death. Conversely, hemorrhage occurs following the rupture of any blood vessel in the 
brain, resulting in rapid cerebral damage, and accounts for the remaining 15% of stroke 
cases. In each situation, the interruption of blood flow to the brain results in the reduced 
supply of oxygen and nutrients to the neurons. At the molecular level, the pathophysiology 
of ischemia is complicated and involves multiple sequential steps: progressive neural injury 
beginning with the activation of glutamate receptors, followed by the production and 
release of proinflammatory cytokines, nitric oxide (NO), free oxygen radicals, and proteases. 
As a result, neurons in an ischemic brain suffer irreversible and fatal damage. From the 
electrophysiological viewpoint, neurons depolarize massively giving rise to anoxic 
depolarization (Bureš et al., 1974) or to peri-infarct depolarizations (Gyngell et al., 1995). 
They are both characterized by swelling of neurons, massive influx of Na+ and Ca2+ into 
neurons, massive release of K+ into the interstitial space, release of glutamate, acidification 
of the tissue (Somjen, 2001; Dreier, 2011; Balestrino, 1995).  
The lack of blood supply results in two identifiable areas, namely the core and the 
penumbra. The core is a neuronal dead area that is not therapeutically accessible, whereas 
the penumbra is a still salvageable zone (Bandera et al., 2006). As a consequence of the 
reduced blood supply inside the core, adenosine triphosphate (ATP) levels are reduced, 
leading to the depression of cellular metabolism. Energy loss results in impaired ion 
homeostasis, which leads to rapid depolarization and a large influx of calcium and 
potassium ions. The increased levels of intracellular calcium induces the activation of 
excitotoxic glutamatergic transmission, NO synthase, caspase, xanthine oxidase, and the 
release of reactive oxygen species. Glutamate release activates phospholipases, 
phospholipid hydrolysis, and the release of arachidonic acid. The generation of free radicals 
and lipid peroxidation and the activation of immediate early genes, such as c-fos, c-jun, and 
the inflammatory cascade, lead to progressive ischemic damage, resulting in necrotic as well 
as apoptotic cell death. Conversely, the penumbra represents viable tissue surrounding the 
core and receives a trivial amount of blood from collateral arteries; therefore, the penumbra 
is the target for drug intervention and has the potential for recovery. 
Precisely controlled mild hypothermia has been proven to have neuroprotective properties 
and reduces the risk of the detrimental effects that often occur during profound 
hypothermia. Large numbers of the phenomena observed in ischemic brains can be 
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ameliorated by hypothermia, including the reduction of oxygen radical production, with the 
subsequent reduction in peroxidase damage to lipids, proteins, and DNA, thereby 
supporting the behavioral recovery of patients. Hypothermia also decreases microglial 
activation, ischemic depolarization, cerebral metabolic demand for oxygen, and the release 
of glycerin and excitatory amino acids. We and others have demonstrated that inflammation 
potentiates cerebral ischemic injury and that hypothermia can reduce inflammation by 
suppressing the infiltration of neutrophils into ischemic regions (Ohta et al., 2007; Shintani 
et al., 2011; Terao et al., 2009; Zheng and Yonari, 2004). Furthermore, the inhibition of 
reactive oxygen species production by leukocytes and microglia in the ischemia brain (Kil et 
al., 1996), NF-κB activation (Han et al., 2003), neutrophil infiltration (Wang et al., 2002), and 
cytochrome c release (Yenari et al., 2002) has been also reported in hypothermia-treated 
ischemic rat brains. 
Recently, Lin et al., (2011) reported that whole-body hypothermia broadens the therapeutic 
window of intranasally administered recombinant human insulin-like growth factor 1 (IGF-
1) in a neonatal rat cerebral hypoxia–ischemia model. They ligated the right common carotid 
artery of postnatal day 7 rat pups, followed by 8% oxygen inhalation for 2 h. After the 
hypoxia-ischemia treatment, the pups were divided into 2 groups and maintained under 
different temperatures, room temperature (24.5 ± 0.2°C) and a cool environment (21.5 ± 
0.3°C), for 2 or 4 h before being returned to room temperature. IGF-1 was administered 
intranasally at 1 h intervals starting at 0, 2, or 4 h after hypothermia. Although the 
administration of hypothermia or IGF-1 alone at 2 h after hypoxia-ischemia treatment did 
not provide neuroprotection, the combined treatment of hypothermia and IGF-1 
significantly protected the neonatal rat brain from hypoxia-ischemia injury. Hypothermia 
extended the therapeutic window of IGF-1 to 6 h after hypoxia-ischemia. It was observed 
that the combination therapy decreased the infiltration of polymorphonuclear leukocytes, 
the activation of microglia/macrophages, and the attenuation of nuclear factor kappa-B 
(NF-κB) activation. These findings broaden the potential application of hypothermia, i.e., 
not only for its neuroprotective effects but also for its synergistic effects by the combined use 
of hypothermia with already existing therapeutic drugs. 
3. Molecular mechanisms of hypothermia-induced neuroprotection 
3.1 Proteins influenced by hypothermia 
The detailed molecular mechanisms underlying the neuroprotection induced by 
hypothermia against ischemia have been approached by degrees. In most cases, molecules, 
whose expression is known to be affected by ischemia, have been identified and the effects 
of hypothermia on the molecule have been explored retrospectively. Table 1 lists the 
molecules whose expression is affected by hypothermia during ischemia and/or 
reperfusion. The majority of these proteins are apoptosis, inflammation-related, and 
signalling molecules, such as kinases and transcription factors. For example, apoptosis-
related molecules, such as B-cell lymphoma 2 (Bcl2), Bcl-associated X protein (Bax), 
caspases, calpains, cytochrome c, and Fas/Fas ligand (FasL), are up- or down-regulated by 
hypothermia in accordance with its neuroprotective effect, thereby preventing neuronal cell 
death. Inflammatory molecules, such as tumor necrosis factor alpha (TNF), interleukin 
(IL)-1, IL-6, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-3  
 
Advances in the Treatment of Ischemic Stroke 
 
44
In the past few decades, the neuroprotective effects of hypothermia have been well 
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release of proinflammatory cytokines, nitric oxide (NO), free oxygen radicals, and proteases. 
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Table 1 Proteins of which expression and/or modification are altered by ischemia and 
hypothermia 
alpha (MIP-3), and NF-B, are also up-regulated after middle cerebral artery occlusion 
(MCAO) and down-regulated by hypothermia. These molecules are considered to enhance 
cell damage through the activation of microglia and/or astrocytes. Recently, more direct 
and dynamic inflammatory changes have been speculated to be induced by hypothermia 
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during ischemia. And now it has become clear that the neuroinflammatory response could 
be detrimental and that even peripheral immune responses can be regulated by the brain 
(Ceulemans et al., 2011). 
Another type of change evoked by hypothermia in ischemic brains is protein modification. 
For instance, Li et al. (2011) reported that hypothermia reduced the activation of 5′ 
adenosine monophosphate-activated protein kinase (AMPK), a ubiquitously distributed 
kinase, by the dephosphorylation of its regulatory residues in ischemic mice. They showed 
that hypothermic neuroprotection was ameliorated by compound C, an AMPK inhibitor, 
and that genetic deletion of one of the catalytic isoforms of AMPK completely reversed the 
effects of hypothermia on stroke outcome after acute and chronic survival. Their study 
provides evidence that hypothermia exerts its protective effects, in part, by inhibiting 
AMPK activation, at least in experimental focal stroke. AMPK is known to participate in an 
energy sensing cascade and to serve as a master regulator of metabolism in response to ATP 
depletion. Recently, additional roles of AMPK in a variety of other cellular processes have 
been revealed, in the cytoplasm and nucleus, as a controllor of cell polarity and a 
transcriptional regulator. A more interesting function of AMPK in signaling pathways is its 
role as a responder to cellular stress and damage, and the relevance of AMPK signaling in 
various diseases is becoming a hot topic in the investigation of ischemic physiology. 
3.2 Inflammatory proteins 
3.2.1 Cytokines 
Neuroinflammation is involved in the pathogenesis of many central nervous system (CNS) 
diseases. In stroke, excess inflammatory activation results in brain injury and ultimately causes 
severe neuronal apoptosis (Zheng and Yonari, 2004). Anti-inflammatory therapies using 
immunosuppressants (Furuichi et al., 2004) or biogenetics, e.g., an anti-ICAM-1-neutralizing 
antibody (Matsuo et al., 1994), have been applied in preclinical and clinical trials. In this 
context, the effect of hypothermia on neuroinflammation has been vigorously explored. 
Webster et al. (2009) measured the levels of proinflammatory cytokines, such as TNF-α and 
IL-β, in microglial culture supernatants after stimulation with lipopolysaccharide (LPS) or 2 
h oxygen–glucose deprivation (OGD) exposure followed by 24 h reperfusion. There was a 
marked increase in the production and release of inflammatory cytokines by microglia 
following LPS stimulation and OGD, which was attenuated by hypothermia. Glutamate, a 
major neurotransmitter, was also released from microglia stimulated with LPS at 37°C, but 
reduced levels were observed when they were stimulated with LPS at 33°C. IL-18 is another 
proinflammatory cytokine that may contribute to brain injury. Fukui et al. (2006) showed 
that the effects of hypothermia treatment after hypoxia-ischemia (rectal temperature of 32°C 
for 24 h) on IL-18 expression. IL-18 expression in the ipsilateral hemispheres of the 
normothermia group significantly increased at 72 h after hypoxia-ischemia compared with 
controls; however, IL-18 expression was significantly decreased in the hypothermia group. 
NF-kB is a transcription factor that is activated after cerebral ischemia. The activation of NF-
kB leads to the expression of many inflammatory genes involved in the pathogenesis of 
stroke. Yenari and Han (2006) showed that hypothermia decreases the translocation of NF-
kB from the cytoplasm to nucleus and its binding activity to NF-kB regulatory proteins. 
Mild hypothermia appears to suppress the phosphorylation of IkB-, an NF-kB inhibitory 
 

















No change No change 
8 min hypoxia or 
ischemia, and 30 min or 
4 h of cerebral 
reperfusion 









10 min ischemia 
followed by 1-3 d 
reperfusion 










10 min ischemia 
followed by 1-3 d 
reperfusion 









36°C in a 
step-by-step 
manner. 
Decrease Increase 1 h MCAO Colbourne  et al., 2003 





Increase Decrease 1 h MCAO Han et al., 2002 
GPR78 34±0.5°C  Decrease Increase 
ischemic for 15 min and 
then reperfused for  
3 h under 



















15 min ischemia Teilum et al., 2007 
N.D. = not determined. 
Table 1 Proteins of which expression and/or modification are altered by ischemia and 
hypothermia 
alpha (MIP-3), and NF-B, are also up-regulated after middle cerebral artery occlusion 
(MCAO) and down-regulated by hypothermia. These molecules are considered to enhance 
cell damage through the activation of microglia and/or astrocytes. Recently, more direct 
and dynamic inflammatory changes have been speculated to be induced by hypothermia 
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during ischemia. And now it has become clear that the neuroinflammatory response could 
be detrimental and that even peripheral immune responses can be regulated by the brain 
(Ceulemans et al., 2011). 
Another type of change evoked by hypothermia in ischemic brains is protein modification. 
For instance, Li et al. (2011) reported that hypothermia reduced the activation of 5′ 
adenosine monophosphate-activated protein kinase (AMPK), a ubiquitously distributed 
kinase, by the dephosphorylation of its regulatory residues in ischemic mice. They showed 
that hypothermic neuroprotection was ameliorated by compound C, an AMPK inhibitor, 
and that genetic deletion of one of the catalytic isoforms of AMPK completely reversed the 
effects of hypothermia on stroke outcome after acute and chronic survival. Their study 
provides evidence that hypothermia exerts its protective effects, in part, by inhibiting 
AMPK activation, at least in experimental focal stroke. AMPK is known to participate in an 
energy sensing cascade and to serve as a master regulator of metabolism in response to ATP 
depletion. Recently, additional roles of AMPK in a variety of other cellular processes have 
been revealed, in the cytoplasm and nucleus, as a controllor of cell polarity and a 
transcriptional regulator. A more interesting function of AMPK in signaling pathways is its 
role as a responder to cellular stress and damage, and the relevance of AMPK signaling in 
various diseases is becoming a hot topic in the investigation of ischemic physiology. 
3.2 Inflammatory proteins 
3.2.1 Cytokines 
Neuroinflammation is involved in the pathogenesis of many central nervous system (CNS) 
diseases. In stroke, excess inflammatory activation results in brain injury and ultimately causes 
severe neuronal apoptosis (Zheng and Yonari, 2004). Anti-inflammatory therapies using 
immunosuppressants (Furuichi et al., 2004) or biogenetics, e.g., an anti-ICAM-1-neutralizing 
antibody (Matsuo et al., 1994), have been applied in preclinical and clinical trials. In this 
context, the effect of hypothermia on neuroinflammation has been vigorously explored. 
Webster et al. (2009) measured the levels of proinflammatory cytokines, such as TNF-α and 
IL-β, in microglial culture supernatants after stimulation with lipopolysaccharide (LPS) or 2 
h oxygen–glucose deprivation (OGD) exposure followed by 24 h reperfusion. There was a 
marked increase in the production and release of inflammatory cytokines by microglia 
following LPS stimulation and OGD, which was attenuated by hypothermia. Glutamate, a 
major neurotransmitter, was also released from microglia stimulated with LPS at 37°C, but 
reduced levels were observed when they were stimulated with LPS at 33°C. IL-18 is another 
proinflammatory cytokine that may contribute to brain injury. Fukui et al. (2006) showed 
that the effects of hypothermia treatment after hypoxia-ischemia (rectal temperature of 32°C 
for 24 h) on IL-18 expression. IL-18 expression in the ipsilateral hemispheres of the 
normothermia group significantly increased at 72 h after hypoxia-ischemia compared with 
controls; however, IL-18 expression was significantly decreased in the hypothermia group. 
NF-kB is a transcription factor that is activated after cerebral ischemia. The activation of NF-
kB leads to the expression of many inflammatory genes involved in the pathogenesis of 
stroke. Yenari and Han (2006) showed that hypothermia decreases the translocation of NF-
kB from the cytoplasm to nucleus and its binding activity to NF-kB regulatory proteins. 
Mild hypothermia appears to suppress the phosphorylation of IkB-, an NF-kB inhibitory 
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protein, by decreasing the expression and activity of IkB kinase- (IKK). As a consequence, 
hypothermia suppressed the expression of 2 NF-kB target genes, inducible nitric oxide 
synthase (iNOS) and TNF. 
We previously determined that the therapeutic time window of post-ischemia mild 
hypothermia was 4 h after reperfusion (Ohta et al., 2007). Thus, we considered that the gene 
expression changes that occur before the 4 h time point might be important for the 
neuroprotective effect induced by mild hypothermia, even though the neuroprotection 
afforded by hypothermia alone during this period was found to be insufficient. After a 
series of investigations with hypothermia, we hypothesized that the gene expression 
changes that were observed after the 4 h timepoint, following the discontinuation of 
hypothermia, are related to the ischemic damage detected at 2 d after MCAO. Genes that 
were upregulated after the 4 hr timepoint, including early growth response-2 (Egr-2), 
neurotransmitter-induced early genes-1 (Ania-1), and macrophage inflammatory protein-3 (MIP-
3, were found to be important for the neuroprotection afforded by hypothermia. We 
selected the following 12 genes that might exert substantial neuroprotective activity: c-Fos, 
Egr-1, Egr-4, neuron-derived orphan receptor-1 (Nor1), MAP kinase phosphatase-1 (MKP-1), MKP-
CPG21, MIP-3, monocyte chemotactic protein-1 (MCP-1), brain-derived neurotrophic factor 
(BDNF), IL-1, Ania-1, and Ania-7. Egr-1 is known as a master switch that is activated by 
ischemia to trigger the expression of pivotal regulators of inflammation, e.g., IL-1, MCP-1, 
and MIP-2, in addition to coagulation and vascular hyperpermeability. 
3.2.2 Chemokines 
Chemokines are also well known to be detrimental factors in the brain. For instance, MCP-1 
is considered to be a promising drug target due to its possible role in exacerbating ischemic 
injury, controlling blood-brain barrier permeability, and driving leukocyte infiltration into 
the brain parenchyma in stroke (Dimitrijevic et al., 2006, 2007; Schilling et al., 2009). We have 
observed that MCP-1 gene expression was upregulated by ischemia and that the expression 
stimulated by ischemia was supressed by hypothermia (Ohta et al., 2007). 
We further conducted comprehensive gene expression analyses of ischemic rat brains with or 
without hypothermia by using a rat ischemia-reperfusion model in order to elucidate the 
underlying mechanisms and discover novel target molecules. In this study, we revealed that 
cerebral MIP-3α and CC-chemokine receptor 6 (CCR6) genes were significantly induced in the 
core and penumbra regions of MCAO rat brains, and hypothermia suppressed the expression 
of both genes (Terao et al., 2009). MIP-3α is expressed in macrophages, dendritic cells, and 
lymphocytes. Depending on the conditions, MIP-3α can act constitutively or inducibly and 
serves as a chemoattractant, especially in epithelial immunological systems such as those of 
the skin and mucosa (Charbonnier et al., 1999; Cook et al., 2000). In the CNS, MIP-3α 
expression has been reported in autoimmune encephalomyelitis (Ambrosini et al., 2003) and 
stroke patients (Lu et al., 2004; Utans-Schneitz et al., 1998), but its full role has not yet been 
determined. CCR6, the sole receptor for MIP-3α, is expressed in multiple leukocyte subsets, 
and is implicated in diverse inflammatory responses in animal models, such as allergic airway 
disorders, inflammatory bowel disease, and autoimmune encephalitis (Schutyser et al., 2003). 
Strikingly, the intracerebral administration of an anti-rat MIP-3α-neutralizing antibody 
significantly reduced infarct volumes in MCAO rats compared with those of vehicle- and 
control mouse IgG-treated rats, suggesting that MIP-3α-CCR6 signaling is dominant in the 
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neuroinflammatory cascades of brain ischemia. Interestingly, the administration of MIP-3α 
into the striatum induced CCR6 gene expression in a dose-dependent manner, but not CCR1 or 
CCR2 expression. The intrastriatal injection of IL-1β and TNF-α into control rats upregulated 
MIP-3 and CCR6 mRNA expression levels in a sequential fashion. Taken together with the 
robust induction of IL-1β and TNF-α in ischemic brains during an acute phase of MCAO prior 
to MIP-3α expression, these cytokines may directly evoke MIP-3α production in the CNS. 
Furthermore, MIP-3 mRNA expression was markedly induced by IL-1β and TNF-α in rat 
astrocytes, but not in microglia or neurons. Astrocytes stimulated by ischemic stress turn into 
their active form, expressing glial fibrillary acidic protein (GFAP), and appear around the 
damaged area after ischemic injury (Zoli et al., 1997). Rat primary microglia constitutively 
express the CCR6 gene under normal culture conditions, while astrocytes and neurons do not. 
Interestingly, we found that the expression of iNOS and IL-1β was induced in MIP-3α-treated 
microglia. Microglia are activated and accumulate around the injured area following ischemia 
(Wood, 1995). We observed that MIP-3α was produced by rat primary cultured astrocytes in 
response to IL-1β and TNF-α treatment, while hypothermia significantly suppressed the 
expression of both cytokines. Therefore, the activation of astrocytes and microglia may 
accelerate brain injury-induced neuroinflammation via MIP-3α-CCR6 signaling, whereas 
hypothermia suppresses this signaling. The physiological roles of MIP-3α-CCR6 signaling in 
the CNS have yet to be fully determined because various roles for chemokines in the brain 
have recently been proposed, e.g., neurotransmitters and neuromodulators (de Haas et al., 
2007; Rostène et al., 2007). The interactions between MIP-3α-CCR6 signaling and other 
pathways involved in ischemic pathology, e.g., excitotoxicity, acidotoxicity, oxidative stress, 
and apoptosis, should also be examined.  
3.3 Apoptotic proteins 
Apoptosis is another important factor for ischemic damage because of its contribution to the 
cell death subsequent to ischemia/reperfusion injury (Broughton et al., 2009). To date, 
mitochondrial dysfunction, oxidative stress, and impaired cerebral energy metabolism have 
been observed during the neuronal cell death that is responsible for much of the poor 
neurologic outcome from these events. Recent studies using in vitro and in vivo neuronal cell 
death models point toward several molecular mechanisms that are either induced or 
promoted by the oxidative modification of macromolecules, including the consumption of 
cytosolic and mitochondrial nicotinamide adenine dinucleotide (NAD+) by poly-ADP ribose 
polymerase (PARP), opening of the mitochondrial inner membrane permeability transition 
pore, and the inactivation of key, rate-limiting metabolic enzymes, such as the pyruvate 
dehydrogenase complex. In addition, the relative abundance of proapoptotic proteins in 
immature brains and neurons, and particularly within their mitochondria, predisposes these 
cells to the intrinsic, mitochondrial pathway of apoptosis, which is mediated by the Bax- or 
Bak-triggered release of proteins into the cytosol through the mitochondrial outer 
membrane. On the basis of these cell dysfunction and death pathways, several approaches 
toward neuroprotection are being investigated that show promise for their future clinical 
application. These strategies include minimizing oxidative stress to avoid unnecessary 
hypoxia, promoting aerobic energy metabolism by the repletion of NAD+, and providing 
alternative oxidative fuels, e.g., ketone bodies, directly interfering with apoptotic pathways 
in mitochondria, and pharmacologically inducing antioxidant and anti-inflammatory gene 
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protein, by decreasing the expression and activity of IkB kinase- (IKK). As a consequence, 
hypothermia suppressed the expression of 2 NF-kB target genes, inducible nitric oxide 
synthase (iNOS) and TNF. 
We previously determined that the therapeutic time window of post-ischemia mild 
hypothermia was 4 h after reperfusion (Ohta et al., 2007). Thus, we considered that the gene 
expression changes that occur before the 4 h time point might be important for the 
neuroprotective effect induced by mild hypothermia, even though the neuroprotection 
afforded by hypothermia alone during this period was found to be insufficient. After a 
series of investigations with hypothermia, we hypothesized that the gene expression 
changes that were observed after the 4 h timepoint, following the discontinuation of 
hypothermia, are related to the ischemic damage detected at 2 d after MCAO. Genes that 
were upregulated after the 4 hr timepoint, including early growth response-2 (Egr-2), 
neurotransmitter-induced early genes-1 (Ania-1), and macrophage inflammatory protein-3 (MIP-
3, were found to be important for the neuroprotection afforded by hypothermia. We 
selected the following 12 genes that might exert substantial neuroprotective activity: c-Fos, 
Egr-1, Egr-4, neuron-derived orphan receptor-1 (Nor1), MAP kinase phosphatase-1 (MKP-1), MKP-
CPG21, MIP-3, monocyte chemotactic protein-1 (MCP-1), brain-derived neurotrophic factor 
(BDNF), IL-1, Ania-1, and Ania-7. Egr-1 is known as a master switch that is activated by 
ischemia to trigger the expression of pivotal regulators of inflammation, e.g., IL-1, MCP-1, 
and MIP-2, in addition to coagulation and vascular hyperpermeability. 
3.2.2 Chemokines 
Chemokines are also well known to be detrimental factors in the brain. For instance, MCP-1 
is considered to be a promising drug target due to its possible role in exacerbating ischemic 
injury, controlling blood-brain barrier permeability, and driving leukocyte infiltration into 
the brain parenchyma in stroke (Dimitrijevic et al., 2006, 2007; Schilling et al., 2009). We have 
observed that MCP-1 gene expression was upregulated by ischemia and that the expression 
stimulated by ischemia was supressed by hypothermia (Ohta et al., 2007). 
We further conducted comprehensive gene expression analyses of ischemic rat brains with or 
without hypothermia by using a rat ischemia-reperfusion model in order to elucidate the 
underlying mechanisms and discover novel target molecules. In this study, we revealed that 
cerebral MIP-3α and CC-chemokine receptor 6 (CCR6) genes were significantly induced in the 
core and penumbra regions of MCAO rat brains, and hypothermia suppressed the expression 
of both genes (Terao et al., 2009). MIP-3α is expressed in macrophages, dendritic cells, and 
lymphocytes. Depending on the conditions, MIP-3α can act constitutively or inducibly and 
serves as a chemoattractant, especially in epithelial immunological systems such as those of 
the skin and mucosa (Charbonnier et al., 1999; Cook et al., 2000). In the CNS, MIP-3α 
expression has been reported in autoimmune encephalomyelitis (Ambrosini et al., 2003) and 
stroke patients (Lu et al., 2004; Utans-Schneitz et al., 1998), but its full role has not yet been 
determined. CCR6, the sole receptor for MIP-3α, is expressed in multiple leukocyte subsets, 
and is implicated in diverse inflammatory responses in animal models, such as allergic airway 
disorders, inflammatory bowel disease, and autoimmune encephalitis (Schutyser et al., 2003). 
Strikingly, the intracerebral administration of an anti-rat MIP-3α-neutralizing antibody 
significantly reduced infarct volumes in MCAO rats compared with those of vehicle- and 
control mouse IgG-treated rats, suggesting that MIP-3α-CCR6 signaling is dominant in the 
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neuroinflammatory cascades of brain ischemia. Interestingly, the administration of MIP-3α 
into the striatum induced CCR6 gene expression in a dose-dependent manner, but not CCR1 or 
CCR2 expression. The intrastriatal injection of IL-1β and TNF-α into control rats upregulated 
MIP-3 and CCR6 mRNA expression levels in a sequential fashion. Taken together with the 
robust induction of IL-1β and TNF-α in ischemic brains during an acute phase of MCAO prior 
to MIP-3α expression, these cytokines may directly evoke MIP-3α production in the CNS. 
Furthermore, MIP-3 mRNA expression was markedly induced by IL-1β and TNF-α in rat 
astrocytes, but not in microglia or neurons. Astrocytes stimulated by ischemic stress turn into 
their active form, expressing glial fibrillary acidic protein (GFAP), and appear around the 
damaged area after ischemic injury (Zoli et al., 1997). Rat primary microglia constitutively 
express the CCR6 gene under normal culture conditions, while astrocytes and neurons do not. 
Interestingly, we found that the expression of iNOS and IL-1β was induced in MIP-3α-treated 
microglia. Microglia are activated and accumulate around the injured area following ischemia 
(Wood, 1995). We observed that MIP-3α was produced by rat primary cultured astrocytes in 
response to IL-1β and TNF-α treatment, while hypothermia significantly suppressed the 
expression of both cytokines. Therefore, the activation of astrocytes and microglia may 
accelerate brain injury-induced neuroinflammation via MIP-3α-CCR6 signaling, whereas 
hypothermia suppresses this signaling. The physiological roles of MIP-3α-CCR6 signaling in 
the CNS have yet to be fully determined because various roles for chemokines in the brain 
have recently been proposed, e.g., neurotransmitters and neuromodulators (de Haas et al., 
2007; Rostène et al., 2007). The interactions between MIP-3α-CCR6 signaling and other 
pathways involved in ischemic pathology, e.g., excitotoxicity, acidotoxicity, oxidative stress, 
and apoptosis, should also be examined.  
3.3 Apoptotic proteins 
Apoptosis is another important factor for ischemic damage because of its contribution to the 
cell death subsequent to ischemia/reperfusion injury (Broughton et al., 2009). To date, 
mitochondrial dysfunction, oxidative stress, and impaired cerebral energy metabolism have 
been observed during the neuronal cell death that is responsible for much of the poor 
neurologic outcome from these events. Recent studies using in vitro and in vivo neuronal cell 
death models point toward several molecular mechanisms that are either induced or 
promoted by the oxidative modification of macromolecules, including the consumption of 
cytosolic and mitochondrial nicotinamide adenine dinucleotide (NAD+) by poly-ADP ribose 
polymerase (PARP), opening of the mitochondrial inner membrane permeability transition 
pore, and the inactivation of key, rate-limiting metabolic enzymes, such as the pyruvate 
dehydrogenase complex. In addition, the relative abundance of proapoptotic proteins in 
immature brains and neurons, and particularly within their mitochondria, predisposes these 
cells to the intrinsic, mitochondrial pathway of apoptosis, which is mediated by the Bax- or 
Bak-triggered release of proteins into the cytosol through the mitochondrial outer 
membrane. On the basis of these cell dysfunction and death pathways, several approaches 
toward neuroprotection are being investigated that show promise for their future clinical 
application. These strategies include minimizing oxidative stress to avoid unnecessary 
hypoxia, promoting aerobic energy metabolism by the repletion of NAD+, and providing 
alternative oxidative fuels, e.g., ketone bodies, directly interfering with apoptotic pathways 
in mitochondria, and pharmacologically inducing antioxidant and anti-inflammatory gene 
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expression. Hypothermia is known to reduce oxidative stress, metabolic dysfunction, 
delayed neuronal death, and short- and long-term neurobehavioral impairment. However, 
despite successful clinical trials of hypothermia, its neuroprotective mechanisms have not 
been well investigated. 
We investigated the activity of apoptotic proteases, calpains, and caspase-3 in 2 h MCAO rat 
brains using α-fodrin, a cytoskeletal protein enriched in the synaptosome-rich fraction, as a 
substrate for each (Fig. 1). α-Fodrin is fragmented by calpains and caspase-3 to 145/150-kDa 
and 120-kDa cleavage products from its intact 240-kDa protein, respectively (Wang, 2000). 
Harada et al. (2002) reported that ischemia-reperfusion induced the proteolysis of -fodrin 
with the generation of the 150-kDa fragment, while hypothermia inhibited this ischemia-
reperfusion-induced proteolysis. As shown in Fig. 1, an anti-α-fodrin antibody detected 
several bands, including the 240-kDa intact protein and the 145/150-kDa and 120-kDa 
breakdown products. We also detected the 145/150-kDa bands at 48 h after MCAO in 
normothermia. Surprisingly, mild hypothermia (34°C) did not change the density of those 
bands. These finding suggest that the inhibition of protein degradation by hypothermia is 
not dominant in our model or that α-fodrin is not a suitable substrate to determine apoptotic 
degradation. 
 
Fig. 1. Lack of effect of hypothermia on α-fodrin degradation in MCAO rat brains 
Protease activity in brain tissues of rats maintained at normothermic (37°C) or hypothermic 
(34°C) conditions at 0 or 48 h after MCAO and in control brain tissues was shown by the 
degree of α-fodrin degradation. In controls, α- fodrin was detected mainly as a 240-kDa (*) 
band, although α-fodrin was severely degraded into 145/150- (**) and 120-kDa (#) bands in 
the core (A) and penumbra (B) regions. Unexpectedly, hypothermia did not affect the 
degradation of α- fodrin in contralateral (C) regions in MCAO rat brains. 
3.4 Cold-inducible RNA-binding proteins 
Having some analogy to mild hypothermia, mammalian hibernation serves as a natural 
model of tolerance to extreme reductions of blood flow, energy consumption, and body 
temperature, and to the capacity to deliver oxygen to tissues at otherwise lethal levels 
(Frerichs et al, 1994; Frerichs and Hallenbeck, 1998). As hibernating animals suffer no CNS 
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damage or cellular loss because of these special adaptive changes (Carey et al, 2003; Storey, 
2003), the molecular mechanisms that regulate these adaptations are potential targets for 
drug discovery. Generally, low temperatures reduce the rate of enzymatic reactions, 
diffusion, and membrane transport due to the inhibition of chemical reaction rates. 
Although certain microorganisms are able to adapt to cold environments, apart from the 
over-expression of a defined set of cold-shock proteins, by the modification of enzyme 
kinetics, in mammalian cells, the molecular mechanisms that govern adaptation to mild 
hypothermia are not well known, although they may involve a series of events that 
modulate transcription, translation, the cytoskeleton, the cell cycle, and metabolic processes. 
Furthermore, it has been demonstrated that cells exposed to moderate hypothermia, even 
for short periods of time, have broad changes in their gene expression patterns. Upon 
exposure to moderate hypothermia, certain specific cold-shock proteins respond 
immediately to ensure that the cell rapidly adapts to the novel environmental conditions 
(Fujita, 1999). For decades, it was assumed that the proteins activated upon exposure to mild 
cold temperatures are somehow responsible for the general metabolic deceleration that 
occurs when mammalian cells are exposed to mild cold shock. Nonetheless, cold-shock 
proteins actually “facilitate” the accurate and enhanced translation of specific mRNAs at 
temperatures below physiological temperatures (Durandy, 2008). 
Several hypothermia-induced genes have been identified mainly by using in vitro cellular 
models. For example, Tanaka et al. (2010) showed that the exposure of cultured cells to 32°C 
for as long as 24 h suppressed the hypoxia-induced activation of hypoxia-inducible factor 1 
(HIF-1) and the subsequent upregulation of HIF-1 target genes, e.g., vascular endothelial 
growth factor (VEGF) or glucose transporter 1 (GLUT-1), although HIF-1 protein stability 
was not affected by hypothermic treatment. Yang et al. (2009) reported that hypothermia 
markedly reduced OGD-induced apoptosis in human umbilical endothelial cells (HUVEC), 
which was induced by changing the media of HUVEC subjected to OGD for 5 h with 
oxygenated media. The cells were then placed in an incubator for 0–20 h at normothermic 
(37°C) or hypothermic (33°C) conditions to mimic reperfusion. Hypothermia reduced the 
expression of cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP), but, in contrast, 
it reversed the OGD-induced activation of Fas/caspase-8, the increase of Bax and decrease 
of Bcl-2, and the inhibition of JNK1/2 activation via MKP-1 induction, suggesting that 
hypothermia represses OGD-induced endothelial cell apoptosis by inhibiting the extrinsic- 
and intrinsic-dependent apoptotic pathways and the activation of JNK1/2. Lee et al. (2009) 
showed that moderate hypothermia (30°C) reduces ischemic damage after permanent distal 
MCAO in rats. They showed that early and delayed hypothermia blocked -protein kinase C 
(PKC) cleavage, suggesting that the degradation of proteins by caspases might be 
suppressed by hypothermia. 
We attempted to identify genes whose expression is specifically induced by mild 
hypothermia using cDNA subtraction between normothermia- and hypothermia-treated rat 
cortex-derived primary neurons. The culture temperature of the cells was lowered to 32C 
for 14 h and then increased to 37C. The cells were incubated for 0 (A) or 7 h (B) before their 
mRNA was collected. Control neurons were maintained at 37C for 21 h (C). We synthesized 
cDNA from each mRNA sample as described in our previous report (Terao et al., 2009) and 
generated a subtraction cDNA library for each condition. To identify the specific genes 
associated with mild hypothermia, we screened subtracted cDNAs between (A) and (C) or 
(B) and (C). We identified candidate genes whose expression were specifically induced in 
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expression. Hypothermia is known to reduce oxidative stress, metabolic dysfunction, 
delayed neuronal death, and short- and long-term neurobehavioral impairment. However, 
despite successful clinical trials of hypothermia, its neuroprotective mechanisms have not 
been well investigated. 
We investigated the activity of apoptotic proteases, calpains, and caspase-3 in 2 h MCAO rat 
brains using α-fodrin, a cytoskeletal protein enriched in the synaptosome-rich fraction, as a 
substrate for each (Fig. 1). α-Fodrin is fragmented by calpains and caspase-3 to 145/150-kDa 
and 120-kDa cleavage products from its intact 240-kDa protein, respectively (Wang, 2000). 
Harada et al. (2002) reported that ischemia-reperfusion induced the proteolysis of -fodrin 
with the generation of the 150-kDa fragment, while hypothermia inhibited this ischemia-
reperfusion-induced proteolysis. As shown in Fig. 1, an anti-α-fodrin antibody detected 
several bands, including the 240-kDa intact protein and the 145/150-kDa and 120-kDa 
breakdown products. We also detected the 145/150-kDa bands at 48 h after MCAO in 
normothermia. Surprisingly, mild hypothermia (34°C) did not change the density of those 
bands. These finding suggest that the inhibition of protein degradation by hypothermia is 
not dominant in our model or that α-fodrin is not a suitable substrate to determine apoptotic 
degradation. 
 
Fig. 1. Lack of effect of hypothermia on α-fodrin degradation in MCAO rat brains 
Protease activity in brain tissues of rats maintained at normothermic (37°C) or hypothermic 
(34°C) conditions at 0 or 48 h after MCAO and in control brain tissues was shown by the 
degree of α-fodrin degradation. In controls, α- fodrin was detected mainly as a 240-kDa (*) 
band, although α-fodrin was severely degraded into 145/150- (**) and 120-kDa (#) bands in 
the core (A) and penumbra (B) regions. Unexpectedly, hypothermia did not affect the 
degradation of α- fodrin in contralateral (C) regions in MCAO rat brains. 
3.4 Cold-inducible RNA-binding proteins 
Having some analogy to mild hypothermia, mammalian hibernation serves as a natural 
model of tolerance to extreme reductions of blood flow, energy consumption, and body 
temperature, and to the capacity to deliver oxygen to tissues at otherwise lethal levels 
(Frerichs et al, 1994; Frerichs and Hallenbeck, 1998). As hibernating animals suffer no CNS 
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damage or cellular loss because of these special adaptive changes (Carey et al, 2003; Storey, 
2003), the molecular mechanisms that regulate these adaptations are potential targets for 
drug discovery. Generally, low temperatures reduce the rate of enzymatic reactions, 
diffusion, and membrane transport due to the inhibition of chemical reaction rates. 
Although certain microorganisms are able to adapt to cold environments, apart from the 
over-expression of a defined set of cold-shock proteins, by the modification of enzyme 
kinetics, in mammalian cells, the molecular mechanisms that govern adaptation to mild 
hypothermia are not well known, although they may involve a series of events that 
modulate transcription, translation, the cytoskeleton, the cell cycle, and metabolic processes. 
Furthermore, it has been demonstrated that cells exposed to moderate hypothermia, even 
for short periods of time, have broad changes in their gene expression patterns. Upon 
exposure to moderate hypothermia, certain specific cold-shock proteins respond 
immediately to ensure that the cell rapidly adapts to the novel environmental conditions 
(Fujita, 1999). For decades, it was assumed that the proteins activated upon exposure to mild 
cold temperatures are somehow responsible for the general metabolic deceleration that 
occurs when mammalian cells are exposed to mild cold shock. Nonetheless, cold-shock 
proteins actually “facilitate” the accurate and enhanced translation of specific mRNAs at 
temperatures below physiological temperatures (Durandy, 2008). 
Several hypothermia-induced genes have been identified mainly by using in vitro cellular 
models. For example, Tanaka et al. (2010) showed that the exposure of cultured cells to 32°C 
for as long as 24 h suppressed the hypoxia-induced activation of hypoxia-inducible factor 1 
(HIF-1) and the subsequent upregulation of HIF-1 target genes, e.g., vascular endothelial 
growth factor (VEGF) or glucose transporter 1 (GLUT-1), although HIF-1 protein stability 
was not affected by hypothermic treatment. Yang et al. (2009) reported that hypothermia 
markedly reduced OGD-induced apoptosis in human umbilical endothelial cells (HUVEC), 
which was induced by changing the media of HUVEC subjected to OGD for 5 h with 
oxygenated media. The cells were then placed in an incubator for 0–20 h at normothermic 
(37°C) or hypothermic (33°C) conditions to mimic reperfusion. Hypothermia reduced the 
expression of cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP), but, in contrast, 
it reversed the OGD-induced activation of Fas/caspase-8, the increase of Bax and decrease 
of Bcl-2, and the inhibition of JNK1/2 activation via MKP-1 induction, suggesting that 
hypothermia represses OGD-induced endothelial cell apoptosis by inhibiting the extrinsic- 
and intrinsic-dependent apoptotic pathways and the activation of JNK1/2. Lee et al. (2009) 
showed that moderate hypothermia (30°C) reduces ischemic damage after permanent distal 
MCAO in rats. They showed that early and delayed hypothermia blocked -protein kinase C 
(PKC) cleavage, suggesting that the degradation of proteins by caspases might be 
suppressed by hypothermia. 
We attempted to identify genes whose expression is specifically induced by mild 
hypothermia using cDNA subtraction between normothermia- and hypothermia-treated rat 
cortex-derived primary neurons. The culture temperature of the cells was lowered to 32C 
for 14 h and then increased to 37C. The cells were incubated for 0 (A) or 7 h (B) before their 
mRNA was collected. Control neurons were maintained at 37C for 21 h (C). We synthesized 
cDNA from each mRNA sample as described in our previous report (Terao et al., 2009) and 
generated a subtraction cDNA library for each condition. To identify the specific genes 
associated with mild hypothermia, we screened subtracted cDNAs between (A) and (C) or 
(B) and (C). We identified candidate genes whose expression were specifically induced in 
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cells incubated at 32C compared with controls. All of the genes thus obtained were 
different gene fragments of the same cold-inducible RNA-binding protein (CIRP) (data 
not shown). CIRP (also known as A18 hnRNP) is an 18-kD protein that consists of an 
amino-terminal RNA-binding domain and a carboxyl-terminal glycine-rich domain 
(Fujita, 1999; Lleonart, 2010). It exhibits structural similarity to a class of stress-induced 
RNA-binding proteins found in plants. Nishiyama et al. (1997) reported that cirp cDNA 
was induced at a low culture temperature of 32C in a mouse-derived cell line. In the last 
decade, a considerable number of cold-shock proteins have been identified in human 
cells; however, only 2 of these proteins, CIRP and RNA-binding motif protein 3 (RBM3), 
have been well characterized since their initial discovery. Although cirp expression was 
clearly identified in cell-based experiments, a comprehensive approach comparing MCAO 
rat brains with or without hypothermia did not identify the modulation of the cirp gene 
by hypothermia. We speculate that the experimental design of the in vivo ischemia-
hypothermia model may be not appropriate or that the changes in cirp gene expression 
were too small to be detected on oligonucleotide chips. Since Liu et al. (2010) reported that 
CIRP expression was upregulated even by ischemia alone, it might be difficult to see the 
difference in cirp gene expression between ischemia alone and ischemia plus hypothermia 
rat brains. We identified several transcription factors, including AP-1, Pax-4, lmo2, MyoD, 
ADR1, cdxA, and Pax-8, that have potential binding sites on the human and mouse cirp 
genome promoter regions (data not shown). Importantly, cold-inducible RNA-binding 
proteins, e.g., CIRP and RBM3, are also able to regulate their expression at the level of 
translation by binding to different transcripts, thus allowing the cell to respond rapidly to 
environmental signals. The binding of certain proteins to the 5′-untranslated region (UTR) 
or 3′-UTR of their mRNAs can affect the rate of translation initiation and the stability of 
the transcript. Xue et al. (1999) reported that hypothermia induces CIRP expression in the 
CNS in vitro (PC12 neuroblastoma cells) and in vivo (rat brains) and that oxidative stress 
and/or ischemia counteract this phenomenon. In contrast, Liu et al. (2010) reported no 
correlation between CIRP expression and brain metabolism; therefore, it is suggested that 
CIRP has unrevealed neuroprotective activity.  
More recently, Chip et al. (2011) reported that a low temperature (32C) induces the 
expression of a small subset of proteins, including RBM3. Immunohistochemistry of the 
developing postnatal murine brain revealed that the spatiotemporal neuronal expression 
pattern of RBM3 was very similar to that of doublecortin, a marker of neuronal precursor 
cells. Mild hypothermia profoundly promoted RBM3 expression and rescued neuronal cells 
from forced apoptosis, as observed in primary neurons, PC12 cells, and cortical organotypic 
slice cultures. Blocking RBM3 expression in neuronal cells by specific RBM3 small 
interfering RNAs significantly diminished the neuroprotective effects of hypothermia, while 
RBM3 overexpression reduced the cleavage of PARP, prevented internucleosomal DNA 
fragmentation, and reduced lactate dehydrogenase release, suggesting that RBM3 is a novel 
apoptosis modulator. Taken together, these data indicate that neuronal RBM3 induction in 
response to hypothermia apparently accounts for a substantial proportion of hypothermia-
induced neuroprotection. Therefore, they concluded that RBM3 may be one of the potential 
neuroprotective factors induced by hypothermia. 
3.5 Chaperones 
In response to various forms of stress, cells activate a highly conserved heat shock response 
in accordance with the induction of a set of heat shock proteins (Hsps) that play important 
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roles in cellular repair and protective mechanisms (Moseley, 2000). Evidence suggests that 
manipulation of the cellular stress response may offer strategies to protect brain cells from 
the damage that is encountered following cerebral ischemia or during the progression of 
neurodegenerative diseases. Hsp70 is a chaperone protein that can fold or refold proteins, 
coordinate protein trafficking, inhibit protein aggregation or degradation, and exhibits anti-
apoptotic and anti-inflammatory activities under physiological conditions. Over-expression 
of Hsp70 reduced ischemic injury in the mammalian brain (Marber et al., 1995; Zheng et al., 
2008). Investigation of the domains within Hsp70 that confer ischemic neuroprotection 
revealed the importance of the carboxyl-terminal domain (Sun et al., 2006). Arimoclomol, a 
co-inducer of Hsps, delayed the progression of amyotrophic lateral sclerosis in a mouse 
model in which motor neurons in the spinal cord and motor cortex degenerate (Kieran et al., 
2004). Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, 
induced the expression of a set of Hsps in differentiated neurons grown in tissue culture 
(Chow and Brown, 2007). Heat shock “preconditioning” protected the nervous system at the 
functional level of the synapse, and selective over-expression of Hsp70 enhanced the level of 
synaptic protection (Ge et al., 2008). Following hyperthermia, constitutively expressed 
Hsc70 increased in synapse-rich areas of the brain where it associates with Hsp40 to form a 
complex that can refold denatured proteins. Stress tolerance in neurons is not solely 
dependent on their own Hsps, but can be supplemented by Hsps from adjacent glial cells; 
hence, the application of exogenous Hsps at neural injury sites is an effective strategy to 
maintain neuronal viability. 
We identified Hsp70 as a hypothermia-induced protein. Interestingly, we found that Hsp70 
was induced by hypothermia after ischemia, although hypothermia by itself did not induce 
Hsp70 in non-ischemic brains (Terao et al., 2009). Hsp27 was also induced by ischemia, but it 
was not induced by hypothermia. Other Hsps, including Hsp40, Hsp90, Grp78, Grp94, PDI, 
and ORP150, were detectable under normal conditions and were not affected by hypothermia 
or ischemia (Shintani et al., 2011). Recently, Hagiwara et al. (2007) reported that mild 
hypothermia at 34°C increased the expression level of Hsp70 in LPS-stimulated RAW264.7 
cells, although IL-1β, IL-6, and TNF-α expression levels were reduced under the same 
conditions. In contrast, Tirapelli et al. (2010) recently reported the increase of Hsp70 protein 
and gene expression in 1 h MCAO rat brains and the role of neuroprotection with 
hypothermia. However, they showed that the number of Hsp70-positive cells in the ischemic 
areas was reduced by hypothermia. In our model, we observed the suppression of Hsp70 
mRNA expression by hypothermia, in contrast to the protein level of Hsp70, as observed by 
Tirapelli et al. (2010). Since we currently do not know the mechanism of induction or the 
neuroprotective roles of Hsp70 in hypothermia, it is worthy of further investigation.  
4. Autophagy 
Autophagy is a catabolic process whereby cells respond to energy stress by recycling 
intracellular components, e.g., proteins, ribosomes, lipids, and even entire organelles 
(Rabinowitz and White, 2010). In the presence of a sufficient nutrient supply, anabolic 
reactions predominate within cells, and the autophagy system is maintained at the low levels 
that are critical for normal cellular homeostasis and survival. Basal levels of autophagic flux 
are required to degrade long-lived proteins, lipid droplets, and dysfunctional organelles, 
particularly in post-mitotic cells, e.g., cardiomyocytes and neurons, where the capacity for 
regeneration is limited. However, autophagy is rapidly activated in response to starvation or is 
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CIRP has unrevealed neuroprotective activity.  
More recently, Chip et al. (2011) reported that a low temperature (32C) induces the 
expression of a small subset of proteins, including RBM3. Immunohistochemistry of the 
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pattern of RBM3 was very similar to that of doublecortin, a marker of neuronal precursor 
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from forced apoptosis, as observed in primary neurons, PC12 cells, and cortical organotypic 
slice cultures. Blocking RBM3 expression in neuronal cells by specific RBM3 small 
interfering RNAs significantly diminished the neuroprotective effects of hypothermia, while 
RBM3 overexpression reduced the cleavage of PARP, prevented internucleosomal DNA 
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apoptosis modulator. Taken together, these data indicate that neuronal RBM3 induction in 
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neurodegenerative diseases. Hsp70 is a chaperone protein that can fold or refold proteins, 
coordinate protein trafficking, inhibit protein aggregation or degradation, and exhibits anti-
apoptotic and anti-inflammatory activities under physiological conditions. Over-expression 
of Hsp70 reduced ischemic injury in the mammalian brain (Marber et al., 1995; Zheng et al., 
2008). Investigation of the domains within Hsp70 that confer ischemic neuroprotection 
revealed the importance of the carboxyl-terminal domain (Sun et al., 2006). Arimoclomol, a 
co-inducer of Hsps, delayed the progression of amyotrophic lateral sclerosis in a mouse 
model in which motor neurons in the spinal cord and motor cortex degenerate (Kieran et al., 
2004). Celastrol, a promising candidate as an agent to counter neurodegenerative diseases, 
induced the expression of a set of Hsps in differentiated neurons grown in tissue culture 
(Chow and Brown, 2007). Heat shock “preconditioning” protected the nervous system at the 
functional level of the synapse, and selective over-expression of Hsp70 enhanced the level of 
synaptic protection (Ge et al., 2008). Following hyperthermia, constitutively expressed 
Hsc70 increased in synapse-rich areas of the brain where it associates with Hsp40 to form a 
complex that can refold denatured proteins. Stress tolerance in neurons is not solely 
dependent on their own Hsps, but can be supplemented by Hsps from adjacent glial cells; 
hence, the application of exogenous Hsps at neural injury sites is an effective strategy to 
maintain neuronal viability. 
We identified Hsp70 as a hypothermia-induced protein. Interestingly, we found that Hsp70 
was induced by hypothermia after ischemia, although hypothermia by itself did not induce 
Hsp70 in non-ischemic brains (Terao et al., 2009). Hsp27 was also induced by ischemia, but it 
was not induced by hypothermia. Other Hsps, including Hsp40, Hsp90, Grp78, Grp94, PDI, 
and ORP150, were detectable under normal conditions and were not affected by hypothermia 
or ischemia (Shintani et al., 2011). Recently, Hagiwara et al. (2007) reported that mild 
hypothermia at 34°C increased the expression level of Hsp70 in LPS-stimulated RAW264.7 
cells, although IL-1β, IL-6, and TNF-α expression levels were reduced under the same 
conditions. In contrast, Tirapelli et al. (2010) recently reported the increase of Hsp70 protein 
and gene expression in 1 h MCAO rat brains and the role of neuroprotection with 
hypothermia. However, they showed that the number of Hsp70-positive cells in the ischemic 
areas was reduced by hypothermia. In our model, we observed the suppression of Hsp70 
mRNA expression by hypothermia, in contrast to the protein level of Hsp70, as observed by 
Tirapelli et al. (2010). Since we currently do not know the mechanism of induction or the 
neuroprotective roles of Hsp70 in hypothermia, it is worthy of further investigation.  
4. Autophagy 
Autophagy is a catabolic process whereby cells respond to energy stress by recycling 
intracellular components, e.g., proteins, ribosomes, lipids, and even entire organelles 
(Rabinowitz and White, 2010). In the presence of a sufficient nutrient supply, anabolic 
reactions predominate within cells, and the autophagy system is maintained at the low levels 
that are critical for normal cellular homeostasis and survival. Basal levels of autophagic flux 
are required to degrade long-lived proteins, lipid droplets, and dysfunctional organelles, 
particularly in post-mitotic cells, e.g., cardiomyocytes and neurons, where the capacity for 
regeneration is limited. However, autophagy is rapidly activated in response to starvation or is 
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induced either by an inadequate nutrient supply or by defects in growth factor signaling 
pathways; when cells are exposed to stress, such as starvation and hypoxia, autophagic 
mechanisms are triggered to liberate energy substrates and eliminate defective organelles. 
Apart from conditions of emergent nutrient scarcity, the acceleration of autophagy is often 
observed in other clinically important circumstances, including neurodegenerative disorders, 
cancer, misfolded protein accumulation, microbial invasion, and cardiovascular diseases (Beau 
et al., 2011). There is now increasing evidence that, under certain pathological conditions, 
autophagy is able to trigger and mediate programmed cell death (type II death) (Galluzzi et al., 
2008). Such cell death might be involved in the neuronal death observed after global and focal 
cerebral ischemia (Balduini et al., 2009 and Sheng et al., 2010). Recently, it was reported that 
delayed neuronal death occurring in the CA1 pyramidal layer of the gerbil hippocampus after 
ischemia is apoptotic in nature and autophagosomes/autolysosomes are abundant in these 
neurons before DNA fragmentation (Xu and Zhang, 2011), i.e., under ischemic conditions, 
autophagy follows the activation of the mitochondrial pathway of apoptosis; cytochrome c is 
released from mitochondria, and caspase-9/caspase-3 are activated. Turkmen et al. (2011) 
recently showed that autophagy and autophagic flux are reduced in cold ischemic kidneys 
treated with bafilomycin A1. Reduced autophagy and autophagic flux were associated with a 
significant reduction in apoptotic cell death. These results suggest that hypothermia is able to 
suppress the autophagic phenomena induced by ischemia; however, since the relationship 
between autophagy and hypothermia is not well understood, detail analyses should be 
conducted in the future.  
5. Conclusion 
Hypothermia is a strong therapeutic methodology for delaying and suppressing ischemic 
damage in the brain. However, as we do not clearly know the precise mechanisms of 
hypothermia, the technique is still a kind of art and its usage is very limited. To resolve this 
situation, we should clarify the detailed molecular mechanisms of hypothermia, identify the 
dominant effectors for neuroprotection, and substitute the function of hypothermia into a 
therapeutic drug. In this review, we summarized potential drug targets to be considered for 
developing “hypothermia-like” drugs. At the present time, as we speculate that these 
targets are still a piece of the whole picture, we should improve our analytical technology 
and identify critical factors that change the pathophysiological condition induced by 
ischemia into a hypothermic one.  
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1. Introduction 
Stroke ranks as the most common reason to disable adult patients and the second most 
common reason for mortality. Current treatment of ischemic stroke through trombolysis or 
trombectomy aims to initiate successful early reperfusion into the ischemic penumbral 
tissue. If it is promptly and properly performed, it may reverse the ischemic cascade and 
rescue the ischemic penumbra from being further recruited into infarct and thus improve 
neurological outcome. Once the infarct is formed, no treatment is currently available to 
enhance the post stroke brain repair. Under physiological conditions, neurons in the 
cerebral cortex are terminally differentiated shortly after birth. The phenomenon that a 
cavity usually forms in the post stroke adult brain elicits the histological postulation that 
adult brains do not have the capacity to generate new neurons in the cerebral cortex after 
pathological insults i.e., stroke. Nevertheless, neurological recovery of various degrees is 
commonly seen in stroke patients with clinical improvement that starts from a week after 
stroke onset and may last up to 18 months. The underlying mechanisms for this recovery are 
only sparsely understood, although many factors have been suggested such as de-
afferentiating, activity-dependent synaptic changes, altered membrane excitability, and 
outgrowth of axons and dendrites.  
We have been interested in the post stroke brain repair through cell regeneration in the 
adult brains. One animal model being used for this purpose is the photothrombotic ring 
stroke in adult rats (Gu et al. 1999a; Hu et al. 1999; Hu et al. 2001; Wester et al. 1995) and 
mice (Jiang et al. 2006). This stroke model features a large anatomically predefined cortical 
penumbra (spatially confined by a ring-shaped ischemic locus) in the somatosensory cortex 
that undergoes critical hypoperfusion and subsequently spontaneous reperfusion (Gu et al. 
1999a). Quick induction of immediate early genes in the penumbral cortex (Johansson et al. 
2000) is followed by neuronal necrosis and apoptosis with progressively altered neuropil 
and nerve cell morphology that reach their maximum severity at 48 hours after stroke onset 
(Gu et al. 1999b; Hu et al. 2002). With a spontaneous reperfusion into the penumbral cortex 
starting at 72 hours, a remarkable morphologic restoration of the nerve cells starts, that 
evolves into a chiefly unremarkable cytologic appearance at 7 to 28 days after stroke 
induction (Gu et al. 1999b). To investigate the mechanism behind the dramatic 
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morphological recovery in the reperfused penumbral cortex, we examine the cell 
proliferation process in the post stroke cerebral cortex by in vivo delivery of a DNA 
duplication marker 5-bromodeoxy-uridine (BrdU) into the post stroke animals that is 
detected by single/double immunohistochemistry / immunofluorescence (Gu et al. 2000). 
The thymidine analogue BrdU is incorporated into cell DNA during the S-phase of a cell 
cycle, which can be detected immunohistochemically. BrdU cell labelling is currently a 
standard method to identify cell proliferation. Surprisingly, widespread BrdU-incorporated 
cells are consistently observed in the penumbral cortex at 48h and 72h after photothrombotic 
ring stroke. While the majority of these BrdU-immunopositive cells are proliferating 
astrocytes and macrophages, 3% to 6% of them are double-immunolabelled by BrdU and 
one of the neuron-specific marker Map-2 or beta-tubulin III at 7 and 100 days after stroke 
onset. Three dimension confocal analyses show colocalization of the neuron-specific marker 
NeuN and the BrdU in the same cells, suggesting stroke induced cortical neurogenesis in the 
adult cerebral cortex (Gu et al. 2000). To examine the generalizability of this novel finding, 
the rat model of reversible focal cerebral ischemia by middle cerebral artery (MCA) suture 
occlusion is also studied (Jiang et al. 2001). In this stroke model, reperfusion is induced 
mechanically through a withdrawal of the suture at 2h after MCA occlusion. Similarly with 
our previous findings, widespread BrdU single-immunopositive cells appear in the 
postischemic cerebral cortex, corpus callosum, striatum and dentate gyrus of the 
hippocampus ipsilateral to the ischemic infarct at 30 and 60 days after MCA occlusion. 
Approximately 6-10% of the BrdU positive cells are double immunopositive to one of the 
neuron markers Map-2, beta-tubulin III or NeuN in the penumbral cortex, indicating a long 
time survival of the newborn neurons in the post stroke cortex (Jiang et al. 2001). 
To trace the origin of the post stroke newborn neurons in the photothrombotic ring stroke 
model in adult rats (Gu et al. 2009), BrdU is repeatedly injected. Brain sections are collected 
at different time points after stroke induction and examined by BrdU 
immunohistochemistry so that the initial spatial appearance of the proliferating cells and 
their possible migration inside the brains can be evaluated. To detect ongoing cell mitosis or 
cell death, the M-phase specific marker phosphorylated histone H3 (Phos H3) and the 
spindle components α-tubulin/γ-tubulin are examined by double immunofluorescence with 
the DNA duplication marker BrdU or nuclear apoptosis marker TUNEL. Cell type is 
ascertained by double immunolabeling with the neuronal markers Map-2ab/β-tubulin III 
and NeuN/Hu or the astrocyte marker GFAP. From 16h poststroke, BrdU-immunolabeled 
cells appear initially in the penumbral cortex. From 24h after stroke induction, Phos H3 starts 
to be expressed in the penumbral cortex that is colocalized with BrdU in the same nuclei. 
Meanwhile, mitotic spindles immunolabeled by α-tubulin/γ-tubulin appear inside the 
cortical cells containing BrdU-immunopositive nuclei. Unexpectedly, the markers of 
neuronal differentiation, Map-2ab/β-tubulin III/NeuN/Hu, are expressed in the Phos H3-
immunolabeled cells, and NeuN is detected in some cells containing spindles. These date 
suggest that endogenous cells with neuronal immunolabeling may duplicate their nuclear 
DNA and commit cell mitosis to generate daughter neurons in the penumbral cortex, which 
contribute to the very early cortical neurogenesis in this stroke model in adult rats (Gu et al. 
2009). This is in contrast with the reports of cortical neurogenesis after MCA occlusion 
where neural progenitor cells migrate from subventricular zone into post stroke cortex at 7-
14 days after MCA occlusion that contributes to a late stage post stroke neurogenesis 
(Kreuzberg et al. 2010; Tsai et al. 2006). Therefore, stroke induced cortical neurogenesis may 
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originate either from remote progenitor cell migration or in situ cell division depending on 
different stroke models used and various phases studied. 
The functional status of the observed post stroke neurogenesis is one of our major interests. 
To elucidate a conceivable functional capacity, neurotransmitter synthesis is studied in the 
post ischemic rat brains subjected to photothrombotic ring stroke and subsequent BrdU 
delivery (Gu et al. 2010). In order to detect a possible synthesis of neurotransmitters in the 
newborn cortical neurons, single/double/triple immunofluorescence cell labelling is 
performed with the neurotransmitter marker acetycholine (Ach) and its substrate enzyme 
choline acetyltransferase (ChAT), the neurotransmitter marker GABA and the substrate 
enzyme glutamic acid decarboxylase (GAD) and BrdU. Among the BrdU-immunolabeled 
newborn cells at 48h, 5 days, 7 days, 30 days, 60 days and 90 days after stroke, some of these 
are doubly immunopositive to the cholinergic neuron-specific marker ChAT or GABAergic 
neuron-specific marker GAD. As analyzed by 3-D confocal microscopy, the 
neurotransmitters Ach and GABA are colocalized with BrdU in the same cortical cells. In 
order to confirm the neuronal identity of these neurotransmitter synthesizing newborn cells, 
NeuN, BrdU and GABA triple immunofluorescence is performed. Under 3-D confocal 
analyses, the BrdU-immunolabeled newborn cell which is synthesizing GABA is further 
triple-immunolabeled by NeuN. These data suggest that the newborn neurons are capable 
of synthesizing the neurotransmitters acetylcholine and GABA in the penumbral cortex (Gu 
et al. 2010), which is one of the fundamental requisites for these neurons to function during 
the poststroke recovery. 
Stroke is the most common reason to handicap humans in the adult life and the second most 
common reason for clinical mortality. Post stroke patient care is one of the largest 
economical burdens in modern society. About 85% of clinical stroke is ischemic origin. A 
sudden occlusion or severe stenosis of a large or small cerebral artery leads to quick 
decrease of local cerebral blood flow in the brain tissue down to two critical penumbral 
thresholds, i.e., electrophysiological and membrane thresholds that differs the ischemic 
penumbra from ischemic core. If not promptly treated, ischemic penumbra is quickly 
recruited into the ischemic core and paninfarct of the brain tissue ensues. Aphasia, 
hemiplegia, and hemianopia are among the most common neurological deficits that 
handicap stroke patients. Intravenous thrombolysis within the 4.5 hours time window and 
thrombectomy within the 6 hours time window in MCA or vertebrobasilar stroke are the 
current treatment for acute ischemic stroke. Prompt recanalization may be achieved in some 
of the stroke patients that is associated with better clinical outcome. Once a cerebral infarct 
is formed, no specific treatment is currently available to enhance the poststroke brain repair. 
Historically neurons were believed not to be regenerated in the adult brains (Ramón y Cajal 
1913). In 1960s, Altman and Das reported neurogenesis in the hippocampus in post natal 
rats (Altman and Das 1965a). Through [3H]-thymidine DNA labelling and histology, they 
found that some cells that were [3H]-thymidine labelled in their nuclei had neuron 
morphological appearance in the postnatal hippocampus. Using the same DNA labelling 
technique, Altman reported further that neurogenesis persists in olfactory bulbs (Altman 
1969). Proliferation and migration of neural stem cell from subventricular zone along a 
rostral migrating stream into olfactory bulbs was traced to be the cell resource for a life time 
continuous neurogenesis in the olfactory bulbs (Altman and Das 1965b). Proliferation of 
neural stem cells in the subgranular layer and their migration into granule layer contributed 
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to the continuous neurogenesis in the dentate gyrus of the hippocampus (Altman and Bayer 
1990). In recent years neurogenesis in the dentate gyrus of hippocampus and olfactory bulbs 
has been extensively studied in different species including humans. Neurogenesis in these 
brain regions becomes enhanced or inhibited under different physiological and pathological 
conditions such as physical exercise, learning, stress, depression, drugs and stroke (Brown et 
al. 2003; Eriksson et al. 1998; Kempermann et al. 1997; Liu et al. 1998; Samuels and Hen. 
2011; van Praag et al. 1999). 
Ischemic stroke within the middle cerebral artery territory (MCA) is the most common form 
of stroke in humans. With a MCA stroke, tissue infarct occurs in part of cerebral cortex, 
striatum, or both. Aphasia, hemiplegia, apraxia, and hemineglect are among the most 
common neurological deficits to handicap the patients. Under physiological conditions, 
neurons in the cerebral cortex are terminally differentiated in the adult brains (Rakic 1985). 
Several weeks after ischemic stroke, a cavity usually appears in the infarct brain region, 
suggesting an inadequate capacity of the adult brain to compensate the cell loss through 
regeneration of neurons and glial cells. Nevertheless, spontaneous neurological 
improvement of various degrees occurs in the majority of poststroke patients. It starts from 
days after stroke, maximizes in the first 3 months, and may last up to 18 months (Hankey et 
al. 2007; Twitchell 1951). The pathophysiological mechanisms responsible for the poststroke 
spontaneous neurological improvement are sparsely understood. Emission of ischemic 
edema, spontaneous reperfusion of the ischemic penumbra, reversal of ischemic neuronal 
damage, sprouting of collateral axons and local dendrites, unmasking of potential neuronal 
pathways, induction of activity dependent synaptic activity, altered membrane excitability 
have been proposed to be the potential pathways. 
In order to meet various purposes of experimental stroke studies, different animal models of 
focal cerebral ischemia have been established. One of the experimental stroke models being 
used is photothrombotic stroke in adult rodents. Hence, reproducible thrombosis can be 
induced photochemically in the cortex of adult rodents, wherein the ischemic lesion may be 
placed in any desirable location (Watson et al. 1985). In the photothrombotic “ring” version 
of this model, a large anatomically predefined cortical penumbra is induced in the 
somatosensory cortex of adult rats (Wester et al. 1995) within the ischemic annulus of the 
ring. The interior of the ring annulus is concentrically encroached by the radially expanding 
ring annulus, thus simulating penumbral stroke-in-evolution in an inherently reproducible 
fashion (Fig. 1). Microvascular platelet thrombi appear in the cortical lesion (Gu et al. 1999a; 
Wester et al. 1995), reminiscent of clinical thromboembolic stroke. Delayed, but consistent, 
spontaneous reperfusion of the cortical penumbra can be presaged in the ring model by 
manipulation of the irradiating laser beam intensity (Fig. 1) (Gu et al. 1999a), by which local 
cerebral blood flow in the penumbra first decreases to 59, 34, 26, and 33% of baseline values 
at 1, 2, 24, and 48h after ischemia and then gradually recovers to 56 and 87% of baseline 
values at 72 and 96h (Gu et al. 1999c).  
Dramatic changes in tissue morphology take place in the cortical penumbra (Fig. 2). Neuronal 
necrosis and apoptosis with a progressively altered neuropil prevail at 24–48h post ischemia 
(Gu et al. 1999b; Hu et al. 2002), reaching their maximum severity at 48h after stroke with most 
of the neurons exhibiting eosinophilia and pyknosis (Gu et al. 1999b). Meanwhile, VEGF-
mediated angiogenesis is initiated in the same penumbral cortex to facilitate a late 
spontaneous reperfusion (Gu et al. 2001). At 72h after ischemia, a remarkable morphologic 
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restoration of the nerve cells in the penumbra cortex starts, which evolves into a chiefly 
unremarkable cytologic appearance at 7 to 28 days after stroke induction (Gu et al. 1999b). 
 
Fig. 1. Photograph of brain samples from post stroke (B-H) and sham-operated (A) rats that 
are transcardially perfused with carbon-black. A ring-shaped cortical-perfusion deficit is 
consistently observed on the surface of somatosensory cortex at 4h post ischemia (B). It 
progressively increases at 10h (C), 24h (D), and reaches its maximum at 48h (E). Thus, the 
centrally located penumbral cortex enclosed by the ring-shaped ischemic locus looks pale, 
with a branch of the distal middle cerebral artery being narrowed, but not completely 
occluded. At 72h postischemia (F), the distal MCA with its small branches in the penumbral 
cortex becomes patent, representing reperfusion. It becomes more pronounced at 7 days  
(G) and 28 days (H) after stroke induction. (From Gu W, Jiang W, Wester P., Exp Brain Res 
125:163-170, 1999. With permission from Springer-Verlag Heidelberg) 
 
Fig. 2. Hematoxylin and Eosin (HE) staining of the coronal brain sections through the epicenter 
of the ring lesion showing tissue morphology in the central penumbral cortex. (A) At 4h post 
stroke induction, the neuropil is slightly pale and the nerve cells are mildly swollen. (B) At 48h 
after stroke, the majority of the nerve cells are eosinophilic in their cytoplasm and pyknotic 
and hyperchromatic in their nuclei. The neuropil is pale and edematous. (C) At 72h after 
stroke, dramatic recovery of tissue morphology is seen in the penumbral cortex, where only 
mild cytological changes, e.g., somal and nuclear swelling are observed. (D) At 28 days after 
ischemia, tissue morphology becomes unremarkable. (From Gu el al., Exp Brain Res 125:171-
183, 1999. With permission from Springer-Verlag Heidelberg)  
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restoration of the nerve cells in the penumbra cortex starts, which evolves into a chiefly 
unremarkable cytologic appearance at 7 to 28 days after stroke induction (Gu et al. 1999b). 
 
Fig. 1. Photograph of brain samples from post stroke (B-H) and sham-operated (A) rats that 
are transcardially perfused with carbon-black. A ring-shaped cortical-perfusion deficit is 
consistently observed on the surface of somatosensory cortex at 4h post ischemia (B). It 
progressively increases at 10h (C), 24h (D), and reaches its maximum at 48h (E). Thus, the 
centrally located penumbral cortex enclosed by the ring-shaped ischemic locus looks pale, 
with a branch of the distal middle cerebral artery being narrowed, but not completely 
occluded. At 72h postischemia (F), the distal MCA with its small branches in the penumbral 
cortex becomes patent, representing reperfusion. It becomes more pronounced at 7 days  
(G) and 28 days (H) after stroke induction. (From Gu W, Jiang W, Wester P., Exp Brain Res 
125:163-170, 1999. With permission from Springer-Verlag Heidelberg) 
 
Fig. 2. Hematoxylin and Eosin (HE) staining of the coronal brain sections through the epicenter 
of the ring lesion showing tissue morphology in the central penumbral cortex. (A) At 4h post 
stroke induction, the neuropil is slightly pale and the nerve cells are mildly swollen. (B) At 48h 
after stroke, the majority of the nerve cells are eosinophilic in their cytoplasm and pyknotic 
and hyperchromatic in their nuclei. The neuropil is pale and edematous. (C) At 72h after 
stroke, dramatic recovery of tissue morphology is seen in the penumbral cortex, where only 
mild cytological changes, e.g., somal and nuclear swelling are observed. (D) At 28 days after 
ischemia, tissue morphology becomes unremarkable. (From Gu el al., Exp Brain Res 125:171-
183, 1999. With permission from Springer-Verlag Heidelberg)  
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To explain this remarkable morphologic restoration, we assumed that cell proliferation 
might have occurred in the reperfused cortical penumbra in this stroke model (Gu et al. 
2000). To test this hypothesis, the cell proliferation-specific marker 5-bromodeoxyuridine 
is delivered into the poststroke rats through repeated intraperitoneal injections (Gu et al. 
2000). As a thymidine analogue, BrdU is incorporated into the cell nuclei when 
proliferating cells duplicate their DNA during the S-phase, which can be detected 
immunohistochemically (Gratzner 1982; Miller and Nowakowski 1988). After each 
injection, BrdU lasts for about two hours for cell uptake (Nowakowski et al.  
1989). Repeated BrdU injection maximizes the chance for brain cells that proliferate at 
different times post stroke to incorporate BrdU into their nuclei. To minimize the 
possibility of any potential neurotoxic effect of BrdU to the ischemic penumbral tissue, a 
relative low dose of BrdU injections is used, i.e., 10 mg/kg at each delivery as compared 
with 75 to 120 mg/kg used elsewhere (Craig et al. 1999). To follow up a possible long-
term survival of the newborn cells in the post stroke cortex, the animals are sacrificed 
either on the same day after the last BrdU delivery or on day 14 or on day 20 after the last 
BrdU injection. 
 
Fig. 3. BrdU immunohistochemistry in rat brains after photothrombotic ring stroke (A) BrdU 
single immunohistochemistry at 7 days after photothrombotic ring stroke. Widespread 
BrdU-immunolabeled cells (brown) are observed in the cerebral cortex near the two wedge-
shaped infarct cores and the penumbral cerebral cortex that are lying between. (B) A BrdU-
immunolabeled cell (arrow, brown) in the penumbral cortex exhibits a large round cell 
nucleus with a single nucleolus in the center at 7 days after stroke. (C) A BrdU-
immunolabeled cell (arrow, brown) in the penumbral cortex exhibits a large round cell 
nucleus with a single nucleolus in the center at 100 days after stroke. (D) A newborn 
astrocyte in the penumbral cortex is BrdU-immunolabeled in the nucleus (arrow, red) and 
GFAP- immunopositive in the cytoplasm (brown) at 7 days post ischemia. (E) A newborn 
cell in cortical layer II in the penumbral cortex evinces a BrdU-immunolabeled cell nucleus 
(arrow left, red) and Map-2 immunopositive cytoplasm (brown) at 100 days after stroke 
induction. (From Gu W, Brannstrom T, Wester P., J Cereb Blood Flow Metab 20:1166-1173, 
2000. With permission from Nature Publishing Group) 
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Detected through BrdU immunohistochemistry, widespread BrdU-incorporated cells are 
consistently observed in the penumbral cortex and the ischemic core at 7 days after stroke 
induction (Fig. 3A). At 100 days after ischemia, these cells are still seen, though the BrdU 
nuclear labeling is generally faded as compared with that observed at 7 days post ischemia. In 
the penumbral cortex, the majority of the BrdU incorporated cells at 7 days post ischemia 
represent glial cells (62 ± 9.5% of the total 113 ± 34 BrdU single labeled cells counted per brain), 
macrophages (20 ± 9.7%), and endothelial cells (12 ± 3.7%). The corresponding proportions at 
100 days after stroke are 84 ± 2.1% for glial cells (out of a total 82 ± 30 BrdU single-labeled cells 
counted per brain), 3.2 ± 3.9% for macrophages, and 8.8 ± 5.1% for endothelial cells. However, 
some of the BrdU-immunolabeled cell nuclei exhibit neuronal morphologic characteristics, that 
is, a large round nucleus with a single nucleolus in the center (Fig. 3B-C). To identify the cell 
lineage of these newborn cortical cells, the neuron-specific marker Map-2ab and the astrocyte 
specific marker GFAP are employed for double immunohistochemistry with BrdU (Fig. 3D-E). 
Among the dominant newborn astrocytes (Fig. 3D) in the post stroke penumbral cortex , we 
are surprised to see that some cells that are BrdU-immunolabeled in their nuclei are further 
Map-2-immunopositive in their cytoplasm (Fig. 3E), which suggests that these newborn cells 
are neurons (Gu et al. 2000). These cells are scattered randomly in cortical layers II-VI in the 
penumbral cortex and count for 3.3 ± 0.3% of the total 1405 ± 108 BrdU single-labeled cells per 
brain counted at 7 days, and 5.8 ± 1.4% of the total 745 ± 95 BrdU-positive cells counted per 
brain at 100 days after stroke induction. 
 
Fig. 4. 3D confocal analyses of NeuN and BrdU double immunofluorescence in the 
penumbral cortex at two adjacent Z-series planes at 30 days after photothrombotic ring 
stroke. The left column shows the signal intensity for NeuN, the middle column displays the 
signal intensity for BrdU, and the right column exhibits a merged image of the NeuN (red) 
and BrdU (green). The cell designated by the yellow arrows in square is both NeuN-
immunopositive (left) and BrdU-immunopositive (middle), resulting in a yellow NeuN and 
BrdU double-immunopositive nucleus in the merged image (right). White arrowheads 
indicate a neighbouring NeuN-negative but BrdU-positive nonneuronal newborn cell. 
White arrows outside the square are pointed at two NeuN-immunopositive but BrdU-
negative mature neurons. (From Gu W, Brannstrom T, Wester P., J Cereb Blood Flow Metab 
20:1166-1173, 2000. With permission from Nature Publishing Group) 
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To confirm the co-localization of BrdU with a neuron-specific marker within the same 
cortical cells after stroke, three-dimensional confocal analyses of BrdU and NeuN double 
immunofluorescence is conducted (Fig. 4). At 3 days and 30 days after stroke induction, the 
neuron-specific marker NeuN is colocalized with BrdU in the same cortical cells under 3-D 
confocal analyses. These data suggest an occurrence of neurogenesis in the penumbral 
cerebral cortex in adult rats after photothrombotic ring stroke (Gu et al. 2000). 
An obvious question raised about this finding is whether or not this phenomenon is stroke 
model specific. In other word, can cortical neurogenesis be found in any other stroke 
models? To explore the generality of poststroke cortical neurogenesis, cell regeneration is 
further explored in adult rats subjected to unilateral MCA suture occlusion (Jiang et al. 
2001)- an animal model being widely used in stroke research (Longa et al. 1989; Memezawa 
et al. 1992). To induce the reperfusion, the intraluminal filament is withdrawn at 2 hours 
after MCA occlusion. BrdU is injected with a similar schedule as the previous study. Brain 
samples are collected at 30 days and 60 days after stroke induction. 
 
Fig. 5. BrdU immunohistochemistry in rat brains after MCA occlusion (A) BrdU single 
immunohistochemistry of coronal brain section at 30 days after stroke. Widespread BrdU-
immunolabeled cells (brown) are observed in the ipsilateral cortex, with densest distribution in 
the boundary zone close to the pannecrotic region. BrdU-positive cells are also seen in the 
corpus callosum and the dentate gyrus of the hippocampus. (B) High magnification 
photograph of the periinfarct cortex from the left square in A, showing that some cells in the 
cortical layer II have a large round BrdU-immunolabeled cell nucleus with a single nucleolus 
in the center (arrow, brown). (C) High magnification photography of the dentate gyrus of the 
hippocampus from the right square in A, showing that some cells are BrdU-immunopositive 
in their nuclei (brown, arrow). (D) BrdU and Map-2 double immunohistochemistry at 30 days 
after ischemia. In a cell in the cortical layer IV, the BrdU-immunolabeled nucleus (arrow, blue) 
is surrounded by a Map-2–immunopositive cytoplasm (purple) with dendritic processes. The 
arrowhead shows a Map-2–immunopositive mature neuron. (E) BrdU and -tubulin III double 
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immunohistochemistry at 30 days after stroke. A cell in the cortical layer V has its BrdU-
immunolabeled nucleus (arrow, red) surrounded by -tubulin III-immunopositive cytoplasm 
(brown) with an extending neurite. (From Jiang et al., Stroke 32:1201-1207, 2001. With 
permission from Wolters Kluwer Health) 
Widespread BrdU single-immunopositive cells are observed in the post ischemic cerebral 
cortex, striatum, corpus callosum, and dentate gyrus of the hippocampus ipsilateral to the 
ischemic infarct at 30 and 60 days after stroke induction (Fig. 5A). Some of them exhibit 
neuronal morphologic characteristics, i.e., a large round nucleus with a single nucleolus in the 
center (Fig. 5B). Three different neuron-specific markers, Map-2, -tubulin III, and NeuN, are 
used in conjunction with BrdU to perform double-labeling immunohistochemistry. The cells 
doubly labelled by BrdU and Map-2 (Fig. 5D), -tubulin III (Fig. 5E), or NeuN are randomly 
distributed through cortical layers II through VI, at higher density in the peri-infarct regions 
than in remote cortical regions. Some BrdU-immunopositive cells, doubly labelled by Map-2, 
-tubulin III, or NeuN, are also found in the striatum close to the ischemic lesion. These cells 
varied in shapes and sizes and often have one or more recognizable Map-2– or -tubulin III-
immunopositive dendrites extending from their cell bodies. They count for approximately 6% 
to 10% of the total BrdU-immunopositive cells in the penumbral cortex. In 3-D confocal 
analysis, co-localization of BrdU and NeuN immunofluorescence is detected in the cortical 
cells at 30 days (Fig. 6) and 60 days after stroke induction. In these cells, the intense BrdU 
immunofluorescent signal in the cell nuclei is completely merged with the nuclear NeuN–
immunopoitive signal, from which the NeuN -immunopositive proximal dendrites are 
extended (Fig. 6). Therefore, neurogenesis occurs also in the penumbral cortex and striatum in 
adult rats after MCA occlusion (Jiang et al. 2001). In agreement with this study, cortical 
neurogenesis has been reported by several studies in MCA stroke in adult rats and mice (Chen 
et al. 2004; Jiang et al. 2001; Jin et al. 2003; Kreuzberg et al. 2010; Leker et al. 2007; Ohab et al. 
2006; Tsai et al. 2006). 
 
Fig. 6. 3D confocal analyses of NeuN and BrdU double immunofluorescence of cortical cells 
at two adjacent Z-series planes at 30 days after MCA occlusion. The left column shows the 
signal intensity for NeuN, the middle column displays the signal intensity for BrdU, and the 
right column exhibits a merged image of the NeuN and BrdU immunolabeling. In the right 
column, NeuN (red) and BrdU (green) are co-localized in the same nucleus (arrow) that 
results in a yellow appearance in the nucleus, which is surrounded by the NeuN cytoplamic 
labelling with a neurite-like extension. (From Jiang et al., Stroke 32:1201-1207, 2001. With 
permission from Wolters Kluwer Health)  
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The reliability of using BrdU nuclear incorporation as the final judgement of adult 
neurogenesis, in contrast to DNA repair, is questioned especially in the poststroke brain 
tissue (Kuhn and Cooper-Kuhn 2007; Nowakowski and Hayes 2000). To address this debate, 
the cellular origin of the progenitor cells that divide and give birth to poststroke newborn 
cortical neurons must be clarified. In adult mice after MCA stroke, neural stem cells are 
traced to proliferate and migrate from subventricular zone into the post stroke penumbral 
cortex. It takes 7-14 days for the stem cells to arrive at the peri-infarct cortex where they 
differentiate into cortical neurons expressing the neuron-specific marker NeuN (Kreuzberg 
et al. 2010; Ohab et al. 2006). In contrast, newborn neurons are already identified in the 
reperfused penumbral cortex at 72 hour after photothrombotic ring stroke in rats (Gu et al. 
2000). This time frame is far beyond the migrating speed that SVZ stem cells could make. 
Therefore we postulate that the newborn cortical neurons may have a cortical origin in this 
cortical stroke model (Gu et al. 2000). 
The crucial point to prove this hypothesis is to determine whether or not cell division has 
occurred in the poststroke brain tissue, and if it does, when, where and who start to divide. 
To achieve this purpose, the S-phase marker BrdU is injected intraperitoneally every 4h after 
stroke induction up to 72h after stroke, then two times daily, and is ended at poststroke day 
7. The brain samples are collected at 4, 10, 16, 24, 48, and 72h and 7 and 14 days after stroke 
induction for analysis (Gu et al. 2009). To explore a possible cell mitosis which is 
theoretically anticipated during the poststroke cortical neurogenesis, cell mitosis specific 
marker phosphorylated histone H3 (Phos H3) (Hans and Dimitrov 2001; Hendzel et al. 1997) 
is investigated through immunohistochemistry/immunofluorescence in the brain sections. 
During a cell cycle, massive phosphorylation of the nuclear protein histone H3 takes place 
immediately after the proliferating cells complete their DNA duplication in order to initiate 
the cell mitosis (Hans and Dimitrov 2001; Hendzel et al. 1997; Van Hooser et al. 1998), and 
the phosphorylated histone H3 becomes quickly dephosphorylated after cell division 
(Hendzel et al. 1998). Therefore the Phos H3 detects specifically mitotic cell nuclei. To 
visualize mitotic spindles, spindle components α-tubulin (Wittmann et al. 2001) and γ-
tubulin (Lajoie-Mazenc et al. 1994) are detected by immunocytochemistry and 
immunofluorescence. TUNEL labelling is used to detect DNA damage. 
In 4h and 10h poststroke rats, a few BrdU-immunolabeled cells are randomly scattered in the 
brain sections. At 16h poststroke, BrdU-immunolabeled cells are consistently observed in the 
penumbral cortex. When consecutive sagittal brain sections are examined at this time, a few 
BrdU-immunolabeled cells are observed on the tangential migrating pathway from the SVZ 
toward the olfactory bulbs, but not toward the penumbral cortex. At 24h, 48h, 72h, 7 days, and 
14 days poststroke, the number of BrdU-immunolabeled cells increases gradually in the 
penumbral cortex. From at 24h poststroke, Phos H3 starts to be detected in the same cell nuclei 
doubly immunolabeled by BrdU (Fig. 7B). Meanwhile, α-tubulin and γ-tubulin 
immunolabeled mitotic spindles are observed inside the cortical cells containing BrdU- and 
Phos H3-immunolabeled cell nuclei (Fig. 7C-D). Some of these cells exhibit anaphase or 
telophase morphology (Fig. 8B-C, Fig. 8F), indicating the completion of cell division. The cell 
density of Phos H3-immunopositive cells reaches its maximum at 48h and 72h poststroke and 
then declines at 7 days. These mitotic cells are dispersed among but distinctly separated from 
TUNEL-labelled cells (Fig. 7E). To identify a possible cell lineage of the mitotic cells, the 
neuronal marker Map-2ab, β-tubulin III, NeuN, and Hu and the astrocyte marker GFAP  
 




Fig. 7. (A) Low-magnification photograph of Phos H3 single immunohistochemistry in a 
coronal brain section through the ischemic lesion at 48h after photothrombotic ring stroke. 
Two wedge-shaped cortical lesions corresponding to the annular ischemic core are 
demarcated in the cortex, between which lies the ischemic penumbra. Phos H3-
immunopositive cells (brown) are observed in the penumbral cortex, ipsilateral corpus 
callosum, and subgranule layer of the hippocampus. (B) Confocal analyses of Phos H3 and 
BrdU double immunofluorescence in the penumbral cortex at 48h post stroke. Numerous cells 
are BrdU-immunolabeled (red) in the cortical penumbra. Among which, three cells are doubly 
immunolabeled by Phos H3 (green) in this field, which yields a yellow appearance in the BrdU 
and Phos H3 double-immunopositive nuclei (arrows). (C) 3D confocal analyses of BrdU and  
γ-tubulin double immunofluorescence in a cortical cell at 24h poststroke. The γ-tubulin (green) 
appears as a spindle that is co-localized with the BrdU-immunolabeled nucleus (red) in the 
same cell. The γ-tubulin-immunolabeled microtubules (green) are penetrating through the 
BrdU-immunolabeled nucleus (red), which in combination produces a yellow color in the 
nucleus (arrow). (D) Maximal projection confocal image of Phos H3 and γ-tubulin double 
immunofluorescence in the penumbral cortex at 48h post stroke. In a cell from cortical layer II, 
the Phos H3-immunopositive nucleus (red) is superimposed on a γ-tubulin-immunolabeled 
spindle (green) with the pole bodies at the opposite ends (arrows) and the linking 
microtubules stretching in between. (E) Confocal microscopy of TUNEL and Phos H3 double 
immunofluorescence in the penumbral cortex at 48h after stroke. The Phos H3-immunolabeled 
cells (arrows, green) are separate from the TUNEL-positive cells (arrowheads, red). (From Gu 
el al., Stem Cell Res 2:68-77, 2009. With permission from Elsevier) 
are used for double immunohistochemistry and immunofluorescence. Some Phos H3-
immunolabeled cell nuclei are enveloped by the cytoplasm immunopositive to the neuron-
specific markers β-tubulin III and Map-2 (Fig. 8A-C), or the astrocyte marker GFAP. Under 
3D confocal analysis, NeuN or Hu is co-localized with Phos H3 (Fig. 8D), α-tubulin- or  
γ-tubulin (Fig. 8E-F) in the same cells. 
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The reliability of using BrdU nuclear incorporation as the final judgement of adult 
neurogenesis, in contrast to DNA repair, is questioned especially in the poststroke brain 
tissue (Kuhn and Cooper-Kuhn 2007; Nowakowski and Hayes 2000). To address this debate, 
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traced to proliferate and migrate from subventricular zone into the post stroke penumbral 
cortex. It takes 7-14 days for the stem cells to arrive at the peri-infarct cortex where they 
differentiate into cortical neurons expressing the neuron-specific marker NeuN (Kreuzberg 
et al. 2010; Ohab et al. 2006). In contrast, newborn neurons are already identified in the 
reperfused penumbral cortex at 72 hour after photothrombotic ring stroke in rats (Gu et al. 
2000). This time frame is far beyond the migrating speed that SVZ stem cells could make. 
Therefore we postulate that the newborn cortical neurons may have a cortical origin in this 
cortical stroke model (Gu et al. 2000). 
The crucial point to prove this hypothesis is to determine whether or not cell division has 
occurred in the poststroke brain tissue, and if it does, when, where and who start to divide. 
To achieve this purpose, the S-phase marker BrdU is injected intraperitoneally every 4h after 
stroke induction up to 72h after stroke, then two times daily, and is ended at poststroke day 
7. The brain samples are collected at 4, 10, 16, 24, 48, and 72h and 7 and 14 days after stroke 
induction for analysis (Gu et al. 2009). To explore a possible cell mitosis which is 
theoretically anticipated during the poststroke cortical neurogenesis, cell mitosis specific 
marker phosphorylated histone H3 (Phos H3) (Hans and Dimitrov 2001; Hendzel et al. 1997) 
is investigated through immunohistochemistry/immunofluorescence in the brain sections. 
During a cell cycle, massive phosphorylation of the nuclear protein histone H3 takes place 
immediately after the proliferating cells complete their DNA duplication in order to initiate 
the cell mitosis (Hans and Dimitrov 2001; Hendzel et al. 1997; Van Hooser et al. 1998), and 
the phosphorylated histone H3 becomes quickly dephosphorylated after cell division 
(Hendzel et al. 1998). Therefore the Phos H3 detects specifically mitotic cell nuclei. To 
visualize mitotic spindles, spindle components α-tubulin (Wittmann et al. 2001) and γ-
tubulin (Lajoie-Mazenc et al. 1994) are detected by immunocytochemistry and 
immunofluorescence. TUNEL labelling is used to detect DNA damage. 
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toward the olfactory bulbs, but not toward the penumbral cortex. At 24h, 48h, 72h, 7 days, and 
14 days poststroke, the number of BrdU-immunolabeled cells increases gradually in the 
penumbral cortex. From at 24h poststroke, Phos H3 starts to be detected in the same cell nuclei 
doubly immunolabeled by BrdU (Fig. 7B). Meanwhile, α-tubulin and γ-tubulin 
immunolabeled mitotic spindles are observed inside the cortical cells containing BrdU- and 
Phos H3-immunolabeled cell nuclei (Fig. 7C-D). Some of these cells exhibit anaphase or 
telophase morphology (Fig. 8B-C, Fig. 8F), indicating the completion of cell division. The cell 
density of Phos H3-immunopositive cells reaches its maximum at 48h and 72h poststroke and 
then declines at 7 days. These mitotic cells are dispersed among but distinctly separated from 
TUNEL-labelled cells (Fig. 7E). To identify a possible cell lineage of the mitotic cells, the 
neuronal marker Map-2ab, β-tubulin III, NeuN, and Hu and the astrocyte marker GFAP  
 




Fig. 7. (A) Low-magnification photograph of Phos H3 single immunohistochemistry in a 
coronal brain section through the ischemic lesion at 48h after photothrombotic ring stroke. 
Two wedge-shaped cortical lesions corresponding to the annular ischemic core are 
demarcated in the cortex, between which lies the ischemic penumbra. Phos H3-
immunopositive cells (brown) are observed in the penumbral cortex, ipsilateral corpus 
callosum, and subgranule layer of the hippocampus. (B) Confocal analyses of Phos H3 and 
BrdU double immunofluorescence in the penumbral cortex at 48h post stroke. Numerous cells 
are BrdU-immunolabeled (red) in the cortical penumbra. Among which, three cells are doubly 
immunolabeled by Phos H3 (green) in this field, which yields a yellow appearance in the BrdU 
and Phos H3 double-immunopositive nuclei (arrows). (C) 3D confocal analyses of BrdU and  
γ-tubulin double immunofluorescence in a cortical cell at 24h poststroke. The γ-tubulin (green) 
appears as a spindle that is co-localized with the BrdU-immunolabeled nucleus (red) in the 
same cell. The γ-tubulin-immunolabeled microtubules (green) are penetrating through the 
BrdU-immunolabeled nucleus (red), which in combination produces a yellow color in the 
nucleus (arrow). (D) Maximal projection confocal image of Phos H3 and γ-tubulin double 
immunofluorescence in the penumbral cortex at 48h post stroke. In a cell from cortical layer II, 
the Phos H3-immunopositive nucleus (red) is superimposed on a γ-tubulin-immunolabeled 
spindle (green) with the pole bodies at the opposite ends (arrows) and the linking 
microtubules stretching in between. (E) Confocal microscopy of TUNEL and Phos H3 double 
immunofluorescence in the penumbral cortex at 48h after stroke. The Phos H3-immunolabeled 
cells (arrows, green) are separate from the TUNEL-positive cells (arrowheads, red). (From Gu 
el al., Stem Cell Res 2:68-77, 2009. With permission from Elsevier) 
are used for double immunohistochemistry and immunofluorescence. Some Phos H3-
immunolabeled cell nuclei are enveloped by the cytoplasm immunopositive to the neuron-
specific markers β-tubulin III and Map-2 (Fig. 8A-C), or the astrocyte marker GFAP. Under 
3D confocal analysis, NeuN or Hu is co-localized with Phos H3 (Fig. 8D), α-tubulin- or  
γ-tubulin (Fig. 8E-F) in the same cells. 
 




Fig. 8. (A) Phos H3 and β-tubulin III double immunohistochemistry in the penumbral cortex at 
48h after stroke. In a cortical cell, the Phos H3-immunolabeled nucleus appears in a partially 
duplicated shape (arrows, blue), which is surrounded by β-tubulin III-immunolabeled 
cytoplasm (purple). The arrowhead points to a cortical neuron that is singly immunolabeled 
by β-tubulin III. (B) Phos H3 and β-tubulin III double immunohistochemistry in the penumbral 
cortex at 48h after stroke. A pair of Phos H3 (arrows, blue) and β-tubulin III (purple) double-
immunolabeled cells is nearly separated but still slightly connected through β-tubulin III-
immunolabeled cytoplasm. (C) Phos H3 and Map-2 double immunohistochemistry in the 
penumbral cortex at 48h after stroke. A pair of Phos H3 (blue) and Map-2 (purple) double-
positive cells (arrows) is splitting while slightly connected through Map-2-immunolabeled 
cytoplasm (purple). The arrowhead points to a cortical neuron singly immunolabeled by  
Map-2. (D) Projection confocal image of Phos H3 and Hu double immunofluorescence in the 
penumbral cortex at 24h after stroke. A large cortical cell that is Hu-immunolabeled in the 
cytoplasm (arrow, red) contains a Phos H3-immunopositive nucleus in a duplicated shape 
(green). (E) Confocal microscopy of α-tubulin, NeuN and DAPI triple immunofluorescence in 
the penumbral cortex at 24h post stroke. In a large cortical cell in layer III (delineated),  
α-tubulin (green) appears as a bipolar spindle while the nuclear DNA is transformed into 
chromosomes (blue) randomly scattered inside the NeuN-immunopositive cytosol (red).  
(F) 3D confocal image of NeuN, γ-tubulin and DAPI triple immunofluorescence in layer III of 
the cortical penumbra at 48 h poststroke. In a cortical cell containing a γ-tubulin-
immunolabeled spindle (green), the cell DNA (arrows, blue) is pulled toward its opposite ends 
while NeuN immunoreactivity (red) is detected at the central part of the cytosol. (From Gu el 
al., Stem Cell Res 2:68-77, 2009. With permission from Elsevier)  
The initial appearance of the BrdU-immunolabeled cells within the penumbral cortex rather 
than in other parts of the brains suggests that the cells starting to proliferate belong to 
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endogenous cortical cells. Their initial entrance into S-phase occurs at 16h poststroke. Their 
transition from S-phase cells into M-phase, as hallmarked by the nuclear Phos H3 expression 
(Fig. 7B) and cytoplasmic spindle formation (Fig. 7C), occurs at 24h poststroke. The length of 
the S-phase is therefore estimated about 8h and the length of the whole cell cycle is about 8–
10h. This is in agreement with the cell cycle calculation performed in normal mouse brains 
(Nowakowski et al. 1989). The concurrence whereas distinct separation of these mitotic cells 
from TUNEL labelling suggests that cell regeneration concurs with but differs distinctly 
from DNA damage and cell death in the same penumbral cerebral cortex after the 
photothrombotic ring stroke (Fig. 7E). These data provide morphological evidence to 
support our claim that the sustained BrdU-incorporated neurons in the poststroke 
penumbral cortex represent neurogenesis (Gu et al., 2000; Gu et al., 2009) rather than DNA 
repair (Kuhn and Cooper-Kuhn 2007; Nowakowski and Hayes 2000). 
It is not clear why differentiated neuronal markers are expressed in cells in metaphase 
during the poststroke cortical neurogenesis (Fig. 8E-F). In cell culture, differentiated neuron 
markers are expressed in newborn neurons immediate after their birth from the mother cell, 
i.e., after cytokinesis (Svendsen et al. 1995). A possible explanation of this phenomenon is 
that in response to ischemic stroke the endogenous progenitor cells may undergo cell 
division with a quickened cell differentiation. In agreement with this explanation, neural 
progenitor cells isolated from the poststroke penumbral cerebral cortex are cultured to 
generate neurons expressing differentiated neuronal markers (Shimada et al. 2010). An 
alternative possibility is that after ischemic insult somatic cortical neurons may reprogram 
themselves and thus function as pluripotent stem cells so that they start to divide and give 
birth to newborn neurons while they keep their neuronal identity throughout cell division. 
Future studies are needed to address on this issue. 
Whether or not the adult cortical neurogenesis may contribute to the poststroke neurological 
improvement is one of our major interests. For the newborn neurons to function in the 
poststroke cerebral cortex, they must fulfil many basic criteria. For example, they must be 
able to establish synaptic connections with their surrounding neurons, to synthesize various 
neurotransmitters and receptors, and in response to afferent stimuli to generate action 
potentials and to release the corresponding neurotransmitters in order to activate their 
target receptors. Proper neurotransmitter deactivation system is also needed in order to 
terminate the action. To explore the function potential of poststroke cortical neurogenesis, 
we start with an examination on the possible biosynthesis of the excitatory 
neurotransmitter acetycholine (ACh) and its substrate enzyme choline acetyltransferase 
(ChAT) and the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and the 
corresponding substrate enzyme glutamic acid decarboxylase (GAD) in adult rats after 
photothrombotic ring stroke. To detect the newborn cells, BrdU is repeatedly delivered as 
mentioned previously. To detect neurotransmitter synthesis, brain sections are examined 
through double immunohistochemistry or immunofluorescence with BrdU and the 
neurotransmitter markers. To ascertain the cell identify, neuron-specific marker NeuN is 
used for triple immunofluorescence. With ACh, ChAT, GABA and GAD single 
immunohistochemistry, ACh, ChAT, GABA and GAD-immunolabeled neurons are 
frequently observed in the cerebral cortex outside the penumbral region. In contrast, all of 
the cells in the pannecrotic ischemic core and the majority of the cells inside the cortical 
penumbra are not immunolabeled by the neurotransmitters ACh and GABA. However,  
 




Fig. 8. (A) Phos H3 and β-tubulin III double immunohistochemistry in the penumbral cortex at 
48h after stroke. In a cortical cell, the Phos H3-immunolabeled nucleus appears in a partially 
duplicated shape (arrows, blue), which is surrounded by β-tubulin III-immunolabeled 
cytoplasm (purple). The arrowhead points to a cortical neuron that is singly immunolabeled 
by β-tubulin III. (B) Phos H3 and β-tubulin III double immunohistochemistry in the penumbral 
cortex at 48h after stroke. A pair of Phos H3 (arrows, blue) and β-tubulin III (purple) double-
immunolabeled cells is nearly separated but still slightly connected through β-tubulin III-
immunolabeled cytoplasm. (C) Phos H3 and Map-2 double immunohistochemistry in the 
penumbral cortex at 48h after stroke. A pair of Phos H3 (blue) and Map-2 (purple) double-
positive cells (arrows) is splitting while slightly connected through Map-2-immunolabeled 
cytoplasm (purple). The arrowhead points to a cortical neuron singly immunolabeled by  
Map-2. (D) Projection confocal image of Phos H3 and Hu double immunofluorescence in the 
penumbral cortex at 24h after stroke. A large cortical cell that is Hu-immunolabeled in the 
cytoplasm (arrow, red) contains a Phos H3-immunopositive nucleus in a duplicated shape 
(green). (E) Confocal microscopy of α-tubulin, NeuN and DAPI triple immunofluorescence in 
the penumbral cortex at 24h post stroke. In a large cortical cell in layer III (delineated),  
α-tubulin (green) appears as a bipolar spindle while the nuclear DNA is transformed into 
chromosomes (blue) randomly scattered inside the NeuN-immunopositive cytosol (red).  
(F) 3D confocal image of NeuN, γ-tubulin and DAPI triple immunofluorescence in layer III of 
the cortical penumbra at 48 h poststroke. In a cortical cell containing a γ-tubulin-
immunolabeled spindle (green), the cell DNA (arrows, blue) is pulled toward its opposite ends 
while NeuN immunoreactivity (red) is detected at the central part of the cytosol. (From Gu el 
al., Stem Cell Res 2:68-77, 2009. With permission from Elsevier)  
The initial appearance of the BrdU-immunolabeled cells within the penumbral cortex rather 
than in other parts of the brains suggests that the cells starting to proliferate belong to 
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endogenous cortical cells. Their initial entrance into S-phase occurs at 16h poststroke. Their 
transition from S-phase cells into M-phase, as hallmarked by the nuclear Phos H3 expression 
(Fig. 7B) and cytoplasmic spindle formation (Fig. 7C), occurs at 24h poststroke. The length of 
the S-phase is therefore estimated about 8h and the length of the whole cell cycle is about 8–
10h. This is in agreement with the cell cycle calculation performed in normal mouse brains 
(Nowakowski et al. 1989). The concurrence whereas distinct separation of these mitotic cells 
from TUNEL labelling suggests that cell regeneration concurs with but differs distinctly 
from DNA damage and cell death in the same penumbral cerebral cortex after the 
photothrombotic ring stroke (Fig. 7E). These data provide morphological evidence to 
support our claim that the sustained BrdU-incorporated neurons in the poststroke 
penumbral cortex represent neurogenesis (Gu et al., 2000; Gu et al., 2009) rather than DNA 
repair (Kuhn and Cooper-Kuhn 2007; Nowakowski and Hayes 2000). 
It is not clear why differentiated neuronal markers are expressed in cells in metaphase 
during the poststroke cortical neurogenesis (Fig. 8E-F). In cell culture, differentiated neuron 
markers are expressed in newborn neurons immediate after their birth from the mother cell, 
i.e., after cytokinesis (Svendsen et al. 1995). A possible explanation of this phenomenon is 
that in response to ischemic stroke the endogenous progenitor cells may undergo cell 
division with a quickened cell differentiation. In agreement with this explanation, neural 
progenitor cells isolated from the poststroke penumbral cerebral cortex are cultured to 
generate neurons expressing differentiated neuronal markers (Shimada et al. 2010). An 
alternative possibility is that after ischemic insult somatic cortical neurons may reprogram 
themselves and thus function as pluripotent stem cells so that they start to divide and give 
birth to newborn neurons while they keep their neuronal identity throughout cell division. 
Future studies are needed to address on this issue. 
Whether or not the adult cortical neurogenesis may contribute to the poststroke neurological 
improvement is one of our major interests. For the newborn neurons to function in the 
poststroke cerebral cortex, they must fulfil many basic criteria. For example, they must be 
able to establish synaptic connections with their surrounding neurons, to synthesize various 
neurotransmitters and receptors, and in response to afferent stimuli to generate action 
potentials and to release the corresponding neurotransmitters in order to activate their 
target receptors. Proper neurotransmitter deactivation system is also needed in order to 
terminate the action. To explore the function potential of poststroke cortical neurogenesis, 
we start with an examination on the possible biosynthesis of the excitatory 
neurotransmitter acetycholine (ACh) and its substrate enzyme choline acetyltransferase 
(ChAT) and the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and the 
corresponding substrate enzyme glutamic acid decarboxylase (GAD) in adult rats after 
photothrombotic ring stroke. To detect the newborn cells, BrdU is repeatedly delivered as 
mentioned previously. To detect neurotransmitter synthesis, brain sections are examined 
through double immunohistochemistry or immunofluorescence with BrdU and the 
neurotransmitter markers. To ascertain the cell identify, neuron-specific marker NeuN is 
used for triple immunofluorescence. With ACh, ChAT, GABA and GAD single 
immunohistochemistry, ACh, ChAT, GABA and GAD-immunolabeled neurons are 
frequently observed in the cerebral cortex outside the penumbral region. In contrast, all of 
the cells in the pannecrotic ischemic core and the majority of the cells inside the cortical 
penumbra are not immunolabeled by the neurotransmitters ACh and GABA. However,  
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some BrdU-immunolabeled cortical cells in the penumbral cortex are ChAT, ACh, GAD, or 
GABA- immunolabeled in their cytoplasm. These cells are randomly distributed in cortical 
layers II–VI in the penumbral cortex at 48h, 5 days, 7 days, 30 days, 60 days, and 90 days 
after stroke. Under 3-D confocal analyses, BrdU is colocalized with ACh (Fig. 9A) or GABA 
(Fig. 9B) in the same cells in the corresponding double immunofluorescence, in which the 
BrdU-immunolabelled cell nucleus is surrounded by ACh or GABA-immunolabelled 
cytoplasm. In the GABA, NeuN, and BrdU triple immunofluorescence (Fig. 9D-F), the 
neuron-specific marker NeuN is colocalized with the BrdU in the same nucleus (Fig. 9E), 
around which the GABA-immunoreactive cytoplasm is detected (Fig. 9F). This observation 
verifies the neuronal identity of these newborn cortical cells synthesizing corresponding 
neurotransmitters. In addition, it also helps to address on a theoretical concern that the 
presence of the neuronal marker NeuN inside the dividing cells might be a consequence of 
phagocytosis, i.e., the cells that look like dividing neurons are dividing macrophages that 
have taken neuronal markers. In the setting of focal cerebral ischemia the CBF threshold for 
neurotransmitter release (corresponding to 40–60% of the baseline CBF) is higher than that 
of the membrane threshold (corresponding to 20–40% of the baseline CBF) beyond which 
morphological damage of the ischemic tissue occurs (Hossmann 1994). Timewise, 
postischemic neurotransmitter release occurs earlier than cell apoptosis and necrosis 
through which ischemic cell death takes place. In the photothrombotic ring stroke the local 
CBF in the cortical penumbra drops to 34% of the baseline level at 2h after ischemia (Gu et 
al. 1999a). This CBF level is already well below the neurotransmitter threshold at which a 
nonspecific neurotransmitter release is triggered, while the tissue morphology remains 
intact (Gu et al. 1999b). Consequently, all of the neurons in the ischemic core and the 
majority of neurons inside the penumbral cortex are not immunolabeled by Ach or GABA at 
24-48h (Gu et al. 2010). While some of the cortical cells in the penumbral cortex are DNA 
damaged in their nuclei, i.e., TUNEL-positive, they are distinctly separated from the 
dividing cells expressing the mitotic marker Phos H3 (Fig. 7E). Thus, neurons lose their 
neurotransmitters at 2-16h after ischemia, and they die through apoptosis/necrosis at 24-48h 
after the photothrombotic ring stroke. Meanwhile, local cells in the penumbral cortex are 
induced to proliferate from at 16h after ischemia incorporating BrdU into their nuclei, and 
then they start to divide at 24-48h poststroke that give birth to daughter neurons expressing 
various neuronal markers and synthesizing neurotransmitters (Gu et al. 2009; Gu et al. 2000; 
Gu et al. 2010). It is not until from at 72h postischemia and later ED-1-immunopositive 
microglias start to appear in the postischemic cortex to clean up the dead cells through 
phagocytosis (Gu et al. 1999b). Therefore, cell division starts earlier than phagocytosis in the 
setting of photothrombotic ring stroke. Being a functional marker for living GABAergic 
neurons, the neurotransmitter GABA should never appear in the debris of dead neurons. 
The homogeneous colocalization of GABA and NeuN in the same cytoplasm including the 
proximal dendrites of the newborn neurons (Fig. 9F) speaks directly against the hypothesis 
that the NeuN immunoreactivity in the dividing cells comes from exogenous fragments of 
dead neurons. It is conceivable that one or several pieces of neuronal fragments may be 
engulfed by an activated microglia into its cytoplasm (Takahashi et al. 2005). In that case, it 
should be debris of dead neurons that becomes engulfed, not a whole living neuron 
exhibiting intact cell morphology including neurite-like extensions. In the newborn neurons, 
the neuronal marker NeuN labels both the BrdU-immunolabeled cell nucleus and the 
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perinuclear cytoplasm including the proximal dendrites in the newborn cortical neurons 
(Fig. 9E) (Gu et al. 2009; Gu et al. 2000; Gu et al. 2010). This NeuN cell labelling pattern 
agrees with what has been reported in normal adult neurons (Wolf et al. 1996). Therefore, 
the NeuN nuclear labelling itself speaks also against the exogenous NeuN hypothesis. It is 
because if a neuronal fragment is engulfed by a dividing microglia, it should barely be taken 
into the cytoplasm of the dividing microglia. It has no chance to integrate its 
immunoreactivity into the BrdU/Phos H3-immunopositive dividing nucleus of the 
phagocyte. Thus, the neuronal markers and neurotransmitters observed belong indeed to 
the same cells exhibiting dividing cell nuclei. 
Therefore, the capability of neurotransmitter biosynthesis by these newborn neurons 
qualifies themselves for one of the fundamental prerequisites for their further function 
during the poststroke neurological and neuropsychological improvement.  
 
Fig. 9. (A) 3-D confocal analysis of Ach, BrdU, and DAPI triple immunofluorescence from 
layer IV of the cortical penumbra at 30 days after photothrombotic ring stroke. In a large 
cortical cell, the cell nucleus is BrdU-immunolabeled (green) and DAPI counterstained 
(arrow, blue), which is surrounded by Ach-immunopositive cytoplasm (red). Many non-
cholinergic cells are seen in the same field (arrowhead, blue). (B) 3-D confocal analysis of 
GABA and BrdU double immunofluorescence in layer III of cortical penumbra at 48h after 
stroke. A cortical cell that is BrdU-immunolabeled in the nucleus (arrow, green) is GABA-
immunopositive in the cytoplasm (red). (C) A section confocal image of GAD, BrdU, and 
DAPI triple immunofluorescence in layer III of penumbral cortex at 7 days after stroke. A 
cortical cell that contains a BrdU- immunolabeled (arrow, green) DAPI counterlabeled 
nucleus (arrow, blue) is GAD-immunopositive (red) in its cytoplasm. (D-F) GABA, BrdU 
and NeuN triple immunofluorescence (D) Projection image of GABA (red), BrdU (green), 
and NeuN (blue) triple immunofluorescence at low magnification. A cortical cell (framed) is 
triply immunolabeled by GABA (red), BrdU (green), and NeuN (blue). The arrowhead 
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some BrdU-immunolabeled cortical cells in the penumbral cortex are ChAT, ACh, GAD, or 
GABA- immunolabeled in their cytoplasm. These cells are randomly distributed in cortical 
layers II–VI in the penumbral cortex at 48h, 5 days, 7 days, 30 days, 60 days, and 90 days 
after stroke. Under 3-D confocal analyses, BrdU is colocalized with ACh (Fig. 9A) or GABA 
(Fig. 9B) in the same cells in the corresponding double immunofluorescence, in which the 
BrdU-immunolabelled cell nucleus is surrounded by ACh or GABA-immunolabelled 
cytoplasm. In the GABA, NeuN, and BrdU triple immunofluorescence (Fig. 9D-F), the 
neuron-specific marker NeuN is colocalized with the BrdU in the same nucleus (Fig. 9E), 
around which the GABA-immunoreactive cytoplasm is detected (Fig. 9F). This observation 
verifies the neuronal identity of these newborn cortical cells synthesizing corresponding 
neurotransmitters. In addition, it also helps to address on a theoretical concern that the 
presence of the neuronal marker NeuN inside the dividing cells might be a consequence of 
phagocytosis, i.e., the cells that look like dividing neurons are dividing macrophages that 
have taken neuronal markers. In the setting of focal cerebral ischemia the CBF threshold for 
neurotransmitter release (corresponding to 40–60% of the baseline CBF) is higher than that 
of the membrane threshold (corresponding to 20–40% of the baseline CBF) beyond which 
morphological damage of the ischemic tissue occurs (Hossmann 1994). Timewise, 
postischemic neurotransmitter release occurs earlier than cell apoptosis and necrosis 
through which ischemic cell death takes place. In the photothrombotic ring stroke the local 
CBF in the cortical penumbra drops to 34% of the baseline level at 2h after ischemia (Gu et 
al. 1999a). This CBF level is already well below the neurotransmitter threshold at which a 
nonspecific neurotransmitter release is triggered, while the tissue morphology remains 
intact (Gu et al. 1999b). Consequently, all of the neurons in the ischemic core and the 
majority of neurons inside the penumbral cortex are not immunolabeled by Ach or GABA at 
24-48h (Gu et al. 2010). While some of the cortical cells in the penumbral cortex are DNA 
damaged in their nuclei, i.e., TUNEL-positive, they are distinctly separated from the 
dividing cells expressing the mitotic marker Phos H3 (Fig. 7E). Thus, neurons lose their 
neurotransmitters at 2-16h after ischemia, and they die through apoptosis/necrosis at 24-48h 
after the photothrombotic ring stroke. Meanwhile, local cells in the penumbral cortex are 
induced to proliferate from at 16h after ischemia incorporating BrdU into their nuclei, and 
then they start to divide at 24-48h poststroke that give birth to daughter neurons expressing 
various neuronal markers and synthesizing neurotransmitters (Gu et al. 2009; Gu et al. 2000; 
Gu et al. 2010). It is not until from at 72h postischemia and later ED-1-immunopositive 
microglias start to appear in the postischemic cortex to clean up the dead cells through 
phagocytosis (Gu et al. 1999b). Therefore, cell division starts earlier than phagocytosis in the 
setting of photothrombotic ring stroke. Being a functional marker for living GABAergic 
neurons, the neurotransmitter GABA should never appear in the debris of dead neurons. 
The homogeneous colocalization of GABA and NeuN in the same cytoplasm including the 
proximal dendrites of the newborn neurons (Fig. 9F) speaks directly against the hypothesis 
that the NeuN immunoreactivity in the dividing cells comes from exogenous fragments of 
dead neurons. It is conceivable that one or several pieces of neuronal fragments may be 
engulfed by an activated microglia into its cytoplasm (Takahashi et al. 2005). In that case, it 
should be debris of dead neurons that becomes engulfed, not a whole living neuron 
exhibiting intact cell morphology including neurite-like extensions. In the newborn neurons, 
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perinuclear cytoplasm including the proximal dendrites in the newborn cortical neurons 
(Fig. 9E) (Gu et al. 2009; Gu et al. 2000; Gu et al. 2010). This NeuN cell labelling pattern 
agrees with what has been reported in normal adult neurons (Wolf et al. 1996). Therefore, 
the NeuN nuclear labelling itself speaks also against the exogenous NeuN hypothesis. It is 
because if a neuronal fragment is engulfed by a dividing microglia, it should barely be taken 
into the cytoplasm of the dividing microglia. It has no chance to integrate its 
immunoreactivity into the BrdU/Phos H3-immunopositive dividing nucleus of the 
phagocyte. Thus, the neuronal markers and neurotransmitters observed belong indeed to 
the same cells exhibiting dividing cell nuclei. 
Therefore, the capability of neurotransmitter biosynthesis by these newborn neurons 
qualifies themselves for one of the fundamental prerequisites for their further function 
during the poststroke neurological and neuropsychological improvement.  
 
Fig. 9. (A) 3-D confocal analysis of Ach, BrdU, and DAPI triple immunofluorescence from 
layer IV of the cortical penumbra at 30 days after photothrombotic ring stroke. In a large 
cortical cell, the cell nucleus is BrdU-immunolabeled (green) and DAPI counterstained 
(arrow, blue), which is surrounded by Ach-immunopositive cytoplasm (red). Many non-
cholinergic cells are seen in the same field (arrowhead, blue). (B) 3-D confocal analysis of 
GABA and BrdU double immunofluorescence in layer III of cortical penumbra at 48h after 
stroke. A cortical cell that is BrdU-immunolabeled in the nucleus (arrow, green) is GABA-
immunopositive in the cytoplasm (red). (C) A section confocal image of GAD, BrdU, and 
DAPI triple immunofluorescence in layer III of penumbral cortex at 7 days after stroke. A 
cortical cell that contains a BrdU- immunolabeled (arrow, green) DAPI counterlabeled 
nucleus (arrow, blue) is GAD-immunopositive (red) in its cytoplasm. (D-F) GABA, BrdU 
and NeuN triple immunofluorescence (D) Projection image of GABA (red), BrdU (green), 
and NeuN (blue) triple immunofluorescence at low magnification. A cortical cell (framed) is 
triply immunolabeled by GABA (red), BrdU (green), and NeuN (blue). The arrowhead 
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points at a newborn nonneuronal cell singly immunolabeled by BrdU (green) 
superimposing on a GABAergic (red) NeuN-immunopositive (blue) cortical neuron.  
(E) BrdU and NeuN double-channel image of the cortical cell framed in panel D. The BrdU 
immunolabeling (arrow, green) is colocalized with NeuN (blue) in the same cell nucleus.  
(F) 3-D analysis of GABA, BrdU, and NeuN triple-channel image from the same scanning 
section as panel E. The GABA (red) is colocalized with NeuN (blue) and BrdU (green) in the 
same cell (arrow). (From Gu el al., Stem Cell Res 4:148-154, 2010. With permission from 
Elsevier) 
In summary, neurogenesis occurs in the penumbral cerebral cortex in adult rodents after 
photothrombotic ring stroke and unilateral middle cerebral artery occlusion. Quick cell 
division within the penumbral cerebral cortex contributes to an early in situ cortical 
neurogenesis in the photothrombotic ring stroke model in rats. In contrast, neural stem cell 
migration from SVZ into the cortical penumbra provides a remote cell resource for a late 
stage cortical neurogensis in the periinfarct cerebral cortex after middle cerebral artery 
occlusion. As early as at 48h after the photothrombotic ring stroke, the newborn cortical 
neurons start to synthesize the neurotransmitters GABA and acetycholine exhibiting 
neurite-like extensions, which optimizes their further function in the post stroke recovery.  
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Cytoprotection and brain regeneration are both potential future therapies in the treatment of 
cerebral ischemia, both based on animal research data. Since Kaas and colleagues first 
described the reorganization of the sensory cortex after peripherial nerve injury it has 
become clear that “we can no longer consider the injured brain as a normally wired brain 
with a missing puzzle piece” (Kaas et al., 1983 as cited in Nudo, 2006) and thus there has 
been intense research subsequently focused on understanding the regeneration processes 
following different brain injuries. 
In rodent models, permanent and transient middle cerebral artery occlusions (MCAO) are 
the most relevant for representing human ischemic stroke. The lesioned brain areas in these 
experimental cases are well comparable to those found in humans. Global cerebral ischemia 
has been investigated using several models including (1) hypotension with bilateral carotid 
occlusion, or (2) four vessel (2 carotid arteries + 2 vertebral arteries) occlusion with 
normotension, (3) hypoxia, and (4) cardiac arrest models in rats or mice, or (5) the transient 
carotid occlusion in gerbil. These global brain ischemia models mimic severe hypotension, 
cardiac arrest, hypoxia, cardiac surgery, among other conditions in the human, however, 
while in rodent models the most vulnerable region is the hippocampus, in human both 
cortical and subcortical lesions are common. This is one reason why these models are 
difficult to translate into human studies in global cerebral ischemia, however, longer 
ischemic periods in rodents also result in patchy cortical and subcortical damage together 
with the hippocampal damage (Back et al., 2004; Erdő and Hossmann, 2007; Wappler et al., 
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Cytoprotection and brain regeneration are both potential future therapies in the treatment of 
cerebral ischemia, both based on animal research data. Since Kaas and colleagues first 
described the reorganization of the sensory cortex after peripherial nerve injury it has 
become clear that “we can no longer consider the injured brain as a normally wired brain 
with a missing puzzle piece” (Kaas et al., 1983 as cited in Nudo, 2006) and thus there has 
been intense research subsequently focused on understanding the regeneration processes 
following different brain injuries. 
In rodent models, permanent and transient middle cerebral artery occlusions (MCAO) are 
the most relevant for representing human ischemic stroke. The lesioned brain areas in these 
experimental cases are well comparable to those found in humans. Global cerebral ischemia 
has been investigated using several models including (1) hypotension with bilateral carotid 
occlusion, or (2) four vessel (2 carotid arteries + 2 vertebral arteries) occlusion with 
normotension, (3) hypoxia, and (4) cardiac arrest models in rats or mice, or (5) the transient 
carotid occlusion in gerbil. These global brain ischemia models mimic severe hypotension, 
cardiac arrest, hypoxia, cardiac surgery, among other conditions in the human, however, 
while in rodent models the most vulnerable region is the hippocampus, in human both 
cortical and subcortical lesions are common. This is one reason why these models are 
difficult to translate into human studies in global cerebral ischemia, however, longer 
ischemic periods in rodents also result in patchy cortical and subcortical damage together 
with the hippocampal damage (Back et al., 2004; Erdő and Hossmann, 2007; Wappler et al., 
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2009 and 2010). Though, these models are useful to investigate the pathophyshiological 
mechanisms of brain ischemia, but it is important to note that in human stroke patients there 
are usually several other factors to consider, such as obesity, hypertension, diabetes, age and 
medications a patient may be using (Li and Carmichael, 2006; Popa-Wagner et al., 2007; 
Wappler et al., 2010) which may also determine the size of the lesion together with the 
regenerative potential of the tissue. This emphasizes the importance of experiments that 
utilize disease model and not just young, healthy male subjects to investigate brain injury, 
which will hopefully bring us closer to an understanding of the complex clinical conditions 
that result in stroke (Nudo, 2007; Popa-Wagner et al., 2007; Wappler et al., 2010). In addition 
to understanding the process of ischemic brain injury, examining the potential effects of the 
drugs that afford protection against ischemia is just as crucial under different conditions.  
In this chapter we present an overview of the studies describing the regenerative potential 
of the brain due to ischemic damage. Furthermore, we discuss drugs that increase brain 
plasticity after ischemic insult in animal models, focusing on estrogen. In addition, we 
describe a brief study examining acute 17β-estradiol treatment on synaptic plasticity in the 
brain with a short (4 days) and a long term (25 days) follow up in young (4 months old) and 
old (18 months old) gerbils after global cerebral ischemia. The aim of this study was to 
investigate whether changes in synaptic density can be maintained after a longer period of 
single dose estrogen treatment, as we have demonstrated an early induction of neuronal 
plasticity using this model (Wappler et al., 2011b). Maintenance of synaptic density may be 
an important factor underlying the previously described better functional outcome using 
this model that was investigated up to the 2nd week after brain ischemia (Wappler et al., 
2010). In our current study, we examined two different age groups because synaptic 
reorganization is known to decrease with advancing age (Kim and Jones, 2010). Our results 
can help elucidate how synaptic reorganization progresses in the brain after global cerebral 
ischemia due to a single treatment of a cerebroprotective drug and how brain plasticity is 
influenced by age. 
2. Brain regeneration after cerebral ischemia 
Cerebral plasticity is the ability of the brain to change its structure and function during 
maturation, learning, environmental challenges or pathology (Di Filippo et al., 2008; Lledo 
et al., 2006). The exact mechanism of spontaneous brain regeneration after brain ischemia is 
not fully understood; however, there is a remarkable number of publications that describe 
several mechanisms participating in this process. 
Here we discuss the following features in brain regeneration: 1. neural plasticity 2. vascular 
plasticity and 3. glial plasticity. 
2.1 Neuronal plasticity 
For almost one hundred years neuroscientists have believed that the adult primate brain, 
and therefore the human brain, is structurally stable and does not form new synapses or 
grow new cells (Gould et al., 1999). It is clear by now that certain brain regions generate 
new cells, and that the continuous “rewiring“ of the brain is an important physiological 
function. 
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Cortical interneurons but not pyramidal cells have been described to have intense 
arborization as axonal sprouting, dendritic growth and branching under physiological 
conditions (Lee et al., 2006) throughout adulthood. The “baseline” cerebral plasticity; 
however, is much more limited in the mature brain, compared to the developing brain, 
where high activity takes place. This phenomenon is generated by those structural and 
functional “brakes”, such as myelin, and several neuromodulators, that actively suppress 
plasticity in the adulthood (Bavelier et al., 2010). 
Following cerebral ischemia, or other types of brain insult; however, neuronal plasticity is 
reactivated in the surviving cells in order to compensate for cell death and to preserve 
functionality of the damaged but not dead areas (Blizzard et al. 2011; Carmichael, 2006). The 
possible mechanisms of neural plasticity include dendritic reorganization, axonal sprouting, 
and activation of endogenous pluripotent cells that can differentiate into neurons. While it 
has been shown that interneurons undergo structural remodeling in post-traumatic cortical 
lesions, signs of neural plasticity have not been detected in pyramidal neurons (Blizzard et 
al., 2011). 
2.1.1 Dendritic, axonal and synaptic plasticity 
Early studies demonstrated that following entorhinal lesion, as the result of neuronal 
projections from the contralateral hippocampus, new synapses are formed in the damaged 
cortex (Lynch et al., 1973). In addition, several subsequent studies have shown dendritic and 
axonal reorganization after experimental brain ischemia with dynamic changes of synaptic 
density in the injured brain region (Benowitz and Carmichael, 2010; Brown et al., 2010; Lu et 
al., 2004; Mostany et al., 2010; Scheff et al., 2005; Sulkowski et al., 2006; Takatsuru et al., 2009; 
etc.). The most active neuronal regeneration occurs up to 2-3 weeks after brain injury 
(Blizzard et al. 2011; Jones and Schallert, 1992), which provides a wide therapeutic window 
in cerebral ischemia. 
Cerebral ischemia induces axonal sprouting within the peri -infarct zone and contralateral 
side. This post-ischemic axonal sprouting establishes new neuronal connection pattern for 
the damaged brain areas (Carmichael, 2003). Axonal sprouting after different central 
nervous system injuries can be detected by using growth-associated protein-43 (GAP-43) as 
it is a marker of regeneration in the adulthood (Benowitz and Routtenberg, 1987; Benowitz 
and Perrone-Bizzozero, 1991; Simon et al., 2001; Wappler et al., 2011b). During brain 
development GAP-43 is highly associated with the elongating axons (Benowitz and 
Routtenberg, 1987; Benowitz and Perrone-Bizzozero, 1991), which becomes less 
concentrated proximal to the cell soma while the axon is growing, but stays in the growth 
cone (Benowitz and Perrone-Bizzozero, 1991). GAP-43 is also thought to be involved in 
neurotransmitter release. The highest GAP-43 immunoreactivity was detected on the 4th 
postnatal day, when the most active synaptogenesis takes place. This is followed by a rapid 
decrease in the immunoreactivity with only a few brain regions expressing GAP-43 later in 
the adulthood. These regions are the cerebral cortex, the hippocampus, the hypothalamus, 
the amygdala, the striatum, the medial substantia nigra, raphe nuclei, locus coeruleus, 
olfactory bulb, olfactory tubercule, preoptic area, and stria terminalis (Benowitz and 
Perrone-Bizzozero, 1991; Yao et al., 1993). Each of these regions has a different level of 
constant reorganization. In the hippocampus, this reorganization is related to synaptic 
remodeling during memory formation (Benowitz and Perrone-Bizzozero, 1991; Holahan et 
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2010). In our current study, we examined two different age groups because synaptic 
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not fully understood; however, there is a remarkable number of publications that describe 
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the damaged brain areas (Carmichael, 2003). Axonal sprouting after different central 
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al., 2007). Astrocytes and perivascular extracellular matrix are involved in guiding axonal 
growth and provide a scaffolding surface for this growth (Nedergaard and Dirnagl, 2005). 
Shortly after focal cerebral ischemia many neurons in the penumbra lose their dendritic 
spines in an attempt to survive (Brown et al., 2008; Benowitz and Carmichael, 2010). 
Nevertheless up to two weeks after stroke dendritic density and turnover increases in the 
peri-infarct cortex and also in the contralateral hemisphere, which plays a major role in 
brain regeneration (Brown et al., 2010; Mostany et al., 2010; Takatsuru et al., 2009). In 
addition, following cardiac arrest decreased microtubule-associated protein 2 (MAP-2) 
expression was detected in the rat reflecting lower dendritic density (Sulkowski et al., 2006). 
Recent studies have shown dendritic arbor shortening in the ischemic penumbra in the first 
weeks following stroke with further loss of dendritic branches after the first month in 
cortical pyramidal cells (Mostany and Portera-Cailliau, 2011). However, dendritic changes in 
the basilar tree of these cells or in other neuronal cell types in the cortex could not be ruled 
out. In contrast, enhanced dendritic arborization has been described in cortical pyramidal 
neurons following photothrombotic brain ischemia (Brown et al., 2010). Thus, the changes in 
dendrite vary among different cerebral ischemia models. 
In different central nervous system injuries synaptogenesis (formation of new synapses) is 
critical because new connections restore the cell communication and signaling. Following 
injury, surviving neurons have been described to form new synapses to compensate for the 
lost contact surfaces even if pre-traumatic synapse number is not achieved in the 
traumatized area (Lu et al., 2004; Scheff et al., 2005). Therefore examining synaptic density is 
a widely used technique to track neuronal plasticity following brain lesions. Both 
synaptophysin (SYP) and synapsin-I are widely used synaptic markers to assess synaptic 
density. The vesicular transmembrane protein, SYP, is expressed in the presynaptic terminal 
and its expression seems to be dispensable in neurotransmission (Becher et al., 1996; 
Eshkind and Leube, 1995; McMahon et al., 1996) but may be involved in fine-tuning of 
synaptic activity and in vesicle biogenesis (Becher et al., 1996; Janz and Sudhof, 1998). 
Synapsin-I is a phosphoprotein located on the small synaptic vesicles in the presynaptic 
terminal (De Camilli et al., 1983; Schiebler et al., 1986), and participates in regulating 
plasticity (Roshal et al., 1993; Wei et al., 2011). Following axonal sprouting and dendritic 
reorganization, sometimes just 21 days after the ischemia, synaptic density increases 
suggesting the development of mature synapses (Stroemer et al., 1995 as cited in 
Carmichael, 2003). In addition it has been shown in a rodent model that synaptic density 
steadily decreased up to one week following global cerebral ischemia (Sulkowski et al., 
2006). 
2.1.2 Endogenous neurogenesis 
While it was not believed that the adult human brain was able to form new neurons, Altman 
and Das provided the first evidence that neurogenesis occurred in the mature rodent brain 
(Altman and Das 1965 and 1967). These data opened a new chapter in neuroscience 
research. Besides the physiological functions, such as memory formation and learning, 
endogenous neurogenesis has become a major focus of research in different brain lesions 
(Gao et al., 2009; Kokaia and Lindvall, 2003; Shen et al., 2010; etc.) and their potential 
therapies (Kim et al., 2009; Leker et al., 2009; Xiong et al., 2011). The majority of the 
endogenous cerebral stem cells are located in the subventricular zone and hippocampal 
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subgranular zone and can generate either neuronal or glial cells (Zhao et al., 2008) in the 
lesion site using signals from the damaged cells for their activation and migration released. 
These pluripotent cells express certain proteins that are typically present during brain 
development, and therefore are useful markers to track neurogenesis in adulthood 
following brain injury, such as ischemia. One of the markers is nestin, an intermediate 
filament protein, which is expressed in the astrocytes and radial glia cells in the developing 
brain and disappears after the 11th postnatal day in the rat (Kalman and Ajtai, 2001). 
Although previous data suggest that nestin immunopositivity in the adult bran is associated 
with immature cells that are involved in neuogenesis (von Bohlen und Halbach, 2007; Yue et 
al. 2006), it also a marker of reactive gliosis following various brain lesions (see e.g. Duggal 
et al. 1997). It also have been reported that following focal ischemia in the rat nestin positive 
cells from the ipsilateral subventricular zone can differentiate into glial cells (Holmin et al., 
1997; Nakagomi et al., 2009; Shen et al., 2010). Therefore, in the adult brain, nestin 
expression recurs in both proliferating cells and in reactive astrocytes. 
2.2 Vascular plasticity 
Vascular plasticity includes processes such as angiogenesis and arteriogenesis. Angiogenesis 
is related to hypoxia and results in new capillaries from the pre-existing vessels, whereas 
arteriogenesis is induced most importantly by increased shear stress that results in newly 
formed blood vessels (Heil and Sharper, 2004; Heil et al., 2006; Schierling et al., 2009; Xiong 
et al., 2010); however, the differences in the cause and the result is usually are not this clear 
cut. Angiogenesis has a major role in brain regeneration after ischemia as increased blood 
supply directly enhances cell survival and regenerative processes (Font et al., 2010). Blood 
vessels not only provide metabolic support but also participate in neurogenesis by leading 
progenitor cells to the site of injury (Jin et al., 2002; Kojima et al., 2010 as cited in Font et al., 
2010; Sun et al., 2010; Udo et al., 2008; Xiong et al., 2010; Yang et al., 2010).There is extensive 
evidence that neovascularization (both angiogenesis and arteriogenesis) is induced 
following acute (del Zoppo and Mabuchi, 2003; Issa et al., 2005) and chronic (Busch et al., 
2003; Wappler et al., 2011a) brain ischemia.  
Hypoxia induced hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor 
(VEGF) are the most common angiogenesis stimulators (Busch et al., 2003; Carmeliet and 
Collen, 1997; Liu et al., 1995; Levy et al., 1995) and are involved in capillary sprouting rather 
than in larger collateral vessel remodeling (Busch et al., 2003; Carmeliet and Collen, 1997) 
because they act on endothelial cells without inducing smooth muscle proliferation (Busch 
et al., 2003). In addition, several other factors, such as fibroblast growth factor (FGF) (Issa et 
al., 2005), angiopoetins (Lin et al., 2000), transforming growth factor β (TGFβ) (Haggani et 
al., 2005; Krupinski et al., 1996), platelet derived growth factor (PDGF) (Issa et al., 2005; 
Krupinski et al., 1997), tissue-type plasminogen activator (Carmeliet and Collen, 1997), etc. 
are just as critical in new vessel formation after brain injury. Most of these molecules have 
separate effects on cerebroprotection and regeneration, such as the TGFβ-s (Vincze et al., 
2010). In addition, nitric oxide derived from endothelial nitric oxide synthetase (eNOS) also 
induces endothelial cell proliferation and migration, smooth muscle cell differentiation, and 
other angiogenic processes, where ischemia and shear stress are triggering mechanisms 
(Amano et al., 2003; Cui et al., 2009; Murohara et al., 1998; Papapetropoulos et al., 1997; Prior 
et al., 2003; Rudic et al., 1998). Angiogenesis inhibitors, such as endostatin, angiostatin, 
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thrombospondin-1 and thrombospondin-2 have also been detected following brain ischemia 
(Issa et al., 2005), which provide another avenue for therapeutic interventions.  
In addition to these growth factors extracellular matrix proteins, such as laminin and 
dystroglycan complex (DGC) proteins, are also involved in vascular remodeling in the brain 
(Wappler et al., 2011a). The DGC proteins may have an important function in signal 
transduction connecting the extracellular signals and laminin itself with a wide variety of 
intracellular proteins, such as nitric oxide synthase, ion channels, kinases, and actin 
(Culligan and Ohlenieck, 2002; Wappler et al., 2011a). Thus, certain DGC proteins make 
good immunohistochemical markers of vascular reorganization (Wappler et al., 2011a) in 
addition to the more frequently used laminin. 
Neuroregenerative agents that increase angiogenesis, such as estrogen (Ardelt et al., 2005), 
have been described to improve functional outcome in models of cerebral ischemia 
(Hermann and Zechariah, 2009; Goldstein, 2009). These experimental data correlate with 
clinical data where higher microvessel density in the brain after ischemia was accompanied 
by shorter recovery time and longer survival (Christoforidis et al., 2005; Font et al., 2010; 
Krupinski et al., 1994; Navarro-Sobrino et al., 2011; Wei et al., 2001). 
2.3 Glial plasticity 
Glial cells in the brain include astrocytes, microcytes, and oligodendrocytes, of which 
astrocytes are the most numerous. In the last decade glial cells have been recognized not just 
for structural but for metabolic and for throphic support. By secreting nerve growth factor 
[NGF], basic fibroblast growth factor [bFGF], transforming growth factor β [TFG-β], platelet-
derived growth factor [PDGF], brain-derived neurotrophic factor [BDNF], ciliary 
neurotrophic factor, Neuropilin-1, vascular endothelial growth factor [VEGF], etc., they 
modulate the function of neurons and other cell types. Glial cells are active participants of 
synaptic interactions and higher level of cerebral function; and key elements of cerebral 
blood flow regulation (Araque and Navarrete, 2010; Attwell et al., 2010; Iadecola and 
Nedergaard, 2007; Metea and Newman, 2006; Nedergaard and Dirnagl, 2005). Glial cells 
also play a key role in regulating neuronal survival and regeneration by regulating the 
extracellular ion homeostasis, supporting other cells` energy metabolism, reducing 
glutamate toxicity, promoting neurogenesis, synaptogenesis and angiogenesis, activating 
endothelial cells, disrupting blood brain barrier (BBB), increasing inflammation, etc. 
(Himeda et al., 2007; Nedergaard and Dirnagl, 2005; Trendelenburg and Dirnagl, 2005). 
Generating new astrocytes is also an important feature in brain regeneration that has been 
mentioned previously in this chapter. 
The formation of glial scar and its beneficial and non-beneficial properties are also of great 
interest when investigating astrocytic reaction following focal brain ischemia. Unlike other 
tissues where injury repair results in a fibrous scar, brain injury is followed by a special scar 
formed by the activated astorocytes and the extracellular matrix molecules of proteoglycans. 
These include heparan sulfate, dermatan keratan sulfate, sulfate proteoglycans, and 
chondroitin sulfate, which are released by reactive astrocytes to compose a barrier of axonal 
growth. The role glial scar formation following brain ischemia is still unknown and intense 
research is ongoing to understand if it is harmful or supportive (Rolls et al., 2009; Silver and 
Miller, 2004). Besides its support on the injured tissue (Rolls et al., 2009), its inhibitory effect 
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on axonal growth is equally important (Cole and McCabe, 1991; Filder et al., 1999; Katoh-
Semba et al., 1995; Rudge and Silver, 1990; Smith-Thomas et al., 1994; Snow et al., 1990). 
Nevertheless, sulphated proteoglycans have also been described as supporting axonal 
growth (Hikino et al., 2003; Nakanishi et al., 2006), making glial cell based therapeutic 
strategies more difficult to design. On In contrast, myelin-associated inhibitors from 
oligodendrocytes and myelin debris, namely myelin-associated glycoprotein (MAG), Nogo-
A and oligodendrocyte myelin glycoprotein (OMgp) have clearly inhibitory effect on neurite 
outgrowth (for review see Yiu and He, 2006) and are under investigation because blocking 
their function results in enhanced brain regeneration. 
3. Inducing cerebral plasticity following brain ischemia 
A therapeutic window for drugs that increase neural plasticity is wider than those that 
target cytoprotection following cerebral ischemia (Zhang and Chopp, 2009) giving hope for 
improved functional outcomes in more stroke patients. A cerebroprotective drug can 
increase synaptic density in several ways. Cytoprotection, a process where cells can utilize 
more energy to maintain features that are not necessary in cell survival, can contribute to 
increased neuronal survival and therefore plasticity in the injured area. Presumably for the 
same reason increased oxygen and metabolic support improve cellular plasticity after 
different ischemic events in the brain as already mentioned above.  
Whether anti-apoptotic genes are able to induce neuronal plasticity by themselves other 
than by improving metabolic status is important to understand the pathophysiology of 
brain ischemia. In order to investigate this question we used Bcl-Xl or Bcl-2 gene construct 
transfections in an in vitro hypoxia model and we observed increased expression of 
synaptophysin-I and nestin mRNAs and proteins under normoxic conditions. Following 
hypoxia only nestin expression was significantly different from the untreated hypoxic group 
(Gal et al., 2009). These data indicate increased that anti-apoptotic gene expression itself can 
contribute to the amelioration of brain plasticity and its effect might be modified under 
different stress conditions. Several drugs that are known to be cytoprotective against 
cerebral ischemia, such as (-)-D-Deprenyl (Simon et al, 2001), and 17-estradiol (Wappler et 
al., 2011), also participate in brain regeneration. Although both have anti-apoptotic effect, (-
)-D-Deprenyl increases GAP-43 expression whereas 17-estradiol treatment does not, 
suggesting that similar pathways may mediate enhanced regeneration through different 
intracellular signaling (Simon et al, 2001; Szilagyi et al., 2009; Wappler et al., 2011) both in 
vitro and in vivo. This is supported by btudies on other cerebroprotective drugs, such as 
erythropoietin (EPO) (Iwai et al., 2010), statins (Céspedes-Rubio et al., 2010), amphetamine 
(Liu et al., 2011), melatonin (Chen et al., 2009; González-Burgos et al., 2007), and different 
spices (Kannappan et al., 2011), where different ways of imporoved brain plasticity was 
described.  
3.1 Estrogen 
3.1.1 Estrogen in the brain, estrogen receptors 
Corpechot and colleges described the first time that the cerebral sex steroid concentration is 
much higher than the circulating estrogen level both in men and women (Corpechot et al., 
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strategies more difficult to design. On In contrast, myelin-associated inhibitors from 
oligodendrocytes and myelin debris, namely myelin-associated glycoprotein (MAG), Nogo-
A and oligodendrocyte myelin glycoprotein (OMgp) have clearly inhibitory effect on neurite 
outgrowth (for review see Yiu and He, 2006) and are under investigation because blocking 
their function results in enhanced brain regeneration. 
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A therapeutic window for drugs that increase neural plasticity is wider than those that 
target cytoprotection following cerebral ischemia (Zhang and Chopp, 2009) giving hope for 
improved functional outcomes in more stroke patients. A cerebroprotective drug can 
increase synaptic density in several ways. Cytoprotection, a process where cells can utilize 
more energy to maintain features that are not necessary in cell survival, can contribute to 
increased neuronal survival and therefore plasticity in the injured area. Presumably for the 
same reason increased oxygen and metabolic support improve cellular plasticity after 
different ischemic events in the brain as already mentioned above.  
Whether anti-apoptotic genes are able to induce neuronal plasticity by themselves other 
than by improving metabolic status is important to understand the pathophysiology of 
brain ischemia. In order to investigate this question we used Bcl-Xl or Bcl-2 gene construct 
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hypoxia only nestin expression was significantly different from the untreated hypoxic group 
(Gal et al., 2009). These data indicate increased that anti-apoptotic gene expression itself can 
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suggesting that similar pathways may mediate enhanced regeneration through different 
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vitro and in vivo. This is supported by btudies on other cerebroprotective drugs, such as 
erythropoietin (EPO) (Iwai et al., 2010), statins (Céspedes-Rubio et al., 2010), amphetamine 
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described.  
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3.1.1 Estrogen in the brain, estrogen receptors 
Corpechot and colleges described the first time that the cerebral sex steroid concentration is 
much higher than the circulating estrogen level both in men and women (Corpechot et al., 
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1981). Subsequently, estrogen synthesis (Le Gascone et al., 1987) and the essential enzymes 
(Hojo et al., 2004) involved were detected in the brain. 
The majority of the investigated intracellular effects of estrogen are related to two estrogen 
receptors (ERs) in the brain, ER- and ER-. Both of these receptors are expressed in the 
central nervous system; however, their distribution show different pattern. While ER-α is 
highly expressed in the hippocampus, hypothalamus, and preoptic area accompanied by a 
low expression in the cortex, ER-β is densely expressed in the cortex together with a high 
receptor density in the hippocampus, amygdala, cerebellum, etc. (Brann et al., 2011; 
Merchenthaler et al., 2003; Shughrue et al., 1997, Shughrue and Merchenthaler, 2000). Both 
of these ERs form homo- or hetero dimers after binding an estrogen molecule, such as 
estrone, estriol, or the most effective 17β-estradiol (E2). These dimers can bind to the 
estrogen responsive elements of the DNA and regulate the expression of several genes, such 
as bcl-2, IGF-1 (insulin like growth factor-1), NGF, (BDNF (McKenna and O’Malley, 2002; 
Merchenthaler et al., 2003; Nilsson et al., 2001; Sharma and Mehra, 2008). However, besides 
this “classical” signaling pathway, which requires hours to days to take place, estrogen can 
induce rapid changes via its non-genomic pathways. These non-genomic responses are 
mediated through extranuclear ERs, and occur within minutes of estrogen exposure through 
activation of several signaling cascades, such as phosphatidylinositol-3-kinase (PI3K), 
extracellular signal regulated kinase (ERK), mitogen-activated protein kinase (MAPK) or 
protein kinase C (PKC) (Bourque et al., 2009; Brann et al., 2011; Koszegi et al., 2011; 
Lebesgue et al., 2009; Rebas et al., 2005). Extranuclear receptors have been detected in the 
cytoplasm of the cell body, but also in the dendrites and axons of the neurons, while ER 
immunoreactivity was also seen in the organelle membranes, and synaptic vesicles (Milner 
et el., 2005). In addition, other brain cells, such as glial cells, have also been shown to express 
ERs (Milner et al., 2005; Woolley, 2007). 
A third estrogen receptor, the G-protein-coupled ER (GPR30), has also been detected in the 
brain (Funakoshi et al., 2006); however, limited data is available regarding its role under 
physiological and pathological conditions. One of its reported functions in the hippocampus 
is to increase synaptic transmission (Filardo et al., 2002; Lebesgue et al., 2009). This receptor 
is more likely to be associated with the ERK/CREB intracellular signaling pathway 
(Lebesgue et al., 2009), and presumably activates other intracellular signaling cascades as 
well. GPR30 protein expression was described in the neuronal plasma membrane and 
endoplasmic reticulum in several brain regions, such as the hippocampus (Funakoshi et al., 
2006; Matsuda et al., 2008). 
There is strong evidence that the three different estrogen receptors can crosstalk, for 
example regulating gene expression through ERK and Src signaling via transcription factor, 
and histone phosphorylation (Brann et al., 2011; Madak-Erdogan et al., 2008). GPR30 
pathway also can crosstalk with other extranuclear pathways through Akt activation 
(Lebesgue et al., 2009). 
The effect of age on ERs is worth to mention here as the incidence of cerebral ischemia is 
higher in the elderly and the old, which can modify the effect of estrogen therapy. Both ER-α 
and ER-β expressing cell number decreased significantly in the hippocampus of the aged 
rats; however, optical density of immunoreactivity per cell showed a significant increase for 
both ER-α and ER-β immunoreactivity in the CA1 neurons, whereas in CA3 neurons, it was 
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significantly reduced (Mehra et al., 2005). Increased expression of ERs per cell is supposedly 
a compensatory phenomenon. ER-β immunoreactivity was, however, found decreased in 
the CA1 dendritic synapses in old female rats in another study (Waters et al., 2011).  
3.1.2 Estrogen: Afforded protection and plasticity following brain ischemia 
Estrogens are known to increase synaptic density in the intact brain (McEwen, 2002; 
Merchenthaler et al., 2003; Rune et al., 2006; Sá et al., 2009; Sharma et al., 2007; Woolley, 
2007) even following administration of a single dose of this hormone (Sá et al., 2009; 
Wappler et al., 2011b). Even during oestrus cycle there is an intense fluctuation in dendritic 
density in rodents. Furthermore, ovariectomy or menopause itself results in a significant 
decrease of synaptic and dendritic density (Ojo et al., 2011; Woolley and McEwen, 1992). 
Data on estrogen effect also suggest that it acts directly at synapses by activating second 
messenger signaling, resulting in a rapid altering in neuronal excitability, synaptic 
transmission, and/or synaptic plasticity (Woolley, 2007). There is; however, limited data on 
neuronal plasticity following brain ischemia (Wappler et al., 2011b). 
Several studies have shown that E2 therapy is neuroprotective in cerebral ischemia. 
Estrogen increases the number of surviving cells following ischemia (Liu et al., 2009; 
Merchenthaler et al., 2003; Platha et al., 2004; Wappler et al., 2010), reduces excitotoxicity 
(Connell et el., 2007; Herson et al., 2009; Weaver et al., 1997), inflammation (Herson et al., 
2009 ; Stein, 2001; Suzuki et al., 2007), moderates blood–brain barrier dysfunction (Liu et al., 
2005), is antioxidant (Connell et el., 2007), increases cerebral blood flow (Herson et al., 2009; 
Hurn et al., 1995; Pelligrino et al., 1998), reduces spontaneous postischemic hyperthermia 
(Platha et al., 2004), etc. Cerebral ischemia studies in ER-α and ER-β KO mice models, and 
pharmacological receptor inhibition have shown that ER-α is the primary mediator of 
neuroprotection. (Brann et al., 2011; Dubal et al., 2001; Liu et al., 2009; Merchenthaler et al., 
2003; Miller et al., 2005). Both genomic and non-genimic effects seem to be involved in 
estrogen afforded neuroprotection (Merchenthaler et al., 2003). Selective GPR30 agonists 
have also been found neuroprotective in in vitro and in vivo models of brain ischemia 
(Gingerich et al., 2010; Lebesque et al., 2010; Zhang et al., 2010), however, its specific role in 
the pathophysiology of ischemic attack is still unknown. 
Genomic effects of estrogen includes the inhibition of apoptosis (through bcl-2, bax, caspase-
3); the diminution of inflammation (e.g. through tumor necrosis factor-α; interleukin 1, and 
6); the induction of growth factor, structural protein, and neuropeptide expression; etc. 
(Merchenthaler et al., 2003). High dose, acute estrogen treatment in global cerebral ischemia 
also induces cerebral plasticity by increasing synapsin-I and nestin gene expression in 
gerbils as we described previously (Wappler et al., 2011b). GAP-43 expression was however 
not elevated further due to the treatment compared to the already increased level after brain 
ischemia in our model. 
Most of the data on estrogen`s effect in brain ischemia were observed following chronic 
rather than acute treatment in rodents, which is a postmenopausal estrogen 
supplementation model as opposed to a model of acute therapy. There have also been a 
small number of studies that used older, or diseased animals, or females, especially 
investigating long term outcome (Wappler et al., 2010).  
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transmission, and/or synaptic plasticity (Woolley, 2007). There is; however, limited data on 
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6); the induction of growth factor, structural protein, and neuropeptide expression; etc. 
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also induces cerebral plasticity by increasing synapsin-I and nestin gene expression in 
gerbils as we described previously (Wappler et al., 2011b). GAP-43 expression was however 
not elevated further due to the treatment compared to the already increased level after brain 
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Most of the data on estrogen`s effect in brain ischemia were observed following chronic 
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supplementation model as opposed to a model of acute therapy. There have also been a 
small number of studies that used older, or diseased animals, or females, especially 
investigating long term outcome (Wappler et al., 2010).  
 
Advances in the Treatment of Ischemic Stroke 
 
98
4. Estrogen modulates synaptic density age, and subregion dependently in 
the gerbil hippocampus after global brain ischemia  
Our previous reports have demonstrated protective effects of E2 pre-treatment in gerbils 
following ischemia by increased cell survival, memory function and attention (Wappler et 
al., 2010). We also showed that increased cerebral plasticity takes place 4 days after the 
ischemia in the same model (Wappler et al., 2011b). Therefore, we hypothesized that E2 pre-
treatment increase the hippocampal synaptic plasticity both in shorter (4 days) and longer 
(25 days) time points in gerbils at different ages. 
4.1 Materials and methods 
4.1.1 Animals 
Ovariectomized gerbils of 4 (young), and 18 (old) months of age were used in our 
experiments. The animals were housed in an air-conditioned room at 22±1 ◦C with a 12 h 
light/dark cycle, and had free access to water and food. All the procedures on animals were 
approved by the Animal Examination Ethical Council of the Animal Protection Advisory 
Board at the Semmelweis University, Budapest, Hungary. 
4.1.2 Surgery and 17β-estradiol treatment 
The gerbils were anaesthetized with halothane (induction: 4%, maintaining: 1.5-2.5%) in a 30% 
O2/70% N2O mixture, breathing spontaneously via a face mask. Bilateral ovariectomy, and 10 
min bilateral carotid occlusion or sham neck surgery were performed as previously described 
(Wappler et al. 2010). Briefly, bilateral ovariectomy was performed through lateral incisions in 
each animal. Two weeks later transient bilateral carotid artery occlusion (10 min) was 
established through a midline cervical incision using atraumatic aneurysm clips (Codman, 
Johnson and Johnson, Le Locle, NE, Switzerland). The neck tissue was reunited in two layers 
with non-absorbable, 4.0 silk sutures (Ethicon, Johnson and Johnson). Sham surgery consisted 
of the midline cervical incision and carotid preparation followed by 10 min period, after which 
the incision was closed. Thirty minutes prior to surgery, estradiol treated group wasgiven 17β-
estradiol (Sigma Chemical Co. St Louis, MO, USA) 0.4 ml/100 g (4 mg/kg) body weight. On 
the other hand, sham-operated and untreated ischemic animals were injected vehicle solution 
(50% alcohol in normal saline) in a dose of 0.4 ml/100 g body weight intraperitoneally. 
4.1.3 Immunohistochemistry 
On the post-operative day (POD) 4 or 25 (n=5 in each groups) animals were sacrificed under 
deep halothane anesthesia, and brains were isolated and immersion fixed first in 10% 
buffered paraformaldehyde for 2 days, then in 4% buffered paraformaldehyde for another 5 
days. The brain tissues were then embedded into paraffin. From each animal five 20μm-
thick coronal sections, 100 m apart from each other were prepared as previously described 
(Mehra et al., 2005; Mehra et al., 2007). Goat anti-polyvalent IHC Staining Kit (Labvision, 
Neomaker lab, USA) was used according to manufacturer protocol for the 
immunohistochemical localization. SYP specific rabbit polyclonal antibody (Santa Cruz 
Biotechnology, USA) in a 1:200 dilution was used for 48 – 72 hours at 4 °C for the incubation. 
Sections were then incubated with biotinylated secondary antibody for 24 hours at 4 °C 
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followed by streptavidin-HRP complex for 2 hours at RT. For proper maintenance of the 
cytoarchitectural integrity including preventing undesirable background staining, the 
sections were thoroughly rinsed with wash buffer (0.1M PBS, pH 7.4) between each 
incubation steps. Localization of the antigen-antibody site was done with the substrate-
chromogen reaction using DAB. Immunoreactive sites became brownish under the bright 
field microscope. Adjacent sections were stained with cresyl violet (CV) to facilitate 
demarcation of various layers and subfields of the hippocampus. Intermittently some IHC 
stained sections were also counterstained with CV for the same purpose. 
To eliminate non-specific staining, negative controls were processed by incubating the 
sections with species-specific normal serum, whereas human breast cancer tissue served as 
the positive controls (data not shown). Sections from all the groups and the 
immunohistochemical controls were processed simultaneously and repeatedly to rule out 
any procedural variations. 
4.1.4 Image analysis 
Semi-quantitative estimation of synaptophysin immunoreactivity (SYP-ir) was carried out 
on every layer (such as the stratum oriens, stratum pyramidale, and stratum radiatum) in 
the CA1 and CA2-3 subfields of the dorsal hippocampus in all animals. For the semi-
quantitative analysis, integrated optical density (IOD) of SYP-ir was measured using image 
from five hippocampal sections of each animal, 100 m apart from each other as previously 
described (Mehra et al., 2005). These images were viewed under the Nikon Microphot -Fx 
microscope mounted with a Cool Snap Digital camera (Roper Scientific, USA) and attached 
to the image analysis system driven by Image Pro-Plus software (v 6.2, Media Cybernetics, 
USA). The size of the sampling field was 5000 m2, where 7-9 non-overlapping digital 
photomicrographs per section were taken. The quantitative analysis was the same as 
previously described (Mehra et al., 2005). In brief, photomicrographs were first converted to 
gray scale with proper background correction, and a standard optical density curve was 
generated for each image prior to analysis (density of corpus callosum devoid of any pre-or 
postsynaptic protein was measured as background, and substracted from the image). IOD 
was measured as cumulative sum of the optical density of immunodense areas. 
Mathematical values of IOD for comparison between the groups were obtained as arbitrary 
units (mathematical algoritm) by the analysis software. Data from individual animals of 
each group were pooled together and the results were expressed as mean IOD ± SD. 
4.1.5 Statistics 
Statistical analysis was performed using GraphPad Prism version 5.02 for Windows 
(GraphPad Software, San Diego California USA). One-way ANOVA with post-hoc 
Newman-Keuls Multiple Comparison Test was done to compare mean IOD between 
groups. The level of significance was set at p<0.05. 
4.2 Results 
4.2.1 Synaptophysin immunoreactivity: Aspect of age 
Cell loss in this model of cerebral brain ischemia can be detected both in CA1, and CA3 
regions following 10 minutes occlusion, in contrast to the short occlusion times, where only 
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4. Estrogen modulates synaptic density age, and subregion dependently in 
the gerbil hippocampus after global brain ischemia  
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immunohistochemical localization. SYP specific rabbit polyclonal antibody (Santa Cruz 
Biotechnology, USA) in a 1:200 dilution was used for 48 – 72 hours at 4 °C for the incubation. 
Sections were then incubated with biotinylated secondary antibody for 24 hours at 4 °C 
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incubation steps. Localization of the antigen-antibody site was done with the substrate-
chromogen reaction using DAB. Immunoreactive sites became brownish under the bright 
field microscope. Adjacent sections were stained with cresyl violet (CV) to facilitate 
demarcation of various layers and subfields of the hippocampus. Intermittently some IHC 
stained sections were also counterstained with CV for the same purpose. 
To eliminate non-specific staining, negative controls were processed by incubating the 
sections with species-specific normal serum, whereas human breast cancer tissue served as 
the positive controls (data not shown). Sections from all the groups and the 
immunohistochemical controls were processed simultaneously and repeatedly to rule out 
any procedural variations. 
4.1.4 Image analysis 
Semi-quantitative estimation of synaptophysin immunoreactivity (SYP-ir) was carried out 
on every layer (such as the stratum oriens, stratum pyramidale, and stratum radiatum) in 
the CA1 and CA2-3 subfields of the dorsal hippocampus in all animals. For the semi-
quantitative analysis, integrated optical density (IOD) of SYP-ir was measured using image 
from five hippocampal sections of each animal, 100 m apart from each other as previously 
described (Mehra et al., 2005). These images were viewed under the Nikon Microphot -Fx 
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generated for each image prior to analysis (density of corpus callosum devoid of any pre-or 
postsynaptic protein was measured as background, and substracted from the image). IOD 
was measured as cumulative sum of the optical density of immunodense areas. 
Mathematical values of IOD for comparison between the groups were obtained as arbitrary 
units (mathematical algoritm) by the analysis software. Data from individual animals of 
each group were pooled together and the results were expressed as mean IOD ± SD. 
4.1.5 Statistics 
Statistical analysis was performed using GraphPad Prism version 5.02 for Windows 
(GraphPad Software, San Diego California USA). One-way ANOVA with post-hoc 
Newman-Keuls Multiple Comparison Test was done to compare mean IOD between 
groups. The level of significance was set at p<0.05. 
4.2 Results 
4.2.1 Synaptophysin immunoreactivity: Aspect of age 
Cell loss in this model of cerebral brain ischemia can be detected both in CA1, and CA3 
regions following 10 minutes occlusion, in contrast to the short occlusion times, where only 
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the CA1 region is affected (Wappler et al., 2010), however, there are surviving cells that 
gives positive staining to synaptic markers. In the present study, the observed changes in 
SYP-ir were not limited to just one layer (stratum oriens, stratum pyramidale, or stratum 
radiatum), but the whole hippocampal region in each case, therefore we discuss our data 
using the CA1 or the CA3 hippocampal regions. 
Young animals showed a significantly lower SYP-ir compared to the old animals after 
ovariectomy, which resulted in a significant difference between the baseline levels (p<0.01 
young control vs. old control) (Fig.1., panel A). This might have been caused by the more 
pronounced change in the circulating estrogen level after ovariectomy in the young than in 
the old, where the estrogen production of the ovaries is low or there is no estrogen 
production at all. Due to this difference between the baseline values, age-comparisons were 
more difficult to make between age groups. Changes are therefore presented as percentages 
of the age-matched controls (Fig.1., panel B). Old gerbils had more severe synaptic loss in 
the CA1 area than young gerbils where no significant change following the injury was 
detected (see 4.2.2. for more details and significant differences among each age group). 
Estrogen treatment had, however, a positive impact on the synaptic density following 
ischemia in young animals in the CA3 region (see 4.2.2. for more details and significances 
between treated and non-treated groups), whereas, the same treatment was less effective in 
the old gerbils, but still helped imporved SYP-ir to a certain extent (Fig.1., panel B).  
 
Fig. 1. SYP-ir in the gerbil hippocampus after global cerebral ischemia and estrogen 
treatment: age comparison. Panel A: control (OVX) groups. Data are expressed as 
means±SEM. See detailed description in the text. **p<0.01 vs. young group same 
hippocampal region. Panel B: effect of ischemia and ischemia+E2 treatment. Data are 
expressed as percentages of the age-matched controls±SEM. See detailed description in the 
text. *p<0.05, **p<0.01, ***p<0.001 vs. the same treatment group of the 4 months old animals. 
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Please note that not every significant change is marked on this figure that you can find in 
the text. 
4.2.2 Synaptophysin immunoreactivity: Aspect of time and synaptic regeneration 
Cerebral ischemia itself decreased SYP-ir only in the CA2-3 region in the young, but 
decreased in both CA1 and CA2-3 regions in the old animals. This can be explained by the 
fact that ovariectomy itself decreases synaptic density in the young animals (Woolley and 
McEwen, 1992), and not every area is affected the same way. Areas that are more dependent 
on E2 to preserve their synapses might show a relatively lower decrease after ischemia, as 
theire baseline synaptic density is very low, and another stress that is not severe enough, can 
not cause a significant decrease. In contrast, ovariectomy does not make a significant 
difference in the circulating E2 levels in the old gerbils, however, there is a slight, but 
progressive loss of synaptic density and an increased vulnerability to ischemia with age (Ojo 
et al., 2011; Popa-Wagner et al., 2007), the latter causing a significant decrease even 
compared to a slightly lower control level. In addition, in the young, at the early time point 
there was an improvement due to E2 pre-treatment in the CA1 region (p<0.05 young 
ischemia POD4 vs. young ischemia+E2 POD4; significance not shown on figure), but at the 
later time point there was a decrement in synaptic density in the E2-treated group compared 
to the ischemic group (p<0.05 young ischemia POD25 vs. young ischemia+E2 POD25; 
significance not shown on figure). This can be explained by a higher estrogen-dependency 
and vulnerability in the CA1 region compared to the CA2-3 region in gerbils. In the old 
animals ischemia significantly decreased synaptic density in the CA1 region, however, we 
did not observe significant improvement with the estrogen pre-treatment in POD4. It only 
was observed at the late time point, which was close to be significant (p=0.054 old ischemia 
POD25 vs. old ischemia+E2 POD25). This is probably because of the decreasing tendency in 
SYP-ir following ischemia itself by POD25 that made a more prominent difference between 
the treated and non-treated group, as E2 treatment seemed to preserve the POD4 synaptic 
density level. We would like to note that there was no signs of recovery in the old animals 
following ischemia itself as SYP-ir did not icrease by POD25 compared to the POD4 value in 
the same group. 
Moreover, in this study, estrogen pre-treatment increased synaptic density in the 
hippocampal CA2-3 region in both age groups, however, the increment was more 
pronounced in the young. The young group showed further increment in synaptic density 
following ischemia (Fig.2.). In the CA2-3 region at the early and late time point synaptic 
density increased following estrogen pre-treatment in the young group (p<0.01 young 
ischemia POD4 vs. young ischemia+E2 POD4; and p<0.001 young ischemia POD25 vs. 
young ischemia+E2 POD25; significances not shown on figure), in addition, following 
ischemia itself SYP-ir also increased in the young in the CA2-3 area (p<0.05 young ischemia 
POD4 vs. young ischemia POD25; significance not shown on figure). However, no 
significant changes were detected in the old group with the estrogen pre-treatment, and no 
regenerative changes were observed after ischemia itself either. 
4.2.3 Summarizing our results 
Even a single dose of E2 treatment can induce long term changes in synaptic density in the 
injured hippocampus in our gerbil model of cerebral ischemia. At the same time, differences 
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the CA1 region is affected (Wappler et al., 2010), however, there are surviving cells that 
gives positive staining to synaptic markers. In the present study, the observed changes in 
SYP-ir were not limited to just one layer (stratum oriens, stratum pyramidale, or stratum 
radiatum), but the whole hippocampal region in each case, therefore we discuss our data 
using the CA1 or the CA3 hippocampal regions. 
Young animals showed a significantly lower SYP-ir compared to the old animals after 
ovariectomy, which resulted in a significant difference between the baseline levels (p<0.01 
young control vs. old control) (Fig.1., panel A). This might have been caused by the more 
pronounced change in the circulating estrogen level after ovariectomy in the young than in 
the old, where the estrogen production of the ovaries is low or there is no estrogen 
production at all. Due to this difference between the baseline values, age-comparisons were 
more difficult to make between age groups. Changes are therefore presented as percentages 
of the age-matched controls (Fig.1., panel B). Old gerbils had more severe synaptic loss in 
the CA1 area than young gerbils where no significant change following the injury was 
detected (see 4.2.2. for more details and significant differences among each age group). 
Estrogen treatment had, however, a positive impact on the synaptic density following 
ischemia in young animals in the CA3 region (see 4.2.2. for more details and significances 
between treated and non-treated groups), whereas, the same treatment was less effective in 
the old gerbils, but still helped imporved SYP-ir to a certain extent (Fig.1., panel B).  
 
Fig. 1. SYP-ir in the gerbil hippocampus after global cerebral ischemia and estrogen 
treatment: age comparison. Panel A: control (OVX) groups. Data are expressed as 
means±SEM. See detailed description in the text. **p<0.01 vs. young group same 
hippocampal region. Panel B: effect of ischemia and ischemia+E2 treatment. Data are 
expressed as percentages of the age-matched controls±SEM. See detailed description in the 
text. *p<0.05, **p<0.01, ***p<0.001 vs. the same treatment group of the 4 months old animals. 
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Please note that not every significant change is marked on this figure that you can find in 
the text. 
4.2.2 Synaptophysin immunoreactivity: Aspect of time and synaptic regeneration 
Cerebral ischemia itself decreased SYP-ir only in the CA2-3 region in the young, but 
decreased in both CA1 and CA2-3 regions in the old animals. This can be explained by the 
fact that ovariectomy itself decreases synaptic density in the young animals (Woolley and 
McEwen, 1992), and not every area is affected the same way. Areas that are more dependent 
on E2 to preserve their synapses might show a relatively lower decrease after ischemia, as 
theire baseline synaptic density is very low, and another stress that is not severe enough, can 
not cause a significant decrease. In contrast, ovariectomy does not make a significant 
difference in the circulating E2 levels in the old gerbils, however, there is a slight, but 
progressive loss of synaptic density and an increased vulnerability to ischemia with age (Ojo 
et al., 2011; Popa-Wagner et al., 2007), the latter causing a significant decrease even 
compared to a slightly lower control level. In addition, in the young, at the early time point 
there was an improvement due to E2 pre-treatment in the CA1 region (p<0.05 young 
ischemia POD4 vs. young ischemia+E2 POD4; significance not shown on figure), but at the 
later time point there was a decrement in synaptic density in the E2-treated group compared 
to the ischemic group (p<0.05 young ischemia POD25 vs. young ischemia+E2 POD25; 
significance not shown on figure). This can be explained by a higher estrogen-dependency 
and vulnerability in the CA1 region compared to the CA2-3 region in gerbils. In the old 
animals ischemia significantly decreased synaptic density in the CA1 region, however, we 
did not observe significant improvement with the estrogen pre-treatment in POD4. It only 
was observed at the late time point, which was close to be significant (p=0.054 old ischemia 
POD25 vs. old ischemia+E2 POD25). This is probably because of the decreasing tendency in 
SYP-ir following ischemia itself by POD25 that made a more prominent difference between 
the treated and non-treated group, as E2 treatment seemed to preserve the POD4 synaptic 
density level. We would like to note that there was no signs of recovery in the old animals 
following ischemia itself as SYP-ir did not icrease by POD25 compared to the POD4 value in 
the same group. 
Moreover, in this study, estrogen pre-treatment increased synaptic density in the 
hippocampal CA2-3 region in both age groups, however, the increment was more 
pronounced in the young. The young group showed further increment in synaptic density 
following ischemia (Fig.2.). In the CA2-3 region at the early and late time point synaptic 
density increased following estrogen pre-treatment in the young group (p<0.01 young 
ischemia POD4 vs. young ischemia+E2 POD4; and p<0.001 young ischemia POD25 vs. 
young ischemia+E2 POD25; significances not shown on figure), in addition, following 
ischemia itself SYP-ir also increased in the young in the CA2-3 area (p<0.05 young ischemia 
POD4 vs. young ischemia POD25; significance not shown on figure). However, no 
significant changes were detected in the old group with the estrogen pre-treatment, and no 
regenerative changes were observed after ischemia itself either. 
4.2.3 Summarizing our results 
Even a single dose of E2 treatment can induce long term changes in synaptic density in the 
injured hippocampus in our gerbil model of cerebral ischemia. At the same time, differences 
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in age, as well as differences in the investigated brain regions, modulate the degree and the 
permanence of this E2 effect. 
 
Fig. 2. SYP-ir in the gerbil hippocampus after global cerebral ischemia and estrogen 
treatment: dynamic changes with time. See detailed description in the text. Data are 
expressed as means±SEM. *p<0.05, ** p<0.01, ***p<0.001 vs. age-matched control. Please 
note that only significant changes vs. control groups are shown on the figure, differences 
between ischemia and ischemia+E2, etc. can be found in the text. 
It was an unexpected result for us, that the CA3 region was more vulnerable to ischemia, in 
terms of synaptic loss, than the CA1 region in the young animals. This result, however, was 
probably due to the previous ovariectomy that might have had a bigger impact on the CA1 
region. This is consistent with our results in the aged animals, where the ischemia decreased 
synaptic density more in the CA1 region, as expected in this model. It is also possible that 
aging may predispose to a tendency of diminished synaptogenesis and ability to improve 
synaptic density, especially in the hippocampal CA3 subfield. Our results emphasize the 
importance of investigating cerebral regenerative potential in older, female animals as well 
as at later time points following ischemic injury. 
5. Conclusion 
Post-ischemic brain regeneration is well documented at the tissue, cellular, and subcellular 
levels that offer further opportunities for drug development to improve functional outcome. 
In addition, estrogen, a well known regulator of synaptic density, has a long term impact on 
regeneration after global cerebral ischemia even as a single, high-dose treatment. Age, 
however, has influence on its effects, which highlights the importance of using old animals 
in this field. 
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1. Introduction  
Stroke is the leading cause of permanent disability in industrialized nations (Lloyd-Jones et 
al, 2010). Ischemic stroke occurs secondary to blood flow interruption to the brain, typically 
secondary to the occlusion of an intra- or extra-cranial artery. This lack of blood supply to 
the brain results in a paucity of nutrients, glucose, and oxygen, which leads to cerebral 
ischemia and infarction (Wardlaw et al, 2003). However, intracranial artery occlusion results 
in varied rates of tissue injury depending on the local anatomy, as well as numerous still-to-
be-deciphered physiologic factors. Generally, the ischemic core of the occluded vascular 
territory rapidly infarcts and becomes unsalvageable tissue. However, the surrounding 
region of ischemia, known as the penumbra, often receives enough collateral supply that it 
may be saved, providing adequate perfusion is reestablished in a timely fashion. The 
concept of restoring normal perfusion to the penumbra, thereby rescuing crucial brain 
tinssue and hence neurological function, is fundamental.  
To date, the significant majority of stem cell stroke research has focused on evaluating the 
potential of Neural Stem Cells in cerebral ischemic repair (Garzon-muvdi et al, 2009; Miljan 
et al, 2009; Bersano et al, 2010; Locatelli et al, 2009; Burns et al, 2009). However, the field of 
Hematopoietic stem cell (HSC) research in stroke is not barren, as a small volume of 
literature has recently emerged. HSC have recently been shown to mobilize to the peripheral 
circulation from bone marrow in response to stroke (Hennemann et al, 2008), and increasing 
circulating HSC levels correlate with improved neurological function following stroke, 
suggesting a potentially critical role for HSC in limiting stroke injury and/or facilitating 
stroke recovery (Yip et al, 2008; Taguchi et al, 2009). Moreover, post-ischemic intravascular 
administration of exogenous HSC has recently been shown to ameliorate ischemic stroke in 
mice (Schwarting et al, 2008). Additionally, well established therapeutics that are known to 
mobilize HSC have shown very exciting preliminary results in animal models and are 
currently undergoing clinical evaluation for other modes of central nervous system injuries 
(Luo et al, 2009). Increasing levels of circulating HSC have recently been demonstrated to 
correlate with improved neurological function following stroke, suggesting a potentially 
critical role for HSC in limiting stroke injury and/or facilitating stroke recovery (Yip et al, 
2008; Taguchi et al, 2009).  
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2. What are hematopoietic stem cells? 
A stem cell has the capacity for self-renewal and the ability to differenretiate into multiple 
cell types (potentcy) (Melton et al, 2004). A progenitor cell has similar characteristics to a 
stem cell, however, it has limited potential for differentiation (it has limited self renewal 
capacity and can only differentiate into limited types of cells (Melton et al, 2004). 
Hematopoietic Stem Cells (HSC) are circulating bone marrow derived mononuclear cells 
that promote repair in areas of injury (Baum et al, 1998). HSC travel thru peripheral blood 
from the fetal liver to the bone marrow and seed the bone marrow with immature and 
maturing cells (Melton et al, 2004); the bone marrow then remains the main site of 
hematopoiesis in adult life (Melton et al, 2004). During embryogenesis the three embryonic 
germ layers partition into 3 embryonic layers: ectoderm, mesoderm and endoderm (Hall et 
al, 2000). The ectoderm gives rise to skin and neural cells and tissues (Hall et al, 2000); the 
mesoderm gives rise to the blood cells, bone, fat, cartilage and muscle and the endoderm 
gives rise to the respiratory system and digestive tract (Wells et al 1999). The resulting 
tissues and organs from these three layers retain their original specification throughout 
adulthood. The neural crest is the only exception to that rule; it is of ectoderm origin and 
gives rise to neural, muscle and bone cell lineages. Based on the three germ layers, it would 
seem that stem cells generate mature cells corresponding to the tissue of that origin only. 
However, stem cells can transdifferentiate into cells of a completely different lineage. Some 
tissues in the adult, have been shown to respond very well to re-generation by HSC, for 
example liver (Varga et al, 2010), and others have been shown to respond poorly, for 
example, heart (Rumyantsev et al 1987). This may indicate the presence of stem cells within 
these tissues The brain used to be thought of as a non renewing organ, however, it has now 
been shown to have a high cell turnover (Kajsutra et al 1999; Altman et al, 1965; Lois et al, 
1993).  
HSC can self renew themselves at a single cell level and can differentiate to mature 
progeny of non-renewing and terminally differentiated cells (Seita et al, 2010). In contrast 
totipotent cells (can give rise to all embyonic and extraembyonic cell types), pluripotent 
(can give rise to all cell types of the embryo), oligopotent (can give rise to limited cell 
lineages), or unipotent cells (can give rise to a unique mature cell type), HSC have 
multipotent developmental potential (can give rise to a subset to cell lineages) (Seita et al, 
2010). The HSC in the bone marrow proliferate and differentiate into erythroid, lymphoid 
and myeloid lineages (Figure 1) (Kondo et al, 2003). Commitment to each lineage is 
dictated by several growth factors such as VEGF, EGF, IGF, FGF and PDGF. HSC are 
recruited to the peripheral circulation from bone marrow in response to stress or injury 
such as stroke (Paczkowska et al, 2005; Machalinski et al, 2006; Henneman et al, 2008). 
Bone marrow HSC give rise to the hemangiobalst (Urbick 2004; Hristov et al, 2004; 
Rumpold et al, 2004), which in turn give rise to mature endothelial cells (Hristov et al, 
2004).  
Bone marrow derived HSC contribute to hematopoietic tissues (tissues which can stimulate 
the bone marrow) such as: skin (krause et al, 2001), kidney (Kale et al, 2003), central nervous 
tissue (Brazelton et al, 2000, Weimann et al, 2003) and have also been found to contribute to 
non hematopoietic tissues such as: myocardium (Orlic et al, 2001) and Skeletal muscle 
(Ferrari et al, 1998). This phenomenon may be due to circulating HSC lodging in non-
hematopoietic tissues or due to lineage conversion of HSC. HSC can either transdifferentiate 
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(alter their lineage specificity by activation of alternate genes), de-differentiate and re-
differentiate (HSC can de-differentiate to a more primitive state (multipotent state) and then 
re-differentiate along a different lineage pathway), come from a homogenous starting 
population of cells or be a result of cell-cell fusion. Most HSC studies are done by injecting 
or implanting a large number of cells, many of these cells may be contaminating impurities 
resuting from harvesting or enriching techniques (described below). The presence of HSC in 
non-hematopoietic tissues may be due to the impurities present in the starting population 
(Kanof et al, 2001). Another contributing phenomeon for the presence of HSC in non-
hemaoptopoietic tissues may be due to cell-cell fusion (Anderson et al, 2000). Cell-cell fusion 
is a natural occurence in skeletal myofibres (Anderson et al, 2000) but may also be 
pathologic, for excample in HIV infection of T-lymphocytes (Mccune et al, 1998). Terada et 
al (2002) were the first group to show that stem cells may fuse with cells of the central 
nervous system without commiting to the parent cell lineage. These fusion cells take on the 
phenotype of the parent cell without complete differentiation to their specific lineage. 
Alvarez-Dolado et al (2003) also showed that bone marrow derived HSC contribution to 
non-hematopoietic tissue repair was due to cell-cell fusion rather than transdifferentiation of 
the HSC. 
 
Fig. 1. Multipotent stem cells from the bone marrow can give rise to erythroid, lymphoid 
and myeloid lineages. 
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2.1 Mobilization and neovascularization  
Mobilization of HSC to the blood occurs via trans-endothelial migration thru the bone 
marrow. Proteinases, such as elastase, cathepsin G, and matrix metalloproteinases, cleave 
and release the HSC from the bone marrow stroma and surrounding cells (Heissig et al, 
2002). The HSC leave the bone marrow in response to several growth factors, such as SDF1-
A, VEGF, EPO and G-CSF. All of these growth factors have been shown to increase levels of 
circulating HSC in the blood. Neovascularization is the de novo synthesis of blood vessels 
and it differs from Angiogenesis which refers to sprouting of capillaries from existing blood 
vessels (Carmeliet et al, 2005). Vasculogenesis/vascularization refers to differentiation of 
HSC into endothelial cells and was thought to occur only in the embryo (Shi et al, 1998). 
Bone marrow derived HSC have now been showed to home to a site of neovascularization, 
proliferate and differentiate into endothelial cells (Masuda et al, 2003). Several groups have 
shown that neovascularization occurs in response to ischemia in the heart (Hur et al, 2007; 
Cook et al, 2009; Shintani et al, 2001; Sanganalmath et al 2011). HSC injected into myocardial 
infarction patients showed an increase in blood flow and an improvement in heart function. 
In addition, HSC injected into a hind limb ischemia model also results in increased 
neovascularization in the ischemic limb. Cohorts with ischemic hind limbs were also 
injected autologous bone marrow which resulted in reduced chest pain and an 
augmentation of the ankle-brachial index. These studies show that HSC contribute to 
ischemic rescue, however, the mechanism of this rescue is unclear. If HSC are injected 
without an injury, there is very little incorporation of the cells and in the presence of 
ischemia, the rate of incorporation of the HSC is dependent on degree of ischemia (Shintani 
et al, 2001; Sanganalmath et al, 2011). However, even in the presence of a large ischemic 
injury, very few HSC have been detected at the site of injury. So then how can a few HSC 
contribute to blood vessel repair in the presence of a large ischemic injury such as a stroke? 
This may be accomplished by the paracrine release of growth factors by the few HSC that 
home to the site of injury. Growth factors secreted by these cells at the site include IGF-1 and 
FGF, which increase proliferation of HSC, MCP-1, which increases migration of the HSC 
towards the ischemic core, and TGFb, which promotes differentiation of the cells into 
mature endothelial cells.  
Hematopoietic stem cells mobilize from the bone marrow to the blood in response to injury 
(Kucia et al, 2004). The HSC are associated with bone marrow stromal cells and exist as 
quiescent cells in the bone marrow. The HSC in the bone marrow must transform from this 
quiescent state to an active proliferative state before they can be mobilized to the peripheral 
blood. Proteinases, for example, elastase, cathpsin G and MMP’s cleave the extracellular 
matrix which anchors the HSC to the bone marrow stroma (Heissig et al, 2002). MMP-9, 
secreted by the bone marrow stromal cells cleaves the membrane bound receptor mKitL 
(Heissig et al, 2002). Cleavage of the receptor converts it to the soluble KitL which can bind 
to the cKit receptor present on HSC (Figure 2). Binding of the sKitL to the cKit receptor 
activates signalling cascades enabling proliferation and mobilization of the cells to the 
peripheral blood (Heissig et al, 2002). While MMP-9 -/- mice were shown to have a reduced 
recruitment o the peripheral blood, MMP-9+/+ mice treated with SDF or VEGF showed a 
marked increase in mobilization of the HSC from the bone marrow to the peripheral blood 
(Heissig B, 2002). Presence of HSC in the peripheral blood was first shown in the 1960’s and 
70’s (Korbling et al, 1994). Since then, peripheral blood HSC counts have been used as 
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biomarkers in diseases such as: diabetes (Fadini et al, 2006), Hyperhomocystenemia (Zhu et 
al, 2006), Aging (Heiss et al, 2005), Hypertension (Pirro et al, 2007), Systemic Scelrosis (Del 
Papa et al, 2006), Chronic smoking (Kondo et al, 2004) and Coronray Artery Disease (Kunz 
et al, 2006). 
 
Fig. 2. Bone marrow stromal cells (green) secrete MMP-9, which cleaves the membrane 
bound cKIT receptor present on HSC (purple). Cleavage of the receptor converts it to the 
soluble KitL which can bind to the cKIT receptor present on the HSC. Binding of the KitL to 
the receptor enables proliferation and migration of the HSC to the peripheral blood. 
2.2 Growth factors in HSC mobilization  
Growth Factors which have remained in the forefront of HSC research include Vascular 
Endothelial Growth Factor (VEGF) (Leung et al, 1998) and Stromal Derived Growth Factor-1 
A (SDF1-A) (Ma Q et al, 1998). VEGF is produced by many cells, not only HSC (Leung et al, 
1989) and is formed by alternate splicing of a single gene (Leung et al 1989). Alternate 
splicing of the parent gene leads to the formation of VEGF (Leung et al 1989), VEGFB 
(Olofesson et al, 1996), VEGFC (Chilov et al, 1997), VEGFD (Latitinen et al, 1997) and VEGFE 
(Ogawa et al, 1998), however, VEGF is by far the most studied growth factor (Leung et al, 
1998). Carmeliat et al (1996) and Ferrara (1996) both showed that homozygous knockouts of 
VEGF (VEGF +/-) die in utero due to impaired hematopoiesis (Ferrara et al, 1996) and 
anigogenesis (Carmeliat et al, 1996). VEGF can bind to 2 receptors: VEGFR1 (flt) (Ortega et 
al, 1997; Shalaby et al, 1995) and VEGFR2 (kdr) (Terman et al, 1992). Binding of VEGF to 
VEGFR1 contributes to vascular remodelling (Fang et al, 1996) and binding to VEGFR2 
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biomarkers in diseases such as: diabetes (Fadini et al, 2006), Hyperhomocystenemia (Zhu et 
al, 2006), Aging (Heiss et al, 2005), Hypertension (Pirro et al, 2007), Systemic Scelrosis (Del 
Papa et al, 2006), Chronic smoking (Kondo et al, 2004) and Coronray Artery Disease (Kunz 
et al, 2006). 
 
Fig. 2. Bone marrow stromal cells (green) secrete MMP-9, which cleaves the membrane 
bound cKIT receptor present on HSC (purple). Cleavage of the receptor converts it to the 
soluble KitL which can bind to the cKIT receptor present on the HSC. Binding of the KitL to 
the receptor enables proliferation and migration of the HSC to the peripheral blood. 
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1989) and is formed by alternate splicing of a single gene (Leung et al 1989). Alternate 
splicing of the parent gene leads to the formation of VEGF (Leung et al 1989), VEGFB 
(Olofesson et al, 1996), VEGFC (Chilov et al, 1997), VEGFD (Latitinen et al, 1997) and VEGFE 
(Ogawa et al, 1998), however, VEGF is by far the most studied growth factor (Leung et al, 
1998). Carmeliat et al (1996) and Ferrara (1996) both showed that homozygous knockouts of 
VEGF (VEGF +/-) die in utero due to impaired hematopoiesis (Ferrara et al, 1996) and 
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initiates proliferation, migration and differentiation of HSC (Ortega et al, 1997; Matthews et 
al, 1991) through the PI3K/AKT/NFkb pathway (Byrne M, 2005). Oxygen levels in the bone 
marrow are typically lower than the peripheral blood (Harrison et al, 2002) thus leading to 
lower oxidative stress and higher HSC survival and proliferation (Jang et al, 2007).  
  
Fig. 3. Hypoxia Inducible Factor (HIF) is composed of two subunits: HIF1-A and HIF1-B. 
Normoxia leads to degradation of HIF1-A and hypoxia causes it to translocate to the nucleus 
for activation. In the nucleus, HIF1-A binds with HIF1-B to form heterodimers and bind to 
hypoxia Response Elements (HRE) to activate transcription of VEGF. 
Hypoxic environments activate hypoxia Induced Factor-1 (HIF-1) (Wang et al, 2005). HIF1 
is composed of 2 subunits: HIF-1A (the oxygen sensing domain) and HIF-1B (Wang et al, 
2005). Under conditons of normoxia, HIF1-A is degraded by proteasomes (Jaakkola et al, 
2001) and under hypoxia both units form heterodimers (Figure 3) and bind to Hypoxia 
Response Genes to activate transcription of VEGF (Wang et al, 1995). Shuweiki et al (1992) 
showed that hypoxia increases VEGF production which is necessary for hematopoietic 
activity in the bone marrow (Carmeliat et al, 1992; Gerber et al, 2002). Gerber et al (2002) 
also showed bone marrow engraftment failure if VEGF negative HSC were injected into 
lethally irradiated mice. In addition, Hooper et al (2009) showed that impaired VEGFR2 
on the HSC also failed to engraft lethally irradiated mice (Hooper et al, 2009). Rehn et al 
(2011) recently futher confrimed that loss of VEGF expression in VEGF knockout mice 
increased impaired HSC which were not able to engraft secondary lethally irradiated mice 
(Rehn et al, 2011). 
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Stromal Derived Growth Factor-1 Alpha (SDF1-A) is released by cells following stress, 
injury or hypoxia (Muller et al, 2001). SDF1-A is localized to chromosome 10q11.1 and is 
highly conserved between species. SDF1-A belongs to the CXC family of chemokines and 
was originally described as a pre B cell growth stimulating factor. SDF1-A is a ligand for 
CXCR4, a G protein coupled receptor, and their interaction mediates a chemotactic response 
followed by cell migration. The receptor for SDF1-A is a 7 transmembrane receptor, CXCR4 
(Kucia et al, 2004). Binding of the SDF1-A to its receptor, initiates the PI3K-AKT and NfkB 
Pathway. This pathway leads to the phosphorylation of MAPK, an intracellular calcium 
efflux and a subsequent adhesion of the cells to fibronectin (Kucia et al, 2004). SDF1-A and 
its receptor CXCR4 have been shown to regulate trafficking of HSC in response to injury 
(Ma et al, 1998; Lapidot O et al, 2002; Pituch-Noworolska et al, 2003). Increasing SDF1-A 
expression in a hind limb ischemia model has been shown to increase mobilization of HSC 
and increased angiogensis in the hind limb (Hiasa et al, 2004). An increase in SDF1-A levels 
in the blood leads to an increase in CXCR4 positive cells to the injured/hypoxic area (Kucia 
et al, 2004). Following injury, bone marrow levels of SDF1-A decrease (Petit et al, 2002), 
while those in the peripheral blood increase (Morris et al, 2003). Reduced levels of SDF1-A 
in the bone marrow mediates secretion of MMP-9 which facilitates mobilization of the cells 
from the bone marrow to the peripheral blood (Janowska-Wieczoveka et al, 2000). Once in 
the circulation, the HSC can differentiate into myeloid cells, lymphocytes, erythrocytes, 
platelets or endothelial progenitor cells (Kondo et al, 2003). Increased levels of SDF1-A help 
to retain recruited bone marrow HSC in close proximity to angiogenic blood vessel growth 
(Grunewald et al, 2006). 
Eventhough SDF1-A leads to an increase in mobilization of the HSC from the bone marrow, 
it has also been shown to cultivate a protease rich environment in the bone marrow, which 
can be both beneficial (Janowska-Wieczoveka et al, 2000; Hiasa et al, 2004) and harmful 
(McQuibban et al, 2001). An upregulation in SDF1-A levels also leads to an increase in 
MMP-2 expression which cleaves SDF1-A to a toxic fragment which is incapable of binding 
to its receptor (CXCR4) and has been shown to be neurotoxic (McQuibban et al, 2001; Zhang 
et al, 2003). To overcome this unwelcomed cleavage, Segers et al (2011) designed deliverable 
SDF1-A with mutations which made it resistant to MMP-2 cleavge. This mutated form of 
SDF1-A sustained local SDF1-A levels, increased SDF1-A levels in the ischemic limb and 
increased vascular density (Segers et al, 2011). However, the role of SDF1-A in generation of 
mature vessels is unknown. Therapies using angiogenic growth factors leads to unstable 
vessel formation which regress following cessation of the therapy (Gounis et al, 2005). In 
contrast to VEGF, SDF1-A prevents tortuos blood vessel formation (due to extensive 
proliferation of endothelial cells) which are hyper-permeable (Segers et al, 2010). A study by 
Moore et al (2001) looked at the synergistic effect of SDF1-A and VEGF; IV delivery of 
replication incompetent adenovectors expressing the SDF1-A gene incresed plasma SDF1-A 
levels and increased mobilization of bone marrow derived cells which were positive for 
VEGFR2 (Moore et al, 2001). Delivery of replication incompetent adenovector expressing 
VEGF increased plasma VEGF levels and increased moblization of HSC which were positive 
for VEGFR1. In addition these authors looked at the possibility of combining VEGF with 
other growth factors such as Angiopoietin-1. The combination treatment prolonged HSC 
mobilization and increased proliferation of capillary beds (Moore et al, 2001). 
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3. Sources of hematopoietic stem cells 
Very little information is available on human fetal tissue research, which is done mostly in 
Europe. Gallacher et al (2000) first reported the presence of HSC in aborted human fetuses 
and subsequent work focused on fetal tissues of vertebral animals (Dzierzak et al, 1999). 
Embryonic stem cells have also been shown to have high proliferative capacity (Rolletschek 
et al, 2004) along with the ability of differentiating into several types of blood cells (Hole et 
al, 1999). Embryonic tissues are a rich source of HSC; however, due to the lack of a source 
for obtaining these cells, very little data is available on their use in humans. Human cord 
blood cells (HUCB), produced by the placenta, support a developing fetus and are discarded 
upon delivery. HUCB are multipotent (able to generate multiple germ layers) and a rich 
source of HSC which have been used in research studies. The first successful cord blood 
transplant was done in children with Fanconi’s anemia (Laughlin et al, 2001) and more 
recently have been used in clinical trials for autoimmune disorders, cerebral palsy and Type 
I diabetes(Laughlin et al, 2001). HUCB offer an ethical source of HSC (McGuckin et al, 2008), 
have a low risk of host versus graft disease and are readily available from bio banks (Forraz 
et al, 2011). 
Bone marrow stem cells (BMSC) are obtained from a donor from the hip bone (Diefenderfer 
et al, 2011). The donor is anesthetized and bone marrow drawn up in a syringe (Lee et al, 
2004). This procedure is painful and may require a hospital stay (Lee et al, 2004). BMSC 
contain HSC, stromal and progenitor cells (Diefenderfer et al, 2011). Peripheral blood also 
has circulating HSC, which can also be induced to mobilize from the bone marrow into the 
blood in response to GCSF administration (Elfenbein et al, 2004). This procedure is easier on 
the donor and can be used for autologous and allogeneic administration (Brown et al, 1997; 
Lickliter et al, 2000). Peripheral blood stem cells have also been used successfully in patients 
(Verbik et al, 1995; Brown et al, 1997). The biggest difference in obtaining HSC from 
different sources is the quantity of cells. While HUCB may be a viable source for HSC, very 
few HSC can be obtained, thereby limiting use to children and not adults. BMSC offers the 
best viable option, for autologous HSC administration and higher yields. 
4. Isolation of hematopoietic stem cells 
HSC isolation can be a multistep process requiring the use of Ficoll (Fuss et al, 2009), FACS 
(Schlenke et al, 1998), Magnetic microbeads (Woywodt et al, 2005), or culturing of Early and 
late outgrowth cells (Asahara et al, 1997). Depending on the source of sample and the 
species, protocols may need to be adjusted accordingly. HSC vary in size and density 
compared to other cells present in the bone marrow or the blood (Fuss et al, 2009). 
Therefore, they move through specialized density media such as Ficoll (Fuss et al, 2009), at a 
specific rate when a centrifugal force is applied. The red blood cells and granulucytes are 
more dense than the HSC and can easily be separated from them following the 
centrifugation (Kanof et al, 2001; Jaatinen et al, 2007). HSC are isolated from the monouclear 
cell layer, however, since this layer has impurities, such as lymphocytes (which have 
overlapping densities with the HSC) (Kanof et al, 2001; Jaatinen et al, 2007), further 
purification is needed to obtain a pure HSC fraction. In addition to using a density medium, 
several groups (Schlenke et al, 1998; Ruitenberg et al, 2006) have used a cell preparation tube 
(CPT) which contains a cell separater solid at the bottom of a vaccutainer tube. The CPT 
tube requires fewer steps to obtain the mononuclear layer and Ruitenberg et al (2006) 
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reported that there was no significant difference in using either the Ficoll density medium or 
the CPT tube.  
The HSC can be further purified from the bone marrow or peripheral blood and depleted 
for lineage markers by using either flow cytomtery (Schlenke et al, 1998) or microbeads 
coated with antibodies (Woywodt et al, 2005). Flow cytometery can be used to select for the 
presence or absence of markers simultaneously, however, this method cannot process a 
large number of cells quickly (Schlenke et al, 1998). Column based methods offered a much 
quicker way of enriching HSC, however, an additional step had to be included to elute cells 
from the columns (Jaatinen et al 2007). Consequently, magentic bead technology was 
developed which allowed for either a negative or positive selection of selected markers 
(Horrocks et al, 1998; Woywodt et al, 2005). A positive selection (an antibody is used to 
target an antigen which is expressed on the surface of desired cells) yields a higher purity of 
HSC due to the use of one antibody and a negative selection (use of antibodies to target 
antigens not expressed on desired cells) requires several antibodies to remove unwanted 
cells (Woywodt et al, 2005). In contrast to using freshly isolated cells, Asahara et al (1997) 
first isolated HSC and cultured them in specific media on fibornectin coated dishes. The 
cells that grew in these cultures were called either early or late endothelial progenitor cells. 
Both types of cells were positive for acetylated LDL and lectin binding, however, only the 
Late endothelial progenitor cells were positive for VE-Cadherin, von Willebrand factor and 
CD31 (all markers of mature endothelial cells) (Asahara et al, 1997).  
In addition to a variety of techniques which can be used to isolate the HSC, an array of cell 
surface markers can be used to enrich for the desired HSC fraction. Asahara et al (1997) were 
the first to report that mononuclear cells enriched in CD34+ cells can also mature to 
endothelial cells. They used the peripheral blood monouclear cells to isolate progenitors 
using magnetic microbeads. The progenitors wre plated onto fibronectin coated plates and 
confirmed to have endothelal characteristics. Subsequently, cells expressing CD133, CD34 
and VEGFR2 were defined as HSC (Asahara et al, 1997; Hristov et al, 2004). CD133 is a 
membrane glycoprotein which is lost after differentiation and VEGFR2 is present on all 
endothelial cells. Hemangioblasts in the bone marrow express CD133, CD34 and VEGFR2; 
once these cells are activated and committed to an endothelial lineage, they gain expression 
of CD31 and retain CD133, CD34 and VEGFR2. Fully differentiated endothelial cells express 
CD34, Von Willebrand Factor, VEGF, CD31, VE- Cadherin and E-Selectin (Figure 4). In mice, 
lineage depletion includes removal of CD5, CD45R, Cd11b, Ly6G and TER119 (Spangrude et 
al, 1998; Horrocks et al, 1998) and subsequent selection of the SCA and cKIT positive cells 
(Uchida et al, 1992; Osawa et al, 1996; Lois et al, 2001). 
5. Stroke 
Chen et al (2001) were the first to report the use of Human cord blood cells (HUCB) 
following stroke (Chen et al, 2001). The authors used a middle cerebral artery occlusion 
(MCAO) model in Wistar rats. The HUCB were injected at either day 1 or 7 post stroke. 
Behavior (rotarod) analysis and neurological score were recorded on days 1, 7, 14, 21, 28 and 
35 days post stroke. Behavior was significantly improved in animals which received the 
HUCB at 1 day post stroke whereas day 7 only showed an improvement in the neurological 
score and not the behavior testing. The lesion volume was determined by H&E staining on 
day 35 post stroke and no significant differences were observed in animals which received  
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Fig. 4. Hematopoietic stem cells (HSC) express CD133, CD34 and VEGFR2. Mature 
endothelial cells (EC) express CD34, CD31, VEGFR2, Von Willebrand Factor, E-Selectin and 
VE-Cadherin. Early endothelial progenitor cells (EPC) express CD31 in addition to the 
markers carried by the HSC and late EPC express Von Willebrand factor, E-selectin and VE-
cadherin in addition to the early EPC markers. 
the HUCB and those that did not. HUCB were localized in the ischemic hemisphere by 
immunostaining for MAB1281 (an anti-human nuclei monoclonal antibody). Additionally 
co-staining was done for neurons (using micro-tubule-associated protein 2 and NeuN), 
astrocytes (using glial fibrillar acidic protein) and endothelial cells (using von Willebrand 
Factor). Animals which did not receive any HUCB showed no positive cells for MAB1281 
and of the positive cells in the transplanted animals, 2% of the cells were positive for NeuN 
markers, 3% for neuronal markers, 6% for astrocytic markers and 8% for endothelial 
markers. The ability of HUCB to migrate towards an ischemic area was also tested in vitro 
using a chemotaxis assay. Ischemic brain extracts stimulated migration of HUCB in vitro. 
This study showed that IV transplantation of HUCB significantly improved behavior when 
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the cells were administered at day 1(Chen et al, 2001) , however, no explanations were 
offered for the mechanism of action for these cells other than the possibility of release of 
trophic growth factors from the HUCB.  
A possible mechanism by which HUCB may be contributing to a reduction in behavior 
deficits was suggested by Regelsberger et al (2011). These authors postulated that the HUCB 
may be modulating delayed apoptosis in the ischemic hemisphere leading to the reduction 
in behavior deficit. Spontaneously hypertensive rats were used in this study for either a 
histological evaluation (at 25, 48, 72 and 96 hours) or a molecular biology study (at 6, 24, 36 
and 48 hours) post stroke. The HUCB were injected intravenously and histological analysis 
was done for infarct volumes by assessing the loss of MAP-2 positive neutrophil staining 
and cleaved caspase-3 positive cells were also counted. The results of this study showed that 
the number of cleaved caspase-3 cells in the infarct area increased from days 1 to 4 and were 
not affected by the IV administration of the HUCB. Molecular analysis by real time PCR also 
showed no differences in the levels of caspase-3 mRNA or survivin (an anti-apoptotic 
protein) in groups that received or did not receive the HUCB. Unlike other studies using 
HUCB (Vendrame et al, 2006), the infarct volumes in this study were not affected by the 
administration of HUCB. The study could not provide any evidence that HUCB contributed 
to the reduced behavior deficits due to anti-apoptotic effects. Another study (Leonardo CC 
et al, 2010) suggested that HUCB may lead to a reduced recruitment of pro-inflammatory 
cells to the ischemic hemisphere and hence faster recovery. Sprague Dawley rats were used 
to induce an MCAO and HUCB were delivered intravenously. Brain sections were stained 
for CD11b (inflammatory cell marker) and MMP-9 (causes basement membrane degradation 
leading to blood brain barrier leakage). Animals which did not get any HUCB had a 
significantly higher number of CD11b staining cells in the ischemic hemisphere and these 
cells were also positive for MMP-9 (Leonardo et al, 2010). 
In contrast to the previous studies, Makinen et al (2006) have reported that IV 
administration of HUCB does not contribute to the functional recovery of Wistar rats. These 
authors suggested that studies evaluating functional behavior outcome following stroke do 
not utilize a comprehensive battery of tests to evaluate sensorimotor, cognitive and 
histological tests for the animals. This study used the beam walking test (assesses forelimb 
and hind limb function), cylinder paw placement (use of impaired contralateral (to lesion) 
paw to assess forelimb asymmetry, water maze (for length, latency and swimming speed). 
The HUCB were administered at 24 hours post stroke to avoid an inflammatory response 
which can complicate recovery if the HUCB are administered immediately after stroke. 
Previously mentioned studies (Vendrame et al, 2006) had used 106 HUCB for IV 
administration and this study used 1-5x107, to ensure that enough HUCB were injected to be 
detected. None of the behavioral tests showed any significant rescue with IV administration 
of HUCB. The infarct volumes did not show any difference in either group of animals, 
however, histological analysis showed the presence of a few HUCB in the ipsilateral 
hemisphere in close proximity to blood vessels in animals which received the HUCB. In 
addition to the histological study, Makinen et al injected 111In-Oxine labeled HUCB for Bio-
imaging of the live animals. The images revealed that the HUCB were trapped in the liver, 
lungs, spleen and kidneys. No signal was picked up in the brain. The authors argued that 
since other studies don’t use a comprehensive evaluation method for the animals, they 
report the presence of HUCB in the brain and a functional recovery following HUCB 
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administration. However, a comprehensive battery of tests performed in this study revealed 
that HUCB do not contribute to behavior recovery following stroke (Maiken et al, 2006). 
Nystedt et al (2006) took a different approach to the previous studies: instead of injecting 
whole HUCB, they used an enriched CD34+ population from the HUCB. CD34+ cells have 
been shown to promote angiogenesis (Shyu et al, 2006) and neurogenesis (Taguchi et al, 
2004); therefore, the authors reasoned that injection of a pure population of targeted HSC 
would provide better functional rescue following stroke. Wistar rats were subjected to 
transient and permanent MCAO, CD34+ cells were injected IV 24 hours post-surgery. The 
animals were administered CD34+ cells obtained from 2 unrelated HUCB units for better 
engraftment; one unit acts as a ‘fertilizer’ and the other unit contributes to hematopoiesis. 
The animals were pre-trained on the beam walking and cylinder test and evaluated at days 
4, 12 and 20; water maze was evaluated at days 22, 23, and 25 post stroke. There was no 
significant difference in infarct volumes in either model of MCAO and human nuclei 
specific MAB1281+ cells were not detected in ipsilateral or the contralateral hemisphere at 
day 25 post stroke. However, both models did show an upward trend in sensorimotor and 
cognitive performance in animals which received CD34+ cells in both models. Infarct 
volume did not change in either model following administration of CD34+ cells and these 
cells were not detected in the ipsilateral hemisphere, yet an improvement in functional 
recovery was observed. The authors reasoned that recovery may have been due to factors 
secreted by the CD34+ cells which contributed to the recovery or that the CD34+ cells were 
indeed present in the brain, but were below the detection limits of the antibodies used for 
detection. Taguchi et al (2004) also used an enriched CD34+ fraction to show that these cells 
contribute to new vessel formation following stroke. This study used SCID mice and Brdu 
labeling to visualize endothelial cell proliferation in the vasculature surrounding the 
penumbral region. The Brdu label was co-localized with CD31 (expressed by angiogenic 
endothelial cells) at day 1 and 3 post stroke. The highest density of newly formed 
vasculature was observed in the ischemic hemisphere of CD34+ transplanted animals. This 
effect was blocked with the administration of Endostatin (suppresses endothelial 
proliferation) and erythropoietin (a pro-angiogenic agent) increased the neovascularization. 
Functional recovery was also seen (at day 90 post transplant) in animals which received the 
CD34+ cells (Nystedt et al, 2006). These studies indicate that an enriched CD34+ fraction 
from HUCB may be better suited for regeneration of blood vessels in the brain rather than 
the whole HUCB fraction. 
Use of autologous BMSC stem cells (BMSC) avoids ethical, infectious and immunological 
concerns. BMSC are abundant and therefore negate a need for cell expansion by culturing 
prior to administration. Iloshi et al (2004) used BMSC from rats, transfected with a LacZ 
reporter gene and administered IV following MCAO. The cells were administered at 3 or 72 
hours post stroke. Animals which received BMSC had a significant reduction in behavior 
deficit (Morris water maze and treadmill stress test) at 2 weeks following stroke. Animals 
which received BMSC within 3 hours of stroke had an almost non-existent lesion and LacZ+ 
cells were detected in and around the ischemic zone. The authors suggested that the BMSC 
secrete angiogenic growth factors (e.g. VEGF and bFGF) (Chen et al, 2002; Kurozumi et al, 
2005) which cause the functional recovery. Another mechanism suggested by the authors is 
that the BMSC integrate into the ischemic area and differentiate into mature cells rather than 
fuse with resident cells. Another study by Keimpema et al (2009) also evaluated the use of 
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BMSC following MCAO. This study, in contrast to the previous one, injected the BMSC 
intra-arterially (IA) at 3, 6, 12 and 24 hours post stroke. BMSC were observed in the blood 
vessels (when administered 3 hours post stroke), at the lesion (when administered at 6 hours 
post stroke) and phagocytic activity when BMSC were administered 24 hours post stroke. 
All time points evaluated showed a reduction in infarct volume. The authors defended their 
choice of arterial and administration of the BMSC at later time points by stating that signals 
from the lesion are relatively lower immediately following the stroke, thus IV injected 
BMSC get trapped in the spleen and are not observed in the ischemic regions of the brain. 
The authors also suggested that BMSC may release angiogenic growth factors which may 
also contribute to the reduction of infarct size. BMSC have also been engineered to 
overexpress potentially beneficial genes to the brain. For example, erythropoietin (EPO) is a 
known antioxidant, anti-apoptotic and anti-inflammatory (Chong et al, 2003). However, 
EPO cannot cross the blood barrier if injected IV and therefore its beneficial effect on the 
brain cannot be evaluated (Cho et al, 2010). Cho et al transduced BMSC to produce 
increased levels of EPO, and sterotaxically implanted 6x105 cells. The transduced cells were 
shown to secrete higher levels of BDNF, SDF1-A and TGF1-b. Animals which received the 
transduced BMSC had improved neurological function, lower infarct volumes and higher 
levels of phosphorylated AKT (a downstream effector of EPO) (Cho et al, 2010).  
6. Are HSC a viable avenue for stroke therapy? 
It appears likely that a viable stroke therapy may be generated from HSC research, but 
much investigation is yet to be done. There are discrepancies in evaluation modalities 
currently being employed for studying the contribution of HSC to recovery following 
stroke. There is a lack of an overall consensus for which animal strain, stroke model, 
anesthetic, duration of occlusion, HSC markers, number of HSC to be injected, source of 
HSC, route of delivery, time of delivery, time for evaluation and kind of end point testing 
(for behavior), should be used for research. Several studies have either used Wistar rats 
(Nystedt et al, 2006) or Sprague Dawley (Leonardo et al, 2010) for the research. However, 
Bardutzky et al (2005) reported that the ischemic lesion evolution was substantially different 
between the Wister and Spargue Dawley strains. The authors used cortical blood flow and 
apparent diffusion co-efficient maps and 2,3,5-Triphenyltetrazolium chloride staining to 
arrive at that conclusion (Bardutzky et al, 2005). Other studies have also confirmed 
differences in the middle cerebral artery occlusion model in different strains (Fox et al, 1993; 
Sauter et al, 1995; Oliff et al, 1996). The rat model for middle cerebral artey was first 
described by Robinson et al in 1975 and has since been modified by several groups (Tamura 
et al, 1981; Bederson et al, 1986). As this model was refined over the years, researchers have 
chosen the best adaptation of this model for their research. For example, the anesthetic used 
for the rats varies from chloral hydrate (Bederson et al, 1986), ketamine hydrochloride 
(Longa et al, 1989), Halothane (Chen et al, 1992), and isoflurane (Belayev et al, 2009). While 
these anesthetic agents are used for the surgery, none of the publications report on the effect 
of the choice of the anesthetic on the injected HSC or the level of neuroprotection imparted 
by the choice of anesthetic. Culley et al (2011) showed that isoflurane does not kill stem cells, 
but does affect their proliferative capacity, which is an important feature for stem cell 
survival and engraftment into the area of injury. The mouse model of middle cerebral artery 
occlusion has been described by Connolly et al (1996) and has also been been modified and 
used by several researchers (Olsen et al, 1986; Clark et al, 1997; Belayev et al, 1999). Various 
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anesthetic gases have also been used for the mouse model of middle cerebral artery 
occlusion (Yanamoto et al, 2003) with no correlation on the effect of the choice of anesthetic 
to the engraftment potential of the HSC. The duration of occluison also varies from 45 
minutes to 120 minutes (Campagne et al, 1999). Campagne et al (1999) showed that the time 
of occlusion affects the infarct size and hence would affect how quickly tissue can recover 
following occlusion. Li et al (2005) and Popp et al (2009) also showed that extent of infarct 
volume increases with occlusion time and leads to varying areas of confinement for 
neuronal and glial markers.  
Studies have also used a variety of sources for the HSC that are injected following stroke: 
HUCB (Vendrame M et al, 2006) , bone marrow (Iloshi et al, 2004) and Peripheral blood 
(Lickliter et al, 2000). In addition, there appears to be no consensus as to the number of cells 
injected for evalaution; Vendrame et al (2006) used 1x106 and Makinen et al (2007) used  
1-5x107. Not only are the cell sources and numbers variable, but methods for enrichment 
before injection also vary (Iloshi et al, 2004; Taguchi et al, 2004). It seems logical that HSC 
fractions enriched for markers that are more committed towards an endothelial lineage (for 
example, CD34+ cells in humans) (Asahara et al, 1997) would offer a faster recovery than 
those that are whole enriched fractions. Since HSC have an intrinsic potential for 
proliferation in response to growth factor, such as VEGF (Ortega et al, 1997), it would seem 
that unnecessarily increasing the number of injected cells may not be needed. If injected cells 
can contribute to recovery directly and by paracrine secretion of tropic growth factors, then 
an exorbitant number of HSC may not be needed. Actual HSC numbers needed for 
adminitration in stroke patients for receovery is critical for those considering an autologus 
transplantation from their own bone marrow. The route of injection of HSC also varied from 
IV (Nystedt et al, 2006; Leonardo et al, 2010; Regelsberger et al, 2011), to IA (Keimpema et al, 
2009) and direct implantation in the brain (Cho et al, 2010). Maikinen et al (2006) showed 
that IV injection of HSC lead to them being trapped in the spleen and kidneys and none of 
the cells were detected in the brain following the stroke. In contrast, Keimpura et al (2004) 
injected the HSC intra-arterially and showed that if the HSC were injected within 3 hours of 
the stroke, they would be found in the blood vessels in the brain. People have long focussed 
on an IV route of delivery of HSC for easier translation to human clincal trials. However, it 
is logical for the spleen to trap and remove cells which are not part of the normal circulation, 
hence reducing the number of cells which are available for contribution to recovery in the 
brain. Intra-arterial administration of the HSC is a viable alternate for the delivery of HSC 
since it places the cells in close proximity to the injury and avoids clearence of masses of 
cells by the spleen. Intra-arterial delivery may be challenging in smaller rodents, such as 
mice, however, it has been successfully used (Torrente et al, 2001).  
End point testing after HSC administration has relied on immunohistochemical staining 
(Kramer et al, 2000) or behavioral outcome (Chen et al, 2001). Infarct volumes are evaluated 
using a variety of methods: 2,3,5-Tetrazolium Chloride staining (Kramer et al, 2000), Nissl 
staining (Popp et al, 2009), Cresyl violet staining (Tureyen et al, 2004), or MRI imaging 
(Lansberg et al, 2001). Immunohsitochemistry of tissues lends itself to artifacts from 
incomplete fixation, excessive dehydration and overstaining (Werner et al, 2000; Fowler et 
al, 2008), so the variability in these techniques is well known. However, some studies have 
used these stains to report no changes in infarct volumes following administration of HSC 
(Regelsberger et al 2011; Nystedt et al, 2006). This may be due to artifacts inherent in the 
nature of the staining methods rather than ineffective HSC contribution to reducing infarct 
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volume following stroke. MRI imaging offers the best option for in vivo evaluation of infarct 
volumes following stroke (Moseley et al, 2001). However, access to MRI imaging for 
reasearchers may not be as feasible as doing an imunohistochemical staining for infarct 
volume. Behavior testing has become a hallmark end point testing for stroke in rodents 
(Chen et al, 2001), however, Makinen et al (2006) were not incorrect in suggesting that the 
majority of studies do not utilize the full battery of tests to arrive at a conclusion. Even 
within the battery of tests recommended by Makinen et al (2006), there is plently of room for 
variability within studies. Behavior tests are not sensitive enough to forgive minor 
differences in testing protocols which may be due to availability of resources for the 
research. For example, studies have evaluated end point behavior testing in rodents as early 
as 24 hours post stroke (Nystedt et al, 2006) and as late as 25 days post stroke (Taguchi et al, 
2004). Earlier time points for behavior may not have allowed sufficient times for the HSC to 
have an affect and the later time points may be too far away from the time of injury and thus 
allow for spontaneous recovery. 
Studies have either reported the presence or absence of of HSC in the ipsilateral hemisphere 
following stroke (Makinen et al, 2006). However, few studies have addressed issues of cell-
cell fusion (Terada et al, 2004) whereby the resident vascular endothelial cells and the 
injected HSC fuse together and the HSC do not take on the mature phenotype of the 
resident cell. While it may difficult to differentitate a maturing HSC from a resident 
endothelial cell, since a maturing cell would carry the same markers as the resident cell, it is 
important for future stroke HSC therapy to be able to differentiate whether certain 
treatments lead to integrating HSC or mere cell to cell fusion. HSC also have the ability to 
transdifferentiate, dedifferentiate and re-differentiate depending on the cues provided by 
the local environment. It is entirely possible that some HSC integrate into the vasculature 
and others transdifferentiate into neurons. However, the majority of studies focus either on 
vascular beds (Taguchi et al, 2009) or neuronal regeneration (Garzon-muvdi et al, 2009) 
rather than both.  
In conclusion, it seems likely that HSC investigation may contribute critical knowledge to 
our constantly evolving understanding of stroke pathophysiology. However, this 
enthusiasm must be tempered with realistic expectations that this will only occur with 
detailed, diligent labortory investigation. It is our hope that with such critical investigation 
our field will achieve it’s goal of providing a viable new therapy for stroke. 
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anesthetic gases have also been used for the mouse model of middle cerebral artery 
occlusion (Yanamoto et al, 2003) with no correlation on the effect of the choice of anesthetic 
to the engraftment potential of the HSC. The duration of occluison also varies from 45 
minutes to 120 minutes (Campagne et al, 1999). Campagne et al (1999) showed that the time 
of occlusion affects the infarct size and hence would affect how quickly tissue can recover 
following occlusion. Li et al (2005) and Popp et al (2009) also showed that extent of infarct 
volume increases with occlusion time and leads to varying areas of confinement for 
neuronal and glial markers.  
Studies have also used a variety of sources for the HSC that are injected following stroke: 
HUCB (Vendrame M et al, 2006) , bone marrow (Iloshi et al, 2004) and Peripheral blood 
(Lickliter et al, 2000). In addition, there appears to be no consensus as to the number of cells 
injected for evalaution; Vendrame et al (2006) used 1x106 and Makinen et al (2007) used  
1-5x107. Not only are the cell sources and numbers variable, but methods for enrichment 
before injection also vary (Iloshi et al, 2004; Taguchi et al, 2004). It seems logical that HSC 
fractions enriched for markers that are more committed towards an endothelial lineage (for 
example, CD34+ cells in humans) (Asahara et al, 1997) would offer a faster recovery than 
those that are whole enriched fractions. Since HSC have an intrinsic potential for 
proliferation in response to growth factor, such as VEGF (Ortega et al, 1997), it would seem 
that unnecessarily increasing the number of injected cells may not be needed. If injected cells 
can contribute to recovery directly and by paracrine secretion of tropic growth factors, then 
an exorbitant number of HSC may not be needed. Actual HSC numbers needed for 
adminitration in stroke patients for receovery is critical for those considering an autologus 
transplantation from their own bone marrow. The route of injection of HSC also varied from 
IV (Nystedt et al, 2006; Leonardo et al, 2010; Regelsberger et al, 2011), to IA (Keimpema et al, 
2009) and direct implantation in the brain (Cho et al, 2010). Maikinen et al (2006) showed 
that IV injection of HSC lead to them being trapped in the spleen and kidneys and none of 
the cells were detected in the brain following the stroke. In contrast, Keimpura et al (2004) 
injected the HSC intra-arterially and showed that if the HSC were injected within 3 hours of 
the stroke, they would be found in the blood vessels in the brain. People have long focussed 
on an IV route of delivery of HSC for easier translation to human clincal trials. However, it 
is logical for the spleen to trap and remove cells which are not part of the normal circulation, 
hence reducing the number of cells which are available for contribution to recovery in the 
brain. Intra-arterial administration of the HSC is a viable alternate for the delivery of HSC 
since it places the cells in close proximity to the injury and avoids clearence of masses of 
cells by the spleen. Intra-arterial delivery may be challenging in smaller rodents, such as 
mice, however, it has been successfully used (Torrente et al, 2001).  
End point testing after HSC administration has relied on immunohistochemical staining 
(Kramer et al, 2000) or behavioral outcome (Chen et al, 2001). Infarct volumes are evaluated 
using a variety of methods: 2,3,5-Tetrazolium Chloride staining (Kramer et al, 2000), Nissl 
staining (Popp et al, 2009), Cresyl violet staining (Tureyen et al, 2004), or MRI imaging 
(Lansberg et al, 2001). Immunohsitochemistry of tissues lends itself to artifacts from 
incomplete fixation, excessive dehydration and overstaining (Werner et al, 2000; Fowler et 
al, 2008), so the variability in these techniques is well known. However, some studies have 
used these stains to report no changes in infarct volumes following administration of HSC 
(Regelsberger et al 2011; Nystedt et al, 2006). This may be due to artifacts inherent in the 
nature of the staining methods rather than ineffective HSC contribution to reducing infarct 
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volume following stroke. MRI imaging offers the best option for in vivo evaluation of infarct 
volumes following stroke (Moseley et al, 2001). However, access to MRI imaging for 
reasearchers may not be as feasible as doing an imunohistochemical staining for infarct 
volume. Behavior testing has become a hallmark end point testing for stroke in rodents 
(Chen et al, 2001), however, Makinen et al (2006) were not incorrect in suggesting that the 
majority of studies do not utilize the full battery of tests to arrive at a conclusion. Even 
within the battery of tests recommended by Makinen et al (2006), there is plently of room for 
variability within studies. Behavior tests are not sensitive enough to forgive minor 
differences in testing protocols which may be due to availability of resources for the 
research. For example, studies have evaluated end point behavior testing in rodents as early 
as 24 hours post stroke (Nystedt et al, 2006) and as late as 25 days post stroke (Taguchi et al, 
2004). Earlier time points for behavior may not have allowed sufficient times for the HSC to 
have an affect and the later time points may be too far away from the time of injury and thus 
allow for spontaneous recovery. 
Studies have either reported the presence or absence of of HSC in the ipsilateral hemisphere 
following stroke (Makinen et al, 2006). However, few studies have addressed issues of cell-
cell fusion (Terada et al, 2004) whereby the resident vascular endothelial cells and the 
injected HSC fuse together and the HSC do not take on the mature phenotype of the 
resident cell. While it may difficult to differentitate a maturing HSC from a resident 
endothelial cell, since a maturing cell would carry the same markers as the resident cell, it is 
important for future stroke HSC therapy to be able to differentiate whether certain 
treatments lead to integrating HSC or mere cell to cell fusion. HSC also have the ability to 
transdifferentiate, dedifferentiate and re-differentiate depending on the cues provided by 
the local environment. It is entirely possible that some HSC integrate into the vasculature 
and others transdifferentiate into neurons. However, the majority of studies focus either on 
vascular beds (Taguchi et al, 2009) or neuronal regeneration (Garzon-muvdi et al, 2009) 
rather than both.  
In conclusion, it seems likely that HSC investigation may contribute critical knowledge to 
our constantly evolving understanding of stroke pathophysiology. However, this 
enthusiasm must be tempered with realistic expectations that this will only occur with 
detailed, diligent labortory investigation. It is our hope that with such critical investigation 
our field will achieve it’s goal of providing a viable new therapy for stroke. 
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1. Introduction 
Cerebral ischemia remains the main cause of adult disability in Western countries. More 
than 50% of stroke survivors are left with a motor disability, causing a huge burden for 
patients, relatives and healthcare systems (Bonita et al., 1997). Cell-based therapies have 
emerged as some of the most promising experimental approaches to restore brain function 
after stroke (Bliss et al., 2010; Banerjee et al., 2011; Lindvall & Kokaia, 2011). A wide variety 
of cell types have been studied, such as neural progenitors from different sources, including 
bone marrow- and blood-derived stem cells. Preclinical data with cell therapies are 
promising (Bliss et al., 2007; Hicks & Jolkkonen, 2009; Hicks et al., 2009a; Janowski et al., 
2010). The understanding of how transplanted cells exert their therapeutic effect is, 
however, not clear, but it is believed that the positive outcome is due to paracrine effects 
with an improved protective cellular environment (e.g., reduced inflammation, 
neuroprotection, reduced apoptosis, activation of endogenous repair) rather than as a 
consequence of neuronal differentiation and cell replacement (Zhang & Chopp, 2009).  
The robust therapeutic effect shown in the majority of preclinical studies is somewhat 
surprising given that cell preparations, experimental models and outcome measures have 
varied greatly (Table 1). More work is definitely needed to establish standard treatment 
protocols, which in turn should be expected to lead to effective translation of experimental 
data. The recently published STEPS guidelines are one step forward to guide future cell-
based research in stroke (STEPS Participant, 2009; Savitz et al., 2011). In addition to 
preclinical recommendations, guidelines on designing early-stage clinical trials are included.  
The first patient studies have shown the safety and feasibility of systemic cell therapy, but 
only marginal therapeutic benefit has so far been observed (Bang et al., 2005; Battistella et 
al., 2011; Honmou et al., 2011). Whether this is related to the type of cells, study design or 
low engraftment of the delivered cells is not known. This review provides an update of the 
current progress in intravascular cell therapy in stroke with a particular emphasis on 
strategies of how to improve the therapeutic effects. 
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Stroke model tMCAO, pMCAO, endothelin-1, cortical 
photothrombosis, hypoxia-ischemia 
Species rats, mice
Cell type rat/mouse/human cells from BM, UCB or 
adipose tissue, neural cells, genetically 
modified cells
Delivery route intravenous (tail vein, femoral vein), intra-
arterial (common carotid artery, internal 
carotid artery, external carotid artery) 
Delivery time 30 min - 1 month after the ischemic event 
Outcome measures histology (e.g., MAB1248), behavioral 
testing (e.g. sensorimotor, cognitive), 
imaging (e.g. MRI, SPECT, optical imaging) 
BM – bone marrow; MRI – magnetic resonance imaging; UCB – umbilical cord blood; SPECT – single 
photon emission computed tomography; tMCAO – transient middle cerebral artery occlusion;  
pMCAO – permanent middle cerebral artery occlusion 
Table 1. Variables with cell-based therapy in experimental stroke 
2. Special challenges in intravascular cell therapy in stroke 
Cell-based therapy after massive ischemic damage in stroke patients can be challenging 
compared to diabetes or Parkinson's disease, in which a restricted population of cells is lost. 
Not only neurons, but also glial cells and blood vessels need to be repaired. Severe odema 
and vascular compression associated with ischemic damage may limit the engraftment of 
cells, particularly in areas adjacent to infarct. Another distinction is that stroke is an acute 
injury with little or no degenerative process. Appropriate transplantable cells may not be 
immediately available for such an emergency. In addition, while early cell transplantation 
may provide neuroprotection, the hostile environment endangers the long-term survival of 
transplanted cells. Transplantation at later time points may be more realistic, targeting 
secondary neurodegeneration and promoting enhancement of the brain’s own repair 
mechanisms (Zhang & Chopp, 2009). Although cell survival may be preferable, scar 
formation and a lack of functional vasculature may limit the therapeutic benefit. The 
advantage is, however, that cell transplantation can be combined with other rehabilitative 
treatments to ensure maximal therapeutic benefit (Hicks et al., 2009b).  
Efficient cell delivery and an optimal delivery route are the keys to successful clinical 
outcomes, especially in all novel forms of cell therapy. Optimal cell delivery will be 
indication-dependent and local transplantation has until now been considered as the 
primary choice for regenerative tissue treatments. Systemic introduction should, however, 
be the ultimate goal for cell therapy, enabling rapid off-the-shelf therapy in any clinic and 
this would also allow less invasive treatments. Both stereotactic transplantation of cells into 
the brain and systemic delivery have been applied in experimental stroke (Guzman et al., 
2008; Hicks & Jolkkonen, 2009). Given that stroke often produces large ischemic damage, it 
is not known whether a targeted approach can provide efficient and extensive cell 
engraftment, even with the aid of anatomical and functional imaging to explore the location 
of cell transplantation. Another concern is the invasive nature of intracerebral 
transplantation. In contrast, the systemic introduction is minimally invasive and thus 
perhaps more easily applied in the clinic.  
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There are, however, some obstacles in the intravenous delivery route for cellular therapeutics, 
one of the main ones being massive lung adhesion, which has been observed after intravenous 
injection (Allers et al., 2004; Barbash et al., 2003; Fischer et al., 2009; Gao et al., 2001; 
Hakkarainen et al., 2007; Kang et al., 2006; Mäkinen et al., 2006; Meyerrose et al., 2007; Nystedt 
et al., 2006; Schrepfer et al., 2007; Tolar et al., 2006; Vilalta et al., 2008). In addition to the 
negative impact this has on the possibility of reaching clinically relevant cell numbers in target 
organs, lung entrapment of mesenchymal stem cells (MSC) has also been observed causing 
severe lung damage in mouse models (Anjos-Afonso et al., 2004; Lee et al., 2009a). 
Importantly, pulmonary toxicity is reported as one of the most common non-hematological 
complications after autologous bone marrow transplantation in humans, a complication that is 
also detectable in a mouse model (Bhalla & Folz, 2002). Interestingly, and on the contrary, 
beneficial effects have been found after MSC lung entrapment, where embolized human MSCs 
improved myocardial infarction in mice through secreting the anti-inflammatory protein 
tumour factor-stimulated gene-6 (TSG-6) (Lee et al., 2009b).  
3. Cell types used in stroke 
Stem cells are defined as undifferentiated cells capable of self-renewal and differentiation. 
Truly totipotent stem cells can only be found in the embryo and these are capable of 
producing a new individual upon implantation. Depending on their origin, stem cells are 
classified as pluripotent (i.e., embryonic) or multipotent (i.e., fetal and adult) stem cells, 
referring also to their differentiation capacity. Intracerebral transplantation is the primary 
delivery route for embryonic stem cells (ESC), induced pluripotent stem cells and fetal stem 
cells in experimental stroke. Thus only intravascular delivery of adult stem/progenitor cells 
and genetically modified cells will be discussed in the following chapters. 
3.1 Adult stem/progenitor cells 
The majority of systemic transplantation studies in stroke have used non-neural cells; cells 
from bone marrow (BM), umbilical cord blood (UCB), adipose tissue, or peripheral blood. 
These are all typically defined as adult stem/progenitor cells and represent a group of 
heterogeneous cell types. Usually many cell types are present in the population, such as 
mesenchymal stem/stromal cells, hematopoietic progenitors and endothelial progenitors, as 
well as more mature cell types (Erices et al., 2000; Herzog et al., 2003; Harris et al., 2008). 
Typically either the whole cell population has been used or a subpopulation has been 
selected with, e.g., cell surface markers or culture conditions (like adherent MSCs). Adult 
stem cells lack the ethical controversies associated with embryonic or fetal cells and they are 
rather easily obtained from different clinical sources.  
Different adult stem/progenitor cell populations have been reported to enhance functional 
recovery in experimental stroke models. When considering studies using human cells, 
mostly bone marrow stem/stromal cells (BM-MSC) (Li et al., 2002; Zhao et al., 2002; Chen et 
al., 2003; Zhang et al., 2004; Omori et al., 2008; Andrews et al., 2008; Mays et al., 2010; Yang 
et al., 2010; Bao et al., 2011) or UCBCs (Chen et al., 2001; Willing et al., 2003a; Borlongan et 
al., 2004; Vendrame et al., 2004; Xiao et al., 2005; Newcomb et al., 2006; Chen et al., 2006; 
Mäkinen et al., 2006; Zhang et al., 2011; Riegelsberger et al., 2011) have been used. Most 
studies have administered cells early (6-48 h) or at subacute phase (2-7 days) after stroke 
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al., 2003; Zhang et al., 2004; Omori et al., 2008; Andrews et al., 2008; Mays et al., 2010; Yang 
et al., 2010; Bao et al., 2011) or UCBCs (Chen et al., 2001; Willing et al., 2003a; Borlongan et 
al., 2004; Vendrame et al., 2004; Xiao et al., 2005; Newcomb et al., 2006; Chen et al., 2006; 
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and only few comparisons have been made. Omori et al. (2008) compared multiple time 
points and found that the greatest functional benefit was achieved when BM-MSCs were 
injected 6 h after stroke compared to later time points, which is supported by the finding of 
Yang et al. (2010) that cells delivered 1 day have greater effect than those at 7 days. Instead, 
Mays et al. (2010) reported time window from 1 to 7 days post-stroke to be equally 
beneficial. For UCBCs, time window up to 30 days post-stroke was found to be 
therapeutically beneficial (Zhang et al., 2011). 
In addition to BM and UCB cells, peripheral blood progenitor cells (Willing et al., 2003b), 
endothelial progenitors (Fan et al., 2010; Moubarik et al., 2011), CD34-positive progenitors 
from UCB (Taguchi et al., 2004; Boltze et al., 2005; Nystedt et al., 2006), CD133-positive cells 
from BM (Borlongan et al., 2005; Bakondi et al., 2009), as well as MSCs from placenta (Kranz 
et al., 2010) have provided therapeutic benefit in stroke. Also in these studies mostly early 
administration has been employed. For CD133 cells, delayed administration (7 d) was 
shown to improve graft survival but behavioral improvement was only apparent in 
immediate intravenous delivery (Borlongan et al., 2005). 
MSCs from BM or UCB (or other tissues) are a particularly promising candidate for cell 
therapy in stroke. MSCs are defined as multipotent stem cells that are adherent and express 
CD73, CD90 and CD105. They show the potential to differentiate into bone, cartilage and fat, 
and also exhibit additional differentiation capacity (Dominici et al., 2006). MSCs can be 
highly expanded in culture with a minimal loss of multipotency and they show very little 
immunogenic activity. This is a major advantage, allowing them to be potentially used as 
allogeneic "off-the-shelf" products. They have already been explored in many experimental 
models and clinical trials for their beneficial effects to, e.g., regenerate damaged tissue, treat 
adverse immune reactions, promote angiogenesis, and increase tissue protection, and MSCs 
are generally considered safe (Malgieri et al., 2010). 
Adult stem cells are particularly well suited for non-invasive vascular delivery, since they 
have been shown to target injured tissue and exert their therapeutic effect through secreted 
factors (Karp & Teo, 2008; Hess & Hill, 2011). The targeting of cells to the brain and 
especially their survival in situ have proven challenging, as in most studies very few cells 
are actually found in the brain. Interestingly, however, this may not be crucial, as 
intravenously administered cells may have a therapeutic effect on the brain by acting from 
peripheral organs as well, such as the spleen and the lung (Hess & Hill, 2011).  
As a summary, adult stem cells have been shown to exert their positive effect through 
soluble factors that reduce apoptosis and promote neuroprotection, angiogenesis, brain 
plasticity, and/or endogenous progenitor proliferation. Some studies have shown 
differentiation towards neuronal phenotype, but the significance of this remains unclear. 
3.2 Genetically modified cells 
In addition to stem cells, several neural cell lines have been reported to enhance functional 
recovery after experimental stroke by intravenous delivery of cells (Jeong et al., 2003; Chu et 
al., 2004; Lee et al., 2008; Narantuya et al., 2010). These cell lines are immortalised and thus 
have the advantage of unlimited expansion in culture. However, there is a potential risk of 
malignant transformation (Newman et al., 2005).  
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One approach has been to use immortalised human MSCs to, e.g., expand the limited life-
span of MSCs or include a gene for efficient in vivo tracking of cells. These cells have also 
shown positive effects in experimental stroke models when delivered intravenously 
(Honma et al., 2006; Wakabayashi et al., 2010). A critical aspect with these cells is that they 
should not lose their MSC phenotype upon modification. 
Human BM-MSCs have also been genetically modified to express neuroprotective/ 
angiogenic growth factors, such as brain derived neurotrophic factor (BDNF) (Kurozumi et 
al., 2004; Nomura et al., 2005), placental growth factor (PlGF) (Liu et al., 2006), glial cell line-
derived neurotrophic factor (GDNF) (Horita et al., 2006), erythropoietin (Cho et al., 2010), 
and vascular endothelial growth factor (VEGF) combined with angiopoietin-1 (Toyama et 
al., 2009). All these modified MSCs have shown their ability to improve functional recovery 
in ischemic rats, compared to unmodified MSCs, when delivered intravenously. GDNF-
modified human UCB CD34+ cells have also shown similar positive effects in vivo 
supporting the combined gene and stem cell therapy for the treatment of stroke (Ou et al., 
2010).  
4. Cell modifications that improve the efficiency of cell therapy 
The major problem with intravenous delivery is cell trapping within organs that filter the 
bloodstream. Previous studies have explored different strategies to minimize lung adhesion 
and improve homing of systemically introduced cells: use of vasodilators (Schrepfer et al., 
2007), pre-bolus injection of MSCs (Fischer et al., 2009), reducing the number of injected cells 
(Lee et al., 2009b), blockade of 6 and 4 integrins (Bonig et al., 2007; Qian et al., 2006; Bonig 
et al., 2009; Fischer et al., 2009), heparin saturation of MSCs (Deak et al., 2010) or 
preincubation of cells with white blood cells (Chute, 2006). Some beneficial effects on lung 
adhesion have been concluded, but the major mechanism behind this profound 
phenomenon is still unsolved. Interestingly, glycosylation engineering of stem cell surfaces 
by enzymatic ex vivo cell surface fucosylation has improved the homing and engraftment 
capacity of cord blood-derived cells (Xia et al., 2004) and, interestingly, the homing of BM-
MSCs to the bone marrow (Sackstein et al., 2008). One feasible approach to alter cell surface 
structures and migratory behavior is also through culture conditions. A recent preclinical 
study has shown that low passage and low-density cultures of BM-MSCs impact cell 
structures that favour in vivo targeting to the infarcted heart (Lee et al., 2009a). Culturing 
MSCs in low oxygen increases the levels of relevant cell surface chemokine and growth 
factor receptors, subsequently increasing the in vitro migratory behavior and the therapeutic 
potential of MSCs (Hung et al., 2007; Rosova et al., 2008). Cells are normally maintained in a 
20% O2 tension in culture, but a lower oxygen tension in culture is more akin to the 
physiological niche for the MSC in the bone marrow or placenta (2-7% O2) and would 
facilitate in maintaining the authentic in vivo identity of the MSCs. Culturing MSCs without 
animal-derived reagents can produce beneficial changes in expression levels of important 
adhesion receptors and the secretion potential of trophic mediators, which might have an 
important impact on cell migratory behavior and therapeutic potential. To support this, 
Bieback et al. (2009) recently showed differential expression of the fibronectin receptor CD29 
between MSCs cultured in fetal bovine serum versus human blood components. The impact 
of MSC xenofree culture conditions have not yet been studied or reported in preclinical 
stroke models.  
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5. Effect of administration route 
The most effective transplantation route to deliver cells into the brain following cerebral 
ischemia remains to be addressed. Noninvasive intravascular administration of cells has 
perhaps the most immediate access for clinical applications. It provides a broad distribution 
of cells in close proximity to ischemic tissue, although the entry of intravenously injected 
cells into the central nervous system may not be required for therapeutic effects (Borlongan 
et al. 2004). However, a reliable estimation of cell numbers in the brain in relation to other 
organs is lacking.  
Modern imaging methods such as single photon emission computed tomography (SPECT), 
positron emission computed tomography (PET), magnetic resonance imaging (MRI) or 
optical imaging can be used for the in vivo tracking of cells. Excellent reviews on the 
different imaging modalities are available (Sykova & Jendelova, 2007; Gera et al., 2010). 
SPECT imaging with indium oxine (111In-oxine) offers an efficient method to study the 
whole body biodistribution of cells in stroke models (Figure 1). Firstly, the labeling of the 
cells is straightforward and relatively simple without significant loss of cell viability. The 
most common labels are 111In-oxine or technetium-hexamethylpropyleneamine oxime 
(99mTc-HMPAO). Double labeling with 111In and 131I or 18F- fluorodeoxyglucose (FDG) and 
111In is also possible (Blocklet et al., 2006; Stodilka et al., 2006). Secondly, the half-life of 111In 
is optimal for several days follow-up after a single injection. Additional advantages of 
SPECT include high sensitivity, short scanning times (<5 min), and possible multimodal 
imaging (MRI, CT) with the same stereotaxic coordinates. More importantly, whole-body 
imaging provides an estimation of the proportion of injected cells that eventually enter the 
brain in relation to other organs, to help in the assessment of the functional value of 
transplantation. SPECT imaging is also truly translational and the same tracers can be used 
in human studies (Correa et al., 2007; Barbosa da Fonseca et al., 2010).  
 
Fig. 1. Combined SPECT/CT images of 111In-oxine labeled human bone marrow-derived 
mesenchymal stem cells (BM-MSCs) in a rat subjected to middle cerebral artery occlusion 
(MCAO). Images are taken 20 min (A) and 24 h (B) after intra-arterial administration of cells 
(4 × 105 cells; 3 MBq) 24 h after MCAO surgery. Please note the initial high signal in the 
brain followed by relocation of cells into the internal organs. A minor signal remains in the 
ischemic hemisphere.  
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Several studies have compared different administration routes. Willing et al. (2003a) 
concluded that intravenous administration of human UCBCs may be more effective that 
intracerebral transplantation. 111In–oxine labeled human UCBCs have, however, been shown 
to localize primarily to the internal organs post intravenous injection in rats after middle 
cerebral artery occlusion (MCAO) (Mäkinen et al., 2006). Chen and co-workers also showed 
that after intravenous administration of human UCBCs in MCAO rats, only 1% of injected 
cells were detected in the brain (Chen et al., 2001). Undesirable biodistribution is most likely 
caused by the accumulation of cells in the trapping and filtering organs such as the lung, 
liver, and spleen, rather than due to the cell type injected or timing of administration. Thus, 
intra-arterial cell infusion may be a more efficient route to circumvent trapping in the 
internal organs and to target cells towards the ischemic brain (Lappalainen et al., 2008; 
Walczak et al., 2008; Li et al., 2010; Chua et al., 2011). Indeed, intra-arterial infusion resulted 
in minor engraftment of human ESCs into the ischemic hemisphere while no SPECT signal 
was detected after intravenous infusion (Lappalainen et al., 2008). Walczak et al. (2008) 
compared intravenous and intra-arterial delivery of MSCs in MCAO rats by using combined 
laser Doppler blood flow monitoring and MRI of iron labeled cells. The intra-arterial but not 
intravenous cell injection was shown to provide successful but variable cerebral 
engraftment, which was possibly due to microvascular occlusions. Engraftment was 
associated with high morbidity as also confirmed by Li et al. (2010). Later, it was shown that 
a modified injection technique with preserved flow in the carotid artery prevented decrease 
in cerebral blood flow and micro-occlusions (Chua et al., 2011). Intra-arterial over 
intravenous administration is also supported by the transplantation of mouse neural stem 
cells in a hypoxia-ischemia mouse model (Pendharkar et al., 2010). More importantly, a 
sustained presence (2 weeks) of transplanted cells in the brain was observed after intra-
arterial administration. However, recently both intravenous and intra-arterial routes were 
shown to equally improve neurological recovery and provide neuroprotection (Gutierrez-
Fernandez et al., 2011). In all above-mentioned studies, cell were administered within 24-48 
h of ischemia. 
Taken together, the delivery route seems to have an impact on the biodistribution of 
transplanted cells. Intra-arterial administration provides superior delivery of cells to the 
ischemic brain, although this depends on the type of cells and the experimental model 
employed. 
6. Effective dose and therapeutic time window for cell transplantation 
The effective cell dose needed for therapeutic effects in stroke animals is not well known. 
Intravenous infusion of 104 up to 5 x 107 human UCBCs improved behavioral deficits in 
MCAO rats in a dose-dependent manner, when administered at 24 h of ischemia (Vendrame 
et al., 2004). A dose of 106 cells was the threshold to promote functional recovery. Similarly, 
human umbilical tissue-derived cells at doses more than 3 x 106 have improved the 
behavioral outcome and enhanced several brain repair mechanisms (Zhang et al., 2011). A 
meta-analysis of 60 preclinical studies also found a dose-response association between the 
injected cell number and treatment effects (Janowski et al., 2010). Interestingly, the greatest 
therapeutic benefit is achieved following a single high cell dose injection of human MSCs 
(3.0 x 106) within 6 h of ischemia rather than multiple low dose injections (Omori et al., 
2008). Thus, repeated dosing may not provide additional benefit. While the dose in 
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preclinical studies is established to be around 106 cells per animal, it is more complicated to 
estimate the optimal dose for clinical studies. Dosing should be based on a dose-response 
curve and a maximum tolerated dose, as suggested by STEPS recommendations (STEPS 
Participant, 2009). The doses in early phase clinical trials were scaled to body weight and 
have varied from 5 x 107 (twice) (Bang et al., 2005) to 0.5 - 5 x 108 (Honmou et al., 2011) per 
patient.  
In most of the experimental studies (67%), cells were given <24 h after ischemia (Hicks et al., 
2009a). This is partly because of the opening of the blood-brain barrier after cerebral ischemia, 
which allows cells to enter the brain parenchyma (Belayev et al., 1996). Also, the expression of 
various chemotactic signals peaks at this time point and guides the cells towards ischemic 
areas (Imitola et al., 2004; Wang et al., 2008). However, while early cell transplantation may 
provide neuroprotection (Homna et al., 2006; Horita et al., 2006), the hostile environment 
endangers the long-term survival of transplanted cells. Transplantation at later time points 
may target against secondary neurodegeneration and promote enhancement of the brain’s 
own repair mechanisms (Zhang & Chopp, 2009). Komatsu et al. (2010) showed that MCAO 
rats receiving MSCs up to 1 month after ischemia showed enhanced functional recovery and 
associated angiogenesis in cortical areas adjacent to the infarct. Shen et al. (2007) have also 
showed that cell transplantation 1 month after MCAO is effective by leading to long-lasting 
behavioral improvement. Behavioral and morphological evidence suggest that the post-stroke 
brain displays heightened sensitivity to rehabilitative treatment early after the stroke (1 wk), 
but declines with time (2-4 wk) (Biernaskie et al., 2004). Based on this, the time of cell 
transplantation could be extended to up to 7 days after ischemia.  
7. Clinical perspectives and future directions of intravascular cell therapy for 
stroke 
Promising experimental data have prompted early phase I/II patient studies. In these 
studies, either bone marrow mononuclear cells or bone marrow-derived mesenchymal stem 
cells have been used. Three phase I studies explored the use of bone marrow mononuclear 
(BM-MNC) cells for stroke (Barbosa da Fonseca et al., 2010; Battistella et al., 2011; Suarez-
Monteagudo et al., 2009). The most important finding of these studies is that intra-arterial 
delivery of mononuclear cells directly to the infarcted hemisphere is safe. Interestingly, 
Barbosa da Fonseca et al. (2010) labeled the mononuclear cells with technetium-99m, and 
followed the distribution of the cells in six stroke patients. They were able to show that the 
cells remained at the site of the lesion for two hours, but then the signal disappeared on all 
but two patients after 24 hours. It is unclear whether this short time of action will be enough 
for any therapeutic benefit. 
Bang and co-workers pioneered in the use of MSCs for ischemic stroke with two studies 
(Bang et al., 2005; Lee et al., 2010). In the first one, five patients with stroke received 
autologous MSCs as two intravenous infusions of 5 x 107 cells each. The outcome of the 
patients after one year was compared to 25 randomized controls in an open-label study. The 
second study followed the same protocol as the first one but included 16 patients and 36 
controls, and the patients were followed for five years. Both studies concluded that 
intravenous infusion of MSCs in stroke patients was safe. There was no apparent increase in 
mortality, bovine spongiform encephalitis or other zoonoses, arrhythmias, seizures, or 
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tumors. The true incidence of possible side effects of MSC therapy can, however, only be 
evaluated after much larger patient groups have been treated and followed. Interestingly, 
patients showed significant improvement in the Barthel Index (BI) in both studies, and a 
trend towards improvement in the modified Rankin Scale (mRS) in the first study. There 
was some concern as to whether the improved functional recovery was upheld with time 
(Bang et al., 2005), but later this was confirmed as improvement could still be measured at 
3.5 years (Lee et al., 2010). Because of the time required to produce the autologous 
therapeutic cells used, the infusion of the cells occurred rather late, i.e. the first cell infusion 
was given at weeks 4-5 and the subsequent one at weeks 7-9 after the onset of the stroke. 
Honmou and colleagues (2011) studied the safety and feasibility of intravenous infusion into 
stroke patients of autologous MSCs that had been expanded in autologous serum. The cells 
were infused 33-133 days post-stroke, and the patients were followed and imaged at one 
year after. No adverse events were recorded. 
Several important questions still need to be addressed in both preclinical and clinical testing. 
It is unclear which cell type is therapeutically the most beneficial. Both BM-MNCs and 
MSCs have shown promise in preclinical testing. Selecting the best route of therapeutic cell 
delivery is also a major issue. Presumably, the route yielding the most effective delivery of 
cells to the injured tissue might offer most therapeutic potential. In a recent study 
comparing intra-arterial and intravenous MSC delivery, infusion directly into the internal 
carotid artery resulted in more engrafted cells as well as a more widespread distribution of 
cells within the infarcted hemispheres of rats (Li et al. 2010). However, this mode of 
administration was also associated with high mortality as the MSCs were sequestered in the 
blood vessels of the treated hemisphere and formed micro-occlusions. Careful development 
of safe but effective modes of administration is required for the advancement of this 
technique towards the clinic. In contrast to MSCs, BM-MNCs can apparently be 
administered via the intra-arterial route without harmful effects.  
Another important question is the preferred timing of the cell infusion. There is some 
evidence suggesting that MSCs infused early (within days of the infarct) have more 
therapeutic efficacy than those administered several weeks after the event (Zhou et al., 
2011). Theoretical considerations support these findings: a major mode of action of the MSCs 
in stroke is attenuation of the post-infarct inflammatory milieu, which is at its strongest 
during the early days following the insult (Ohtaki et al., 2008). BM-MNCs have the 
advantage of having no need for cell expansion. Thus, the patient can be treated soon after 
stroke even if autologous cells are used. 
Whether the patient should be given autologous or allogeneic MSCs is a major unanswered 
question. If the patient is given autologous cells, the therapy will necessarily take place 
several weeks after the infarct due to the time required to produce the cells. Allogeneic cells 
offer the critical advantage of being available off-the-shelf. It can be argued that allogeneic 
cells are quickly rejected and will rapidly lose their therapeutic efficacy, but if only short 
term action is required e.g., to modulate post-infarct inflammation, allogeneic cells may be 
an ideal therapeutic vehicle. In experimental animals, allogeneic cells appear to function as 
equally well as autologous MSCs (Li et al., 2006). Furthermore, risks of tumor formation are 
reduced, because the allogeneic cells are eventually rejected by the host’s immune system 
(Poncelet et al., 2007).  
 
Advances in the Treatment of Ischemic Stroke 
 
148 
preclinical studies is established to be around 106 cells per animal, it is more complicated to 
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tumors. The true incidence of possible side effects of MSC therapy can, however, only be 
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Finally, the optimal characteristics of the therapeutic cells need to be determined. Special 
attention needs to be given to the conditions of cell production, because the administration 
of apoptotic or senescent cells is not only ineffective, but positively harmful (Modo et al., 
2003; Prockop et al., 2010). Another important advance will be the adoption of xenofree 
culture methods for MSCs, reducing the risks of anaphylaxis and transmission of diseases 
(Horwitz et al., 2002). Modification of the cell surface prior to administration, to improve the 
delivery or therapeutic efficacy of the cells, is a promising strategy.  
Taken together, there is already preliminary evidence for the safety of intravenously 
delivered BM-MNCs and MSCs for stroke patients. Further work is required to establish this 
safety profile. However, careful studies that also use an intra-arterial application of cells 
should proceed. Futhermore, the use of allogeneic MSCs should be explored, allowing 
treatment during the first week after infarct. 
Currently, eight clinical phase I-II studies are underway, assessing the safety and possible 
efficacy of either fractionated BM cells or culture-expanded MSCs in patients with recent 
ischemic stroke (Table 2). Three studies will address the feasibility and safety of intravenous  
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Table 2. Summary of ongoing clinical trials with intravascular administration of cell therapy 
in stroke. Only recruiting or completed studies are listed. 
 
Toward a More Effective Intravascular Cell Therapy in Stroke 
 
151 
BM-MNCs, and one of these will compare intravenous with intra-arterial delivery. Two 
more trials will utilize BM cells that have been selected using stem cell markers (CD34 or 
aldehyde dehydrogenase). Three studies evaluate the use of MSCs for stroke, one of them 
using the patients’ own and two using allogeneic cells. In most of these early studies, cells 
will be administered via the intravenous route. These studies, and others addressing the 
questions posed above, may help us in ameliorating the devastating consequences of 
ischemic stroke at the personal and societal level. 
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M. Balestrino, L. Dinia, M. Del Sette, B. Albano and C. Gandolfo 
Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Genova,  
Italy 
1. Introduction 
Currently, i.v. thrombolysis with recombinant tissue plasminogen activator (r-TPA) in acute 
ischemic stroke is approved in Europe only for patients 80 y.o. or younger, but data from the 
literature do suggest that patients older than 80 might also benefit from it (Sanossian and 
Ovbiagele, 2009). These older patients do have a worse outcome than younger ones, a 
finding that seems to be due to worse baseline prognostic factors, but they are not more 
prone to r-TPA -induced haemorrhage than younger ones (Engelter et al., 2006; Toni et al., 
2008). Based on these considerations, a randomized clinical trial of i.v. r-TPA vs. usual care 
in acute stroke in patients older than 80 years is currently under way in Italy.  
Even lesser data are available for stroke patients older than 90 years. Recently, it has been 
suggested that these patients may not benefit significantly from i.v. r-TPA, despite the fact 
that this treatment appeared reasonably safe in this age range, too (Mateen et al., 2009; 
Mishra et al., 2010).  
We are reporting our experience with i.v. r-TPA in patients 90 year old or older in acute 
ischemic stroke.  
2. Patients and results 
We treated with i.v. r-TPA for acute stroke 6 patients (1male, 5 females). Median age was 
92.5 y.o. (range 90-95). In all cases a CT scan had ruled out haemorrhagic stroke, and there 
were none of the exclusion criteria of the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study (SITS-MOST (Wahlgren et al., 2007)), apart from age and (in some cases, 
see below) elapsed time from onset of stroke. Specifically, all patient were in good 
neurological conditions before stroke. Modified Rankin Scale (mRS) before stroke was 0 or 1 
in all cases, except in one 91 y.o. female where it was 3 due to severe hip arthrosis (no pre-
existing neurological deficit). Risk factors were none (in 2 patients), hypertension  
(3 patients), previous minor stroke more than 3 months before the index one (2 patients), 
atrial fibrillation (2 patients), diabetes (1 patient). No patient had cognitive impairment. 
In all cases a written informed consent was obtained either from the patient through a 
witness (n = 3) or from a first degree relative (n = 3). 
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The median National Institute of Health Stroke Scale (NIHSS) on presentation was 17.5 
(range 3-21). It should be noted that that in the single case where NIHSS was less than 6, the 
symptoms included aphasia, a condition that is considered to be very disabling, thus worth 
the risk of thrombolysis (Kohrmann et al., 2009). All strokes were in the carotid arteries 
territory. Stroke was due to cardiac emboli in 3 cases and to large vessel disease in 2 cases; 
the remaining case was a lacunar stroke in the basal ganglia area. Median stroke-to-hospital 
time was 84.50’ (range 32’-102’). Upon their arrival into the Emergency Room the advanced 
age of these patients caused them to be initially excluded from thrombolytic treatment, 
therefore they were not handled in the rapid way that prospective r-TPA patients are 
usually treated. Only later the consulting stroke neurologist considered thrombolysis as an 
option. Thus, in-hospital times were rather slow. Median door-to-CT time was 82’ (range 
39’-147’), median CT-to-treatment time was 49.5’ (range 15’-110’). Median door-to-treatment 
time was 150.5’ (range 80’-215’). Median time from stroke onset to thrombolysis (“stroke-to-
needle” time) was 210’ (range 177’-273’). 
Four patients received the standard r-TPA dose of 0.9 mg/Kg i.v., 10% of which was 
administered as an initial bolus, followed by the remaining 90% over 1h. One 94 y.o. patient 
received the lower dose of 0.67 mg/Kg i.v. (10% as a bolus, 90% in 1h) because in the 
Emergency Room she had already been given 500 mg acetyl-salicylic acid i.v. in the belief 
that she was not a candidate to thrombolysis. This same patient suffered shortly after 
thrombolysis a traumatic clavicle fracture, after which a major bleeding, requiring 
transfusion, occurred around the site of fracture. In another 91 y.o. patient r-TPA infusion 
was stopped after 25’ (when about 50% of the full dose had been administered) because of 
headache and a minor gingival bleeding. It should be noted that minor gingival bleeding 
occurred during drug infusion in another 91 y.o. patient who nevertheless went on to 
receive the full standard dose of r-TPA with no other harmful consequences. No bleeding 
was observed in the other patients.  
No symptomatic intracranial haemorrhage occurred in any patient. In 1 patient a 
haemorrhagic transformation of the stroke (categorized HI2 according to ECASS III 
classification (Hacke et al., 2008)) was seen at the 24 hours follow-up CT scan, in all other 
cases no bleeding was observed at routine 24 hours follow-up CT scan.  
In 3 patients transcranial ultrasound examination was carried out both before and 
immediately after thrombolysis. In all these cases occlusion of the middle cerebral artery 
was found, graded 0 (1 case) or 2 (2 cases) according to the TIBI classification (Demchuk et 
al., 2001). In all these cases improvement of flow to a TIBI 3 score was noted after 
thrombolysis. It should be noted that these are the 3 patients that showed good outcome 
at the 3-months follow up (mRS=0-1). In one of the 3 cases where ultrasound examination 
could not be carried out, a dense middle cerebral artery sign (Launes and Ketonen, 1987) 
was found upon non-contrast CT scan before thrombolysis. This patient showed an 
almost full recovery of motor function at the end of tPA infusion, that was followed by 
worsening 1 hour after. A CT scan right after the second worsening ruled out any 
intracranial bleeding. We interpret these findings as r-TPA -induced recanalization 
followed by early restenosis. 
Figure 1 shows the NIHSS score before thrombolysis and at various times after it. As it 
can be seen, both patients with milder symptoms (NIHSS=3 and 6, respectively) had very 
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good outcome (NIHSS=1 and 0, respectively, after 7 days). Of the 4 patients with more 
severe symptoms, 1 had very good improvement (NIHSS=1 after 7 days – this is the lady 
who received 0.67 mg/Kg because she had already received 500 mg ASA), the other 3 had 
minimal or no improvement. Of the latter 3 ones, 1 is the lady whose treatment was 
aborted because of gingival bleeding, and the other 2 are the patients who later died (see 
below).  
 
Fig. 1. NIHSS score before thrombolysis and 2 hours, 24 hours and 7 days after it in each 
patient. One asterisk indicates the patient in whom treatment was aborted before of gingival 
bleeding after 25’, when approximately 50% of the full rTPA dose had been received. Two 
asterisks indicate the patient to whom the reduced rTPA dose of 0.67 mg/Kg was 
administered because she had already received 500 mg ASA i.v. 
Figure 2 shows the score on the modified Rankin Scale (mRS) (Farrell et al., 1991) before 
stroke as well as 7 days and 3 months afterwards (note that mRS=6 was added to the 
original mRS, indicating death (Mateen et al., 2009)). As it can be seen, 2 patients died (14 
and 16 days after thrombolysis, respectively), both of cardiac failure (acute pulmonary 
oedema). Neither one had significantly improved after thrombolysis (see above). One more 
patient was left with moderately severe disability (mRS=4) and 3 patients showed very good 
outcome (mRS=0-1).  
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Fig. 2. mRS score before stroke, 7 days and 3 months after it in each patient. One asterisk 
indicates the patient in whom treatment was aborted before of gingival bleeding after 25’, 
when approximately 50% of the full rTPA dose had been received. Two asterisks indicate 
the patient to whom the reduced rTPA dose of 0.67 mg/Kg was administered because she 
had already received 500 mg ASA i.v. 
3. Discussion 
The present report has the obvious limitation of being retrospective, nevertheless we believe 
that it has some interest given the extreme paucity of literature reports on thrombolysis in 90 
y.o. patients or older. To the best of our knowledge, so far only one such report exists in the 
literature (Mateen et al., 2009), while another recently published paper reports a comparison 
between two different databases (Mishra et al., 2010). Our findings are in agreement with 
those report, as far as they confirm that i.v. thrombolysis with r-TPA is reasonably safe in 
these patients. In our patients no treatment-related worsening occurred, and no intracranial 
symptomatic haemorrhage was observed. Retrospectively, abortion of therapy upon 
gingival bleeding may have been excessive (in the other case of minor gingival bleeding the 
full dose was still given with no harm). Death occurred in two of the three unimproved 
cases 14 and 16 days after thrombolysis because of cardiac failure, unrelated to treatment. 
Three out of six patients improved upon thrombolysis. Although this finding is obviously 
encouraging, randomized clinical trials are needed to reach firm conclusions that may be 
applied to the general population of 90 y.o. patients or older. Finally, we note that our 
patients were not handled rapidly by hospital personnel because it was initially believed 
that their old age should have ruled out thrombolysis. This resulted in a significant delay of 
treatment (see above), that has probably reduced the chances of good outcome in our 
patients (Lees et al., 2010). This finding strongly suggests that stroke therapy is a complex 
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issue, one that, whenever possible, should be managed by stroke physicians having specific 
competence and experience. 
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Mechanical Embolectomy 
Jiří Lacman and František Charvát 
Central Military Hospital Prague 
Czech Republic 
1. Introduction 
After heart attack and cancer, cerebrovascular accident (CVA) is the third leading cause of 
death in the industrialized part of the world and the leading cause of long-term disability. 
Having suffered a stroke, 15% to 30% of patients are incapable of independent existence 
without help of others. After the first ischemic stroke, 10 to 15% of patients die within the 
first 30 days, 20% within 6 months, and this percentage increases to 25 - 30% within one 
year. CVA is a serious problem both in terms of significant disability of the population and 
very high costs of treatment. In addition to the high incidence, which increases with the 
increasing age of patients, also the fact that the cerebrovascular accidents affect younger age 
groups more and more often is serious. Thus, even accidents in patients between 30 - 40 
years of age may occur. 
The aim of treatment of ischemic CVA (iCVA) is to intervene as soon as possible and to 
achieve reperfusion of the affected area. Therefore, the time of recanalization plays a crucial 
role. 
The only causal and potentially effective treatment for iCVA due to the occlusion of cerebral 
arteries is an attempt at recanalization. The first treatment introduced was intravenous 
administration of a thrombolytic agent, in the following years possibilities of intra-arterial 
recanalization using a thrombolytic agent or intra-arterial mechanical embolectomy have 
gradually been introduced and technologically improved. 
2. IV thrombolysis 
Experience with intravenous thrombolysis (IVT) of coronary and peripheral arteries have 
led to the introduction of intravenous thrombolysis also in acute occlusions of the major 
cerebral arteries. However, the method of IVT in the coronary and peripheral bloodstream 
has been abandoned with the passing because of the higher risk of overall complications 
and less pronounced local effect. 
A good final effect of intravenously administered thrombolytic agent in acute CVA has been 
shown in the NINDS study (National Institute of Neurological Disorders and Stroke) (NINDS 
Stroke Study Group, 1995). This study randomized a set of 624 patients with occlusions of 
larger and smaller arteries not verified by angiography, the time interval from the CVA 
occurrence to the beginning of administration was 3 hours. Recombinant tissue plasminogen 
activator (rt-PA) was used, administered at a dose of 0.9 mg/kg up to a maximum dose of 90 
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led to the introduction of intravenous thrombolysis also in acute occlusions of the major 
cerebral arteries. However, the method of IVT in the coronary and peripheral bloodstream 
has been abandoned with the passing because of the higher risk of overall complications 
and less pronounced local effect. 
A good final effect of intravenously administered thrombolytic agent in acute CVA has been 
shown in the NINDS study (National Institute of Neurological Disorders and Stroke) (NINDS 
Stroke Study Group, 1995). This study randomized a set of 624 patients with occlusions of 
larger and smaller arteries not verified by angiography, the time interval from the CVA 
occurrence to the beginning of administration was 3 hours. Recombinant tissue plasminogen 
activator (rt-PA) was used, administered at a dose of 0.9 mg/kg up to a maximum dose of 90 
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mg, 10% bolus, the rest administered in course of 60 minutes. The study showed a better 
clinical outcome in the group treated with IVT (30% of patients had no or minor neurological 
deficit according to the modified Rankin scale mRS ≤ 1). Mortality after three months was 17% 
(versus 21% in placebo-treated patients). Based on the results of this study, the FDA in the U.S. 
approved in 1996 the use of IVT in clinical practice. In Europe, IVT with rt-PA was approved 
in 2002. Safety and efficacy of routinely administered rt-PA in clinical practice has been 
confirmed once more by the SITS-MOST monitoring study (SITS-MOnitoring STudy) based on 
the data from European registries (Wahlgren et al., 2007). 
The ECASS I, II, and ATLANTIS studies have not shown significant benefit to the patient in 
case of use of an intravenous thrombolytic agent (rt-PA) in the time-window of 3 to 6 hours 
after the onset of symptoms. The number of patients with no or minimal neurological deficit 
(mRS ≤ 1) has not improved, but the number of disabled patients (mRS ≤ 2) has decreased 
(Clark et al., 1999; Hacke et al., 1995, 1998). The efficacy in the ECASS studies depended on 
the selection of patients with moderate to severe neurological deficit and without extended 
infarctsigns on the initial CT scan. These studies did not support use of intravenous 
thrombolysis after the 3-hour time window. 
The recently published ECASS III study evaluating safety and efficacy of IVT in the time 
window of 3 - 4.5 hours has showed improvement of the clinical condition in patients after 3 
months compared to placebo (mRS 0-1 52.4% vs. 45.2%). Intracranial hemorrhage occurred 
more often in the group treated with the thrombolytic agent: 27% vs. placebo 17.6%. 
Mortality in both groups did not significantly differ after 3 months (7.7% vs 8.4%) (Hacke et 
al., 2008). The results of this study have led to redefinition of the recommended procedure 
for IVT and the therapeutic window has increased to 4.5 hours. 
The advantage of IVT is its widespread availability and the possibility of its early initiation. 
This treatment does not even require the specialized know-how that is needed to insert and 
navigate a catheter into the cerebral circulation. Unfortunately, experimental studies have 
shown that this treatment is less and less effective as the trombus grows larger and larger. 
(Zivin et al., 1985). More than 50% of patients treated with intravenous rtPA fail to achieve a 
favorable clinical outcome (Papadakis & Buchan, 2006; Qureshi et al., 2001). 
3. IA thrombolysis 
The basic study on intra-arterial thrombolysis (IAT) was a randomized multicenter study 
ProAct (Prolyse in Acute Cerebral thromboembolism), ongoing in phase I and II (del Zoppo 
et al., 1998; Furlan et al., 1999). In this study, recombinant pro-urokinase (r-proUK) was 
compared to placebo. As a placebo, intra-arterial administration of saline solution with 
heparin was used. The first 16 patients received a 100-IU/kg bolus followed by a 1000 IU/h 
constant infusion ("high heparin") for 4 hours. Thereafter, on the recommendation of the 
External Safety Committee, the heparin regimen was altered to a 2000 IU bolus and 500 
IU/h infusion ("low heparin") for the remaining patients. In both groups, the end of the 
microcatheter was placed in the proximal third of the thrombus. Passing through the 
thrombus or mechanical action on it was not allowed. If partial recanalisation occured after 
2 hours, the catheter was introduced more distally into the proximal third of the remaining 
thrombus. The time window was 6 hours, patients with middle cerebral artery occlusion 





In phase I of the PROACT study, 46 patients were randomized, the maximum total dose was 
6 mg of r-proUK in course of 2 hours, recanalization occurred in 57.7% (compared to 14.3% 
in controls), whereas in the group with higher dose of heparin it was in 81.8% and in the 
group with lower dose of heparin it was in 40.0%. Serious cerebral bleeding in the first 24 
hours after thrombolysis occurred on average in 15.4% compared to 7.1% in the control 
group, in the group with the higher administered dose of heparin it was more frequent 
(27.3%), after dose reduction it occurred only in 6.7%. Clinical condition was evaluated after 
3 months according to mRS, 19.2% of patients were stage 0-2 (versus 7.1% of controls). 
In phase II of the study, 180 patients were randomized, the total dose of r-proUK was 
increased to 9 mg, heparin was decreased to 2000 units. The percentage of recanalization 
was 66% in the r-proUK group compared to 18% in the placebo group for TIMI 2-3 and 19% 
in the r-proUK group compared to 2% in the placebo group for TIMI 3. The resulting 
morbidity after 3 months was more favorable by 60% compared to the control group (mRS 
0-2 in 40% r-proUK treated patients in contrast to 25% in the control group), also mortality 
was slightly lower (24% compared to 27% in the control group); the number of symptomatic 
hemorrhage was significantly higher in the first 24 hours (35% versus 13% in the control 
group) but was not significantly different by 10 days (68% in the r-proUK group versus 57%, 
p=0.23); for comparison, in the NINDS study with IVT the ICH rate was 6.5%. 
In phase II of the study with a higher dose of the thrombolytic agent and a lower dose of 
heparin, a higher number of recanalizations and a significant decrease in the number of 
hemorrhages was achieved, leading to better clinical results. However, FDA has not granted 
its approval to use IAT in clinical practice, and so IAT has remained reserved for use in 
studies only. 
Also a number of nonrandomized studies with smaller numbers of patients, a number of 
case studies and meta-analyses have been published, which generally show a higher 
percentage of recanalizations and favorable clinical outcome after intra-arterial 
administration of a thrombolytic agent (Wardlaw et al., 1997; Gönner et al., 1998; Higashida 
et al., 2003). 
In recent years, new antiplatelet medicines acting on the inhibitory IIb / IIIa platelet 
receptors, have been developed, which are highly effective and relatively safe even when 
administered intravenously. They act selectively on platelet thrombi, preventing their 
formation and growth. In the brain arteries they have been used so far mainly to treat 
thromboembolic complications of endovascular procedures, however, several papers on 
their use in acute iCVA has already been published (The Abciximab in Ischemic Stroke 
Investigators, 2000). 
Compared to intravenous thrombolysis, intra-arterial thrombolysis has the advantage of 
achieving higher concentration of the thrombolytic agent at the site of the occlusion with 
lower total dose. This reduces the risk of systemic complications. Also results of a number of 
other studies showing a higher percentage of recanalization and better clinical results 
despite a slightly increased percentage of bleeding complications confirm this (Barnwell et 
al., 1994). 
Opinion of the ASITN Executive Committee (American Society of Interventional and 
Therapeutic Neuroradiology), published in the AJNR in 2001, states that although the 
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results of the PROACT study have not led the FDA to grant the approval, IAT is regarded, 
based on the experience gained so far, as a beneficial and acceptable method of treatment at 
the centers experienced in vascular diagnostic and interventional procedures. Indication for 
the IAT must be considered on an individual basis, with careful assessment of risks and 
benefits (Executive of the American Society of Interventional & Therapeutic Neuroradiology 
[ASITN], 2001). 
In 2003, new guidelines of the ASA (American Stroke Association) and EUSI (European 
Stroke Initiative) were published, which indicate that EUSI acknowledges that the IAT 
performed within 6 hours after development of the CVA improves its course (Klijn & 
Hankey, 2003). 
Thus, IAT is currently an appropriate method of iCVA treatment in patients within the time 
window of 3-6 hours (or 4.5 - 6 hours with regard to the results of the ECASS III study) in 
specialized centers. Intra-arterial thrombolysis may also be used to deal with acute embolic 
complications developed during endovascular procedures and last, but not least, an IA 
thrombolytic agent may be administered after unsuccessful response to its IV 
administration. 
4. Combined IV / IA thrombolysis 
Pursuit of a fast and simple administration of a thrombolytic agent together with 
angiographic monitoring of the treatment effect and the possibility of local intervention led 
to the IMS study (International Management of Stroke Trial) (IMS study investigators, 2004). 
Patients were treated with intravenous administration of a thrombolytic agent and in the 
case of angiographic confirmation of persisting arterial occlusion they were given the 
thrombolytic agent also locally. The treatment led to a partial or complete recanalization of 
the artery in 56% of patients, the percentage of bleeding was low (6.3%), as well as mortality 
was (16%). A subsequent study, IMS II (IMS II Trial Investigators, 2007; Tomsick et al., 2008), 
put together combined IVT and IAT with the use of a special micro-infusion catheter Ekos-
MicroLysUS (Ekos, Washington, USA) or a standard microcatheter. The Ekos catheter 
allows simultaneous infusion of a thrombolytic agent and administration of low-energy 
ultrasound waves transmitted by a probe at the end of the micro-catheter. The median dose 
of the intravenously administered rt-PA in the study was 46.4 mg and that of the intra-
arterial dose was 12 mg. The percentage of hemorrhage, compared to IMS I, increased to 
9.9%, recanalization increased to 73% with 16% mortality. Favorable clinical outcome was 
achieved in 46% of patients. Currently, IMS III is being conducted, comparing the results of 
combined treatment with IVT, IAT, and the Ekos catheter with the MERCI apparatus (Khatri 
et al., 2008) and Synthesis-Expansion trial is comparing the IVT and IAT (Ciccone et al, 
2011). 
There are also other publications reporting improvement of the angiographic and clinical 
finding in different combinations of methods (Burns et al., 2008). 
5. Mechanical embolectomy 
After IAT has been introduced within the framework of clinical studies, first positive 





guide wire or special instrumentation increasing the thrombus surface by means of its 
fragmentation and thus accelerating the effect of thrombolytic agent. For this purpose, 
micro-guide wire, extraction loops and baskets to capture foreign bodies were used 
(Sarimachi et al., 2004; Krajina et al., 2005). 
Mechanical treatment reduces the need for a thrombolytic agent, reducing the risk of ICH 
(intracerebral hemorrhage) and has been used up to 8 hours after stroke, since it is still an 
experimental time window. Mechanical devices are able to recanalize the occluded artery 
faster and may be more effective in removing mature thrombi, cholesterol or calcified 
thrombi, and atherosclerotic plate emboli. 
Mechanical embolectomy plays a role even in patients contraindicated for pharmacological 
treatment with a thrombolytic agent, usually because of recent surgery. 
The disadvantage of mechanical embolectomy is often a difficult access to cerebral arteries, 
due to the anatomical relations of the arteries in the neck and brain, and the possibility of 
perforation or dissection of the artery or distal embolization of the parts of the thrombus 
into the so far unaffected bloodstream. However, the advantages of mechanical intervention 
outweigh the disadvantages and risks. 
 
Fig. 1. Catch retriever 
Mechanical devices vary depending on the site from where they act upon the thrombus. The 
approach is either a proximal one with aspiration of the thrombus or with a device 
"grasping" the thrombus or devices for distal access capturing the thrombus into a basket or 
snare. A study comparing the effectiveness of these approaches, using the Vasco35 micro-
catheter and the Catch retriever (both by Balt Extrusion, France) has demonstrated that the 
use of the micro-catheter allows rapid and repeated use with a low percentage of 
thromboembolic events (3% versus 26%) but also significantly lower success rate as regards 
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thrombus removal compared to the Catch retriever (39% vs. 83%). The percentage of 
embolic events may be reduced by the use of a proximal occlusion balloon (Gralla et al., 
2006). In a recent retrospective case series, the Catch device again appears effective for 
recanalization and improving 90-day outcome in patients with acute ischemic stroke 
(Mourand et al., 2011). 
5.1 Merci retriever 
In 2004 the FDA approved the first extraction device for stroke treatment - Merci Retrieval 
system (by Concentric Medical, Calif., USA). It is a flexible nitinol guide wire, the distal end 
of which has shape memory and, being pushed out of the micro-catheter, it forms into a 
helix. Newer types have the end surrounded by a braided tangle of filaments to better 
capture the thrombus. 
Using the micro-catheter, the system is introduced behind thrombus, it is expanded and 
then retracted under the vacuum in the balloon guide catheter. Merci Retrieval system was 
first used in a small multicenter study in 28 patients with NIHSS ≥ 10 with occlusion of a 
major cerebral artery documented by angiography (Gobin et al., 2004). Occlusion of 
intracranial ICA (internal carotid artery) was present in 5 patients (18%), occlusion of MCA 
(medial cerebral artery) in 18 patients (64%), common occlusion of both ICA and MCA in 3 
patients (11%) and occlusion of basilar artery in 2 patients (7%). Successful recanalization 
(TIMI 2-3) was achieved when using the retriever alone in 12 patients (43%) and when 
combining it with IA rtPA in 18 patients (64%). In 12 patients, an asymptomatic ICH 
developed after the procedure. After one month, clinical improvement was achieved in 9 
patients (32%). 10 patients died within 30 days (36%). 
Another study investigating the effectiveness of the Merci Retrieval system was the MERCI 
study (Mechanical Embolus Removal in Cerebral Ischemia) (Smith et al., 2005). The aim of 
the MERCI study was to broaden the possibilities of treatment for patients contraindicated 
for IVT or for those who have passed the time window for IVT or in whom IVT was not 
successful. The therapeutic window was extended to 8 hours after the onset of complaints. 
IA thrombolytic agents were either not used at all or only in small doses. 151 patients were 
enrolled in the study, the average age was 67 years of age and the NIHSS score was 20. The 
inclusion criteria were: age over 18 years, the clinical picture of stroke with NIHSS ≥ 8, time 
window between 3 to 8 hours after the onset of complaints or 0 to 3 hours in the case of 
contraindicated IV rtPA, and artery occlusion confirmed by angiography. Patients with an 
ICH, significant mass effect with a midline shift, or with a hypodensity exceeding 1/3 of the 
MCA supply area were excluded from the study. In 90% of cases, the occlusion affected the 
anterior supply area. Recanalization was achieved in 48% of patients, in the case of 
combination with thrombolytic therapy it was in 60%. Symptomatic complications of the 
procedure, such as perforation, dissection, distal embolism occurred in 7.1%, symptomatic 
hemorrhage occurred in 7.8% and was partly due to artery perforation (4.3%). Conclusions 
of the first phase of the study showed good clinical results (mRS ≤ 0-2) in 27.7% of the total 
number of patients, i.e. in 46% of patients from the successful recanalization group. 
In the MERCI multicenter study (Smith et al., 2008), the second generation of the retriever- 
type L5 was used. Inclusion and exclusion criteria did not differ from those in the previous 





could be used. The average age was 68 years, and NIHSS score was 19. In 92% of cases, the 
occlusion affected the anterior supply area. 48 patients (29%) were given IV rtPA before the 
procedure, 57 patients received IA rtPA during the procedure. Recanalization was achieved 
using the Merci system alone in 57% of treated arteries, in the case of combination with IA 
thrombolytic and mechanical treatment it was in 69.5%. After 90 days, a good result was 
achieved in the whole group in 36% of patients (mRS 0-2), symptomatic hemorrhage 
occurred in 9.8%. 90-day mortality was 34%. 
 
Fig. 2. Merci retriever, type L5 
5.2 Neuronet 
Neuronet (Abbott Vascular, Calif., USA) is a nitinol basket-shaped device attached to a 
micro-guide wire. The basket is opened distal to the embolus and the embolus is captured in 
it when the basket is pulled back. 
Neuronet was successfully used for the removal of emboli in the cerebral arteries (Mayer et 
al., 2002a; Nesbit et al., 2004) and prospectively evaluated in a small study Neuronet 
Evaluation in Embolic Stroke Disease (Mayer et al., 2002b). This study evaluated 5 patients, 
treated with the Neuronet device. The device was used without flow control in the first 2 
patients and with flow reversal in the basilar artery in the last 3 patients during retraction by 
transiently blocking both vertebral arteries or the left subclavian artery or both vertebral 
arteries with coaxial catheters. Patients 1, 2, and 4 were also administered recombinant 
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thrombus removal compared to the Catch retriever (39% vs. 83%). The percentage of 
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aspirated by the reperfusion micro-catheter, whereas the separator also fragments the 
thrombus and prevents micro-catheter clogging. This mechanical device is capable to restore 
the passage through the vessel without the use of a thrombolytic agent, the entire system is 
designed as a minimally invasive one, acting on the embolus from its proximal end. High 
flexibility and a wide spectrum of sizes (0.26 - 0.54 inch) of reperfusion micro-catheters 
enable their successful use even in smaller branches, such as M2 and A2. 
The Penumbra system was first used in a European study in 20 patients (21 treated arteries) 
with ICA occlusion in 7 patients, MCA occlusion in 5 patients, and BA occlusion in 9 
patients (Bose et al., 2008). The average NIHSS score was 21, patients were treated within 8 
hours after the onset of complaints. Successful recanalization (TIMI 2 and 3) was achieved in 
100%. Nine patients received IA rtPA after the embolectomy. Clinical improvement  
(mRS ≤ 2) within 30 days occurred in 45% of patients. Mortality reached 45%. In 8 patients, 
ICH occurred, two of these were symptomatic. The use of IA rtPA resulted in a higher 
incidence of bleeding. 
In another multicenter prospective study (Penumbra Stroke Trial) 125 patients were treated 
in 24 centers in Europe and the USA (Penumbra Pivotal StrokeTrial Investigators, 2009). 
Inclusion and exclusion criteria were the same as in the MERCI and Multi MERCI studies. 
The average age of patients was 63 years, average NIHSS score was 17, median time from 
the onset of symptoms until the procedure was started was 4.1 hours. The occluded arteries 
were: ICA in 18%, M1 or M2 in 70%, vertebrobasilar artery in 9% and others in 3%. 
Complete or partial recanalization (TIMI 2 to 3) occurred in 81.6% of occluded arteries. 
Major complication of the procedure occurred in 4 patients. Symptomatic ICH occurred in 
14 patients (11.2%) and asymptomatic ICH in 21 patients (16.8%). Good clinical outcome 
(mRS ≤ 2) after 90 days was achieved in 25% of patients. 90-day mortality was 32.8%. Just as 
in the MERCI and Multi MERCI studies, there was a marked improvement of neurological 
status (29% vs. 9%) and mortality (29% vs. 48%) in patients with successful recanalization. 
Based on this study, FDA consented to the use of this system in the treatment of ischemic 
stroke in 2007. 
 





5.4 Stent solitaire 
Stent Solitaire (Solitaire AB, EV3, USA) is a demountable retractable stent originally 
designed for intracranial bloodstream vessels where it served as a remodeling stent during 
coiling of wide neck aneurysms. It is a self-expanding closed cell nitinol stent, which allows 
for its pulling completely back into the microcatheter after having it fully inserted in the 
vessel. Using the device for demounting GDC embolization spirals, the stent may be 
electrolytically detached by the same mechanism as the GDC coils (Stryker, USA) and left at 
the site of the artery occlusion to help restore brain perfusion. Stent diameter expanded at 
maximum is 4 mm, the length is 15 mm or 20 mm. The stent is introduced through a 
microcatheter with an internal lumen of 0.021 inches. Its advantageous use even as a 
mechanical embolectomy device was demonstrated by a prospective study in 20 patients 
with an acute ischemic stroke in the time window up to 8 hours (Castaño et al., 2010). In 18 
patients (90%) the thrombus was successfully removed by the stent and the affected brain 
tissue revascularized (TICI 2b-3); after 90 days, 45% of patients achieved the final mRS ≤ 2. 
 
Fig. 4. Solitaire stent 
5.5 Bonnet retriever 
It is a novelty by Phenox company (Bochum, Germany), which launched Phenox Clot 
Retriever to the market already several years ago. It is a "self-expanding nitinol braiding 
with polyamide filaments." Larger surface helps better fixation of the thrombus and 
increases the chance for its extraction. Retriever is firmly connected to the micro-guide wire, 
it has contrast marks on both ends. It may be introduced distal to the thrombus or opened in 
the thrombus. By pulling it back slowly, the thrombus is captured in the braiding and 
extracted from the artery. 
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Fig. 5. Bonnet retriever 
6. Conclusion 
Endovascular treatment of ischemic cerebral strokes is still developing. There are advances 
both in the field of pharmacology and in the field of mechanical devices. New medicines 
improve the safety of the procedure and together with more and more perfect and efficient 
devices markedly improve the clinical condition of patients. 
Currently, mechanical embolectomy is not merely an auxiliary treatment method but has 
become the method of choice in given indications. Mechanical recanalization has helped not 
only to investigate a longer therapeutic time window, but may also help reducing the 
percentage of bleeding associated with pharmacological thrombolytic therapy. The 
indicated option of mechanical embolectomy in patients with occlusion of a major cerebral 
artery is capable of improving brain perfusion and thus ameliorate the clinical condition of 
the patient and protect him/her from a disabling affliction. 
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1. Introduction 
Cervical carotid artery stenosis frequently causes ischemia by embolic phenomena, but 
stenosis can also induce ischemia via a reduction in blood flow. Cerebral perfusion failure 
can be caused by reductions in blood flow arising from a stenosis or an occlusive vascular 
lesion (Bokkers et al., 2008; Wilkinson et al., 2003). 
Two major mechanisms are involved in cerebral ischemia (Mohr et al., 1997). Cerebral 
perfusion failure may occur as the result of flow reduction mediated by stenosis or occlusive 
vascular damage such as that arising from atheroma plaques that affect the carotid bulb. 
Perfusion failure affects the distal territories, and it is known as a watershed infarction. The 
second mechanism of cerebral ischemia is artery-to-artery embolism, which is considered to 
be the main cause of ischemia associated with plaques in the larger arteries. There are 
thrombosis in situ and embolic infarctions associated with these plaques, which usually 
involve the occlusion of intracranial distal vessels. 
Ischemia is the physiological term indicating a blood flow that is insufficient for the normal 
functioning of cells, whereas infarction is the pathological term denoting permanent tissue 
damage caused by ischemia (Jensen et al., 2005). Classically, atherosclerotic infarctions, 
particularly those in major arteries, are caused by the formation of thrombosis at the 
atheroma plaque site or from an embolism that originates from the same plaque. The most 
common location of plaques in the cerebrovascular circulation is at the carotid bifurcation 
involving the distal common carotid artery and the first 2 cm of the internal carotid artery. 
Treatment options for atherosclerotic carotid artery stenosis include drug therapy and 
surgical treatment (Mas et al., 2006; NASCET, 1991; Ringleb et al., 2006; Yadav et al., 2004). 
Clinical treatment includes antiplatelet aggregation agents and statins, along with the 
control of risk factors such as arterial hypertension, dyslipidemia, hyperglycemia and 
tobacco use (Bates et al., 2007). Two relevant studies comparing clinical and surgical 
treatments showed a significant reduction of cerebral infarction risk in the group of patients 
selected for surgical intervention. In the NASCET (North American Symptomatic Carotid 
Endarterectomy Trial) study, the stroke risk was significantly reduced by surgery (9% in the 
surgical group versus 26% in the clinical treatment group) (NASCET, 1991). In another 
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tobacco use (Bates et al., 2007). Two relevant studies comparing clinical and surgical 
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Endarterectomy Trial) study, the stroke risk was significantly reduced by surgery (9% in the 
surgical group versus 26% in the clinical treatment group) (NASCET, 1991). In another 
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classic trial with asymptomatic patients, the prognosis also improved with surgical 
treatment (4.8% versus 10.6% with drug treatment) (ACAS Trial investigators, 1995). 
Endovascular surgical treatment consists of carotid angioplasty and stenting (CAS), a 
procedure in which the stenosis is approached through a natural passage inside the vessels 
themselves. In this technique, a flexible guidewire and catheter are inserted into the arterial 
system through a peripheral puncture site. The guidewire and catheter are then directed to 
the site of the stenosis, where the stent and the balloon open the narrowing. 
CAS was designed as a less invasive method to treat carotid artery stenosis, and the Carotid 
Revascularization Endarterectomy Versus Stenting Trial (CREST) showed that angioplasty 
was as effective as endarterectomy for the prevention of stroke (Bates et al., 2007; Caldas, 
2006; Chaturvedi & Yadav, 2006; Gurm et al., 2008; Menon & Stafinski, 2006). CAS is also 
advantageous because it most often uses a local anesthetic, maintains a constant blood flow 
to the brain and allows an earlier hospital discharge (Menon & Stafinski, 2006).  
Initially, the “status” of cerebral perfusion in patients with carotid artery stenosis, or the 
changes that occur after angioplasty, was not well known. Research suggesting that the 
modification of cerebral blood flow following angioplasty possibly induces cerebral 
reperfusion syndrome (Fukuda et al., 2007) is relatively recent. The course of other diseases 
can be potentially altered after carotid angioplasty. 
Recent publications show cognitive dysfunction in some patients with carotid artery 
stenosis (Takaiwa et al., 2009; Takaiwa et al., 2006; Turk et al., 2008). Takaiwa et al. observed 
cognitive improvement in elderly patients after CAS (Takaiwa et al., 2009).  
2. Cerebral ischemia and carotid artery stenosis  
Carotid artery stenosis is present in 7% of men and 5% of women aged 65 years or older 
(O'Leary et al., 1992). Severe carotid artery stenosis is a leading cause of cerebral infarction 
and transitory ischemic attack. The estimated risk of ipsilateral carotid artery infarction in a 
5-year period is 4% in the population without carotid artery stenosis, 18% in asymptomatic 
patients with stenosis of over 75% and 27% in symptomatic patients with stenosis of over 
75% (Inzitari et al., 2000).  
3. Poor cerebral perfusion in carotid artery stenosis 
Cerebral infarction resulting from hypotension, which is the result of cerebral blood flow 
that is insufficient to comply with metabolic demands, represents about 0.7 to 3.2% of 
cerebral infarctions. The terms “border-zone” and “watershed” are used synonymously to 
describe this condition in everyday clinical practice. The appearance of these infarcts varies 
but can include wedge-shaped lesions with their base on the surface of the cortex, exhibiting 
a border-zone irrigation topography. There may be a string-of-pearls presentation of the 
infarcts where there are three or more lesions in the deep white matter within the centrum 
semiovale, with a linear orientation parallel to the lateral ventricle. These ischemic lesions 
are identified on magnetic resonance imaging (MRI) studies (Ogata et al., 2005) and on CT 
scan (Del Sette et al., 2010). This appearance can be unilateral when there is ipsilateral 
carotid artery stenosis or bilateral when there is a severe and global hemodynamic event or 
bilateral arterial stenosis (Hamilton, 2005). Regarding pathology, infarctions arising from 
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hypotension occur in border zones and result in encephalomalacia and ulegyria (Hamilton, 
2005). 
The etiology of infarctions in watershed areas is varied and includes global cerebral injury 
resulting from perfusion or oxygenation disorders such as prolonged severe hypotension, 
cardiac arrest with resuscitation, asphyxia and carbon monoxide inhalation. Carotid artery 
stenosis or occlusion is another etiology that predisposes subjects to border-zone infarctions 
during episodes of hemodynamic compromise, often with rosary-like patterns. Carotid 
artery disease infarctions can occur in the cortical and watershed areas as well (Krogias et 
al., 2010; Momjian-Mayor & Baron, 2005). Although embolisms can occur in the border 
zones, they are difficult to identify with precision by imaging (Hamilton, 2005; Marks, 2002; 
Yamada et al., 2010). 
In addition to Perfusion-Weighted Imaging (PWI) by MRI, brain perfusion can be evaluated 
by several techniques including parenchymography, perfusion by helicoidal tomography, 
perfusion by multislice tomography, transcranial Doppler, intracarotid xenon injection and 
MRI volume flow quantification analysis. Transcranial doppler studies have the advantage 
of being non-invasive, but the technique is usually limited to an analysis of a single vessel, 
usually the middle cerebral artery ipsilateral to the carotid artery stenosis. Doppler studies 
can also be impaired by cardiac arrhythmias, which make the recorded velocity on the 
spectral trace unreliable (Kleiser & Widder, 1992; Niesen et al., 2004). Perfusion by 
tomography has attained a level of technical refinement; however, its application is still 
restricted to small slices or only one slice per examination (Jongen et al., 2010; Roberts et al., 
2000; Waaijer et al., 2007). Evaluation by intracarotid xenon has been limited to research 
(Bando et al., 2001).  
3.1 Digital subtraction angiography  
Parenchymography, as described by Theron et al., is an innovative and simple method to 
evaluate cerebral perfusion. The research on parenchymography included an analysis by 
angiography with modified windowing to allow the preferential study of the brain blood 
supply (Theron et al., 1996). Angiography has the capacity to directly assess the degree of 
carotid artery stenosis and, with the addition of parenchymography, the hemodynamic 
effects between the brain and its blood supply (Theron et al., 1996). 
During the angiographic study of many of our patients, we observed (Figure 1 A) a poor 
opacification of the anterior and middle cerebral arteries when ipsilateral severe cervical 
carotid artery stenosis was present.  
3.2 Cerebral perfusion by MRI (PWI) 
Although perfusion evaluation by MRI is semi-quantitative, its advantages are that MRI is a 
non-invasive method of evaluating cerebral blood flow that is available in most large 
centers, avoids ionizing radiation and retains good spatial resolution and good correlation 
with SPECT (Single-photon emission computed tomography) (Bokkers et al., 2008; Martin, 
A. J. et al., 2005; Rasmussen et al., 2010; Rohl et al., 2001; Tavares et al., 2010; Van Laar et al., 
2007). 
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Fig. 1. A 61-year-old patient with severe left cervical carotid artery stenosis. Angiography of 
the left carotid artery in PA position before angioplasty with stenting shows the slight 
opacification of the middle cerebral artery (A). Angiogrpahy of the left carotid artery in PA 
after angioplasty with stenting shows the normal opacification of the left middle cerebral 
artery (B). 
A recent study of PWI by MRI in patients with carotid artery stenosis investigated the 
relative values of cerebral blood volume (CBV), mean transit time (MTT) and time to peak 
(TTP). A reduction in the CBV and a time-to-peak delay in the middle cerebral artery 
territory ipsilateral to the cervical carotid artery stenosis were noted (Tavares et al., 2010). 
The intracranial blood supply was shown to be compromised by a timing delay (increase in 
the TTP) of the contrast peak in the territory fed by the middle cerebral artery ipsilateral to 
the cervical carotid artery stenosis. There was less signal loss (negative wave) in the area 
analyzed (reduction in CBV), which indicated a lower regional blood volume in the middle 
cerebral artery territory (Tavares et al., 2010).  
The TTP delays in the middle cerebral artery ipsilateral to the cervical stenosis compared 
with the contralateral territory have also been observed by Gauvrit et al. (2004). 
Teng et al. showed that analysis of the TTP is a valuable tool for the assessment of the 
hemodynamic changes in carotid artery stenosis that correlates well with the mean transit 
time (MTT) parameter (Teng et al., 2001). 
An earlier study of cerebral perfusion in patients with carotid artery stenosis showed MTT 
prolongation ipsilateral to the carotid artery stenosis and stated that this finding was due to 
hemodynamic compensation between the cerebral hemispheres (Bozzao et al., 2002).  
Even when the perfusion damage is limited, the timing parameters (TTP and MTT) are 
delayed, but these ischemic alterations are not sufficiently significant to be detected by 
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diffusion MRI. Delayed perfusion parameters indicate infarction risk, whereas alterations in 
diffusion indicate an already-established lesion. 
4. Modification of the cerebral flow after carotid angioplasty with stenting 
4.1 Digital subtraction angiography 
The analysis of cerebral perfusion by parenchymography has revealed an improvement in 
cerebral hemodynamic flow achieved by carotid angioplasty (Theron 1996). We observed 
restored intradural artery opacification (Figure 1 B) and a significant improvement in 
parenchymography results following CAS. 
4.2 PWI 
Several authors observed cerebral blood flow modifications after angioplasty (Bozzao et al., 
2002; Martin, A. J. et al., 2005; Van Laar et al., 2007; van Laar et al., 2006) 
A recent publication by our team that assessed patients with carotid artery stenosis used 
PWI by MRI to show that there was a discrete increase in rCBV (p=0.940) and important 
reductions in dMTT (p<0.001) resulting from the reduction in MTT at the site of the 
angioplasty. 
However, during the evaluation before CAS, we observed a delay in the TTP in the middle 
cerebral artery (MCA) territory ipsilateral to the carotid stenosis when compared to the 
contralateral artery. After CAS, there was a remarkable reduction in dTTP (p=0.019)and the 
TPP was earlier at the site of the stent than in the contralateral territory (Tavares et al., 2010).  
Timing parameters such as the MTT proved to be the most sensitive and the most 
reproducible in measuring cerebral hemodynamic alterations (Soinne et al., 2003; Waaijer et 
al., 2007; Wintermark et al., 2006). 
The variations in relative CBV, MTT and TTP are illustrated in Figure 2, where patient 
improvement is shown through the imaging parameters of PWI by MRI after CAS (Figure 2). 
Laar et al. found an increase in cerebral blood flow (CBF) on the side of carotid stenosis, 
after treatment of the stenosis with CAS or EAC; this increased rate of CBF became similar 
value to the CBF of the control group (Van Laar et al., 2007). 
In our study, we observed an increase in CBV in the cerebral territory ipsilateral to the CAS 
as well as in the contralateral territory (Tavares et al., 2010). Other authors have documented 
this same phenomenon in the intracranial territory on the healthy side (Hino et al., 2005; Ko 
et al., 2005). The treatment of the carotid artery stenosis cannot explain this phenomenon 
based solely on hemodynamics (Ko et al., 2005). Other unknown factors must play an 
important role in the perfusion modifications before and after the treatment of carotid artery 
stenosis. This increased flow in the contralateral hemisphere may occur via collateral 
circulation through the anterior communicating artery (Tavares et al., 2010) or from the 
leptomeningeal anastomosis (Matsubara et al., 2009). 
Thus, the benefits and eventual risks resulting from an increase in cerebral blood flow may 
occur in both the ipsilateral and contralateral hemispheres during the treatment of carotid 
artery stenosis. 
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Fig. 2. A 56-year-old patient with severe right cervical carotid artery stenosis evaluated by 
digital angiography (not shown). Perfusion by MRI was performed in a section above the 
lateral ventricles. Before carotid angioplasty, the cerebral blood volume (CBV) of the right 
ACM territory was reduced by 30% compared with the contralateral (A), the mean transit time 
(MTT) was delayed by 12% (C) and the time to peak (TTP) was delayed by 6% (E). In the same 
axial plane after CAS, perfusion studies show improved parameters: the right side CBV 
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became less reduced (10%) compared with the contralateral (B), there was no difference in the 
MTT compared with the left side (D) and the TTP delay was lessened to 2% (F). 
The improvement in cerebral perfusion after CAS, as documented by imaging technologies 
(Ko et al., 2005; Martin, A. J. et al., 2005; Tavares et al., 2010; Van Laar et al., 2007), has also 
been documented through questionnaires for dementia that show clinical improvement in 
scores after CAS(Moftakhar et al., 2005; Takaiwa et al., 2009; Turk et al., 2008). 
According to Takaiwa, patients with carotid artery stenosis who scored below average on 
the questionnaire prior to carotid angioplasty and endarterectomy showed an improvement 
in cognitive function after the procedures (Takaiwa et al., 2009). Scores were decreased 
temporarily at 1 week after carotid endarterectomy (CEA), but not after CAS (Takaiwa et al., 
2009).  
Moftakhar concluded that the improvement in the perfusion parameters shown by MRI is 
predictive of cognitive improvement after angioplasty (Moftakhar et al., 2005).  
These data together suggest that CAS not only prevents stroke but also improves cognitive 
function (Takaiwa et al., 2009).  
In addition to carotid angioplasty, intracranial angioplasty is also associated with perfusion 
improvement as shown by MRI (Bendok et al., 2010). 
According to Takaiwa, rapid improvement in cognitive function occurs following CAS 
(Takaiwa et al., 2009). Some studies, however, showed a worsening of cognitive function 
following CEA, which may be associated with hypoperfusion during the cross-clamping of 
the internal carotid artery (Costin et al., 2002; Heyer et al., 1998; Takaiwa et al., 2009). 
Endarterectomy may interrupt the cerebral blood flow at several moments during the 
procedure, and it certainly does so during the construction of the bypass. However, the 
treatment of carotid artery stenosis by CAS with cerebral protection filters does not 
interrupt the cerebral blood flow, which avoids momentary deficits in cerebral perfusion. 
Complex self-regulatory mechanisms may be set in motion by severe stenosis and may 
include microcirculatory vasodilatation or a direct response from the central nervous 
system. Therefore, it is theoretically possible that the microcirculatory condition that results 
from long-standing severe proximal stenosis might excite a state of microcirculatory 
vasodilatation after CAS, causing some blood volume reduction in the ipsilateral territory. 
This tends to occur during a reduction in the MTT. The equation CBF=CBV/MTT expresses 
the flow equilibrium (Kluytmans et al., 1998).  
5. The risks of the immediate increase in cerebral perfusion following carotid 
angioplasty 
5.1.1 Reperfusion syndrome 
Because CAS induces changes in cerebral perfusion, it has the inherent although low risk of 
complications related to increased cerebral blood flow such as reperfusion syndrome 
(Matsubara et al., 2009; Morrish et al., 2000; Tavares et al., 2010) and even fatal hemorrhagic 
complications (Hartmann et al., 2004; Morrish et al., 2000). Patients who receive 
endarterectomies are exposed to similar risks (Bodenant et al., 2010). 
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Signal alteration, especially as seen with FLAIR sequence imaging, has been reported and is 
located in the spaces of the cortical convolutions that occur unilaterally after CAS. This 
finding may be related to modifications in perfusion that are clinically difficult to correlate 
(Martin, A. J. et al., 2005; Michel et al., 2001; Wilkinson et al., 2003).  
Through MRI studies before and after conventional angioplasty with stenting, we 
observed hypersignal areas in the subarachnoid space of some of our patients in the 
FLAIR sequence after CAS. These areas showed gadolinium enhancement in the T1-
weighted sequence and did not show signs of ischemia or neurological symptoms upon 
diffusion (Figure 3). 
Wilkinson et al. called this finding “unilateral leptomeningeal enhancement” (Wilkinson 
et al., 2003). Although they stated that there was no definite cause, it is possible that there 
is an increase in flow to the territory of the MCA ipsilateral to the stent, and this greater 
flow might contribute to the leptomeningeal enhancement, especially because the 
enhancement occurred in the areas fed by the MCA that experienced transit time 
reductions (Wilkinson et al., 2003). Martin et al. showed similar images ipsilateral to the 
CAS in the liquor space of the ipsilateral cerebral sulcus in the watershed area (Martin, A. 
J. et al., 2005). 
This asymmetric appearance is not fully understood and may be related to factors such as 
the leakage of the contrast agent or the possible alteration of the partial pressure of oxygen 
following treatment (Braga et al., 2003; Michel et al., 2001).  
Patients who showed a signal increase on FLAIR in the subarachnoid space ipsilateral to the 
CAS experienced isolated symptoms (headache, transitory neurological deficit or mental 
confusion) in the series of Grunwald et al. (2009) These authors also reported that the signal 
increase on FLAIR is temporary and disappears within 3 to 5 days.  
Thurley et al. (2009) described a similar unilateral leptomeningeal enhancement in a patient 
exhibiting headache, vomiting, seizure and hypertension after endarterectomy. 
We believe that the finding described by Grunwald et al. (2009) and Thurley et al. (2009) 
may be related to a clinical syndrome of hyperperfusion that is not complicated by 
intracranial hemorrhage. Our patients with leptomeningeal enhancement after CAS (Figure 
3) did not exhibit the classical symptoms of cerebral hyperperfusion, such as transitory focal 
deficit, unilateral migraine and seizures. 
Nevertheless, we believe that areas with chronic ischemia have increased perfusion after 
CAS and that there is some degree of poor hematoencephalic barrier regulation. This notion 
is grounded on the pattern of dural/sulcal enhancement in border zones. 
However, because of the reduction in the timing parameters of perfusion following CAS 
(Tavares et al., 2010) without a reduction in CBV, cerebral hyperflow with possible 
complications such as hyperperfusion syndrome can theoretically exist (Ko et al., 2005; 
Niesen et al., 2004; Wilkinson et al., 2003). This concept follows the equation of 
hemodynamic equilibrium, where cerebral blood flow is proportional to CBV and inversely 
proportional to the timing parameter MTT (Kluytmans et al., 1998; Waaijer et al., 2007; 
Wilkinson et al., 2003).  
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Fig. 3. An 87-year-old patient with right carotid artery stenosis. MRI in diffusion sequence 
before CAS: DWI (A), FLAIR (B) and T1 with gadolinium (C). Conventional angioplasty of 
the carotid artery was performed (not shown), and the patient was asymptomatic after 
endovascular treatment. A new MRI study was performed 12 hours after CAS (D,E,F,G,H,I): 
note the hypersignal in the central and precentral sulcus of the FLAIR sequence (E) without 
expression in DWI (D) or T1 without gadolinium (F). T1 sequences with coronal (G), sagittal 
(H) and axial (I) contrast after CAS: enhancement in the sulcal (pial) space in the right 
posterior frontal area. 
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5.1.2 Carotid stenting without postdilatation  
Some authors hold that cerebral circulation is somehow altered when there is severe carotid 
artery stenosis by a “plegic vasodilatation” induced by chronic ischemia (Abou-Chebl et al., 
2004; Hartmann et al., 2004; Matsubara et al., 2009). 
The study of CBF by intracarotid xenon injection or photon emission tomography showed 
that patients with a two-fold increase in CBF after endarterectomy were at a greater risk of 
developing hyperperfusion syndrome (Bando et al., 2001; Henderson et al., 2001).  
According to Hirooka et al. (2008), cerebral hyperperfusion after CEA is defined as a 100% 
increase in CBF in PWI by MRI. 
Hosoda et al. based on SPECT data obtained before and after CEA, noted that the abrupt 
restoration of cerebral perfusion pressure immediately after the surgical correction of a tight 
carotid stenosis could not be quickly compensated for by vasoconstriction (Hosoda et al., 
2001). However, the arterioles presumably contracted to normal size over the long term, 
thus reducing the CBV. 
Matsubara et al. (2009) postulated that after the treatment of carotid stenosis, if the vascular 
walls of the arterioles were damaged and permeability increased, cerebral edema and 
convulsions could occur.  
Furthermore, rapidly increased CBF and CBV (Matsubara et al., 2009) and a reduction in 
MTT by CAS (Tavares et al., 2010) and CEA may be risk factors for reperfusion syndrome 
after the treatment of carotid stenosis (Fukuda et al., 2007). 
The technique of CAS has not been standardized, and there are technical variations among 
different institutions and neurointerventionists. The CAS technique that we call 
conventional has already been described in the literature (Caldas, 2006; Tavares et al., 2010). 
Briefly, the procedure is performed in an angiography suite and includes transfemoral 
access under local anesthesia, sedation and full heparinization (70 U/kg). All patients 
receive double anti-aggregation agents 5 days before CAS. The activated coagulation time 
(ACT) is not routinely checked. We initially establish access up to the common carotid artery 
with a 6F wired sheath or 8F guiding catheter. Next, a cerebral protection system is 
delicately placed in the internal carotid artery distal to the stenosis. We usually use filter 
protection because it affords intraprocedural safety against emboli without flow 
interruption. Most often, the protection filter is advanced without predilatation. Balloon 
dilatation before stenting is only employed when the filter or the stent cannot pass by the 
stenosis. Next, a self-expandable stent is advanced over the filter guide and released so as to 
cover the atheroma plaque. At this point, the stent is able to perform the partial or the 
subtotal opening of most stenoses and to reduce the friction of the blood flow against the 
plaque. Thus, the stent protects against emboli. The next step is to utilize balloon 
angioplasty within the stent to mold and widen the internal diameter of the stent or to 
continue to reduce the size of the residual stenosis to less than 30%. 
Despite the lack of clear standards, we believe that the consensus is to achieve a post-
stenting stenosis of less than 30%. The CREST study, which compared CAS and 
endarterectomy, required a final stenosis of less than 30% at the end of each procedure. 
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The CAS variation that we employ is a simplification of the technique described above, and 
it does not employ any pre-stenting or post-stenting balloons. By not fully opening the stent 
at the procedure, we seek to avoid the instantaneous increase of carotid flux that occurs 
during conventional angioplasty. 
Because carotid angioplasty is most often indicated to avoid atheroembolic ischemic events 
rather than to correct hemodynamic effects, there is no need for complete stent expansion 
immediately during angioplasty (Bussiere et al., 2008). The restoration of a normal lumen 
diameter should be considered a secondary goal. 
To avoid an abrupt increase in cerebral perfusion as well as the risks of reperfusion 
syndrome with its serious complications, we started a case series in which the release of the 
self-expandable stent was performed without the use of the balloon to completely open the 
stent (Figure 4). In this group, intra-stent angioplasty (post-dilatation balloon) was used 
only when the residual stenosis post-stenting did not change compared with the degree of 
stenosis before the stent placement; intra-stent angioplasty was also used when the residual 
stenosis was greater than 30%. The force of an self-expanding stent alone can dilate severely 
stenosed carotid (Lownie et al., 2005), and as the dilation is gradual, it may function 
protectively against hemorrhagic reperfusion (Maynar et al., 2007). 
 
Fig. 4. A 78-year-old patient with severe aortic valve insufficiency and chronic obstructive 
pulmonary disease who exhibited an episode of amaurosis fugax of the right eye. 
Angiography showed severe (80%) right internal carotid artery stenosis (A). A 7 X 40 mm 
self-expandable stent (arrow) (Protégé®, eV3 Inc., Plymouth, Minnesota,USA) for stenting 
without balloon angioplasty; the immediate result after placement of the stent showed a 
small residual stenosis of about 30% (b). Lateral radiography 1 month later (C) showed 
complete expansion of the stent. 
In a manner similar to that employed by Baldi et al. (2011), our group followed patients after 
the placement of the self-expandable stent with cervical radiographic studies at 3, 6 and 12 
months. These studies showed a tendency for the stents to completely open. Baldi et al. 
showed an average reduction of stenosis from 82% to 30% immediately after stenting. In 
follow-up, however, 14.8% of the patients exhibited restenosis (Baldi et al., 2011). 
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5.1.2 Carotid stenting without postdilatation  
Some authors hold that cerebral circulation is somehow altered when there is severe carotid 
artery stenosis by a “plegic vasodilatation” induced by chronic ischemia (Abou-Chebl et al., 
2004; Hartmann et al., 2004; Matsubara et al., 2009). 
The study of CBF by intracarotid xenon injection or photon emission tomography showed 
that patients with a two-fold increase in CBF after endarterectomy were at a greater risk of 
developing hyperperfusion syndrome (Bando et al., 2001; Henderson et al., 2001).  
According to Hirooka et al. (2008), cerebral hyperperfusion after CEA is defined as a 100% 
increase in CBF in PWI by MRI. 
Hosoda et al. based on SPECT data obtained before and after CEA, noted that the abrupt 
restoration of cerebral perfusion pressure immediately after the surgical correction of a tight 
carotid stenosis could not be quickly compensated for by vasoconstriction (Hosoda et al., 
2001). However, the arterioles presumably contracted to normal size over the long term, 
thus reducing the CBV. 
Matsubara et al. (2009) postulated that after the treatment of carotid stenosis, if the vascular 
walls of the arterioles were damaged and permeability increased, cerebral edema and 
convulsions could occur.  
Furthermore, rapidly increased CBF and CBV (Matsubara et al., 2009) and a reduction in 
MTT by CAS (Tavares et al., 2010) and CEA may be risk factors for reperfusion syndrome 
after the treatment of carotid stenosis (Fukuda et al., 2007). 
The technique of CAS has not been standardized, and there are technical variations among 
different institutions and neurointerventionists. The CAS technique that we call 
conventional has already been described in the literature (Caldas, 2006; Tavares et al., 2010). 
Briefly, the procedure is performed in an angiography suite and includes transfemoral 
access under local anesthesia, sedation and full heparinization (70 U/kg). All patients 
receive double anti-aggregation agents 5 days before CAS. The activated coagulation time 
(ACT) is not routinely checked. We initially establish access up to the common carotid artery 
with a 6F wired sheath or 8F guiding catheter. Next, a cerebral protection system is 
delicately placed in the internal carotid artery distal to the stenosis. We usually use filter 
protection because it affords intraprocedural safety against emboli without flow 
interruption. Most often, the protection filter is advanced without predilatation. Balloon 
dilatation before stenting is only employed when the filter or the stent cannot pass by the 
stenosis. Next, a self-expandable stent is advanced over the filter guide and released so as to 
cover the atheroma plaque. At this point, the stent is able to perform the partial or the 
subtotal opening of most stenoses and to reduce the friction of the blood flow against the 
plaque. Thus, the stent protects against emboli. The next step is to utilize balloon 
angioplasty within the stent to mold and widen the internal diameter of the stent or to 
continue to reduce the size of the residual stenosis to less than 30%. 
Despite the lack of clear standards, we believe that the consensus is to achieve a post-
stenting stenosis of less than 30%. The CREST study, which compared CAS and 
endarterectomy, required a final stenosis of less than 30% at the end of each procedure. 
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The CAS variation that we employ is a simplification of the technique described above, and 
it does not employ any pre-stenting or post-stenting balloons. By not fully opening the stent 
at the procedure, we seek to avoid the instantaneous increase of carotid flux that occurs 
during conventional angioplasty. 
Because carotid angioplasty is most often indicated to avoid atheroembolic ischemic events 
rather than to correct hemodynamic effects, there is no need for complete stent expansion 
immediately during angioplasty (Bussiere et al., 2008). The restoration of a normal lumen 
diameter should be considered a secondary goal. 
To avoid an abrupt increase in cerebral perfusion as well as the risks of reperfusion 
syndrome with its serious complications, we started a case series in which the release of the 
self-expandable stent was performed without the use of the balloon to completely open the 
stent (Figure 4). In this group, intra-stent angioplasty (post-dilatation balloon) was used 
only when the residual stenosis post-stenting did not change compared with the degree of 
stenosis before the stent placement; intra-stent angioplasty was also used when the residual 
stenosis was greater than 30%. The force of an self-expanding stent alone can dilate severely 
stenosed carotid (Lownie et al., 2005), and as the dilation is gradual, it may function 
protectively against hemorrhagic reperfusion (Maynar et al., 2007). 
 
Fig. 4. A 78-year-old patient with severe aortic valve insufficiency and chronic obstructive 
pulmonary disease who exhibited an episode of amaurosis fugax of the right eye. 
Angiography showed severe (80%) right internal carotid artery stenosis (A). A 7 X 40 mm 
self-expandable stent (arrow) (Protégé®, eV3 Inc., Plymouth, Minnesota,USA) for stenting 
without balloon angioplasty; the immediate result after placement of the stent showed a 
small residual stenosis of about 30% (b). Lateral radiography 1 month later (C) showed 
complete expansion of the stent. 
In a manner similar to that employed by Baldi et al. (2011), our group followed patients after 
the placement of the self-expandable stent with cervical radiographic studies at 3, 6 and 12 
months. These studies showed a tendency for the stents to completely open. Baldi et al. 
showed an average reduction of stenosis from 82% to 30% immediately after stenting. In 
follow-up, however, 14.8% of the patients exhibited restenosis (Baldi et al., 2011). 
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In the patients who received CAS without balloon inflation, we also noticed the absence of 
intraprocedural bradycardia and hypotension induced by the compression of the balloon on 
the carotid baroreceptors. This effect was also observed by Rebellino et al. (Rabellino et al., 
2010). This factor may contribute to shorter hospitalizations and increased periprocedural 
safety. 
Each step of an angioplasty procedure includes the risk of thromboembolic events. The 
procedure with the highest risk of embolism is balloon angioplasty (Martin, J. B. et al., 2001; 
Men et al., 2002; Vitek et al., 2000). The use of the simplified technique (without balloon 
dilatation) may reduce such periprocedural risks and improve the clinical results (Jin et al., 
2010; Men et al., 2002). The simplified technique may work especially well in cases with soft 
plaques that can easily rupture and form a large number of emboli.  
We consider accentuated calcification, as shown by ultrasound or other imaging methods 
before angioplasty, to be a relative contraindication for the angioplasty without balloon that 
we used in our case series. 
Other technical variations of CAS have been described in the literature. Maynar et al. (2007) 
published a series of 100 cases where neither the protection system nor balloon angioplasty 
was used. They demonstrated an average reduction of stenosis from 79% to 21% 
immediately after stent release, and in some cases, there was an almost complete opening of 
the stent. In most cases, however, the stent opening occurred gradually over time with an 
average final stenosis of 15% at the 6-month radiographic evaluation (Maynar et al., 2007). 
Bussière published the results of a series of endovascular treatments of carotid stenosis in 
which 79% of the patients received a stent-only procedure (Bussiere et al., 2008). The risk of 
intra-stent restenosis (mostly asymptomatic) was higher than in conventional angioplasty, 
and residual stenosis below 30% occurred in only 25% of the cases at the end of the 
procedure. Bussière stated that plaques with circumferential calcification or very severe 
stenosis (>90%) must be treated with conventional CAS (with postdilatation). 
Jin et al. used a 3-to-5-mm balloon after placement of the protection system (Jin et al., 2010). 
They used predilatation balloons with diameters similar to the luminal caliber of the internal 
carotid artery distal to the stenosis. After the placement of the stent, the arterial lumen 
exhibited minimal residual stenosis in about 70% of cases, which indicates that the use of the 
postdilatation balloon was unnecessary. We find the technique described by Jin et al. (2010) 
to be inadequate because we believe that the stent has a stabilizing action on the plaque that 
reduces embolic phenomena. Because the balloon has the potential to induce plaque 
rupture, it seems contradictory to use the balloon before stenting. 
None of the protection systems now in use can perfectly prevent the occurrence of 
embolism. Emboli have been detected by diffusion MRI when using most of the protection 
systems described in the literature (Angelini et al., 2002; du Mesnil de Rochemont et al., 
2006; Kastrup et al., 2008; Maleux et al., 2006; Muller-Hulsbeck et al., 2003; Schnaudigel et 
al., 2008; Vos et al., 2005; Yamada et al., 2010).  
Indeed, other risk factors for reperfusion syndrome that might be involved include 
hypertension, severe carotid stenosis (>90%), severe stenosis of the contralateral carotid 
artery and recent cerebral ischemic or infarction events. The use of anticoagulants and 
antiplatelet agents may also play a role in this syndrome (Abou-Chebl et al., 2004). 
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Thus, new studies are required to establish whether or not CAS without postdilatation is a 
positive factor in clinical results. 
5.2.1 The association of carotid stenosis with cerebral aneurysms 
Cerebral aneurysms are incidentally found in 5% of adults by autopsy (McCormick & 
Schochet, 1976). The development of neuroimaging techniques has allowed to increasingly 
detect unruptured aneurysms in vivo. The overall risk of hemorrhage from incidental 
aneurysms was initially described as 1% per year by the ISUIA study (ISUIA, 1998). The 
incidence of unruptured, intracranial aneurysms that are present along with carotid artery 
stenosis is 3 to 5% (Suh et al., 2011). In most cases, this association involves unruptured 
aneurysms (Navaneethan et al., 2006). Some risk factors, such as hypertension and tobacco 
use, influence the development of both carotid artery stenosis and cerebral aneurysms 
(NASCET Trial Investigators, 1991; Wiebers et al., 2003). 
Endarterectomy and conventional carotid artery angioplasty can induce an abrupt increase 
in cerebral perfusion. Additionally, any angioplasty technique that employs antiplatelet 
agents and heparin makes subsequent use of surgical correction by craniotomy and clipping 
immediately after CAS impossible. A further complication is that patients with carotid 
artery stenosis are usually greater than 50 years of age and frequently exhibit hypertension 
and diabetes, which are complicating factors in craniotomy and clipping according to the 
results of the ISUIA trial and other studies (Chen et al., 2004; Cowan et al., 2007; Wiebers et 
al., 2003; Xu et al., 2011). 
Some studies have reported on the stability of small unruptured aneurysms after stenting or 
endarterectomy (Ladowski et al., 1984; Stern et al., 1979; Suh et al., 2011). These studies, 
however, do not describe with any uniformity the dimensions of the aneurysms (some 
studies describe aneurysms as large as 4 mm or 7 mm) or the treatments employed to 
control hypertension and to achieve hemodynamic stability; furthermore, the periods of 
observation are short. These studies have a relatively small sample size and include only a 
single center (Kang et al., 2007; Suh et al., 2011). Because only 3 to 5% of the patients have 
both lesions (Kappelle et al., 2000; Suh et al., 2011), 2,000 to 3,334 cases must be included to 
reach the statistically significant number of approximately 100 cases in which patients have 
both carotid artery stenosis and a cerebral aneurysm. 
Stern et al. (1979) reported on one case of a fatal rupture of a cerebral aneurysm after EAC. 
They suggested that the risk of subarachnoid hemorrhage during endarterectomy might be 
increased in patients with aneurysms (Stern et al., 1979). 
The analysis of the NASCET trial data (1991) by Kapelle et al. (2000) identified one case of a 
fatal subarachnoid hemorrhage that occurred 6 days after endarterectomy among 25 
patients, which, according to the authors, increased the risk of rupture to 4% in this 
population (Kappelle et al., 2000). 
Al-Mubarak et al. (2001) reported on the case of one patient with 90% symptomatic right 
carotid artery stenosis who developed a massive and fatal intracerebral and subarachnoid 
hemorrhage (arising from the left sylvian fissure) that occurred immediately after CAS. In 
this case, there was an occlusion of the left carotid artery. 
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In the patients who received CAS without balloon inflation, we also noticed the absence of 
intraprocedural bradycardia and hypotension induced by the compression of the balloon on 
the carotid baroreceptors. This effect was also observed by Rebellino et al. (Rabellino et al., 
2010). This factor may contribute to shorter hospitalizations and increased periprocedural 
safety. 
Each step of an angioplasty procedure includes the risk of thromboembolic events. The 
procedure with the highest risk of embolism is balloon angioplasty (Martin, J. B. et al., 2001; 
Men et al., 2002; Vitek et al., 2000). The use of the simplified technique (without balloon 
dilatation) may reduce such periprocedural risks and improve the clinical results (Jin et al., 
2010; Men et al., 2002). The simplified technique may work especially well in cases with soft 
plaques that can easily rupture and form a large number of emboli.  
We consider accentuated calcification, as shown by ultrasound or other imaging methods 
before angioplasty, to be a relative contraindication for the angioplasty without balloon that 
we used in our case series. 
Other technical variations of CAS have been described in the literature. Maynar et al. (2007) 
published a series of 100 cases where neither the protection system nor balloon angioplasty 
was used. They demonstrated an average reduction of stenosis from 79% to 21% 
immediately after stent release, and in some cases, there was an almost complete opening of 
the stent. In most cases, however, the stent opening occurred gradually over time with an 
average final stenosis of 15% at the 6-month radiographic evaluation (Maynar et al., 2007). 
Bussière published the results of a series of endovascular treatments of carotid stenosis in 
which 79% of the patients received a stent-only procedure (Bussiere et al., 2008). The risk of 
intra-stent restenosis (mostly asymptomatic) was higher than in conventional angioplasty, 
and residual stenosis below 30% occurred in only 25% of the cases at the end of the 
procedure. Bussière stated that plaques with circumferential calcification or very severe 
stenosis (>90%) must be treated with conventional CAS (with postdilatation). 
Jin et al. used a 3-to-5-mm balloon after placement of the protection system (Jin et al., 2010). 
They used predilatation balloons with diameters similar to the luminal caliber of the internal 
carotid artery distal to the stenosis. After the placement of the stent, the arterial lumen 
exhibited minimal residual stenosis in about 70% of cases, which indicates that the use of the 
postdilatation balloon was unnecessary. We find the technique described by Jin et al. (2010) 
to be inadequate because we believe that the stent has a stabilizing action on the plaque that 
reduces embolic phenomena. Because the balloon has the potential to induce plaque 
rupture, it seems contradictory to use the balloon before stenting. 
None of the protection systems now in use can perfectly prevent the occurrence of 
embolism. Emboli have been detected by diffusion MRI when using most of the protection 
systems described in the literature (Angelini et al., 2002; du Mesnil de Rochemont et al., 
2006; Kastrup et al., 2008; Maleux et al., 2006; Muller-Hulsbeck et al., 2003; Schnaudigel et 
al., 2008; Vos et al., 2005; Yamada et al., 2010).  
Indeed, other risk factors for reperfusion syndrome that might be involved include 
hypertension, severe carotid stenosis (>90%), severe stenosis of the contralateral carotid 
artery and recent cerebral ischemic or infarction events. The use of anticoagulants and 
antiplatelet agents may also play a role in this syndrome (Abou-Chebl et al., 2004). 
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Thus, new studies are required to establish whether or not CAS without postdilatation is a 
positive factor in clinical results. 
5.2.1 The association of carotid stenosis with cerebral aneurysms 
Cerebral aneurysms are incidentally found in 5% of adults by autopsy (McCormick & 
Schochet, 1976). The development of neuroimaging techniques has allowed to increasingly 
detect unruptured aneurysms in vivo. The overall risk of hemorrhage from incidental 
aneurysms was initially described as 1% per year by the ISUIA study (ISUIA, 1998). The 
incidence of unruptured, intracranial aneurysms that are present along with carotid artery 
stenosis is 3 to 5% (Suh et al., 2011). In most cases, this association involves unruptured 
aneurysms (Navaneethan et al., 2006). Some risk factors, such as hypertension and tobacco 
use, influence the development of both carotid artery stenosis and cerebral aneurysms 
(NASCET Trial Investigators, 1991; Wiebers et al., 2003). 
Endarterectomy and conventional carotid artery angioplasty can induce an abrupt increase 
in cerebral perfusion. Additionally, any angioplasty technique that employs antiplatelet 
agents and heparin makes subsequent use of surgical correction by craniotomy and clipping 
immediately after CAS impossible. A further complication is that patients with carotid 
artery stenosis are usually greater than 50 years of age and frequently exhibit hypertension 
and diabetes, which are complicating factors in craniotomy and clipping according to the 
results of the ISUIA trial and other studies (Chen et al., 2004; Cowan et al., 2007; Wiebers et 
al., 2003; Xu et al., 2011). 
Some studies have reported on the stability of small unruptured aneurysms after stenting or 
endarterectomy (Ladowski et al., 1984; Stern et al., 1979; Suh et al., 2011). These studies, 
however, do not describe with any uniformity the dimensions of the aneurysms (some 
studies describe aneurysms as large as 4 mm or 7 mm) or the treatments employed to 
control hypertension and to achieve hemodynamic stability; furthermore, the periods of 
observation are short. These studies have a relatively small sample size and include only a 
single center (Kang et al., 2007; Suh et al., 2011). Because only 3 to 5% of the patients have 
both lesions (Kappelle et al., 2000; Suh et al., 2011), 2,000 to 3,334 cases must be included to 
reach the statistically significant number of approximately 100 cases in which patients have 
both carotid artery stenosis and a cerebral aneurysm. 
Stern et al. (1979) reported on one case of a fatal rupture of a cerebral aneurysm after EAC. 
They suggested that the risk of subarachnoid hemorrhage during endarterectomy might be 
increased in patients with aneurysms (Stern et al., 1979). 
The analysis of the NASCET trial data (1991) by Kapelle et al. (2000) identified one case of a 
fatal subarachnoid hemorrhage that occurred 6 days after endarterectomy among 25 
patients, which, according to the authors, increased the risk of rupture to 4% in this 
population (Kappelle et al., 2000). 
Al-Mubarak et al. (2001) reported on the case of one patient with 90% symptomatic right 
carotid artery stenosis who developed a massive and fatal intracerebral and subarachnoid 
hemorrhage (arising from the left sylvian fissure) that occurred immediately after CAS. In 
this case, there was an occlusion of the left carotid artery. 
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Cheung et al. (2003) reported a case of a fatal subarachnoid hemorrhage after 
endarterectomy. The patient had two 4-mm ipsilateral intracranial aneurysms. The authors 
reported, however, that the autopsy failed to identify areas of rupture in these aneurysms. 
Hartmann et al. (2004) reported a case of a fatal subarachnoid hemorrhage after the 
treatment of carotid artery stenosis. Their report did not include the complete angiography 
of the four main cerebral arteries. However, we believe that CAS increases the cerebral 
blood flow in the treated territory and in the other intracranial territories via the polygon 
collateral circulation. Hartmann et al. (2004) further reported that necropsy could not 
definitively rule out saccular aneurysms. 
Riphagen et al. reported a case of one patient with an occlusion of the left carotid artery and 
symptomatic stenosis of the right carotid artery that was treated with endarterectomy. This 
patient developed a 6-mm aneurysm in the anterior communicating artery 10 days after 
endarterectomy with subarachnoid and intraventricular hemorrhage. The patient 
underwent a craniotomy and clipping (Riphagen & Bernsen, 2009). The annual risk of 
rupture from incidental aneurysms smaller than 7 mm in the anterior circulation is close to 
0% in the ISUIA 2003 study (Wiebers et al., 2003). The case described by Riphagen et al. thus 
represents a negative shift in the natural course of this type of aneurysm. 
Although hypertension is a classic factor that contributes to the rupture of cerebral 
aneurysms (Obray et al., 2003; Vlak et al., 2011), there is no consensus concerning the effects 
of CAS on the course of unruptured intracranial aneurysms. However, intracranial 
hemorrhages are associated with high morbidity and high mortality during the treatment of 
carotid artery stenosis (Cheung et al., 2003; Hartmann et al., 2004). We therefore conclude 
that there should be no delay in the treatment of cerebral aneurysms in hypertensive 
patients during the treatment of carotid stenosis. Theoretically, conditions such as 
hypertension and increased cerebral blood flow may contribute to the rupture of aneurysms. 
Other factors inherent to CAS can also worsen the course of hemorrhage, such as the use of 
antiplatelet agents and the non-reversal of heparin after the CAS. 
Badruddin et al. (2010) suggested that intracranial aneurysms might be partially protected 
by the reduced flow and pressure in the intracranial arteries when there is carotid artery 
stenosis (Badruddin et al., 2010). Another author suggested that the intentional partial 
occlusion of the carotid artery might protect cerebral aneurysms, and a reduction of 
intracranial aneurysms has been observed (Cronqvist et al., 1964) 
5.2.2 Minimally invasive treatments for carotid stenosis and cerebral aneurysm 
Because of the potential risk for aneurysm rupture after carotid revascularization surgery 
(endarterectomy or stenting) arising from the increase in cerebral blood flow (Hartmann et 
al., 2004; Suh et al., 2011) and because there is a minimally invasive and safe technique for 
endovascular treatment (coiling) of cerebral aneurysms (Cowan et al., 2007; Higashida et al., 
2007; Molyneux et al., 2009; Raja et al., 2008; Spelle & Pierot, 2008; van Rooij et al., 2006; van 
Rooij & Sluzewski, 2006), we believe that patients must be immediately protected by 
performing embolization (coiling) consecutively after CAS. 
In patients for whom carotid artery stenosis is initially diagnosed and further investigation 
reveals an incidental aneurysm, the treatment of the aneurysm is based upon its rupture 
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risk, which is calculated by the diameter and localization of the aneurysm and the age of 
each patient (Wiebers et al., 2003). However, most neuroradiology interventionists believe 
that aneurysms that are 3 mm or larger must be treated by coiling when it can be safely 
performed (Fang 2009). The decision to treat aneurysms is also based on the geometry of the 
lesion (including the neck-dome ratio) and on the availability of experienced specialists in 
interventionist neuroradiology. 
In patients where a cerebral aneurysm was initially diagnosed and further investigation 
revealed asymptomatic severe carotid stenosis, the ACAS trial showed that treatment of 
asymptomatic carotid stenosis is beneficial (ACAS Trial investigators, 1995). 
We prefer to treat these patients during a single procedure. We treat the carotid artery 
stenosis before the cerebral aneurysm to avoid the crossing of the stenosis by the 
endovascular materials that are necessary for the treatment of the aneurysm and that cause 
the iatrogenic embolism of parts of the cervical plaque (Figure 5). In such patients, we use 
antiplatelet agents by the oral route (or nasogastric tube) just one hour before angioplasty 
(clopidogrel 300 mg and aspirin 300 mg). We employ intravenous heparin to maintain an 
ACT between 200 and 300 seconds.  
We perform the angioplasty with a closed-cell stent, since access of catheters to the 
intracranial carotid seems to us easier. We do not routinely use a post-dilatation balloon 
(intra-stent before removing the embolic protection device) because we want to limit the 
increase of the blood flow towards the intracranial territory. However, if the arterial lumen 
is too small for catheters up to 6F (3 mm) to pass, we perform a stent dilatation with a 4- or 
5-mm balloon. After completion of the angioplasty, a 6F guide catheter is placed in the 
common carotid artery below the stent followed by a microcatheter and micro-guide that 
are carefully advanced through the stent and into the internal carotid artery distal to the 
stent. The microcatheter and micro-guide are then advanced up to the aneurysm, and 
coiling is performed according to the conventional embolization technique. Alternatively, 
the guide catheter can be carefully advanced over the microcatheter through the stent to the 
internal carotid distal to the stent. In cases where we employed CAS immediately followed 
by coiling, the aneurysm was on the same side as the carotid stenosis. 
Aneurysms located outside of the circulation subjected to CAS also received increased blood 
flow after CAS, probably via the Willis polygon (Tavares et al., 2010). Theoretically, then, 
these aneurysms have an increased risk of rupture and can also be treated by CAS and 
coiling together. 
Navaneethan et al. (2006) reported a case of bilateral carotid stenosis and a 25-mm aneurysm 
in the left middle cerebral artery. They performed an angioplasty of the left carotid artery 
and coiling in one single procedure. They believe that craniotomy and clipping of the 
aneurysm may reduce the cerebral blood flow and thus worsen the eventual hypoflow 
resulting from the concomitant carotid artery stenosis (Navaneethan et al., 2006). 
Iwata et al. reported the case of a patient with 60% asymptomatic stenosis of the left cervical 
carotid artery with a 6-mm unruptured aneurysm in the ipsilateral intracranial carotid 
artery. They treated the aneurysm first by coiling, and 1 month later, they performed the 
CAS (Iwata 2008). A disadvantage of this approach to treatment arises from the potential 
risks due to the general anesthesia required for the cooling of the patient to reduce the 
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Cheung et al. (2003) reported a case of a fatal subarachnoid hemorrhage after 
endarterectomy. The patient had two 4-mm ipsilateral intracranial aneurysms. The authors 
reported, however, that the autopsy failed to identify areas of rupture in these aneurysms. 
Hartmann et al. (2004) reported a case of a fatal subarachnoid hemorrhage after the 
treatment of carotid artery stenosis. Their report did not include the complete angiography 
of the four main cerebral arteries. However, we believe that CAS increases the cerebral 
blood flow in the treated territory and in the other intracranial territories via the polygon 
collateral circulation. Hartmann et al. (2004) further reported that necropsy could not 
definitively rule out saccular aneurysms. 
Riphagen et al. reported a case of one patient with an occlusion of the left carotid artery and 
symptomatic stenosis of the right carotid artery that was treated with endarterectomy. This 
patient developed a 6-mm aneurysm in the anterior communicating artery 10 days after 
endarterectomy with subarachnoid and intraventricular hemorrhage. The patient 
underwent a craniotomy and clipping (Riphagen & Bernsen, 2009). The annual risk of 
rupture from incidental aneurysms smaller than 7 mm in the anterior circulation is close to 
0% in the ISUIA 2003 study (Wiebers et al., 2003). The case described by Riphagen et al. thus 
represents a negative shift in the natural course of this type of aneurysm. 
Although hypertension is a classic factor that contributes to the rupture of cerebral 
aneurysms (Obray et al., 2003; Vlak et al., 2011), there is no consensus concerning the effects 
of CAS on the course of unruptured intracranial aneurysms. However, intracranial 
hemorrhages are associated with high morbidity and high mortality during the treatment of 
carotid artery stenosis (Cheung et al., 2003; Hartmann et al., 2004). We therefore conclude 
that there should be no delay in the treatment of cerebral aneurysms in hypertensive 
patients during the treatment of carotid stenosis. Theoretically, conditions such as 
hypertension and increased cerebral blood flow may contribute to the rupture of aneurysms. 
Other factors inherent to CAS can also worsen the course of hemorrhage, such as the use of 
antiplatelet agents and the non-reversal of heparin after the CAS. 
Badruddin et al. (2010) suggested that intracranial aneurysms might be partially protected 
by the reduced flow and pressure in the intracranial arteries when there is carotid artery 
stenosis (Badruddin et al., 2010). Another author suggested that the intentional partial 
occlusion of the carotid artery might protect cerebral aneurysms, and a reduction of 
intracranial aneurysms has been observed (Cronqvist et al., 1964) 
5.2.2 Minimally invasive treatments for carotid stenosis and cerebral aneurysm 
Because of the potential risk for aneurysm rupture after carotid revascularization surgery 
(endarterectomy or stenting) arising from the increase in cerebral blood flow (Hartmann et 
al., 2004; Suh et al., 2011) and because there is a minimally invasive and safe technique for 
endovascular treatment (coiling) of cerebral aneurysms (Cowan et al., 2007; Higashida et al., 
2007; Molyneux et al., 2009; Raja et al., 2008; Spelle & Pierot, 2008; van Rooij et al., 2006; van 
Rooij & Sluzewski, 2006), we believe that patients must be immediately protected by 
performing embolization (coiling) consecutively after CAS. 
In patients for whom carotid artery stenosis is initially diagnosed and further investigation 
reveals an incidental aneurysm, the treatment of the aneurysm is based upon its rupture 
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risk, which is calculated by the diameter and localization of the aneurysm and the age of 
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We prefer to treat these patients during a single procedure. We treat the carotid artery 
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intracranial carotid seems to us easier. We do not routinely use a post-dilatation balloon 
(intra-stent before removing the embolic protection device) because we want to limit the 
increase of the blood flow towards the intracranial territory. However, if the arterial lumen 
is too small for catheters up to 6F (3 mm) to pass, we perform a stent dilatation with a 4- or 
5-mm balloon. After completion of the angioplasty, a 6F guide catheter is placed in the 
common carotid artery below the stent followed by a microcatheter and micro-guide that 
are carefully advanced through the stent and into the internal carotid artery distal to the 
stent. The microcatheter and micro-guide are then advanced up to the aneurysm, and 
coiling is performed according to the conventional embolization technique. Alternatively, 
the guide catheter can be carefully advanced over the microcatheter through the stent to the 
internal carotid distal to the stent. In cases where we employed CAS immediately followed 
by coiling, the aneurysm was on the same side as the carotid stenosis. 
Aneurysms located outside of the circulation subjected to CAS also received increased blood 
flow after CAS, probably via the Willis polygon (Tavares et al., 2010). Theoretically, then, 
these aneurysms have an increased risk of rupture and can also be treated by CAS and 
coiling together. 
Navaneethan et al. (2006) reported a case of bilateral carotid stenosis and a 25-mm aneurysm 
in the left middle cerebral artery. They performed an angioplasty of the left carotid artery 
and coiling in one single procedure. They believe that craniotomy and clipping of the 
aneurysm may reduce the cerebral blood flow and thus worsen the eventual hypoflow 
resulting from the concomitant carotid artery stenosis (Navaneethan et al., 2006). 
Iwata et al. reported the case of a patient with 60% asymptomatic stenosis of the left cervical 
carotid artery with a 6-mm unruptured aneurysm in the ipsilateral intracranial carotid 
artery. They treated the aneurysm first by coiling, and 1 month later, they performed the 
CAS (Iwata 2008). A disadvantage of this approach to treatment arises from the potential 
risks due to the general anesthesia required for the cooling of the patient to reduce the 
 





Fig. 5. A 52-year-old patient with a family history of deaths (brother and mother) from 
subarachnoid hemorrhage presented with an unruptured saccular aneurysm with a narrow 
neck in the left middle cerebral artery and severe ipsilateral cervical carotid artery stenosis. 
Left oblique incidence angiography showed (A) severe (70%) left cervical carotid artery 
stenosis by plaque with ulcers and an aneurysm in the same intracranial territory (arrow). 
Treatment with a self-expandable stent under anesthetic sedation employing a 6F sheath 
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resulted in the satisfactory opening of the stenosis (B). During the same procedure, the 
patent was subjected to general anesthesia, and a 6F guide catheter (white arrow) was 
advanced through the stent (black arrow, C) to the petrous segment of the carotid artery. 
Full embolization of the aneurysm was completed (F). 
cerebral blood flow (Kappelle et al., 2000; Ladowski et al., 1984). This approach to treatment 
decreases the stenotic lumen generated by the atheroma plaque during embolization 
because of the passage of embolization materials through the stenosis, which can hinder the 
cerebral blood flow. We further note that during coiling, the patient was unnecessarily 
exposed to the risk of embolism because of the crossing of embolization materials over the 
cervical atheroma plaque. The authors employed antiplatelet agents, but the additional use 
of statins might afford higher protection. 
The risk of hematoma in the inguinal area of coiling is avoided by use the puncture of the 
femoral artery for CAS. The single femoral approach is safe, and it decreases the risks 
inherent to each separate procedure. 
The technique we described above has some limitations. The use of antiplatelet agents in 
carotid stenting might increase the risk if accidental rupture of the aneurysm occurs during 
coiling. Because the treatment of the carotid artery stenosis is performed first, a sudden 
increase in cerebral perfusion might theoretically increase the risk of aneurysm rupture; 
therefore, special efforts are required to diminish the interval between CAS and cooling. For 
these reasons, we believe that CAS and coiling should be performed exclusively by 
experienced neuroradiologists. A further risk of the combined CAS and coiling technique is 
the increase in exposure to ionizing radiation and contrast. However, experienced 
physicians are agile and employ less contrast, thus reducing the exposure to radiation and 
the risk of kidney damage. 
Finally, in addition to aneurysms, angiographically hidden micro MAVs may theoretically 
cause intracranial hemorrhages for unknown reasons (Berker et al., 2003; Cheung et al., 
2003; Hartmann et al., 2004) after treatment of the carotid artery stenosis. These patients may 
benefit from the treatment of carotid stenosis without the angioplasty balloon to prevent 
intracranial hemorrhages. 
6. Conclusion 
Although angioplasty was initially designed as a minimally invasive therapeutic approach 
to prevent ischemic events, several reports mention its ability to restore cerebral perfusion 
(Tavares et al., 2010).  
The endovascular technique for the treatment of carotid artery stenosis is still being 
developed. Stent placement without post-dilatation by balloon allows the gradual dilatation 
of the stenosis and may reduce the risk of reperfusion syndrome and possibly also reduce 
the embolic load to the protection system. Confirmation of this hypothesis requires further 
studies. 
Although the relationship with the possible rupture of aneurysms after treatment of carotid 
stenosis is not clear, it seems safe to us to suggest that cases with simultaneous carotid 
stenosis and cerebral aneurysm should be treated by endovascular techniques (CAS and 
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coiling) in a single procedure to avoid the increase in cerebral flow, which is a risk factor for 
aneurysm bleeding. Again, further studies are required to confirm this hypothesis. 
7. Acronyms 
ACT - achieve activated clotting time 
CAS - carotid angioplasty and stenting 
CBF- regional cerebral blood flow 
CBV - regional cerebral blood volume 
CEA - carotid endarterectomy 
Coiling – endovascular treatment of cerebral aneurysms 
CREST - Carotid Revascularization Endarterectomy Versus Stenting Trial 
DWI - Diffusion -Weighted Imaging 
FLAIR - Fluid Attenuated Inversion Recovery  
MCA - middle cerebral artery 
MRI – magnetic resonance imaging 
MTT - regional mean transit time 
NASCET - North American Symptomatic Carotid Endarterectomy Trial 
PWI - perfusion weighted images or cerebral perfusion by MRI 
PWI - Perfusion-Weighted Imaging 
SPECT - Single-photon emission computed tomography 
TTP- regional time to peak 
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Elevated intracranial pressure (ICP) is a frequently encountered problem in neurological 
and neurosurgical patients in the intensive care unit (ICU). It is most often seen in the 
setting of acute head trauma, however can also result from such causes as tumor, stroke, 
intracranial hemorrhage, or infection. Regardless of the cause, the degree and duration of 
ICP elevation has a direct and inverse relationship with morbidity and mortality. 
Consequently, despite the severity of the initial injury to the brain, a great deal of attention 
must often be focused on the monitoring and the management of ICP in acute neurological 
patients in the ICU setting.  
2. Physiology 
The brain is enclosed within inelastic container (the skull) or “closed box”, and the sum of 
volumes of intracranial contents is constant. The intracranial contents include blood, 
cerebrospinal fluid (CSF) and brain and an increase in the volume of one must be offset by a 
decrease in one or more of the other contents or an increase in ICP will result. Elevations in 
ICP are the result of an increase in cranial volume and a decrease in cranial compliance. This 
is best described by the Monro-Kellie hypothesis. (Figure 1) CSF is the most accommodating 
of the intracranial contents, however the compensatory capabilities of CSF are limited and 
once exhausted, small increases in intracranial volume result in large increases in ICP.  
The most common cause for raised ICP is severe head trauma. Regardless of etiology, the 
pathophysiology underlying the secondary injury from raised ICP is similar for all patients 
with brain injury and it results from such issues as swelling, edema, and neuronal 
cytotoxicity. Brain edema is a frequent occurrence in neurological diseases and can 
accumulate intracellular or extracellular. Intracellular edema is usully the result of cytotoxic 
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edema damaging the cell membranes often destroying the sodium/potassium exchange 
pump. This leads to unregulated passage of sodium and water into neuronal cells. 
Extracellular edema often results from capillary injuries at specific areas. This leads to 
breakdown of the blood brain barrier and leakage of protein and fluids into the extracellular 
space affected. A third category of edema, interstitial edema, is sometimes seen in acute 
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Table 1. Types of Cerebral Edema 
When ICP remains severely and persistently elevated it is sometimes referred to as 
malignant intracranial hypertension and secondary brain injury is often the far more severe 
and deadly issue for the patient. ICP monitoring should be considered in any traumatic 
head injury presenting with a Glasgow coma score (GCS) of less than 9 and an abnormal 
computed tomography (CT) of head. Even in the absence of an abnormal CT scan, evidence 
suggests severe head trauma patients are still at significant risk of elevated ICP, particularly 
those greater than 40 years of age, showing signs of motor posturing, or having a systolic 
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blood pressure less 90 mmHg or less.1 A GCS of less than 9 and at least two of these three 
risk factors warrants consideration for continuous ICP monitoring, regardless of CT 
findings. ICP monitoring may also be warranted in cases where CSF flow appears disrupted 
or potentially disrupted. This is because of the potential for obstruction of drainage of flow 
of CSF and in the setting of acute brain injury, obstructive hydrocephalus can have an 
accelerating effect on ICP. This is often seen in the context of tumors, infections or 
hemorrhage either within the ventricular system or just outside of it. Whether the result of 
direct intraventricular obstruction or extraventricular mass effect with secondary ventricular 
system obstruction, these situations can lead to rapidly rising ICP and risk of deadly brain 
herniation.  
 
Fig. 1. ICP – Volume Curve showing exponential increases in ICP as skull compensatory 
mechanisms exhaust in the face of increasing intracranial volume. 
3. Monitoring 
Often by the time of clinical deterioration, ICP has been elevated for some time causing 
significant neuronal damage through progressive tissue swelling, ischemia, and 
hypoperfusion. Without emergent intervention, the process of deadly brain herniation may 
have already begun. Unfortunately, only the early stages are reversible and the clinical 
changes can be sudden. As a result, non-clinical modes of assessment such as continuous 
ICP monitoring have proven invaluable in head injury patients. Although there are several 
different forms of ICP monitoring devices, the external ventricular drain or catheter (EVD) 
has become the gold standard for accurate measurement and monitoring of ICP in the ICU. 
As its name implies, the EVD not only provides ICP monitoring, but allows for CSF 
drainage in response to ICP levels. Although associated with small risks of infection and 
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bleeding, the ability to recalibrate over time for sustained accuracy and the ability to drain 
CSF in response to ICP make the EVD superior to other ICP monitoring devices.  
The goal of ICP management is to prevent secondary brain injury, particularly from 
herniation or ischemia and infarction. Brain herniations occur as a result of pressure 
gradients created in the skull by either localized or generalized mass effect. Although, 
herniation is more likely to occur with progressive increases in ICP, there is no specific ICP 
known to be a threshold for herniation. Furthermore, certain herniations can occur without 
raised ICP, resulting solely from a localized pressure gradient such as in tentorial (uncal) 
herniation from a temporal lobe mass.2 Brain herniation is only reversible if treated early 
with aggressive medical and surgical intervention. Delays in treatment and inadequate 
treatment are associated with progressive herniation and severe and irreversible brain 
injury often leading to death. Special attention to the signs of brain herniation must be paid 
to all patients with raised ICP and to all patients with temporal lobe masses.  
Marked elevations in ICP lead to compromise in cerebral perfusion either locally or 
diffusely which in turn leads to ischemia and eventually infarction. CBF is closely correlated 
to cerebral perfusion pressure (CPP) through cerebral vascular resistance (CVR). Although, 
measures of CBF and CVR and not easily accessible, CPP can be calculated as the difference 
between mean arterial pressure (MAP) and ICP and CPP is often used as a surrogate for 
CBF. Although there is some conflicting evidence and opinion regarding the optimal CPP 
for head injury patients with raised ICP, the largest group of patients studied is within the 
traumatic brain injury population. It suggests that a CPP between 60 to 70 mmHg and ICP 
less than 20 mmHg may be associated with improved outcome and fewer complications 
from therapy in patients with brain injury and elevated ICP.3  
4. Managing ICP 
The medical management of ICP starts with principles of physiologic homeostasis including 
optimizing cerebral venous return. Evidence supports the practice of elevating the head of 
the bed to 30° or more for patients with raised ICP, however, in patients who are 
hypovolemic, this change in position may cause decreases in CPP by decreasing the MAP 
more than the ICP. Attention to CPP and ICP should be paid to ensure CPP is not 
compromised. Facilitating physiologic homeostasis also includes early treatment of factors 
that can worsen ICP such as fever, hypercarbia and seizures.  
Other medical management aimed at treating elevated ICP has been investigated for several 
years with limited success. Although several strategies have been shown to reduce ICP for 
short periods of time, very few have proven to be effective long term therapies or have a 
significant impact on patient outcome. One of the more commonly accepted approaches is to 
minimize agitation and excess muscle activity which can worsen ICP. This usually involves 
the use of analgesics and sedatives. The agents most commonly used are narcotics such as 
morphine and fentanyl for analgesics and benzodiazepines such as midazolam and 
lorazepam for sedation. In many cases, barbituates and anesthetics such as propofol, can be 
used in small or large doses in an attempt to decrease cerebral metabolism and cerebral 
oxygen requirements. This has been shown to reduce ICP and the decrease in cerebral 
oxygen requirements may result in a decrease in the absolute amount of cerebral blood flow 
needed to prevent further brain injury. The use of “drug induced coma” to decrease cerebral 
 
Medical and Surgical Management of Intracranial Hypertension 
 
219 
metabolic rate remains controversial. This is largely because of the lack of convincing 
evidence that this approach changes outcome and the significant systemic and 
hemodynamic complications associated with these medications at high doses for long 
periods of time.5,6 Regardless, both barbituates and anesthetics such as propofol have been 
shown to be effective in decreasing ICP in a dose related fashion and assuming a patient is 
hemodynamically stable, these agents can often be used safely for extended periods with 
favorable responses on ICP. 
Occasionally, neuromuscular blockers are required, however routine use of neuromuscular 
blockers has not been shown to improve outcome and is associated with increased 
complications including pneumonia and sepsis. In the setting where paralysis is considered 
to control excess movements in association with persistently elevated ICP, encephalography 
(EEG) be considered to rule out ongoing seizures. Continuous EEG is used in some centres 
to monitor brain wave activity and to observe for the potential of non-clinical seizures. 
Although standard 20 minute EEG has not been shown to correlate with a high detection 
rate of seizures, any concern regarding the possibility of non-clinical seizures warrants 
assessment with EEG, if not continuous then intermittent.5 
Other medications focus on diuresing fluid, presumably edema, from the brain with osmotic 
diuretics or hypertonic solutions. The most extensively used agent is mannitol and various 
clinical and experimental studies have shown reductions in ICP with the use of mannitol.5 
The effect of mannitol on ICP involves several mechanisms including decreasing blood 
viscosity, decreasing CSF production, and fluid shift from brain tissue to intravascular 
compartments. The effects are usually not sustained and repeated doses over a prolonged 
period are often required. Earlier studies have also suggested the effects of mannitol on ICP 
could be prolonged with the concomitant use of furosomide. Whether used alone or in 
combination with another diuretic, prolonged mannitol use can lead to problems with 
dehydration, elevated serum osmolality, and renal impairment. Furthermore, the use of 
mannitol is less effective and potentially aggravating in cases of localized lesions with 
significant vasogenic edema, such as hemispheric ischemic strokes. In such cases, localized 
pressure gradient or a compartmentalized ICP is a more likely cause of neurological 
deterioration rather than a generalized increase in ICP.7 The effects of mannitol in these 
cases will be seen maximally in normal and non affected areas of the brain which can 
potential worsen the pressure gradient further.8 Kauffman et al investigated mannitol in the 
treatment of vasogenic cerebral edema following ischemic stroke and found that with 
multiple mannitol injections, non-infarcted hemisphere shrunk more compared to the 
infarcted hemisphere. He concluded that prolonged mannitol use may actually cause a 
reversal of the osmotic gradient between edematous brain and plasma, and worsen localized 
vasogenic edema in cases of large ischemic strokes with vasogenic edema.9 Similarly, several 
stroke specific trials found that if hyperosmolar therapy was used continuously for greater 
than 48 hours, it was associated with worse outcome and increased risk of herniation. The 
effects are felt to be secondary to increasing ICP differentials between infarcted brain and 
healthy brain and thereby increasing the chances of herniation, as the osmotic agents may 
collect in the infarcted tissue and then induce increasing edema. Consequently, mannitol 
                                                 
5 Scozzafava J, Hussain MS, Brindley PG, Jacka MJ, Gross D. The role of 20 minute EEG in the comatose 
patient. Journal of Clinical Neurosciences. Jan 2010;17(1):64-8. 
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5 Scozzafava J, Hussain MS, Brindley PG, Jacka MJ, Gross D. The role of 20 minute EEG in the comatose 
patient. Journal of Clinical Neurosciences. Jan 2010;17(1):64-8. 
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should be used cautiously in any patient with hemispheric masses or lesions and in cases 
where repeated dose are to be used for a prolonged period of time. In more recent years, 
hypertonic saline has also been used and like mannitol, hypertonic saline acts by pulling 
water from brain tissue to the intravascular space. Hypertonic saline is associated with 
slightly less concerns regarding electrolyte disturbance, dehydration and renal injury, 
however similar precautions should be taken in regards to hemispheric lesions, particularly 
ischemic strokes with significant vasogenic edema. At the present time, there are no 
established guidelines for its use, however most studies have used 3% or 7.5% at rates of 20 
to 40 cc/hr. Prolonged infusions should be run only in an ICU setting and discontinuation 
should be tapered slowly to prevent rebound hyponatremia. 
Several other measures should be considered second tier in the management of ICP because 
of their lack of proven benefit and/or the significant risks associated with their use. These 
include hyperventilation and hypothermia. For years, hyperventilation was thought to be a 
safe and effective method of lowering ICP. Its action is through generalized vasoconstriction 
of small cerebral arteries in response to low carbon dioxide levels in the blood. It causes a 
relatively quick decrease in ICP at the expense of a corresponding decrease in CBF and at 
the risk of resultant cerebral ischemia. Further evidence has shown hyperventilation to be an 
ineffective method of managing ICP and possibly detrimental in several subgroups of 
patients.13 Its use should be avoided in most circumstances. 
The concept of hypothermia as a possible neuroprotectant has been explored for several 
years. Evidence exists that induced hypothermia lowers ICP, likely through decreasing 
cerebral metabolic rate, however it has not been shown to correlate to a decreased rate of 
secondary brain injury. Although increasing evidence suggests a role for therapeutic 
hypothermia to protect the brain from secondary injury following cardiac arrest, similar 
evidence has not developed in other situations, particularly primary brain injury such as 
trauma and stroke. A randomized controlled trial in severe closed head injury failed to show 
any benefit of induced hypothermia on outcome.14 Further trials in various subgroups of 
patients are underway. 
In many cases, ICP proves resistant to aggressive medical management and surgical 
intervention is required beyond the EVD. This is frequently seen in association with mass 
lesions. Mass lesions can include tumors, abscesses or hemorrhages which are all frequently 
prone to edema which further aggravates ICP and poses an increasing risk of herniation. In 
the case of tumors, resection often results in resolution of ICP issues. In the case of abscess, 
drainage not only serves to reduce ICP, but treats the infection and prevents further spread.  
The recommended management of hematoma depends on location, size of hematoma and 
extent of neurological injury as well as ICP. Subdural and epidural hematomas causing 
increased ICP generally should be considered for surgical evacuation. Subarachnoid 
hemorrhage (SAH) is often the result of a ruptured cerebral artery aneurysm or 
arteriovenous malformation. Definitive management of the hemorrhage and the ICP must 
involve securing the ruptured vessel(s). In cases of parenchymal intracerebral hemorrhage 
(ICH) or hemorrhagic stroke, several randomized trials have failed to demonstrate benefit 
associated with surgical evacuation of supratentorial ICH, regardless of ICP.15  
However, there is one sub-group of hemorrhagic stroke that has shown to benefit from 
aggressive and early surgical intervention. Although, there are no randomized trials looking 
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specifically at surgical evacuation of cerebellar hematomas, a non-randomized case series 
has shown urgent surgical evacuation of cerebellar hemorrhage improves outcome 
compared to medical management alone.16 It included patients with GCS < 13, and 
hematoma > 40 mm. 45 patients were treated medically and 30 patients were treated with 
decompressive surgery. Good outcome occurred 58% with surgery while only 18% with 
conservative medical therapy. A large reason for this may be because of the reasonable 
potential for recovery regardless of stroke burden in cerebellum. The factor which is often 
more critical is the acute and progressing edema and/or hemorrhage which may prove to 
compromise the nearby fourth ventricle of the ventricular system and lead to obstructive 
hydrocephalus. As a result, a cerebellar hemorrhage which would otherwise have 
potentially good outcome, could rapidly progress to malignant intracranial hypertension 
and death. Our recommendation is for the prophylactic insertion of EVD or suboccipital 
decompressive craniectomy for patients with cerebellar hemorrhage and hematoma > 3 cm 
in diameter or obstructive hydrocephalus.  
Medically intractable ICP is also frequently seen with severe head trauma. Unlike mass 
lesions and vascular anomalies, an underlying structural abnormality cannot be removed 
unless associated with significant secondary hematoma. Surgical treatment of ICP has 
focused on brain decompression in these patients. Both hemispheric and bifrontal 
craniectomy have both been shown to be effective in managing medically intractable ICP 
following head trauma and should be considered when medical measures have failed.17-22 
Decompressive craniectomy for prevention of fatal brain herniation has been for almost 100 
years. The rationale for surgery is to change the inelastic container or ‘closed box’ and 
provide a mechanical outlet for the edematous brain to stretch beyond the skull thereby 
preventing herniation. As a consequence, secondary benefits include rapid reduction of 
intractable ICP and restoration of cerebral perfusion.  
5. Considerations specific to ischemic stroke 
Issues regarding raised ICP are less often encountered in ischemic stroke compared to 
hemorrhagic stroke. Similarly, the management of malignant intracranial hypertension is far 
less seen is ischemic stroke patients compared to hemorrhagic stroke or other neurology and 
neurosurgery patients presenting with mass lesions. This is because in the case of ischemic 
stroke, a new mass or volume is not immediately introduced into our “closed box” model of 
intracranial contents like with other causes of brain injury like hemorrhage or tumor. However, 
immediately after the onset of ischemia changes begin to occur including cerebral edema. 
It has been estimated that anywhere from 1-10% of supratentorial ischemic strokes can cause 
rapid neurological deterioration from space-occupying cerebral edema. Although ischemic 
strokes display some vasogenic edema as part of the inflammatory phase, the primary 
swelling is the result of cytotoxic edema. Cytotoxic edema is the result of damaged cell 
membranes during ischemia. The result is that neuronal cells fill with plasma ultrafiltrate. 
Although this usually occurs between the second and fifth day after stroke, it can occur as 
early as 24 hours. Such a presentation following an ischemic stroke involving the entire 
middle cerebral artery (MCA) territory is called ‘malignant MCA infarction’ (MMI). This is 
often a consequence of occlusion of the internal carotid artery or the proximal portion of the 
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specifically at surgical evacuation of cerebellar hematomas, a non-randomized case series 
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Although this usually occurs between the second and fifth day after stroke, it can occur as 
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middle cerebral artery. The prognosis of MMI is poor and mortality is as high as 80%, with 
most deaths occurring during the first week from cerebral edema and brain herniation.23  
Multiple non-randomized studies have shown that decompressive surgery, consisting of a 
hemicraniectomy and duraplasty reduces mortality in patients with MMI.24-26 However, its 
popularity decreased because clinicians were concerned as to whether survival was at the 
expense of poor functional outcome. In the midst of uncertainty regarding functional 
outcome, three European trials have addressed the role of decompressive hemicraniectomy 
on functional outcome since 2000: the French DECIMAL (decompressive craniectomy in 
malignant middle cerebral artery infarcts) trial; the German DESTINY (decompressive 
surgery for the treatment of malignant infarction of the middle cerebral artery) trial; and the 
Dutch HAMLET trial (hemicraniectomy after middle cerebral artery infarction with life-
threatening edema trial). A pooled analysis of all three trials confirmed suggestions from 
earlier non-randomized trials. Decompressive hemicraniectomy undertaken within 48 hours 
of onset of MMI reduces mortality and increases the number of patients with a favorable 
functional outcome.27-30  
The trials were both praised and criticized on many points. Analysis of all the trials was 
assumed possible due to similar design and use of the modified Rankin Scale (mRS) as a 
common primary outcome measure. Significant difference between the trials included 
imaging modalities and longer treatment window allowed in HAMLET, which allowed 
patients to be treated up to 96 hours after onset of stroke symptoms. However, the pooled 
analysis included only the patients randomized and treated within 48 hours. The primary 
outcome measure for the pooled analysis was the mRS dichotomized between “favorable” 
(defined as mRS 0-4) and “unfavorable” (mRS 5-6). There was clearly a difference between 
the two treatment arms, with 75% achieving a favorable outcome in the hemicraniectomy 
group as compared to 24% in the medical treatment alone arm (p< 0.01). The most robust 
effect was seen on survival, which increased from 28% to nearly 80% with DCH. Perhaps the 
most significant result was the proportion of patients who were independent with disability 
(mRS 2) which increased more than five times with DCH from 2.5% to 14%. Forty three 
percent of patients had a good clinical outcome with mRS 2-3 after a DCH compared to 
21.5% of patients who received conservative therapy. However, the proportion of patients 
surviving with moderate-to-severe disability was increased more than 12-fold (31% vs. 
2.5%) but the rates of very severe disability was not increased after DCH (4%vs. 5%).  
Despite the evidence provided by these trials, the most crucial question remains the selection 
of patients for surgery because not all middle cerebral infarctions lead to MMI and no single 
prognostic factor has been identified as a predictor of fatal outcome in MMI. Neuroimaging 
combined with clinical examination does provide valuable information to identify patients at 
risk. Early ischemic changes (less than 6 hours) on CT scan that involves greater than 50% of 
the MCA territory have been associated with fatal outcomes. This included such early CT 
changes as localized cerebral edema causing sulcal effacement or compression of the lateral 
ventricle.31 The DECIMAL trial used a critical stroke volume of 145 mL on diffusion-weighted 
MRI and confirmed this cut off value suggested by previous authors. Analysis showed 78% 
mortality in strokes with >145 mL volume and no deaths when the stroke volume was less 
than 145mL. NIHSS > 20 (dominant hemisphere) or > 15 (non-dominant hemisphere) within 6 
hours of symptom onset along with CT findings of hypodensity >50% were also associated 
with high risk for developing malignant cerebral edema. 32  
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Age is another important consideration in this population following MMI. The upper age 
limit in the above randomized trials was 60-years and therefore the results are not easily 
transferable to individuals older than 60 years. As we have seen with many interventions, 
with older patient populations come more medically complex and often fragile patients. 
DESTINY II is underway to evaluate the benefit of surgery in this older patient population, 
which may be more indicative of the stroke population seen in most hospitals. However, 
non-randomized trials which investigated this question showed that mortality and poor 
outcome were significantly higher in patients older than 60 years of age.33,34 Regardless of 
the results of DESTINY II, the decision to operate on patients older than 60 years of age 
should be individualized and must take into consideration patients declared wishes and 
social support. It must be kept in mind that outcomes in this population depend on several 
factors like admission functional status, cognitive ability and presence of social support. 
The timing of surgery is also significant. From the individual results and pooled analysis of 
DECIMAL and DESTINY, patients who were surgically treated with decompressive 
hemicraniectomy within 48 hours did better when compared to the HAMLET trial in which 
there was no improvement in functional outcome despite decrease in mortality in patients 
who received delayed surgical treatment (up to 96 hours after symptoms onset). Early 
decompressive hemicraniectomy (<48hours) is recommended for all patients with MMI and 
impending herniation who are felt to have good potential for recovery from the initial 
ischemic injury of the stroke.  
In contrast to supratentorial ischemic strokes, the question of surgical intervention in large 
cerebellar strokes is less controversial. Fatal space occupying edema can develop in 17% -
54% of cerebellar strokes resulting in obstructive hydrocephalus, transforaminal or 
transtentorial herniation and brain stem compression. Although lacking evidence from 
randomized clinical trials, it is widely accepted that surgical intervention with suboccipital 
decompressive craniectomy or insertion of an external ventricular drainage is lifesaving in 
malignant cerebellar infarctions and with the potential for good clinical outcomes. The long 
term outcome in survivors is also good, especially where there is no associated brainstem 
infarction.35,36 Similar to cerebellar hematoma, these patients should be considered for early 
decompression.  
6. ICP in aneurysmal subarachnoid hemorrhage 
Case report and case series evidence in aneurysmal SAH continues to emerge describing 
beneficial effects of decompressive craniectomy on elevated ICP and on outcome. The 
factors affecting ICP in aneurysmal SAH can include ongoing hemorrhage, edema and 
vasospasm with secondary ischemia. In cases of high grade SAH with severely and 
persistently elevated ICP, decompressive craniectomy should be considered in conjunction 
with early securing of aneurysm in an effort to maximize the chances of good outcome.37,38 
Location of SAH may also play a factor in both outcome and surgical approach. Case series 
evidence has described dramatic recoveries in patients with high grade SAH from anterior 
communicating artery aneurysm ruptures and malignant ICP managed with bifrontal 
decompressive craniectomy.39 The evidence may be related to the observation that high 
grade SAH from anterior communicating artery aneurysm ruptures often present without 
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assumed possible due to similar design and use of the modified Rankin Scale (mRS) as a 
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effect was seen on survival, which increased from 28% to nearly 80% with DCH. Perhaps the 
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mortality in strokes with >145 mL volume and no deaths when the stroke volume was less 
than 145mL. NIHSS > 20 (dominant hemisphere) or > 15 (non-dominant hemisphere) within 6 
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Age is another important consideration in this population following MMI. The upper age 
limit in the above randomized trials was 60-years and therefore the results are not easily 
transferable to individuals older than 60 years. As we have seen with many interventions, 
with older patient populations come more medically complex and often fragile patients. 
DESTINY II is underway to evaluate the benefit of surgery in this older patient population, 
which may be more indicative of the stroke population seen in most hospitals. However, 
non-randomized trials which investigated this question showed that mortality and poor 
outcome were significantly higher in patients older than 60 years of age.33,34 Regardless of 
the results of DESTINY II, the decision to operate on patients older than 60 years of age 
should be individualized and must take into consideration patients declared wishes and 
social support. It must be kept in mind that outcomes in this population depend on several 
factors like admission functional status, cognitive ability and presence of social support. 
The timing of surgery is also significant. From the individual results and pooled analysis of 
DECIMAL and DESTINY, patients who were surgically treated with decompressive 
hemicraniectomy within 48 hours did better when compared to the HAMLET trial in which 
there was no improvement in functional outcome despite decrease in mortality in patients 
who received delayed surgical treatment (up to 96 hours after symptoms onset). Early 
decompressive hemicraniectomy (<48hours) is recommended for all patients with MMI and 
impending herniation who are felt to have good potential for recovery from the initial 
ischemic injury of the stroke.  
In contrast to supratentorial ischemic strokes, the question of surgical intervention in large 
cerebellar strokes is less controversial. Fatal space occupying edema can develop in 17% -
54% of cerebellar strokes resulting in obstructive hydrocephalus, transforaminal or 
transtentorial herniation and brain stem compression. Although lacking evidence from 
randomized clinical trials, it is widely accepted that surgical intervention with suboccipital 
decompressive craniectomy or insertion of an external ventricular drainage is lifesaving in 
malignant cerebellar infarctions and with the potential for good clinical outcomes. The long 
term outcome in survivors is also good, especially where there is no associated brainstem 
infarction.35,36 Similar to cerebellar hematoma, these patients should be considered for early 
decompression.  
6. ICP in aneurysmal subarachnoid hemorrhage 
Case report and case series evidence in aneurysmal SAH continues to emerge describing 
beneficial effects of decompressive craniectomy on elevated ICP and on outcome. The 
factors affecting ICP in aneurysmal SAH can include ongoing hemorrhage, edema and 
vasospasm with secondary ischemia. In cases of high grade SAH with severely and 
persistently elevated ICP, decompressive craniectomy should be considered in conjunction 
with early securing of aneurysm in an effort to maximize the chances of good outcome.37,38 
Location of SAH may also play a factor in both outcome and surgical approach. Case series 
evidence has described dramatic recoveries in patients with high grade SAH from anterior 
communicating artery aneurysm ruptures and malignant ICP managed with bifrontal 
decompressive craniectomy.39 The evidence may be related to the observation that high 
grade SAH from anterior communicating artery aneurysm ruptures often present without 
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significant initial brain tissue injury but with significant subarachnoid hematoma and 
dramatic bilateral cerebral edema. The prominent edema associated with these SAH’s often 
precipitates uncontrollable ICP levels and surgical management of the ICP with craniectomy 
may offer the opportunity for hematoma resolution and often dramatic recovery. A 
randomized controlled trial has been initiated to investigate this further. 
7. Conclusion 
The management of ICP is critical in patients with brain injury, whether from trauma, stroke 
or hemorrhage. Although recovery is inevitably limited by the degree of initial injury 
incurred, morbidity and mortality rise dramatically in the face of uncontrollable ICP. The 
management of elevated ICP has evolved significantly over the past century. Despite 
extensive research for many years, evidence for most medical therapies is lacking. In recent 
years, redirection toward early surgical intervention has re-emerged, particularly with 
subsets of trauma, stroke and subarachnoid hemorrhage patients. Evidence from case 
reports and small trials will need to be supported by larger trials. Even evidence from large 
trials needs to be scrutinized and challenged again with further trials to determine which 
patients may benefit the most from which therapies, particularly decompressive surgery. 
This may lead to more focused and more successful management of all patients with ICP 
issues. Inevitably all therapies have to be individualized to each individual case. In the mean 
time, courage and determination are needed by healthcare providers dealing with these 
emergencies since delays in recognition and intervention are often fatal. 
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Decompressive hemicraniectomy (DH) is a lifesaving surgical procedure to arrest a rapidly 
rising intracranial pressure, not controllable with other methods. This procedure decreases 
the intracranial mass effect, reducing the risk of transtentorial herniation, therefore 
preventing secondary brain injury, brainstem compression and death.  
Currently, malignant hemispheric infarction is one of the main indications for DH (Chen et 
al., 2006; Delashaw et al., 1990; Rengachary et al., 1981; Schwab et al., 1998; Merenda & 
DeGeorgia, 2010) either when the intracranial hypertension does not respond to 
conservative therapies (i.e., osmotic therapy, hyperventilation, etc.); or when there is an 
important brain shift of the midline structures, or both (Gerriets et al., 2001). 
It is estimated that about 10% to 20% of the patients with infarction in the territory of the 
middle cerebral artery (MCA) or of the internal carotid artery (ICA) develop hemispheric 
cerebral edema/swelling, presenting signs of uncal and cingulate herniations and neurological 
deterioration (Paciaroni et al., 2011; Minnerup  et al., 2011; Thomalla et al., 2010; Paciaroni et 
al., 2011). Clinical deterioration of patients with massive MCA infarction (with or without 
additional involvement of anterior cerebral artery or posterior cerebral artery) is the result of 
brain edema, which peaks on days 3 to 5, followed afterwards by progressive edema reduction 
within the following two weeks (Shaw et al., 1959; Merenda & DeGeorgia, 2010; Ng & 
Nimmannitya, 1970). This form of malignant cerebral infarction - often irresponsive to medical 
treatment - is associated with very high mortality rates (i.e. 70% to 90% of cases) (Jourdan et al., 
1993; Rieke et al., 1995; Ropper, 1986; Moulin et al., 1985). 
Decompressive surgery comprehends the surgical measures taken to arrest a rising 
intracranial pressure and can be divided into external and internal decompression – at times 
combined into a single procedure. External decompression involves removal of parts of 
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calvaria and duraplasty. Internal decompression is the term used when removal of affected 
parts of the brain or cerebellum is performed to achieve stabilization of intracranial 
pressure.  
Decompressive surgery has been used in a number of emergency settings as brain trauma 
(Britt & Hamilton, 1978; Ransonhoff et al., 1971; Venes & Collins, 1975), pseudotumor cerebri 
(Martin & Corbett, 1996), encephalitis (Taferner et al., 2001), cerebral venous thrombosis 
(Valença et al., 2009), severe lead encephalopathy (McLaurin & Nichols, 1957), and Reye´s 
syndrome (Ausman et al., 1976). The use of DH has also been reported in the treatment of 
acute rupture of cerebral aneurysms (Fisher CM, Ojemann, 1994; Mitka, 2001).  
2. Decompressive craniectomy – historical note 
The idea of opening the skull to relieve pressure is an old concept. It was exemplified in the 
Greek myth of Athena, goddess of wisdom, according to Hesiod in the poem Theogony (circa 
700 BC). Zeus, the supreme god of Olympus, after swallowing his first wife Metis, had a 
severe and progressively worsening headache attributed to the growth of his daughter 
Athena inside his skull. Hephaestus, the god of fire and metalwork, struck Zeus´ head with 
an axe splitting his cranium in order to alleviate his pain, and Athena was born through this 
primitive craniotomy (Brasiliense et al., 2010). 
Trepanation has been performed since the Mesolithic Era, before the development of metal 
instruments and written language. There is widespread archaeological evidence from South 
America, Europe, Asia and Africa documenting this ritualistic skull opening as long as 
10.000 B.C. (Marino & Gonzales-Portillo, 2000; Martin, 1995, Missios, 2007). 
The ancient Egyptians performed trephinations with local anesthesia, prepared by mixing 
ground marble with vinegar. The success of these procedures is evidenced by the discovery 
of healed wounds in skulls unearthed from tombs dating back 6000 years. On the tomb of 
Bany Hassan, there are paintings that depict a surgeon performing cranial surgery with the 
patient seated (El Gindi, 2002).  
The pre-conquest South America nations were extremely skilled in the art of opening the 
skull. Operations were apparently performed for trauma, fractures, diseases of the cranium, 
scalp and cranial infections, epilepsy, headaches, mental disease, and some thaumaturgic 
rituals. The main archaeological findings related to trephination are associated with 
excavations in the territories of the Paracas, Nazca, Huari, and Içá cultures. They were less 
popular in the more recent Inca culture and were apparently forbidden in the Inca Empire 
long before the Hispanic conquest (Marino & Gonzales-Portillo, 2000).  
The written description and codification of trepanation began in Greece during the fifth 
century B.C. Hippocrates, in his work On Injuries of the Head, described the different types of 
skull fractures and provided specific instructions as well as warnings on the use and 
dangers of trepanation (Martin, 2000).  
Galen of Pergamon (A.D. 129–200) lived in an era when trepanation was better known and 
more widely accepted by practicing physicians as well as the public. He advocated use of 
the procedure for relief of intracranial pressure and drainage of phlegmatous lesions 
(Missios, 2007).  
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After the collapse of Roman Empire, medical knowledge was preserved by Middle Eastern 
cultures. The most famous representative author or this period was Ibn Sina or Avicenna 
(A.D. 980-1037); although he was well versed in intracranial anatomy, his contributions on 
cranial surgery are mostly speculative (Sarrafzadeh et al., 2001).  
The practice of surgery in the Middle Ages was well described by a less well-known author 
called Serefeddin Sanbuncuoglu (A.D. 1385–1468?), the author of Cerrahiyyetü´l-Haniyye 
(Imperial Surgery), which was written in Turkish in 1465. The book contains wonderful 
color illustrations of craniotomy procedures (Elmaci, 2000).  
Berengario da Carpi (1460-1530) wrote the most important work on craniocerebral surgery 
of the Renaissance Period, the Tractatus de Fractura Calvae sive Cranei (Treatise on Fractures 
of the Calvaria or Cranium), in which he described an entire set of surgical instruments to be 
used for cranial operations to treat head traumas, which became a reference for a later 
generation of physicians (Di Ieva et al., 2011).  
The modern concept of decompressive surgery was born with the statement of Kocher, in 1901: 
“If there's no CSF pressure, but brain pressure exists, then pressure relief must be achieved by opening 
the skull.” This author introduced the concept of elevated intracranial pressure as a global 
phenomenon requiring a large skull opening to be treated (Gautschi & Hildebrandt, 2009).  
Harvey Cushing designed a standard subtemporal decompressive craniectomy largely used 
during his huge neurosurgical series with highly impressive results (Cushing, 1905).  
Despite its sporadic use for trauma and other conditions characterized by elevated ICP, 
decompressive surgery was not routinely employed until the 1990s. Probably the initial 
poor results when used in patients without Intensive Care Unit (ICU) support led some 
authors to abandon the procedure. As stated by Clarke in 1968: “The reason for reporting 
this experience is to warn others from doing similar surgery” (Clark et al., 1968).  
The landmark work of Guerra and colleagues (1999) described their results using 
decompressive craniectomy for traumatic brain swelling. The good results from this series 
established the procedure as an appropriate therapy for refractory intracranial pressure of 
any origin (Guerra et al., 1999).  
Decompressive craniectomy for cerebral ischemia was seldom indicated. Ivamoto, in 1974, 
reported the first clinical series, but with no great repercussions (Ivamoto et al., 1974). 
However, after the definition of the “malignant” MCA territorial infarction, which courses 
with dramatic intracranial hypertension, there has been a number of experimental and 
clinical studies on the benefits of early decompression of the brain during ischemic events 
(Hacke et al., 1996).  
Finally the scientific evidence of mortality reduction demonstrated by three randomized 
trials has made decompressive surgery part of the modern arsenal for treatment of ischemic 
stroke (Vahedi et al., 2007).  
3. Decompressive hemicraniectomy for cerebral hemispheric ischemic 
lesions 
The better results obtained after DH in patients with hemispheric lesions (e.g. stroke), when 
compared with patients with severe brain trauma, could be explained by the fact that lesions 
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in unconscious patients after trauma are usually diffuse rather than restricted, as  is the case 
of an  unilateral cerebral hemispheric lesion, such as MCA ischemia.  
3.1 When we should perform a decompressive hemicraniectomy? 
Decompressive hemicraniectomy in cerebral hemispheric ischemia is a lifesaving procedure 
that should be used without delay when the intracranial hypertension does not respond to 
conservative therapies (i.e., osmotic therapy, hyperventilation, etc.); or when there is an 
important brain shift of the midline structures, or both, in a symptomatic patient with motor 
deficit and impairment of consciousness. In a previous healthy patient with no severe 
cognitive deficit the age of the patient (e.g. >75 years of age) or side of the lesion (left sided 
lesion in a right handed patient) does not contraindicate the procedure (Merenda & 
DeGeorgia, 2010).  
In such a setting, the immediate removal of the bone corrects the cerebral displacement, 
relieving the pressure exerted on the rostral midbrain structures. In theory, DH may also 
improve perfusion of the collateral leptomeningeal vessels, improve retrograde perfusion of 
MCA, optimize perfusion of the penumbra, and, consequently reduce the size of the infarct 
and neurological deficit, even in the absence of a brainstem deformation or uncal 
compression. Uncal and cingulate herniations may cause secondary vascular compressions. 
During the development of a cingulate (subfalcine) herniation, the cingulate gyrus shifts 
across and under the falx cerebri and it may compress the anterior cerebral artery, cutting 
off the blood supply to normal brain areas. Uncal herniation, likewise, causes cistern 
obliteration and may compress the posterior cerebral artery. The neurological repercussions 
caused by an uncal herniation (a subtype of transtentorial herniation) due to a MCA 
territory infarction depends on the degree of brain and brainstem atrophy, intracranial 
volume reserve (subaracnoid space/CSF) and the type of variation of the tentorial aperture.  
Since the works of Sunderland (1958) and Corsellis (1958) a relationship between the notch 
size/shape and patterns of uncal herniations was recognized. In this regard, Adler and 
Milhorat (2002) studied 100 human autopsy cases (23 female cadavers) and derived from 
data related to the maximum notch width and notch length, they classified the specimen 
tentorial apertures as: narrow (15%), wide (12%), short (8%), long (15%), typical (24%), large 
(9%), small (10%), and mixed (7%). Accordingly, patients with a wide tentorial notch (i.e. 
maximum notch width >32 mm)( Adler & Milhorat, 2002) and a considerable space between 
the brainstem and the free tentorial edge have a lower chance of brainstem compression by 
cerebral tissue herniation.  
Furthermore, the territory irrigated by the MCA is variable and the volume of ischemic area 
after occlusion of M1 segment of the MCA is unpredictable, it depends on the extension of 
collateral circulations (mainly those supplied by the anterior cerebral artery and posterior 
cerebral artery).  
There are predictive signs of MCA malignant infarction observed on CT-scan (performed 
within 12 hours of ictus), such as: (1) hypodensity in more than 50% of the MCA territory, 
(2) hyperdense MCA, and (3) diffuse attenuation between the cortex and the white matter. 
In addition, MRI findings with diffusion weighted imaging signals occupying >89 ml 
volume is 90% sensitive and 96% specific in predict malignant cerebral hemispheric 
infarction (Arenillas et al., 2002). 
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(2011) observed an incidence of hyperdense MCA and/or ICA arteries of about 15%, which 
was associated with a final infarct involving more than one third of the MCA territory and 
poor functional outcome at 3 months. Overall, 163 patients (16.1%) had a final infarct covering 
more than one third of the MCA territory. 52.7% of the individuals with hyperdense MCA 
and/or ICA had an infarct involving more than one third of the MCA territory compared to 
only 9.9% of the patients without artery hyperdensity. At 3 months, 18 patients were lost to 
follow-up, 325 patients (32.8%) were disabled and 165 died (16.5%).  The following factors 
were associated with unfavorable outcome: age, NIH Stroke Scale score for 1 added point on 
admission, stroke due to atherosclerosis, hemorrhagic transformation of the ischemic lesion, 
and hyperdense MCA and/or ICA (OR 2.0, 95% CI 1.0-4.0). 
 
Fig. 1. Clinical and neuroradiological features predictive of a malignant course after a 
middle cerebral artery (MCA) infarction. ACA, anterior cerebral artery; PCA, posterior 
cerebral artery. 
Recent study (Minnerup  et al., 2011), enrolling 52 ischemic stroke patients with carotid-T or 
MCA main stem occlusion and ischemia (reduced cerebral blood volume) on perfusion CT 
performed on admission, showed that 26 (50%) of them developed malignant MCA 
infarction. Two subgroups were separated according to the development of malignant MCA 
infarction defined by clinical signs of herniation. Age, a decreased level of consciousness on 
admission, cerebral blood volume (CBV) lesion volume, CSF volume, and the ratio of CBV 
lesion volume to CSF volume were significantly different between malignant and 
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in unconscious patients after trauma are usually diffuse rather than restricted, as  is the case 
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the brainstem and the free tentorial edge have a lower chance of brainstem compression by 
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There are predictive signs of MCA malignant infarction observed on CT-scan (performed 
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In addition, MRI findings with diffusion weighted imaging signals occupying >89 ml 
volume is 90% sensitive and 96% specific in predict malignant cerebral hemispheric 
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nonmalignant subgroups. The best predictor of a malignant course was the ratio of CBV 
lesion volume to CSF volume.  
Merenda and DeGeorgia (2010) cited a number of clinical and neuroradiological features 
that appear to be predictive of a malignant course after MCA infarction, as illustrated in 
Figure 1. Although, a significant number of patients presenting predictors of malignant 
course may not develop fatal brain swelling (Merenda & DeGeorgia, 2010). 
3.2 The classic decompressive craniectomy 
The technical recommendations for the performance of DH stress that craniectomy should 
be performed in the frontotempoparietal region, reaching the base of the frontal bone and 
sparing the calvarium ≈ 1 cm from the midline to prevent injury to bridging veins and 
additional bleeding (Wagner et al., 2001).  A diameter of around or above 12 cm is desirable, 
as it has been shown that doubling the diameter from 6 to 12 cm results in an increase in 
decompressive volume from 9 to 86 cm (Wirtz  et al., 1997; Wagner et al., 2001). The bone 
removal towards the occipital squama adds little to the decompressive procedure itself, as 
the falx prevents the medial incursion of cerebrum in this region and has a constant length 
of approximately 6 cm (Rhoton Jr & Ono, 1996), besides, it might produce problems of 
stability and patient positioning (Wagner et al., 2001). 
3.3 Duraplasty 
It is estimated that only 15% reduction is achieved with craniectomy alone and duraplasty 
may decrease intracranial pressure by an additional 55% (Chen et al., 2006). Consequently, a 
generous duraplasty would cause significant intracranial pressure reduction. Usually a 
planed, large skin incision, allows for sufficient quantities of pericranium to be used as a 
dural graft and this has resulted in lower deep wound infection rates (5%) than  when 
foreign material was used (e.g. neuro-patch, 15%) (Malliti et al., 2004), Additionally, CSF 
leaks were more frequent in the neuro-patch group of patients (13% vs. 1.6%). Synthetic 
dural grafts should therefore be reserved for situations when autologous grafts are not 
sufficient or unavailable.  
3.4 Disadvantages and secondary problems following decompressive craniectomy 
As HD increased in popularity among surgeons as a life-saving treatment of malignant 
intracranial hypertension following a vascular insult or brain trauma, reports on its technical 
execution and potential complications have been appearing in the literature. Among them 
are hemorrhagic complications, overindication, problems with flap storage and sterilization, 
metabolic changes associated with lack of bony covering, syndrome of the trephined, 
hydrocephalus and others (Chen et al., 2006; Valença et al., 2009; Faleiro et al., 2008). 
3.5 Hemorragic complications 
Parenchymal hemorrhages and infarcts, secondary to the initial site of ischemia, and 
associated with the hemicraniectomy occurred with high frequency rates (Wagner et al., 
2001). An increasing risk of mortality is also linked to hemicraniectomy-associated bleeding. 
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This hemicraniectomy-associated bleeding is related to the size of the craniectomy 
performed, that is to say, the smaller the hemicraniectomy, the more often lesions will occur.  
The mechanism leading to hemicraniectomy-associated lesions involves the shear forces at 
the edges of the trephination. Small craniectomies cause a higher shear stress on the swollen 
brain, particularly if the craniectomy edges are sharp.  
Creation of vascular channels to reduce the risk of vascular congestion in the herniated 
tissue, thereby decreasing the secondary injury caused by the craniectomy was a procedure 
designed by Csókay and coworks (2002) to decrease the brain lesion induced by the classic 
decompressive hemicraniectomy. 
3.6 Increased brain edema 
After vascular occlusion brain water content increases, reaching its maximum 2-4 days later 
(O´Brien & Waltz, 1973) and significant changes in blood brain barrier may occur for 20 days 
(O´Brien et al., 1974). Thus, we can subdivided the brain swelling in stroke in three phases: 
(1) an immediate increase (within first minute) in brain volume due to vasoparalysis (tissue 
acidosis); (2) a metabolic (cytotoxic) type of brain edema; and (3) a vasogenic brain edema 
which follows the metabolic type of edema after 4-6 hours, reaching its maximum after a 
few days. In about 3-4 days after cerebral arterial occlusion it is detected the maximal 
anatomic brain deformity, and it is only after this period of time that a gradual reabsortion 
of the excessive parenchymal fluid takes place (Hossmann & Schuier, 1979; Ayata & Ropper, 
2002; Valença et al., 2009b; Shaw et al., 1959). 
In addition, the combination of reperfusion and hemicraniectomy experimentally caused an 
increase in brain edema and breakdown of the blood-brain barrier, although a decrease in 
the infarction size was observed (Engelhorn et al., 2003). Comparable results were obtained 
by Cooper and colleagues (1979) in edema induced by cold in dogs, with edema volume 
seven times larger in craniectomized animals. Since the driving force in edema 
pathophysiology is the pressure gradient across the injured capillaries, cerebral 
decompression may decrease interstitial fluid pressure and, as a result, increase edema 
formation. In this regard, craniectomy caused a significant decline in tissue pressure in the 
cortical gray matter in cat models (Hatashita et al., 1985), a phenomenon that probably 
occurs after decompressive craniectomy in a patient with brain infarction caused by 
traumatic vessel occlusion, who had a poor outcome (Venes & Collins, 1975). This increased 
edema can lead to higher shear forces and contribute to hemicraniectomy-associated lesions. 
3.7 Flap storage and sterilization 
The gradual acceptance of decompressive craniectomy as a therapeutic tool in a selected, but 
significant number of patients with stroke or intracranial hypertension will result in an 
increased demand for cranioplastic procedures with its inherent costs. 
During classic decompressive hemicraniectomy procedure, the bony flap is removed and 
stored under the abdominal fat or in a freezer. The replacement of the bone or cranioplasty 
is performed after the resolution of the hemispheric swelling, which occurs six to 20 weeks 
later, in surviving patients. The storage of the a large bony flap under the abdominal fat is 
time-consuming procedure and very probably is a cause of moderate to severe abdominal 
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leaks were more frequent in the neuro-patch group of patients (13% vs. 1.6%). Synthetic 
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intracranial hypertension following a vascular insult or brain trauma, reports on its technical 
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later, in surviving patients. The storage of the a large bony flap under the abdominal fat is 
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pain, not infrequently associated with sizeable hematomas. Infection may occur, as well. It is 
well-know that increase in the intracranial pressure is the result of pain and agitation, thus 
this is another disadvantage of storing the bone in the abdominal subcutaneous tissue. On 
the other hand, bone resorption may be high (up to 50%) after cryopreservation (Grant et al., 
2004).  
Autoclaving the bone flap and sterilization with ethylene oxide were also tried. Missori  and 
coworkers (2003) repositioned the bone after an average period of 4.3 months in 16 patients 
in whom the bone flap was removed for decompressive craniectomy, washed in hydrogen 
peroxide and then placed in hermetically-sealed bags and sterilized using ethylene oxide. 
The authors reported that, after an average follow-up of 20 months, the esthetic and 
functional results were good in 15 patients (Missori et al., 2003).  
Autoclaving the bone flap is another option to be used (Jankowitz & Kondziolka, 2006; 
Osawa et al., 2000, Vanaclocha et al., 1997). Biopsies of the tumor invaded bone flaps 
autoclaved for 20 minutes at 134 degrees C and 1 kg/cm2 and re-implanted showed newly 
formed bone partly re-populated by osteocytes. After studied 6 cases the authors concluded 
that autoclaved calvarial bone, when replaced with direct contact with living bone, will be 
gradually repopulated with osteocytes (Vanaclocha et al., 1997). In this regard, we believe 
that an alternative that may increase the re-population rate of bone flaps that underwent 
autoclave sterilization is to reintroduce bone cells (e.g. osteoclasts and osteoblasts), using 
fresh bone powder or stem cells, into perforations made in the craniotomy flap to be 
replaced.  
3.8 Overindication 
In 1995, Rieke and colleagues reported the first prospective study with the use of DH in 
space-occupying supratentorial infarction, obtaining a significant benefit with the 
combination of bone removal and dural patch enlargement. Subsequently, Schwab and 
associates (1998) demonstrated that if the patients were submitted to decompressive surgery 
within the first 24 hours (even before any significant brain shift of the midline structures), a 
further reduction in mortality rates to 16% occur. The remaining question is: do all patients 
with early (predictive) clinical/neuroimaging signs of malignant cerebral infarction require 
DH for the correction of intracranial hypertension?  
False-positive classification as malignant infarction is of major concern as it may result in 
unnecessary surgical treatment, while a high threshold for indicating this procedure may 
severely compromise results. 
Although this question does not have an answer at this point, it is our feeling that 
performance of a decompressive surgery, using a technique that allows the bony flap to 
open gradually, according to the intracranial pressure (Valença et al., 2009), would be a less 
harmful alternative to some patients, since, in the absence of a gradual mass effect, the flap 
would stay in a normal anatomic position, while absent flap problems and metabolic 
changes due to lack of bone covering would be prevented.  Moreover, a decompressive 
surgery may improve perfusion of the collateral leptomeningeal vessels, optimizing 
perfusion of the penumbra regions. 
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3.9 Syndrome of trephined 
As a larger-sized hemicraniectomy is desirable to prevent complications related to 
insufficient decompression (Stiver, 2009), the number of problems related to a sinking defect 
might be expected to increase.  
The “syndrome of the trephined” or “sinking skin flap syndrome” (Stiver, 2009; Winkler et 
al., 2000) involves the occurrence of severe headache, convulsion, dizziness, undue 
fatigability, poor memory, irritability, and intolerance to vibration. The syndrome of the 
sinking skin flap has been related to the action of atmospheric pressure and changes in 
hydrostatic pressure of cerebrospinal fluid (CSF), and those have been shown to resolve 
after cranioplasty.    
It is known that skull defects are associated with a blood flow decrease related to postural 
changes, suggesting that DH has an impact on dynamic cerebral blood flow regulation. 
Cranioplasty affects postural blood flow regulation, cerebrovascular reserve capacity and 
cerebral glucose metabolism (Winkler et al., 2000). These effects were associated with a 
clinical improvement in all patients except in those whose cranioplasty was delayed for a 
long time following the HD. Therefore early cranioplasty or a decompressive surgery which 
uses a technique that allows the bony flap to be kept in place and open gradually, according 
to the intracranial pressure is desirable to facilitate rehabilitation in patients after 
decompressive surgery (e.g. “window-like”craniotomy) (Valença et al., 2009).  
3.10 Hydrocephalus 
Hydrocephalus is also a common complication after DH, especially in trauma (Stiver, 2009). 
Its causes are multiple, but absence of a bone flap causes major disturbance to the 
intracranial pressure regulatory mechanisms. As a result of the lower intracranial pressure, 
CSF absorption may be deficient, since a pressure gradient between CSF and the venous 
blood is required for this to happen.  
Again, a decompressive surgery which uses a technique that allows the bony flap to be kept 
in place and open gradually, according to the intracranial pressure would result in sooner 
reestablishment of intracranial biomechanical conditions. If such an assumption is correct, a 
lower incidence of hydrocephalus would be expected with the use of our proposed 
“window-like”craniotomy procedure (Valença et al., 2009). 
4. “Window-like”craniotomy versus classic decompressive craniectomy 
Although DH has led to a substantial decline in mortality rates, several problems remained 
to be solved. Many of them resulted from the lack of bony covering and the changes 
associated with it. A decompressive surgery that used a technique allowing the bony flaps 
to be open gradually depending on the intracranial pressure would theoretically sort out 
many of the problems related to DH (Valença et al., 2009).  
The idea of performing an “window-like” craniotomy as an alternative to substitute 
decompressive hemicraniectomy was reported in 2003 (Valença & Valença, 2003). In 2009 we 
published our results with a series of cases (Valença et al., 2009), emphasizing the advantages 
of the new procedure over the classic decompressive hemicraniectomy (Figure 2).  
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further reduction in mortality rates to 16% occur. The remaining question is: do all patients 
with early (predictive) clinical/neuroimaging signs of malignant cerebral infarction require 
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False-positive classification as malignant infarction is of major concern as it may result in 
unnecessary surgical treatment, while a high threshold for indicating this procedure may 
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performance of a decompressive surgery, using a technique that allows the bony flap to 
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Fig. 2. The classic decompressive craniectomy, which causes trephine syndrome. 
5. “Window-like” craniotomy: Surgical technique 
The surgical procedure involves a large semicircular skin incision starting in the proximities 
of the midline and extending to the posterior parietal area, ending at the level of the tragus. 
The scalp must be elevated from the underlying pericranium to ensure greater elasticity and 
a looser skin flap to allow the stitching up of the skin at the end of the “window-
like”operation, covering again the bone with the skin.  
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An extensive, near rectangular-shaped craniotomy is performed involving frontal, temporal, 
and parietal bones, and part of the occipital squama (diameter 12-15 cm). The angle of the 
bone cut must be beveled outwards to allow the upper part of the craniotomy bone flap to 
rest on the adjacent skull and prevent penetration into the intracranial cavity. An anterior 
temporal craniectomy (subtemporal decompression) is added to relieve temporal lobe 
pressure (Figure 3). Dural incisions are performed and the dura is fixed at the bone border 
to prevent epidural bleeding (Valença et al., 2009).  
Using a vertical cut, the bone flap is divided into two similarly sized pieces, which will be 
the opening of the “window lids”. The outer frontal and parietooccipital sides of the flap are 
each one tied to the skull at two points (see arrows in Figure 4) using a synthetic 
nonabsorbable suture (i.e. polypropylene) to function as a hinge joint that allows opening of 
the window but prevents downward movement of the bone inside the skull. We advise 
inserting sutures at the edges of the bone flap in such a way that the lateral portion of the 
window is divided into three parts (Figures 3 and 4). 
The recommended beveling of the craniotomy edges is important in the upper part of the 
craniotomy. What may prevent the bone from sinking in, besides the above-mentioned 
aspect, are the following: 1. the underlying attached dura mater; therefore, the dura-bone 
stitches should be placed 0.5 cm from the bone edge. 2. a good alignment of the bone flaps 
with the calvarium;  3. the intracranial pressure; and 4. the fact that the close of the bone 
“window” and the cranial vault reconstruction follow the principles used in the 
construction of vaults (a semicircular  arch-shaped structure) where many segments are held 
in place by lateral thrust (representing the calvarium where the bone flaps will be fixated, 
Figure 3). The anterior and posterior parts of the craniotomy - the suture placement - should 
be cut vertically in order to permit a good alignment of the bone flaps with the calvarium. 
Thus, the central, bisected portion of the bone does not "sink in" when the brain later 
atrophies after infarct or major trauma (Valença et al., 2009). In our experience we have seen 
a good aesthetic result as early as 2-3 months following the procedure, although a 
foreseeable defect at the edge and along the central vertical line of the craniotomy can be felt 
on palpation.  
After 5 months of follow-up the appearance of the “window-like” craniotomy was similar to 
that of a normal classical “fixated” craniotomy, with no signs of movement of the partially 
free bone flaps.  
A dura patch, using synthetic graft, lyophilized cadaver dura mater, pericardium, or 
homologous pericranium, fascia lata or temporal fascia is placed in the incision ( 13-20 cm 
in length and 4-8 cm wide). The bone flap is divided into two similar-size pieces by a 
vertical cut, which will be the opening of the “window lids”. The outer frontal and parieto-
occipital sides of the flap are tied to the skull at 2 points, to function as a hinge joint that 
allows the opening of the window but prevents the bone from moving downward inside the 
skull.  
A number of difficulties are encountered when performing the duraplasty using the stellar 
durotomy. In order to facilitate the duraplasty we have developed a new form of dural 
closure resembling an anteroposterior bridge between the dural edges (Valença et al., 2009). 
The dura mater is opened in a way that resembles two semicircular “ears” with the bases 
facing the upper and lower bone boundaries, respectively. On the anterior and posterior 
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limits of the craniotomy 1 cm of dura mater is left in order to permit a subsequent suture of 
the rectangular dural graft.  
 
Fig. 3. CT-scan showing the anterior temporal craniectomy and the “window-like” 
craniotomy after 3 months of the procedure. 
 




Fig. 4. Left side “window-like”craniotomy. The outer frontal and parietooccipital sides of 
the flap are each one tied to the skull at two points (see arrows) using a synthetic 
nonabsorbable suture to function as a hinge joint that allows opening of the window but 
prevents downward movement of the bone inside the skull. We advise inserting sutures at 
the edges of the bone flap in such a way that the lateral portion of the window is divided 
into three parts. 
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6. Advantages of decompressive surgery, using a technique that allows the 
bony flap to open gradually, according to the intracranial pressure 
The proposal of decompressive surgery using a craniotomy in an “window-like” fashion 
presents the following advantages: (i) it allows the edematous cerebral parenchyma to 
herniate with a gradual opening, simultaneously relieving the elevated intracranial 
pressure; (ii) it is an anatomic option that preserves the brain-skull biomechanics and avoids 
the use of expensive bio-prosthetic materials; (iii) it may avoid the development of sinking 
skin flap symptoms; (iv) it obviates the need for a second bone-replacement surgical 
procedure at a later stage, which may have an impact on the overall treatment cost; (v) it is 
not necessary the storage of a large bony flap under the abdominal fat, a procedure that is 
time-consuming and is cause of moderate to severe abdominal pain (pain causes agitation 
thereby increasing intra-abdominal and intracranial pressures), sometime associated with 
sizeable hematomas and infection; (vi) probably there is an attenuation in the formation of 
brain edema because the procedure may allow pressure at the herniated tissues close to 
normal levels with the presence of the bone flap. 
The “window-like” procedure allows the performance of a large hemicraniectomy to 
adequately decompress the ischemic brain and avoid hemicraniectomy-associated lesions. 
At the same time, it offers an anatomic, inexpensive solution that allows the gradual 
accommodation of the herniated brain tissue, with a decrease in the intracranial pressure 
after brain insult. This surgical treatment may avoid edge trauma and ischemia, since the 
transcalvarial (external) herniation may be directed more uniformly towards the center of 
the craniotomy by the angle formed between the skull and the partially opened bone flaps. 
Again, the principle of the window-like craniotomy prescribed here mimics the opening of 
the sutures observed in child hydrocephalus.  On the other hand, by recomposing a resistant 
barrier between the brain and the environment, it possibly prevents the sinking flap 
symptoms that detract from the functional outcome. A comparable procedure - hinge 
craniotomy - was recently described (Schmidt et al., 2007). 
As to whether a young survivor could resume sports after the “window-like” procedure, we 
still lack sufficient evidence to confidently state that after one year the bone has healed 
sufficiently to allow sporting activities, we believe that such activities can be recommended 
without the need for further surgery to stabilize the bone. However, to be certain of this, 
further studies are required to clearly demonstrate bone resistance sufficient to sustain 
significant impacts, not only in the case of the procedure presented here but also after the 
subsequent repositioning of the bone to correct the defect left by a conventional 
decompressive hemicraniectomy, since bone resorption might occur (Stiver, 2009, Faleiro et 
al., 2008). 
The “window-like” craniotomy was used by us in eight patients with malignant ischemic 
stroke with no mortality. None of these patients develop hydrocephalus and the aesthetic 
result was good. 
7. Future perspectives 
Present results indicate that, despite adequately addressing several drawbacks of the 
conventional DH, “window-like” techniques for DH will benefit further from observations 
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of clinical practice. From a technical stand-point the technique might be improved by the 
development of two devices: (a) a hinge and (b) a synthetic dura mater substitute in the 
form of an ellipsoid “bag” rather than the commercial available rectangular graft (Valença et 
al., 2009). Although this second device could save time during duroplasty, it can only be 
acceptable if it presents complication rates similar or smaller than using pericranium grafts. 
We reported (Valenca et al., 2009) the possibility of using metal hinges to replace the 
synthetic nonabsorbable sutures. To this end, the hinges (2 on each side of the craniotomy) 
should be fixed into the calvaria and to the bone flaps by using screws. The metallic 
implants must be compatible with the use of MR imaging. The opening must be situated 
toward the outer calvaria, a kind of hinge designed to lock the bone flaps in a natural 
anatomical position (horizontal plane), thus preventing the central portion of the bone from 
sinking in when the brain later atrophies. 
Using the same rational to develop the idea of the “window-like” craniotomy, we recently 
use a similar approach to substitute the bifrontal decompressive craniectomy. The one-piece 
bifrontal craniotomy is tied to the skull posteriorly at two points, allowing the opening of 
the bone flap in a fashion similar to a “car hoop” (car hood decompressive craniotomy). We 
used this procedure with success in two occasions: a man with severe brain trauma with 
diffuse bifrontal contusion and a patient with a large fronto-basal meningeoma with 
significant brain edema. The “car hood” procedure may be useful in patients with bilateral 
infarction involving the anterior cerebral arteries, particularly in those with occlusion of a 
dominant A1.  
8. Conclusion 
Decompressive craniectomy in cerebral ischemia is a lifesaving procedure. The history of the 
development of this treatment, its indications, the techniques available to perform the 
procedure, its expected results and complications were discussed. Alternative procedures to 
the classic decompressive hemicraniectomy, including "window-like” craniotomy, were 
presented. Decompressive surgery, using a technique that allows the bony flap to open 
gradually, according to the intracranial pressure, adds the advantage of avoiding a second 
surgical procedure to close the bone defect, therefore preventing the metabolic cerebral 
impairment associated with lack of the overlying skull. 
In conclusion, the present proposal of decompressive surgery using a craniotomy in an 
“window-like” fashion presents the following advantages: (i) it allows the edematous 
cerebral parenchyma to herniate with a gradual opening, simultaneously relieving the 
elevated intracranial pressure; (ii) it is an anatomic option that preserves the brain-skull 
biomechanics and avoids the use of expensive bio-prosthetic materials; (iii) it may avoid the 
development of sinking skin flap symptoms; (iv) it obviates the need for a second bone-
replacement surgical procedure at a later stage, which may have an impact on the overall 
treatment cost.  
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